

DR REDDYS LABORATORIES LTD

Form 20-F

June 23, 2016

Table of Contents

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 20-F**

**.. REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934**

**OR**

**x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the Fiscal Year Ended March 31, 2016**

**OR**

**.. TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**OR**

**.. SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of event requiring this shell company report \_\_\_\_\_**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 1-15182

**DR. REDDY S LABORATORIES LIMITED**

(Exact name of Registrant as specified in its charter)

**Not Applicable**  
(Translation of Registrant's name

**TELANGANA, INDIA**  
(Jurisdiction of incorporation

into English)

or organization)

**8-2-337, Road No. 3, Banjara Hills**

**Hyderabad, Telangana 500 034, India**

**+91-40-49002900**

(Address of principal executive offices)

**Saumen Chakraborty, Chief Financial Officer, +91-40-49002004, saumenc@drreddys.com**

**8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India**

(Name, telephone, e-mail and/or facsimile number and address of company contact person)

**Securities registered or to be registered pursuant to Section 12(b) of the Act.**

<b>Title of Each Class</b>	<b>Name of Each Exchange on which Registered</b>
<b>American depositary shares, each representing one equity share</b>	<b>New York Stock Exchange</b>
<b>Equity Shares*</b>	

**\* Not for trading, but only in connection with the registration of American depositary shares, pursuant to the requirements of the Securities and Exchange Commission.**

Securities registered or to be registered pursuant to Section 12(g) of the Act. None.

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. None.

Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report.

**170,607,653 Equity Shares**

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes  No

Note: Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer. See the definitions of "accelerated filer" and "large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP  International Financial Reporting Standards as issued  Other

by the International Accounting Standards Board

If "Other" has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

Item 17  Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes  No



---

**Table of Contents**

**Currency of Presentation and Certain Defined Terms**

In this annual report on Form 20-F, references to \$ or U.S.\$ or dollars or U.S. dollars are to the legal currency of United States and references to Rs. or rupees or Indian rupees are to the legal currency of India. Our financial statements are prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB. These standards include International Accounting Standards, or IAS, and their interpretations issued by the International Financial Reporting Interpretations Committee, or IFRIC, or its predecessor, the Standing Interpretations Committee, or SIC. References to a particular fiscal year are to our fiscal year ended March 31 of such year. References to our ADSs are to our American Depositary Shares.

References to U.S. or United States are to the United States of America, its territories and its possessions. References to India are to the Republic of India. References to EU are to the European Union. All references to we, us, our Dr. Reddy's or the Company shall mean Dr. Reddy's Laboratories Limited and its subsidiaries. Dr. Reddy's is a registered trademark of Dr. Reddy's Laboratories Limited in India. Other trademarks or trade names used in this annual report on Form 20-F are trademarks registered in the name of Dr. Reddy's Laboratories Limited or are pending before the respective trademark registries, unless otherwise specified. Market share data is based on information provided by IMS Health Inc. and its affiliates (IMS Health), a provider of market research to the pharmaceutical industry, unless otherwise stated.

Our financial statements are presented in Indian rupees and translated into U.S. dollars for the convenience of the reader. Except as otherwise stated in this report, all convenience translations from Indian rupees to U.S. dollars are at the certified foreign exchange rate of U.S.\$1 = Rs.66.25, as published by Federal Reserve Board of Governors on March 31, 2016. No representation is made that the Indian rupee amounts have been, could have been or could be converted into U.S. dollars at such a rate or any other rate.

Any discrepancies in any table between totals and sums of the amounts listed are due to rounding.

Information contained in our website, [www.drreddys.com](http://www.drreddys.com), is not part of this Annual Report and no portion of such information is incorporated herein.

**Forward-Looking and Cautionary Statement**

IN ADDITION TO HISTORICAL INFORMATION, THIS ANNUAL REPORT CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE SECURITIES ACT OF 1933, AS AMENDED AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (THE EXCHANGE ACT). THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE REFLECTED IN THE FORWARD-LOOKING STATEMENTS. FACTORS THAT MIGHT CAUSE SUCH A DIFFERENCE INCLUDE, BUT ARE NOT LIMITED TO, THOSE DISCUSSED IN THE SECTIONS ENTITLED RISK FACTORS AND OPERATING AND FINANCIAL REVIEW AND PROSPECTS AND ELSEWHERE IN THIS REPORT. READERS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH REFLECT MANAGEMENT'S ANALYSIS ONLY AS OF THE DATE HEREOF. IN ADDITION, READERS SHOULD CAREFULLY REVIEW THE OTHER INFORMATION IN THIS ANNUAL REPORT AND IN OUR PERIODIC REPORTS AND OTHER DOCUMENTS FILED AND/OR FURNISHED WITH THE SECURITIES AND EXCHANGE COMMISSION (SEC) FROM TIME TO TIME.



**Table of Contents**

**TABLE OF CONTENTS**

**PART I**

<b><u>ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</u></b>	4
<b><u>ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</u></b>	4
<b><u>ITEM 3. KEY INFORMATION</u></b>	4
<b><u>ITEM 4. INFORMATION ON THE COMPANY</u></b>	30
<b><u>ITEM 4A. UNRESOLVED STAFF COMMENTS</u></b>	64
<b><u>ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</u></b>	65
<b><u>ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</u></b>	101
<b><u>ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</u></b>	115
<b><u>ITEM 8. FINANCIAL INFORMATION</u></b>	117
<b><u>ITEM 9. THE OFFER AND LISTING</u></b>	118
<b><u>ITEM 10. ADDITIONAL INFORMATION</u></b>	119
<b><u>ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u></b>	132
<b><u>ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</u></b>	134

**PART II**

<b><u>ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</u></b>	136
<b><u>ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</u></b>	136
<b><u>ITEM 15. CONTROLS AND PROCEDURES</u></b>	137
<b><u>ITEM 16. [RESERVED]</u></b>	139
<b><u>ITEM 16.A. AUDIT COMMITTEE FINANCIAL EXPERT</u></b>	139
<b><u>ITEM 16.B. CODE OF ETHICS</u></b>	139
<b><u>ITEM 16.C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</u></b>	139
<b><u>ITEM 16.D. EXEMPTION FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</u></b>	139
<b><u>ITEM 16.E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</u></b>	139
<b><u>ITEM 16.F. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT</u></b>	139
<b><u>ITEM 16.G. CORPORATE GOVERNANCE</u></b>	140
<b><u>ITEM 16.H. MINE SAFETY DISCLOSURE</u></b>	141

**PART III**

<b><u>ITEM 17. FINANCIAL STATEMENTS</u></b>	142
---	-----

ITEM 18. FINANCIAL STATEMENTS

142

ITEM 19. EXHIBITS

SIGNATURES

3



**Table of Contents****PART I****ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS**

Not applicable.

**ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE**

Not applicable.

**ITEM 3. KEY INFORMATION****3.A. Selected financial data**

You should read the selected consolidated financial data below in conjunction with our consolidated financial statements and the related notes, as well as the section titled Operating and Financial Review and Prospects, all of which are included elsewhere in this Annual Report on Form 20-F. The selected consolidated income statement data for the years ended March 31, 2016, 2015, 2014, 2013 and 2012 and the selected consolidated statement of financial position data as of March 31, 2016, 2015, 2014, 2013 and 2012 have been prepared and presented in accordance with IFRS as issued by the IASB, and have been derived from our audited consolidated financial statements and related notes included elsewhere herein. The selected consolidated financial data below has been presented for the five most recent fiscal years. Historical results are not necessarily indicative of future results.

**Income Statement Data**

	<b>For the year ended March 31,</b>					
	<b>2016</b>	<b>2016</b>	<b>2015</b>	<b>2014</b>	<b>2013</b>	<b>2012</b>
	<b>(Rs. in millions, U.S.\$ in millions, both except share and per share data)</b>					
	<i>Convenience translation into U.S.\$</i>					
<b>Revenues</b>	<b>U.S.\$ 2,335</b>	<b>Rs. 154,708</b>	<b>Rs. 148,189</b>	<b>Rs. 132,170</b>	<b>Rs. 116,266</b>	<b>Rs. 96,737</b>
Cost of revenues	942	62,427	62,786	56,369	55,687	43,432
<b>Gross profit</b>	<b>1,393</b>	<b>92,281</b>	<b>85,403</b>	<b>75,801</b>	<b>60,579</b>	<b>53,305</b>
Selling, general and administrative expenses	690	45,702	42,585	38,783	34,272	29,907
Research and development expenses	269	17,834	17,449	12,402	7,674	5,911
Other (income)/expense, net	(13)	(874)	(917)	(1,416)	(2,479)	(765)
<b>Results from operating activities</b>	<b>447</b>	<b>29,619</b>	<b>26,286</b>	<b>26,032</b>	<b>21,112</b>	<b>18,252</b>

Finance (expense)/income, net	(41)	(2,708)	1,682	400	460	160
Share of profit of equity accounted investees, net of tax	3	229	195	174	104	54
<b>Profit before tax</b>	<b>410</b>	<b>27,140</b>	<b>28,163</b>	<b>26,606</b>	<b>21,676</b>	<b>18,466</b>
Tax expense	(108)	(7,127)	(5,984)	(5,094)	(4,900)	(4,204)
<b>Profit for the year</b>	<b>302</b>	<b>20,013</b>	<b>22,179</b>	<b>21,512</b>	<b>16,776</b>	<b>14,262</b>
<b>Attributable to:</b>						
Equity holders of the Company	302	20,013	22,179	21,515	16,777	14,262
Non-controlling interests				(3)	(1)	
<b>Profit for the year</b>	<b>U.S.\$ 302</b>	<b>Rs. 20,013</b>	<b>Rs. 22,179</b>	<b>Rs. 21,512</b>	<b>Rs. 16,776</b>	<b>Rs. 14,262</b>
<b>Earnings per share</b>						
Basic	U.S.\$ 1.77	Rs. 117.34	Rs. 130.22	Rs. 126.52	Rs. 98.82	Rs. 84.16
Diluted	U.S.\$ 1.77	Rs. 116.98	Rs. 129.75	Rs. 126.04	Rs. 98.44	Rs. 83.81
<b>Weighted average number of equity shares used in computing earnings per equity share*</b>						
Basic		170,547,643	170,314,506	170,044,518	169,777,458	169,469,888
Diluted		171,072,780	170,933,433	170,695,017	170,432,680	170,177,944
Cash dividend per equity share**	U.S.\$ 0.30	Rs. 20	Rs. 18	Rs. 15	Rs. 13.75	Rs. 11.25

\* Each ADR represents one equity share.

\*\* Excludes corporate dividend tax.

**Table of Contents****Statement of Financial Position Data**

	As of March 31,											
	2016		2016		2015		2014		2013		2012	
	(Rs. in millions, U.S.\$ in millions, except share data)											
	<i>Convenience translation into U.S.\$</i>											
Cash and cash equivalents	U.S.\$	74	Rs.	4,921	Rs.	5,394	Rs.	8,451	Rs.	5,136	Rs.	7,379
Other investments (current and non-current)		559		37,022		37,076		25,083		17,172		10,773
<b>Total assets</b>		<b>3,134</b>		<b>207,650</b>		<b>194,762</b>		<b>170,223</b>		<b>142,369</b>		<b>119,477</b>
Total long term debt, excluding current portion		161		10,685		14,307		20,740		12,625		16,335
<b>Total equity</b>	U.S.\$	<b>1,937</b>	Rs.	<b>128,336</b>	Rs.	<b>111,302</b>	Rs.	<b>90,801</b>	Rs.	<b>72,805</b>	Rs.	<b>57,287</b>
Number of shares outstanding				170,607,653		170,381,174		170,108,868		169,836,475		169,560,346

**Convenience translation**

For the convenience of the reader, our consolidated financial statements as of March 31, 2016 have been translated into U.S. dollars at the certified foreign exchange rate of U.S.\$1 = Rs.66.25, as published by Federal Reserve Board of Governors on March 31, 2016. No representation is made that the Indian rupee amounts have been, could have been or could be converted into U.S. dollars at such a rate or any other rate.

**Exchange Rates**

The following table sets forth, for the fiscal years indicated, information concerning the number of Indian rupees for which one U.S. dollar could be exchanged based on the noon buying rate in the City of New York on business days during the period for cable transfers in Indian rupees as certified for customs purposes by the Federal Reserve Bank of New York. The column titled *Average* in the table below is the average of the daily noon buying rate on the last business day of each month during the year.

**For the year ended**

March 31, 2012	Period End	Average	High	Low
	50.89	48.01	53.71	44.00

2013	54.52	54.48	57.13	50.64
2014	60.00	60.35	68.80	53.65
2015	62.31	61.34	63.67	58.30
2016	66.25	65.58	68.84	61.99

The following table sets forth the high and low exchange rates for the previous six months and is based on the noon buying rates in the City of New York on business days of each month during such period for cable transfers in Indian rupees as certified for customs purposes by the Federal Reserve Bank of New York.

<b>Month</b>	<b>High</b>	<b>Low</b>
October 2015	65.57	64.70
November 2015	66.86	65.46
December 2015	67.10	66.00
January 2016	68.08	66.49
February 2016	68.84	67.57
March 2016	67.75	66.25

On June 17, 2016, the noon buying rate in the city of New York was Rs.67.11 per U.S. dollar.

### ***3.B. Capitalization and indebtedness***

Not applicable.

### ***3.C. Reasons for the offer and use of proceeds***

Not applicable.

---

**Table of Contents**

**3.D. Risk factors**

You should carefully consider all of the information set forth in this Form 20-F and the following risk factors that we face and that are faced by our industry. The risks below are not the only ones we face. Additional risks not currently known to us or that we presently deem immaterial may also affect our business operations. Our business, financial condition or results of operations could be materially or adversely affected by any of these risks. This Form 20-F also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements as a result of certain factors, including the risks we face as described below and elsewhere. See Forward-Looking Statements.

**RISKS RELATING TO OUR COMPANY AND OUR BUSINESS**

**If we fail to comply fully with government regulations or to maintain continuing regulatory oversight applicable to our research and development activities or regarding the manufacture of our products, or if a regulatory agency amends or withdraws existing approvals to market our products, it may delay or prevent us from developing or manufacturing our products.**

Our research and development activities are heavily regulated. If we fail to comply fully with applicable regulations, then there could be a delay in the submission or approval of potential new products for marketing approval. In addition, the submission of an application to a regulatory authority does not guarantee that approvals required to market the product will be granted. Each authority may impose its own requirements and/or delay or refuse to grant approval, even when a product has already been approved in another country. In many of the international markets into which we sell our products, including the United States, the approval process for a new product is complex, lengthy and expensive. The time taken to obtain approval varies by country but generally takes from six months to several years from the date of application. This approval process increases the cost to us of developing new products and increases the risk that we will not be able to successfully sell such new products.

Regulatory agencies may at any time reassess the safety and efficacy of our products based on new scientific knowledge or other factors. Such reassessments could result in the amendment or withdrawal of existing approvals to market our products, which in turn could result in a loss of revenue, and could serve as an inducement to bring lawsuits against us. In our bio-similars business, due to the intrinsic nature of biologics, our bio-similarity claims can always be contested by our competitors, the innovator company and/or the applicable regulators.

Additionally, governmental authorities, including among others the U.S. Food and Drug Administration ( U.S. FDA ) and the U.K. Medicines and Healthcare Products Regulatory Agency ( MHRA ), heavily regulate the manufacturing of our products, including manufacturing quality standards. Periodic audits are conducted on our manufacturing sites, and if the regulatory and quality standards and systems are not found adequate, it could result in an audit observation (on Form 483, if from the U.S. FDA), or a subsequent investigative letter which may require further corrective actions. More recently, a number of Indian generic pharmaceutical companies were issued import alerts and warning letters by the U.S. FDA. A significant proportion of our manufacturing base of active pharmaceutical ingredients and formulations plants servicing the United States and other markets of our Global Generics business is based out of India. There has been an increasing trend by the U.S. FDA and governmental regulators in other developed countries towards Indian manufacturing site audits. While our quality practices and quality management systems are conducted in a manner designed to satisfy these types of audits, we cannot guarantee that our efforts will prevent adverse outcomes such as audit observations, corrective action requests, warning letters or import bans.

For example, in November 2015, we received a warning letter from the U.S. FDA relating to cGMP deviations at three of our manufacturing facilities - two API manufacturing sites and one formulations injectable manufacturing site

in India. This had an adverse impact on new product approvals from these sites, and we have taken steps to minimize the impact from these sites through site transfers of certain key products. We continue to develop and implement our corrective action plans relating to the warning letter. Unless and until these issues are resolved to the U.S. FDA's satisfaction, the U.S. FDA may withhold approval of our new products and new drug applications, refuse admission of products manufactured at the facilities noted in the warning letter into the United States, and/or take additional regulatory or legal action against us. Any such further action could have a material and negative impact on our ongoing business and operations.

Furthermore, we deal with numerous third party manufacturers and despite our strict oversight, any lapse in their quality practices and quality management systems could lead to similarly adverse outcomes in the event of an audit.

If we or our third party suppliers fail to comply fully with applicable regulations or to take corrective actions that are mandated, then there could be a government-enforced shutdown of our production facilities or an import ban, which in turn

## Table of Contents

could lead to product shortages that delay or prevent us from fulfilling our obligations to customers, or we could be subjected to government fines. For example, the U.S. FDA imposed an import ban on our manufacturing facility at Cuernavaca, Mexico from June 2011 through July 2012.

Further, while physicians may prescribe products for uses that are not described in the product's labeling and that differ from those approved by the U.S. FDA or other similar regulatory authorities (an off-label use), we are permitted to market our products only for the indications for which they have been approved. The U.S. FDA and other regulatory agencies actively enforce regulations prohibiting promotion of off-label uses, and significant liability can be imposed on manufacturers found to be engaged in off-label marketing violations, including fines in the tens or hundreds of millions of dollars, as well as criminal sanctions. If some of our products are prescribed off-label, regulatory authorities such as the U.S. FDA could take enforcement actions if they conclude that we or our distributors have engaged in off-label marketing.

An increasing portion of our portfolio is biologic products. Unlike traditional small-molecule drugs, biologic drugs cannot be manufactured synthetically, but typically must be produced from living plant or animal micro-organisms. As a result, the production of biologic drugs that meet all regulatory requirements is especially complex. Even slight deviations at any point in the production process may lead to batch failures or recalls. In addition, because the production process is based on living micro-organisms, the process could be affected by contaminants that could impact those micro-organisms. In such an event, production shutdowns and extensive and extended decontamination efforts may be required.

The regulatory requirements are still evolving in many developing markets where we sell or manufacture products, including our bio-similar products. In these markets, the regulatory requirements and the policies and opinions of regulators may at times be unclear, inconsistent or arbitrary due to absence of adequate precedents or for other reasons. As a result, there is increased risk of withholding or delay of regulatory approvals for new products or government-enforced shutdowns and other sanctions. And, in some cases, there is increased risk of our inadvertent non-compliance with such regulations.

The U.S. FDA issued final guidance in April 2015 on implementing an abbreviated biosimilar approval pathway. In March 2015, the U.S. FDA approved the first biosimilar product submitted under the abbreviated biosimilar pathway. While the U.S. FDA has issued guidelines, these guidelines contain features that could significantly prolong the biosimilar development process and significant ambiguity and questions remain, including, for example, questions regarding standards and criteria for biosimilars and interchangeables. In addition, due to the recent submissions and approvals of abbreviated biosimilar applications, a number of legal challenges construing the requirements of the abbreviated biosimilar pathway are under review. For example, in July 2015, the U.S. Court of Appeals for the Federal Circuit held that biosimilar applicants were not required to provide copies of the biosimilar application or manufacturing information but needed to provide 180-day commercial marketing notice to the reference sponsor. Although we do not have any existing biosimilar product directly impacted by this decision and other ongoing legal challenges, there remains some uncertainty regarding the abbreviated biosimilar approval pathway.

### **We operate in a highly competitive and rapidly consolidating industry which may adversely affect our revenues and profits.**

Our products face intense competition from products commercialized or under development by competitors in all of our business segments based in India and overseas. Many of our competitors have greater financial resources and marketing capabilities than we do. Our competitors may succeed in developing technologies and products that are more effective, more popular or cheaper than any we may develop or license, thus rendering our technologies and products obsolete or uncompetitive, which would harm our business and financial results.

In our proprietary products business, many of our competitors have greater experience than we do in clinical testing, human clinical trials, obtaining regulatory approvals and in marketing and selling of brand, innovative and consumer-oriented products. They may be able to respond more quickly to new or emerging market preferences or to devote greater resources to the development and marketing of new products and/or technologies than we can. As a result, any products and/or innovations that we develop may become obsolete or noncompetitive before we can recover the expenses incurred in connection with their development. In addition, for these product categories we need to emphasize to physicians, patients and third-party payors the benefits of our products relative to competing products that are often more familiar or otherwise better established. If competitors introduce new products or new variations on their existing products, our marketed products, even those protected by patents, may be replaced in the marketplace or we may be required to lower our prices.

In our generics business, to the extent that we succeed in being the first to market a generic version of a significant product, and particularly if we obtain the 180-day period of market exclusivity in the United States provided under the Hatch-Waxman Act of 1984, as amended, our sales and profit can be substantially increased in the period following the introduction of such product and prior to a competitor's introduction of the equivalent product or the launch of an authorized generic.



## Table of Contents

Prices of generic drugs typically decline, often dramatically, especially as additional generic pharmaceutical companies receive approvals and enter the market for a given product. Consequently, our ability to sustain our sales and profitability of any product over time is dependent on both the number of new competitors for such product and the timing of their approvals.

The number of significant new generic products for which Hatch-Waxman exclusivity is available, and the size of those product opportunities, has decreased in recent years and may decrease in future years in comparison to those available in the past. Patent challenges have become more difficult in recent years. Additionally, we increasingly share the 180-day exclusivity period with other generic competitors, which diminishes the commercial value of the exclusivity.

Our generics business is also facing increasing competition from brand-name manufacturers who do not face any significant regulatory approvals or barriers to enter into the generics market. These brand-name companies sell generic versions of their products to the market directly or by acquiring or forming strategic alliances with our competitor generic pharmaceutical companies or by granting them rights to sell authorized generics. Moreover, brand-name companies continually seek new ways to delay the introduction of generic products and decrease the impact of generic competition, such as filing new patents on drugs whose original patent protection is about to expire, developing patented controlled-release products, changing product claims and product labeling, or developing and marketing as over-the-counter products those branded products that are about to face generic competition.

Our competitors, which include major multinational corporations, are consolidating, and the strength of the combined companies could affect our competitive position in all of our business areas. Furthermore, if one of our competitors or their customers acquires any of our customers or suppliers, we may lose business from the customer or lose a supplier of a critical raw material. In addition, our increased focus on innovative and specialty pharmaceuticals requires much greater use of a direct sales force than does our core generic business. Our ability to realize significant revenues from direct marketing and sales activities depends on our ability to attract and retain qualified sales personnel. Competition for qualified sales personnel is intense. We may also need to enter into co-promotion, contract sales force or other such arrangements with third parties, for example, where our own direct sales force is not large enough or sufficiently well-aligned to achieve maximum penetration in the market. Any failure to attract or retain qualified sales personnel or to enter into third-party arrangements on favorable terms could prevent us from successfully maintaining current sales levels or commercializing new innovative and specialty products.

### **Reforms in the health care industry and the uncertainty associated with pharmaceutical pricing, reimbursement and related matters could adversely affect the marketing, pricing and demand for our products.**

Our success depends, in part, on the extent to which government and health administration authorities, private health insurers and other third-party payors will pay for our products. Increasing expenditures for health care has been the subject of considerable public attention in almost every jurisdiction where we conduct business. Both private and governmental entities are seeking ways to reduce or contain health care costs by limiting both coverage and the level of reimbursement for new therapeutic products. These pressures are particularly strong given the lingering effects of the recent global economic and financial crisis, including the ongoing debt crisis in certain countries in Europe. In many countries in which we currently operate, including India, pharmaceutical prices are subject to regulation. Our products continue to be subject to increasing price and reimbursement pressure that can limit the revenues we earn from our products in many countries due to, among other things:

The existence of government-imposed price controls and mandatory discounts and rebates;

removal of drugs from government reimbursement schemes (for example products determined to be less cost-effective than alternatives);

increased difficulty in obtaining and maintaining satisfactory drug reimbursement rates;

increase in cost containment policies related to health expenses in a context of economic slowdown;

more demanding evaluation criteria applied by Health Technology Assessment ( HTA ) agencies when considering whether to cover new drugs at a certain price level; and

more governments using international reference pricing to set the price of drugs based on international comparisons.

We expect these efforts to continue as healthcare payors around the globe, in particular government-controlled health authorities, insurance companies and managed care organizations, step up initiatives to reduce the overall cost of healthcare.

## Table of Contents

### India

Under the present drug policy of the Government of India, certain drugs have been specified under the Drugs (Prices Control) Order, 2013 (the DPCO ) as subject to price control. The Government of India established the National Pharmaceutical Pricing Authority, 2012 ( NPPA ), to control pharmaceutical prices. Under the DPCO, the NPPA has the authority to fix the maximum selling price for specified products. As a result, hundreds of drugs on India's National List of Essential Medicines were identified and subjected to price controls in India. On May 15, 2013, the Department of Pharmaceuticals of the Government of India released Drugs (Price Control) Order, 2013 governing the price control mechanism for 348 drugs listed in the National List of Essential Medicines.

Recently, there has been a series of proposals and announcements by the Government of India regarding price controls. First, in December 2015 a proposal was issued to list certain additional drugs on the National List of Essential Medicines. That was followed with an announcement on March 3, 2016 of a reduction in the maximum prices of various drugs, as a result of negative inflation as measured by India's Wholesale Price Index. Further, on March 10, 2016, the Department of Pharmaceuticals notified the Drugs (Prices Control) Amendment Order, 2016 ( DPCAO 2016 ), which amended the Drugs (Price Control) Order, 2013 and revised the National List of Essential Medicines. Under the DPCAO 2016, a total of 106 medicines were added to and 70 medicines were deleted from the National List of Essential Medicines, which now contains 376 drugs. The NPPA was in the process of notifying / re-notifying the prices for scheduled drugs as of March 31, 2016. The individual drug price notifications for majority of the products have been released by the NPPA. Based on these notifications, we believe that we could be adversely impacted by approximately 3% to 5% of our annual revenues from sales of all of our products in India.

Additionally, on March 12, 2016, the Department of Health and Family Welfare under the ministry of Health and Family Welfare of the Government of India banned 344 fixed dose combination drugs (i.e., two or more active drugs combined in a fixed ratio into a single dosage). A number of pharmaceutical companies, including us, have filed a writ petition before the Delhi High Court challenging the ban. The Delhi High Court granted an interim stay on the ban notification. In the event that this notification comes into effect, it could adversely impact our revenues by approximately 0.7% on an annual basis. Further, it could adversely impact the Indian pharmaceutical industry by approximately 3.1% on an annual basis (as per AWACS, a provider of market research to the Indian Pharmaceutical Industry).

The NPPA has since notified changes to pricing of different products multiple times, which have impacted certain of our oncology and chronic condition products.

Such ongoing changes can disrupt the Indian branded pharmaceutical market and negatively impact the revenues and profitability of our Indian business and our company.

### United States

In the United States, numerous proposals that would affect changes in the health care system have been introduced in Congress and in some state legislatures.

#### *Patient Protection and Affordable Care Act*

In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the PPACA ), were signed into law. The PPACA is one of the most significant healthcare reform measures in the United States in decades, and is expected to significantly impact the U.S. pharmaceutical industry. The PPACA imposes additional rebates, discounts and fees, mandates certain reporting and

contains various other requirements that could adversely affect our business, as more particularly described under Patient Protection and Affordable Care Act in our Global Generics segment's discussion of U.S. Government regulations below in Item 4.B. Business overview .

On June 28, 2010 the Departments of Health and Human Services, Labor, and the Treasury jointly issued interim final regulations to implement the provisions of the PPACA that prohibit the use of preexisting condition exclusions, eliminate lifetime and annual dollar limits on benefits, restrict contract rescissions, and provide patient protections.

On January 27, 2012, The Centers for Medicare and Medicaid Services ( CMS ) issued its long awaited proposed rule implementing the Medicaid pricing and reimbursement provisions of the PPACA and related legislation. CMS accepted comments on this proposed rule through April 2, 2012.

On June 28, 2012, the U.S. Supreme Court ruled on certain challenged provisions of the PPACA. The U.S. Supreme Court generally upheld the constitutionality of the PPACA, including its individual mandate that requires most Americans to buy health insurance starting in 2014, and ruled that the Anti-Injunction Act did not bar the Court from reviewing that PPACA

## Table of Contents

provision. However, the U.S. Supreme Court struck down the PPACA's provisions requiring each state to expand its Medicaid program or lose all federal Medicaid funds. The Court did not invalidate the PPACA's expansion of Medicaid for states that voluntarily participate; it only held that a state's entire Medicaid funding cannot be withheld due to its failure to participate in the expansion.

On February 1, 2016, the CMS published a Final Regulation in the Federal Register to implement changes to and clarify ambiguities in the Medicaid Drug Rebate Program that were enacted by the PPACA. With some exceptions, the Final Regulation will be applied prospectively effective April 1, 2016. The key provisions covered under the Final Regulation included, without limitation, the following: (i) the adoption of a final definition of retail community pharmacy (RCP), (ii) the adoption of a rule permitting inhalation, infusion, instilled, implanted, or injectable drugs (5i drugs) to be deemed not to be generally dispensed through a RCP, and thus excluded from the calculation of their AMP, if 70% or more of its sales were to entities other than RCPs or wholesalers for drugs distributed to RCPs (the prior threshold was 90%), (iii) the inclusion of authorized generics in calculations of AMP and best price, (iv) narrowing the regulatory definition for best price, (v) requiring additional Medicaid rebate payments for generic drugs, effective as of April 1, 2017, and (vi) clarification of the definition of bona fide service fees based on a four part test.

Pending full implementation of the PPACA, we are continuing to evaluate all potential scenarios surrounding its implementation and the corresponding impact on our financial condition, results of operations and cash flow.

## Germany

In Germany, the government has introduced several healthcare reforms in order to control healthcare spending and promote the prescribing of generic drugs. As a result, the prices of generic pharmaceutical products in Germany have declined, impacting our revenues, and may further decline in the future. Furthermore, in 2007, the shift to a tender (i.e., competitive bidding) based supply model in Germany has led to a significant decline in the prices for our products and impacted our market opportunities in that country. Similar developments may take place in our other key markets. We cannot predict the nature of the measures that may be adopted or their impact on the marketing, pricing and demand for our products.

## European Union

The European Union enacted the European Falsified Medicines Directive (Directive 2011/62/EU) to reform the rules for importing into the European Union active substances for medicinal products for human use. As of January 2, 2013, all imported active substances must have been manufactured in compliance with standards of good manufacturing practices (GMP) at least equivalent to the GMP of the European Union. The manufacturing standards in the European Union for active substances are those of the International Conference for Harmonisation ICH Q7. The provisions of the Directive are intended to reduce the risk of counterfeit medicines entering the supply chain.

## Russia

During the fiscal year ended March 31, 2012, Russia introduced Federal Law # 323, titled "On the Foundations of Healthcare for Russian Citizens". This law imposes stringent restrictions on interactions between (i) healthcare professionals, pharmacists, healthcare management organizations, opinion leaders (both governmental and from the private sector) and certain other parties (collectively referred to as healthcare decision makers), and (ii) companies that produce or distribute drugs or medical equipment and any representatives or intermediaries acting on their behalf (collectively referred to as medical product representatives). Some of the key provisions of this law include prohibitions on:

one-on-one meetings and communications between healthcare decision makers and medical product representatives, except for participation in clinical trials, pharmacovigilance, group educational events and certain other limited exceptions;

the acceptance by a healthcare decision maker of compensation, gifts or entertainment paid by medical product representatives;

the agreement by a healthcare decision maker to prescribe or recommend drug products or medical equipment; or

the engagement by a healthcare decision maker in a conflict of interest transaction with a medical product representative, unless approved by regulators pursuant to certain specified procedures.

Although certain of the above prohibitions technically restrict only the actions of healthcare decision makers, liability for non-compliance with such restrictions nonetheless extends to both the healthcare decision maker and the medical product representative.

## Table of Contents

In March 2015, Russia enacted amendments to Article 61 of the Federal Law "On Circulation of Medicines", which amendments create new rules for the registration, manufacture and quality control of medicines, including new rules for the calculation and registration of the maximum retail prices of vital and essential medicines established by the list of Essential and Vital Drugs (also known as the ZhNVLS).

The Eurasian Economic Union ( EEU ), whose member states are Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan, officially started functioning on January 1, 2015. Among other things, the member states of the EEU signed an international agreement establishing common principles and rules of functioning of the market for medicines within the EEU, which agreement was originally expected to be made effective from January 1, 2016. For these purposes, the member states are working on the necessary regulatory framework and EEU plans for its member states to sign 25 acts governing various stages of drugs circulation. According to the agreement, the market authorization for a particular medicine received in one EEU member state will be valid throughout the whole EEU territory. This agreement, together with Russia's Priority Action Plan for sustainable economic and social stability development in 2015, is expected to have a number of impacts on pharmaceutical pricing and import substitution preferences in Russia.

## Other

Governments throughout the world heavily regulate the marketing of pharmaceutical products. Most countries also place restrictions on the manner and scope of permissible marketing to government agencies, physicians, pharmacies, hospitals and other health care professionals. In certain countries certain prescribed marketing codes or guidelines are required to be followed by the pharmaceutical companies. Although our company policies prohibit our employees and third party distributors from violating such regulations, we may not be able to completely prevent this, especially in markets that have historically been more susceptible to corruption. The effect of such regulations may be to limit the amount of revenue that we may be able to derive from a particular product. Moreover, if we or our third party distributors fail to comply fully with such regulations, then civil or criminal actions could be brought against us, which may have a material adverse effect on our reputation and our business, financial condition or results of operations.

## **We have operations in certain countries susceptible to political and economic instability that could lead to disruption or other adverse impacts upon such operations.**

We expect to derive an increasing portion of our sales from regions such as Latin America, Russia and other countries of the former Soviet Union, Central Europe, Eastern Europe and South Africa, all of which may be more susceptible to political and economic instability. For example, as a result of severe political instability and ongoing conflict in Ukraine, the United States and the European Union have imposed sanctions on certain individuals and companies in Ukraine and Russia, including sanctions targeted at the Crimea region of Ukraine which was annexed by Russia. Political instability in the region has combined with low worldwide oil prices that significantly devalued the Russian rouble and may continue to have a negative impact on the Russian economy. In addition, the Ukrainian hryvnia also experienced significant devaluation in 2014. Some of these are new markets that we have recently entered, and we may decide to enter other new markets in the future and thus may face additional risks arising out of political and economic instability.

We monitor significant political, legal and economic developments in these regions and attempt to mitigate our exposure where possible. However, mitigation is not always possible, and our international operations could be adversely affected by political, legal and economic developments, such as changes in capital and exchange controls; expropriation and other restrictive government actions; intellectual property protection and remedy laws; trade regulations; procedures and actions affecting approval, production, pricing and marketing of, reimbursement for and

access to our products; and intergovernmental disputes, including embargoes and/or military hostilities.

Significant portions of our manufacturing operations are conducted outside the markets in which our products are sold, and accordingly we often import a substantial number of products into such markets. We may, therefore, be denied access to our customers or suppliers or denied the ability to ship products from any of our sites as a result of closing of the borders of the countries in which we sell our products, or in which our operations are located, due to economic, legislative, political and military conditions, including hostilities and acts of terror, in such countries.

**From time to time we enter new markets, and face risks arising out of our limited knowledge of the market and the customs, laws and regulatory systems that may apply.**

From time to time we enter new markets in which we have limited knowledge of the market and the customs, laws, regulatory, political and social systems that may apply. Our success in these new markets is dependent upon the acceptability of our product and brand, the ease of doing business in such market and various other social and economic factors that may be



## **Table of Contents**

specific to such market. Further, limitations by the local authorities of repatriation of generated funds may pose a risk to our success in these new markets. Our sales and profit margins may be adversely affected if we fail to provide competitive options in the market or our brands fail to gain acceptability in the market.

### **Class action lawsuits could expose us to significant liabilities, result in negative publicity, harm our reputation and have a material adverse effect on the price of our ADSs.**

Shareholders of a public company sometimes bring securities class action lawsuits against the company following periods of instability in the market price of that company's securities. As a public company grows in size, the risk of such litigations may increase. If we were to be sued in any such class action suit, irrespective of the merits of the underlying case, it could have adverse effects on us, including among other things: (a) a diversion of management's time and attention and other resources from our business and operations, which could harm our results of operations; (b) negative publicity, which could harm our reputation and restrict our ability to raise capital in the future; (c) requiring us to incur significant expenses to defend the suit; and (d) if a claim against us is successful, we may be required to pay significant damages and, in certain circumstances, to indemnify our directors and officers if they are named as defendants in the class action suit. Any of the foregoing could, individually or in the aggregate, have a material adverse effect on our financial condition and results of operations and/or the price of our ADSs.

### **A relatively small group of products may represent a significant portion of our net revenues, gross profit or net earnings from time to time.**

Sales of a limited number of products may represent a significant portion of our net revenues, gross profit and net earnings. If the volume or pricing of such products declines in the future, our business, financial position and results of operations could be materially adversely affected.

### **The use of tender systems and other forms of price control could reduce prices for our products or reduce our market opportunities.**

A number of markets in which we operate have implemented or may implement tender systems in an effort to lower prices. Under such tender systems, manufacturers submit bids which establish prices for generic pharmaceutical products. Upon winning the tender, the winning company will receive a preferential reimbursement for a period of time. The tender system often results in companies underbidding one another by proposing low pricing in order to win the tender.

For example, this has resulted in more than 90% of generic products currently sold in German retail outlets being supplied through contracts procured in competitive bidding tenders, thereby causing significant pressure on product margins.

Certain other countries may consider the implementation of a tender system or other forms of price controls. Even if a tender system is ultimately not implemented, the anticipation of such could result in price reductions. Failing to win tenders, or the implementation of similar systems or other forms of price controls in other markets leading to further price declines, could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or share price.

### **If we are unable to patent new products and processes or to protect our intellectual property rights or proprietary information, or if we infringe on the patents of others, our business may be materially and adversely impacted.**

Our overall profitability depends, among other things, on our ability to continuously and timely introduce new generic as well as proprietary products. Our success depends, in part, on our ability in the future to obtain patents, protect trade secrets, intellectual property rights and other proprietary information and operate without infringing on the proprietary rights of others. Our competitors may have filed patent applications, or hold issued patents, relating to products or processes that compete with those we are developing, or their patents may impair our ability to successfully develop and commercialize new products.

Our success with our proprietary products depends, in part, on our ability to protect our current and future innovative products and to defend our intellectual property rights. If we fail to adequately protect our intellectual property, competitors may manufacture and market products similar to ours. We have been issued patents covering our innovative products and processes and have filed, and expect to continue to file, patent applications seeking to protect our newly developed technologies and products in various countries, including the United States. Any existing or future patents issued to or

## **Table of Contents**

licensed by us may not provide us with any competitive advantages for our products or may even be challenged, invalidated or circumvented by competitors. In addition, such patent rights may not prevent our competitors from developing, using or commercializing products that are similar or functionally equivalent to our products.

We also rely on trade secrets, unpatented proprietary know-how and continuing technological innovation that we seek to protect, in part by confidentiality agreements with licensees, suppliers, employees and consultants. It is possible that these agreements may be breached and we may not have adequate remedies for any such breach. Disputes may arise concerning the ownership of intellectual property or the applicability of confidentiality agreements. Furthermore, our trade secrets and proprietary technology may otherwise become known or be independently developed by our competitors. Therefore, despite all of our information security systems and practices, we may still not be able to ensure the confidentiality of information relating to such products.

### **If pharmaceutical companies are successful in limiting the use of generics through their legislative, regulatory and other efforts, sales of our generic products may be adversely impacted.**

Many pharmaceutical companies increasingly have used state and federal legislative and regulatory means to delay generic competition. These efforts have included:

pursuing new patents for existing products that may be granted just before the expiration of earlier patents, which could extend patent protection for additional years or otherwise delay the launch of generics;

introducing next-generation products prior to the expiration of market exclusivity for the reference product, which often materially reduces the demand for the generic or the reference product for which we seek regulatory approval;

obtaining extensions of market exclusivity by conducting clinical trials of brand drugs in pediatric populations or by other methods;

selling the brand product as an authorized generic, either by the brand company directly, through an affiliate or by a marketing partner;

using the Citizen Petition process to request amendments to U.S. FDA standards or otherwise delay generic drug approvals;

seeking changes to U.S. Pharmacopeia, an organization that publishes industry recognized compendia of drug standards;

attaching patent extension amendments to non-related federal legislation;

engaging in state-by-state initiatives to enact legislation that restricts the substitution of some generic drugs, which could have an impact on products that we are developing; and

seeking patents on methods of manufacturing certain active pharmaceutical ingredients.

If pharmaceutical companies or other third parties are successful in limiting the use of generic products through these or other means, our sales of generic products may decline, leading to a material adverse effect on our results of operations, financial condition and cash flows.

**If sales of authorized generic products are restricted, our sales of certain authorized generic products may suffer.**

Recently, some U.S. generic pharmaceutical companies who obtained rights to market and distribute a generic alternative of a brand product (i.e., an authorized generics arrangement) under the brand manufacturer's new drug application (NDA) have experienced challenges to their ability to distribute authorized generics during a competitor's 180-day period of abbreviated new drug application (ANDA) exclusivity under the Hatch-Waxman Act. These challenges have come in the form of Citizen Petitions filed with the U.S. FDA, lawsuits alleging violation of the antitrust and consumer protection laws, and seeking legislative intervention. For example, in February 2011, legislation was introduced in both the U.S. Senate and the U.S. House of Representatives that would have prohibited the marketing of authorized generics during the 180-day period of ANDA exclusivity under the Hatch-Waxman Act. If distribution of authorized generic versions of brand products is otherwise restricted or found unlawful, our results of operations, financial condition and cash flows could be materially adversely affected.

**If we are unable to defend ourselves in patent challenges, we could be subject to injunctions preventing us from selling our products, or we could be subject to substantial liabilities that could adversely affect our profits. Further, our patent settlement agreements with the innovators may face government scrutiny, exposing us to significant damages.**

## Table of Contents

There has been substantial patent related litigation in the pharmaceutical industry concerning the manufacture, use and sale of various products. In the normal course of business, we are regularly subject to lawsuits and the ultimate outcome of litigation could adversely affect our results of operations, financial condition and cash flow. Regardless of regulatory approval, lawsuits are periodically commenced against us with respect to alleged patent infringements by us, such suits often being triggered by our filing of an application for governmental approval, such as an ANDA or NDA. The expense of any such litigation and the resulting disruption to our business, whether or not we are successful, could harm our business. The uncertainties inherent in patent litigation make it difficult for us to predict the outcome of any such litigation.

If we are unsuccessful in defending ourselves against these suits, we could be subject to injunctions preventing us from selling our products, resulting in a decrease in revenues, or to damages, which may be substantial. An injunction or substantial damages resulting from these suits could adversely affect our consolidated financial position, results of operations or liquidity.

Further, we have been involved in various litigations involving challenges to the validity or enforceability of registered patents and therefore settling said patent litigations has been and is likely to continue to be an important part of our business. Parties to such settlement agreements in the U.S., including us, are required by law to file them with the Federal Trade Commission ( FTC ) and the Antitrust Division of the Department of Justice for review. The FTC has publicly stated that, in its view, some of the brand-generic settlement agreements violate the antitrust laws and has brought actions against some brand and generic companies that have entered into such agreements. For example, in May 2015, Teva Pharmaceutical Industries agreed to a \$1.2 billion settlement with the FTC to resolve anti-competition charges over sales of provigil, a sleep-disorder prescription drug. Accordingly, we may receive formal or informal requests from the FTC for information about a particular settlement agreement, and there is a risk that the FTC may commence an action against us alleging violations of the antitrust laws.

Such settlement agreements may further expose us to claims by purchasers of the products for unlawfully inhibiting competition.

Similarly, the European Commission has placed European operations of several brand and generic companies, under intense scrutiny in connection with its inquiry into possible anticompetitive conditions in the European pharmaceutical sector. More generally, there is a risk that the increased scrutiny of the European pharmaceutical sector may lead to changes in the regulation of our business that would have an adverse impact on our results of operations in Europe.

### **If we elect to sell a generic product prior to the final resolution of outstanding patent litigation, we could be subject to liabilities for damages.**

At times we seek approval to market generic products before the expiration of patents for those products, based upon our belief that such patents are invalid, unenforceable, or would not be infringed by our products. As a result, we are involved in patent litigation, the outcome of which could materially adversely affect our business. Based upon a complex analysis of a variety of legal and commercial factors, we may elect to market a generic product even though litigation is still pending. This could be before any court decision is rendered or while an appeal of a lower court decision is pending. To the extent we elect to proceed in this manner, if the final court decision is adverse to us, we could be required to cease the sale of the infringing products and face substantial liability for patent infringement. These damages may be significant as they may be measured by a royalty on our sales or by the profits lost by the patent owner and not by the profits we earned. Because of the discount pricing typically involved with generic pharmaceutical products, patented brand products generally realize a significantly higher profit margin than generic pharmaceutical products. In the case of a willful infringer, the definition of which is unclear, these damages may even be trebled.

Furthermore, there may be risks involved in entering into in-licensing arrangements for products, which are often conditioned upon the licensee's sharing in the patent-related risks.

For business reasons, we continue to examine such product opportunities (i.e., involving non-expired patents) going forward and this could result in patent litigation, the outcomes of which may have a material adverse effect on our results of operations, financial condition and cash flows.

**Any failure to comply with the complex reporting and payment obligations under the Medicare and Medicaid programs or other laws regulating marketing practices may result in litigation or sanctions and adversely impact our business.**

The U.S. laws and regulations regarding Medicare and/or Medicaid reimbursement and rebates and other governmental programs are complex. Some of the applicable laws may impose liability even in the absence of a specific intent to defraud.

## **Table of Contents**

The subjective decisions and complex methodologies used in making calculations under these programs are subject to review and challenge, and it is possible that such reviews could result in material changes in the calculation outcomes. In the past several years, state and federal government agencies have conducted ongoing investigations of manufacturers reporting practices with respect to a drug's average wholesale price (AWP) and wholesale acquisition cost (WAC), and in some cases have filed lawsuits in which they have alleged that reporting of inflated AWP or WACs has led to excessive payments by Medicare and/or Medicaid for prescription drugs. In addition, we are notified from time to time of governmental investigations regarding marketing practices or pricing issues. In the United States, we are currently responding to federal investigations into our marketing practices with regard to some of our products, which could result in civil litigation brought on behalf of the federal government.

Responding to such queries and any resulting investigations or lawsuits is costly and unpredictable, and involves a significant diversion of management's attention. Such allegations could, if proven or settled, result in significant monetary penalties and possible exclusion from Medicare, Medicaid and other programs. In addition, government authorities have significant leverage to persuade pharmaceutical companies to enter into corporate integrity agreements, which can be expensive and disruptive to operations.

If any of the above queries and/or investigations were to result in a lawsuit that was determined adversely to us or in a large cash settlement, it could require us to pay significant amounts and may have a material adverse effect on our business, results of operations, financial condition and cash flows.

### **Research and development efforts invested in our differentiated formulations pipeline may not achieve expected results.**

In our Proprietary Products segment, our business model focuses on building a pipeline in the therapeutic areas of neurology and dermatology. We must invest increasingly significant resources to develop differentiated products, both through our own efforts and through collaborations, in-licensing and acquisition of products from or with third parties. The development of differentiated products involves processes and expertise different from those used in the development of generic drugs, which increases the risks of failure. During each stage, we may encounter obstacles that delay the development process and increase expenses, leading to significant risks that we will not achieve our goals and may be forced to abandon a potential product in which we have invested substantial amounts of time and money. These obstacles may include: preclinical failures; difficulty enrolling patients in clinical trials; delays in completing formulation and other work needed to support an application for registration; adverse reactions or other safety concerns arising during clinical testing; insufficient clinical trial data to support the safety or efficacy of the product candidate; and failure to obtain, or delays in obtaining, the required regulatory approvals for the product candidate or the facilities in which it is manufactured.

Because of the amount of capital required to be invested in augmenting our differentiated products pipeline, in some cases we are reliant on partnerships and joint ventures with third parties, and consequently face the risk that some of these third parties may fail to perform their obligations, or fail to reach the levels of success that we are relying on to meet our revenue and profit goals. Accordingly, our investment in research and development of innovative products can involve significant costs with no assurances of future revenues or profits.

### **Our Proprietary Products segment, particularly our Specialty businesses in the United States, faces intense competition from companies that are more entrenched than we are or have greater resources than ours.**

Our risk profile for our Proprietary Products segment is lower than the comparable risk profile of companies working with completely novel entities. Nevertheless, the exposure that the businesses in this segment face is higher than that of the Generics business due to several factors outlined below.

Market penetration requires successful commercial positioning in relation not only to past therapies but also new competitors. All of the therapeutic areas in which we compete have many active competitors, each vying for market share in similar indications with products that may have some similar attributes. As such, success in our Proprietary Products segment requires the ability to strategically differentiate our offerings from those of our competitors, which often requires time and investment in additional clinical studies, and brings with it the typical uncertainty of outcome that faces many clinical studies. An additional emerging challenge is access to physicians, who can explicitly refuse to see our sales representatives, and new approaches need to be found to provide them with the information required in order to make informed and appropriate prescription decisions. While the impact of these challenges is currently limited, they could potentially become significant in the future.

Even if we are able to successfully differentiate our products, adequate reimbursement from third party payors for our products is necessary. Typically, a managed care plan relies on a committee made up of physicians and others to decide which drugs will appear on its formulary. Without a reasonable position on the formulary of managed care plans, patients will not be



## **Table of Contents**

able to obtain access to our products. Further, even after we contract for access on managed care formularies, we often have to provide additional point-of-sale discounts to patients in order to make their out-of-pocket payments affordable. All of these are necessary in this business segment, as all managed care plans attempt to aggressively direct their patients towards generic medicines.

Additionally, because the Specialty business of our Proprietary Products segment works primary with reformulated drugs, another risk is that the patents that protect the product are easier to engineer around than traditional composition of matter patents. While every attempt is made to create a robust intellectual property ring fence around these assets, the products in our U.S. Specialty business portfolio may enjoy lesser exclusivity periods than traditional innovative products.

### **If we fail to comply with environmental laws and regulations, or face environmental litigation, our costs may increase or our revenues may decrease.**

We may incur substantial costs complying with requirements of environmental laws and regulations. In addition, we may discover currently unknown environmental problems or conditions. In all countries where we have production facilities, we are subject to significant environmental laws and regulations that govern the discharge, emission, storage, handling and disposal of a variety of substances that may be used in or result from our operations. In the normal course of our business, we are exposed to risks relating to possible releases of hazardous substances into the environment, which could cause environmental or property damage or personal injuries, and that could require remediation of contaminated soil and groundwater, which could cause us to incur substantial remediation costs that could adversely affect our consolidated financial position, results of operations or liquidity.

If any of our plants or the operations of such plants are shut down, it may severely hamper our ability to supply our customers and we may continue to incur costs in complying with regulations, appealing any decision to close our facilities, maintaining production at our existing facilities and continuing to pay labor and other costs, which may continue even if the facility is closed. As a result, our overall operating expenses may increase and our profits may decrease significantly.

### **If we are sued by consumers for defects in our products, it could harm our reputation and thus our profits.**

Our business inherently exposes us to potential product liability claims, and the severity and timing of such claims are unpredictable. Notwithstanding pre-clinical and clinical trials conducted during the development of potential products to determine the safety and efficacy of products for use by humans following approval by regulatory authorities, unanticipated side effects may become evident only when drugs and bio-similars are introduced into the marketplace. Due to this fact, our customers and participants in clinical trials may bring lawsuits against us for alleged product defects. In other instances, third parties may perform analyses of published clinical trial results which raise questions regarding the safety of pharmaceutical products, and which may be publicized by the media. Even if such reports are inaccurate or misleading, in whole or in part, they may nonetheless result in claims against us for alleged product defects.

Under the current regulatory scheme in the United States, branded drug manufacturers can independently update product labeling through the changes being effected ( CBE ) supplement process, but a generic manufacturer is only permitted to use the CBE process to update its label if the branded drug manufacturer changes its label first. This can prevent generic manufacturers from complying with state law warning requirements and, as a result, state product liability suits based on failure-to-warn and design defect claims against generics manufacturers have generally been determined to be preempted by Federal law.

Following the United States Supreme Court's June 2013 ruling in *Mutual Pharmaceutical Co. v. Bartlett* upholding such preemption and immunity of generic manufacturers, the U.S. FDA proposed a new rule in November 2013 that would allow generic manufacturers to independently update product labeling through the CBE supplement process. If the U.S. FDA's proposed new rule is adopted, it may eliminate this preemption and increase our potential exposure to lawsuits relating to product safety, side effects and warnings on labels. This new potential exposure to lawsuits may also increase the risk that, in the future, we may not be able to obtain the type and amount of coverage we desire at an acceptable price and self-insurance may become the sole commercially reasonable means available for managing the product liability risks of our business.

Additionally, the proposed rule is likely to increase management and operating costs as a result of the need to set up database and software systems to monitor and track changes made, revisit internal processes regarding product label changes by regulatory teams, enable signal detection by pharmacovigilance and make changes in packaging and logistics involving our supply chain teams. Any failure to do this adequately can lead to an increase in our potential exposure to product liability claims and litigation. The U.S. FDA has announced that it will issue a final rule in April 2017.

## **Table of Contents**

The risk of exposure to lawsuits is likely to increase as we develop our own new patented products, or limited competition/complex products, such as injectables or biosimilars, in addition to making generic versions of drugs that have been in the market for some time. In addition, the existence or even threat of a major product liability claim could also damage our reputation and affect consumers' views of our other products, thereby negatively affecting our business, financial condition and results of operations.

### **There has been a trend of increased regulatory review of over-the-counter products for safety and efficacy questions, which could potentially affect our over-the-counter products business.**

In recent years, significant questions have arisen regarding the safety, efficacy and potential for misuse of certain over-the-counter medicine products. Litigation, particularly in the United States, sometimes gives rise to these questions. As a result, health authorities around the world have begun to re-evaluate some important over-the-counter products, leading to restrictions on the sale of some of them and even the banning of certain products. For example, in 2010, the U.S. FDA undertook a review of one cough medicine ingredient to consider whether over-the-counter sales of the ingredient remained appropriate. While the U.S. FDA has not, to date, changed the ingredient's status, further regulatory or legislative action may follow. Additional actions and litigation regarding over-the-counter products are possible in the future. If the U.S. FDA or another regulator were to review one or more of our over-the-counter products for such purposes, and if such review resulted in the U.S. FDA or another regulator charging us with violations applicable to such product, it could have a significant adverse effect on our sales of such over-the-counter products and, thus, our overall profitability.

### **If we have difficulty in identifying candidates for or consummating acquisitions and strategic alliances, our competitiveness and our growth prospects may be harmed.**

In order to enhance our business, we frequently seek to acquire or make strategic investments in complementary businesses or products, or to enter into strategic partnerships or alliances with third parties. It is possible that we may not identify suitable acquisition, strategic investment or strategic partnership candidates, or if we do identify suitable candidates, we may not complete those transactions on terms commercially acceptable to us. We compete with others to acquire companies, and we believe that this competition has intensified and may result in decreased availability or increased prices for suitable acquisition candidates. Even after we identify acquisition candidates and/or announce that we plan to acquire a company, we may ultimately fail to consummate the acquisition. For example, we may be unable to obtain necessary regulatory approvals, including the approval of antitrust regulatory bodies.

All acquisitions involve known and unknown risks that could adversely affect our future revenues and operating results. For example:

We may fail to successfully integrate our acquisitions in accordance with our business strategy.

The initial rationale for the acquisition may not remain viable due to a variety of factors, including unforeseen regulatory changes and market dynamics after the acquisition, and this may result in a significant delay and/or reduction in the profitability of the acquisition.

We may not be able to retain the skilled employees and experienced management that may be necessary to operate the businesses we acquire. If we cannot retain such personnel, we may not be

able to locate or hire new skilled employees and experienced management to replace them.

We may purchase a company that has contingent liabilities that include, among others, known or unknown patent or product liability claims or environmental liability claims.

We may purchase companies located in jurisdictions where we do not have operations and as a result we may not be able to anticipate local regulations and the impact such regulations have on our business.

In addition, if we make one or more significant acquisitions in which the consideration includes equity shares or other securities, our equity shares may be significantly diluted and may result in a reduction of earnings per equity share. If we make one or more significant acquisitions in which the consideration includes cash, we may be required to use a substantial portion of our available cash or incur a significant amount of debt or otherwise arrange additional funds to complete the

## **Table of Contents**

acquisition, which may result in a decrease in our net income and a consequential reduction in our earnings per equity share. Also, an increasing proportion of our alliances begin with research and development. Our results of operations may suffer if existing joint venture or collaboration partners withdraw, or if these products are not timely developed, approved or successfully commercialized. We cannot guarantee the successful outcome of such efforts, nor that they will result in any intellectual property rights or products that inure to our benefit.

**If, as we expand into new international markets, we fail to adequately understand and comply with the local laws and customs, these operations may incur losses or otherwise adversely affect our business and results of operations.**

Currently, we operate our business in certain countries through subsidiaries, joint ventures and equity investees or through supply and marketing arrangements with our alliance partners. In those countries where we have limited experience in operating subsidiaries and joint ventures and in reviewing equity investees, we are subject to additional risks related to complying with a wide variety of national and local laws, including restrictions on the import and export of certain intermediates, drugs and technologies. There may also be multiple, and possibly overlapping, tax structures. In addition, we may face competition in certain countries from companies that may have more experience with operations in such countries. We may also face difficulties integrating new facilities in different countries into our existing operations, as well as integrating employees that we hire in different countries into our existing corporate culture. If we do not effectively manage our operations in these subsidiaries and joint ventures and review equity investees effectively, or if we fail to manage our alliances, we may lose money in these countries and it may adversely affect our business and results of operations.

**If we improperly handle any of the dangerous materials used in our business and accidents result, we could face significant liabilities that would lower our profits.**

We handle dangerous materials including explosive, toxic and combustible materials such as acetyl chloride. If improperly handled or subjected to the wrong conditions, these materials could hurt our employees and other persons, cause damage to our properties and harm the environment. Also, increases in business and operations in our plants, and the consequent hiring of new employees, can pose increased safety hazards. Such hazards need to be addressed through training, industrial hygiene assessments and other safety measures and, if not carried out, can lead to industrial accidents. Any of the foregoing could subject us to significant litigation or adversely impact our other litigation matters then outstanding, which could lower our profits in the event we were found liable, and could also adversely impact our reputation. In a worst case scenario, this could also result in a government forced shutdown of our manufacturing plants, which in turn could lead to product shortages that delay or prevent us from fulfilling our obligations to customers and would harm our business and financial results.

**If there is delay and/or failure in supplies of materials, services and finished goods from third parties or failure of finished goods from our key manufacturing sites, it may adversely affect our business and results of operations.**

In some of our businesses, we rely on third parties for the timely supply of active pharmaceutical ingredients ( API ), specified raw materials, equipment, formulation or packaging services and maintenance services, and in some cases there could be a single source of supply. Although, we actively manage these third party relationships to ensure continuity of supplies and services on time and to our required specifications, events beyond our control could result in the complete or partial failure of supplies and services or in supplies and services not being delivered on time.

In the event that we experience a shortage in our supply of raw materials, we might be unable to fulfill all of the API needs of our Global Generics segment, which could result in a loss of production capacity for this segment. Moreover,

we may continue to be dependent on vendors, strategic partners and alliance partners for supplies of some of our existing products and new generic launches. Any unanticipated capacity or supply related constraints affecting such vendors, strategic partners or alliance partners can adversely affect our business or results of operations. Our key generics manufacturing sites also may have capacity constraints and, at times, we may not be able to generate sufficient supplies of finished goods.

If any of the foregoing delays or prevents us from timely delivery of our products to our customers, our relationships with the adversely affected customers could be harmed and we could be subject to contractually imposed financial penalties and/or lawsuits, any of which may adversely affect our business or results of operations.

**Fluctuations in exchange rates and interest rate movements may adversely affect our business and results of operations.**

A significant portion of our revenues are in currencies other than the Indian rupee, especially the U.S. dollar, the Euro, the Russian rouble, Venezuelan bolivar and the U.K. pound sterling, while a significant portion of our costs are in Indian rupees.

## Table of Contents

As a result, if the value of the Indian rupee appreciates relative to these other currencies, our revenues measured in Indian rupees may decrease and our financial performance may be adversely impacted. This also exposes us to additional risks in the event of devaluations, hyperinflation or restrictions on the conversion of foreign currencies, such as the devaluation of the Venezuelan bolivar that occurred in March 2016, as described below.

In February, 2016, the Venezuelan government announced changes to its foreign currency exchange mechanisms, including the devaluation of its official exchange rate. The following changes became effective as of March 10, 2016:

The CENCOEX preferential rate was replaced with a new DIPRO rate. The DIPRO rate is only available for purchases and sales of essential items such as food and medicine. Further, the preferential exchange rate was devalued from 6.3 VEF per U.S.\$1.00 to 10 VEF per U.S.\$1.00;

The SICAD exchange rate mechanism, which last auctioned U.S. Dollars for approximately 13 VEF per U.S.\$1.00, was eliminated; and

The SIMADI exchange rate mechanism was replaced with a new DICOM rate, which governs all transactions not subject to the DIPRO exchange rate and will fluctuate according to market supply and demand. As of March 31, 2016, the DICOM exchange rate was 272.5 VEF per U.S.\$1.00.

We have not yet received approvals from the Venezuelan government to repatriate any amount at preferential rates beyond the U.S.\$4 million already approved and received during the year ended March 31, 2016. We believe that in the interim, it is appropriate to use the DICOM rate (i.e., 272.5 VEF per U.S.\$1.00) instead of the preferential rate of VEF 10 per U.S.\$1.00 for translating the monetary assets and liabilities of our Venezuelan subsidiary as at March 31, 2016. Accordingly, we recorded foreign exchange loss of Rs.4,621 million in the consolidated income statement during the year ended March 31, 2016. Notwithstanding the ongoing uncertainty, we continue to actively engage with the Venezuelan Government and seek approval to repatriate funds at preferential rates so that we may continue to provide affordable medicine to fulfill the needs of people of their country.

Further, we may also be exposed to credit risks in some of the emerging markets from our customers on account of adverse economic conditions.

We use derivative financial instruments to manage some of our net exposure to currency exchange rate fluctuations in the major foreign currencies in which we operate. We do not use derivative financial instruments or other hedging techniques to cover all of our potential exposure. Therefore, we are subjected to exchange rate fluctuations that could significantly affect our financial results.

In the recent past and particularly since March 2013, the Indian rupee exchange rates as compared to the U.S. dollar have been highly volatile. In the year ended March 31, 2016, the Indian rupee depreciated by approximately 7% against the U.S. dollar. Such depreciation of the Indian rupee against the U.S. dollar has had positive benefits to our financial results. However, the Russian rouble and Euro depreciated by approximately 27% and 7%, respectively, against the Indian rupee during the year ended March 31, 2016. Such depreciation of foreign currencies has caused, and further depreciation in the future will cause, our foreign currency revenues as measured in Indian rupees to decrease, and thus adversely affect our financial results.

**Our success depends on our ability to retain and attract key qualified personnel and, if we are not able to retain them or recruit additional qualified personnel, we may be unable to successfully develop our business.**

We are highly dependent on the principal members of our management and scientific staff, the loss of whose services might significantly delay or prevent the achievement of our business or scientific objectives. In India, it is not our practice to enter into employment agreements with our executive officers and key employees that are as extensive as are generally used in the United States, and each of those executive officers and key employees may terminate their employment upon notice and without cause or good reason. Currently, we are not aware of any executive officer's or key employee's departure that has had, or planned departure that is expected to have, any material impact on our operations. Competition among pharmaceutical companies for qualified employees is intense, and the ability to retain and attract qualified individuals is critical to our success. There can be no assurance that we will be able to retain and attract such individuals currently or in the future on acceptable terms, or at all, and the failure to do so would have a material adverse effect on our business, financial condition and results of operations. In addition, we do not maintain key person life insurance on any officer, employee or consultant.



## **Table of Contents**

### **We have concentrations of sales to certain customers that increases our credit risks. Consolidation among distributors and pharmaceutical companies could increase this risk, and also adversely impact our business prospects.**

In the United States, similar to other pharmaceutical companies, we sell our products through wholesale distributors and large retail chains in addition to hospitals, pharmacies and other groups. During the year ended March 31, 2016, our ten largest customers accounted for approximately 85% of our North America Global Generics segment's revenues. We are exposed to a concentration of credit risk in respect of these customers such that if one or more are affected by financial difficulty, it could materially and adversely affect our financial results. If the recent trend of consolidation among distributors continues, this risk may increase.

Furthermore, the recent trend of consolidation among distributors and pharmaceutical companies, both innovator and generic companies, could have an adverse impact on our business prospects as well as our customers' choices and preferences. There has been increased concern by pharmaceutical companies and their investors and other stakeholders over geographic and customer concentration risks, as well as the implementation of counter-measures and risk mitigation strategies. Some of our key risk mitigation strategies, such as key account management and locking up customer relationships, are likely to be at risk from such consolidations. If our response to these changes is not adequate and timely, our growth prospects and business can be adversely impacted.

### **Counterfeit versions of our products could harm our patients and reputation.**

Our industry has been increasingly challenged by the vulnerability of distribution channels to illegal counterfeiting and the presence of counterfeit products in a growing number of markets and over the Internet. Third parties may illegally distribute and sell counterfeit versions of our products, which do not meet the rigorous manufacturing and testing standards that our products undergo. Counterfeit products are frequently unsafe or ineffective, and can be potentially life-threatening. Counterfeit medicines may contain harmful substances, the wrong dose of the API or no API at all. However, to distributors and patients, counterfeit products may be visually indistinguishable from the authentic version.

Reports of adverse reactions to counterfeit drugs or increased levels of counterfeiting could materially affect patient confidence in the authentic product, and harm the business of companies such as ours. Additionally, it is possible that adverse events caused by unsafe counterfeit products would mistakenly be attributed to the authentic product. In addition, there could be thefts of inventory at warehouses, plants or while in-transit, which are not properly stored and which are sold through unauthorized channels. Public loss of confidence in the integrity of pharmaceutical products as a result of counterfeiting or theft could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our equity shares and ADSs to decline.

### **Significant disruptions of information technology systems or breaches of data security could adversely affect our business.**

Our business is dependent upon increasingly complex and interdependent information technology systems, including Internet-based systems, to support business processes as well as internal and external communications. In addition, our businesses and operating models increasingly depend on outsourcing and collaboration, which requires exchanging data and information. The size and complexity and interconnectivity of our computer systems make them potentially vulnerable to breakdown, malicious intrusion and computer viruses. Any such disruption may result in the loss of key information and/or disruption of production and business processes, which could materially and adversely affect our business.

In addition, our systems are potentially vulnerable to data security breaches, whether by employees or others, that may expose sensitive data to unauthorized persons. Such data security breaches could lead to the loss of trade secrets or other intellectual property, or could lead to the public exposure of personal information (including sensitive personal information) of our employees, clinical trial patients, customers and others. Such breaches of security could result in reputational damage and could otherwise have a material adverse effect on our business, financial condition and results of operations. Further, increasing use of information technology ( IT ) systems in manufacturing processes would require us to manage issues arising out of human error and/or sabotage.

In our pursuit of operational excellence, several change management initiatives across our organization are currently in progress, including but not limited to information technology automation in the areas of manufacturing, research and development, supply chain and shared services. We have outsourced our IT hardware and applications in order to improve IT capability and performance. Any failure by such outsourced service providers to deliver timely and quality services and to

## **Table of Contents**

co-operate with one another could create disruption, which could materially adversely affect our business or results of operations. Further, any failure by us to effectively manage such change initiatives or implement adequate controls in automation, security or availability of information technology systems could have a material adverse effects on our business.

Increased outsourcing or use of cloud services for conducting our business requires highly secure controls to ensure adequate security of information, considering potential for sabotage as well as availability. Data integrity, confidentiality and data privacy requirements are increasingly concerning regulators, and are incorporated into legal contracts. While we have invested heavily in the protection of data and information technology to reduce these risks, there can be no assurance that our efforts or those of our third-party service providers would be sufficient to protect against data deterioration or loss in the event of a system malfunction, or prevent data from being stolen or corrupted in the event of a security breach. We currently do not have any insurance that could mitigate the impact from all such risks.

### **Increasing use of social media could give rise to liability or breaches of data security.**

We and our business associates are increasingly relying on social media tools as a means of communications. To the extent that we seek as a company to use these tools as a means to communicate about our products or about the diseases our products are intended to treat, there are significant uncertainties as to either the rules that apply to such communications, or as to the interpretations that health authorities will apply to the rules that exist. As a result, despite our efforts to comply with applicable rules, there is a significant risk that our use of social media for such purposes may cause us to nonetheless be found in violation of them. In addition, because of the universal availability of social media tools, our associates may make use of them in ways that may not be sanctioned by us, and that may give rise to liability, or that could lead to the loss of trade secrets or other intellectual property, or could lead to the public exposure of personal information (including sensitive personal information) of our employees, clinical trial patients, customers and others. In either case, such uses of social media could have a material adverse effect on our business, financial condition and results of operations.

### **Compliance with new and changing corporate governance and public disclosure requirements adds uncertainty to our compliance policies and increases our costs of compliance.**

Changing laws, regulations and standards relating to accounting, corporate governance and public disclosure, including the Sarbanes Oxley Act of 2002, new SEC regulations, New York Stock Exchange rules, provisions of India's Companies Act 2013, Securities and Exchange Board of India rules and Indian stock market listing regulations, create uncertainty for our company. These new or changed laws, regulations and standards may lack specificity and are subject to varying interpretations. Their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs of compliance as a result of ongoing revisions to such governance standards.

In particular, continuing compliance with Section 404 of the Sarbanes-Oxley Act of 2002 and the related regulations regarding our required assessment of our internal control over financial reporting requires the commitment of significant financial and managerial resources and our independent auditor's independent assessment of the internal control over financial reporting. Further, India's Companies Act 2013 requires companies listed in India to be compliant with provisions concerning Internal Financial Controls.

In connection with this Annual Report on Form 20-F for the year ended March 31, 2016, our management conducted an assessment of the effectiveness of our internal controls over financial reporting as of March 31, 2016 based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring

Organizations of the Treadway Commission (the COSO Framework ). Based on this assessment, our management has concluded that our internal controls over financial reporting were effective as of March 31, 2016. As we continue to undertake management assessments of our internal control over financial reporting in connection with annual reports on Form 20-F for future years, any deficiencies uncovered by these assessments or any inability of our auditors to issue an unqualified opinion could harm our reputation and result in a loss of investor confidence in the reliability of our financial statements, which could cause the price of our equity shares and ADSs to decline.

We are committed to maintaining high standards of corporate governance and public disclosure, and our efforts to comply with evolving laws, regulations and standards in this regard have resulted in, and are likely to continue to result in, increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance activities. In addition, the new laws, regulations and standards regarding corporate governance may make it more difficult for us to obtain director and officer liability insurance. Further, our board members, chief executive

## **Table of Contents**

officer and chief financial officer could face an increased risk of personal liability in connection with the performance of their duties. As a result, we may face difficulties attracting and retaining qualified board members and executive officers, which could harm our business. If we fail to comply with new or changed laws or regulations and standards differ, our business and reputation may be harmed.

### **We are subject to the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws, which impose restrictions and may carry substantial penalties.**

The U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to officials for the purpose of obtaining or retaining business. These laws may require not only accurate books and records, but also sufficient controls, policies and processes to ensure business is conducted without the influence of bribery and corruption. Our policies mandate compliance with these anti-bribery laws, which often carry substantial penalties including fines, criminal prosecution and potential debarment from public procurement contracts. Failure to comply may also result in reputational damages.

We operate in certain jurisdictions that experience governmental corruption to some degree or are found to be low on the Transparency International Corruption Perceptions Index and, in some circumstances, anti-bribery laws may conflict with some local customs and practices. In many less-developed markets, we work with third-party distributors and other agents for the marketing and distribution of our products. Although our policies prohibit these third parties from making improper payments or otherwise violating these anti-bribery laws, any lapses in complying with such anti-bribery laws by these third parties may adversely impact us. Business activities in many of these markets have historically been more susceptible to corruption. If our efforts to screen third-party agents and detect cases of potential misconduct fail, we could be held responsible for the noncompliance of these third parties under applicable laws and regulations, including the U.S. Foreign Corrupt Practices Act.

Compliance with the U.S. Foreign Corrupt Practices Act and other anti-bribery laws has been subject to increasing focus and activity by regulatory authorities in recent years. We may be subject to injunctions or limitations on future conduct, be required to modify our business practices and compliance programs and/or have a compliance monitor imposed on us, or suffer other criminal or civil penalties or adverse impacts, including lawsuits by private litigants or investigations and fines imposed by local authorities.

We need to constantly review and update our compliance program to keep it current and active. If we fail to do so, our vulnerabilities may increase and our controls may be found to be inadequate.

Actions by our employees, or third-party intermediaries acting on our behalf, in violation of such laws, whether carried out in the United States or elsewhere, may expose us to liability for violations of such anti-bribery laws and accordingly may have a material adverse effect on our reputation and our business, financial condition or results of operations.

### **Our success depends on our ability to successfully develop and commercialize new pharmaceutical products.**

Our future results of operations depend, to a significant degree, upon our ability to successfully develop and commercialize additional products in our Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products segments. We must develop, test and manufacture generic products as well as prove that our generic products are bio-equivalent or bio-similar to their branded counterparts, either directly or in partnership with contract research organizations. The development and commercialization process, particularly with respect to proprietary products and biosimilars, is both time consuming and costly and involves a high degree of business risk.

Our products currently under development, if and when fully developed and tested, may not perform as we expect or meet our standards of safety and efficacy. Necessary regulatory approvals may not be obtained in a timely manner, if at all, and we may not be able to successfully and profitably produce and market such products. Our approved products may not achieve expected levels of market acceptance.

Our research and development efforts are increasingly dependent on collaborating with third party partners and contract research organizations which have the capability to handle complex technologies and products. Lack of effective project management at our end, or any failure to manage collaboration arrangements among multiple partners, may pose significant risks to product development, to our ability to obtain requisite regulatory approvals in a timely manner, and to our ability to successfully and profitably produce and market such products. Additionally, if we fail to adequately protect critical proprietary or confidential information or associated intellectual property rights or fail to manage third party partners and contract research organizations that our business depends on, it might have a material adverse impact on our product development execution.

## **Table of Contents**

**We have grown at a very rapid pace. Our inability to properly manage or support this growth may have a material adverse effect on our business.**

We have grown very rapidly over the past few years. This growth has significantly increased demands on our processes, systems and people. We have been making additional investments in personnel, systems and internal control processes to help manage our growth. Attracting, retaining and motivating key employees in various departments and locations to support our growth is critical to our business, and competition for these people can be intense.

To facilitate our growth, we are carrying out reorganizations and deploying initiatives to improve our focus on delivery, to build decisive competitive advantages or/and to build sustainable cost structures. There is also an increasing need to manage information and asset related security.

If we are unable to hire and retain qualified employees, or if we do not invest in systems and processes to manage and support our rapid growth, the failure to do so may have a material adverse effect on our business, financial condition and results of operations.

**Fluctuations in our quarterly revenues, operating results and cash flows may adversely affect the trading price of our shares and ADSs.**

Our quarterly revenues, operating results and cash flows have fluctuated significantly in the past and may fluctuate substantially from quarter to quarter in the future. Such fluctuations result from a variety of factors, including but not limited to changes in demand for our products, timing of regulatory approvals and of launches of new products by us and our competitors (particularly where we obtain the 180-day period of market exclusivity in the United States provided under the Hatch-Waxman Act of 1984), timing of our retailers' promotional programs and successful development and commercialization of limited competition and complex products. Such fluctuations may result in volatility in the price of our equity shares and our ADSs. In such an event, the trading price of our shares and ADSs may be adversely affected.

**Impairment charges or write downs in our books could have a significant adverse effect on our results of operations and financial results.**

A substantial portion of the value of our assets pertains to various intangible assets and goodwill. The proportion of the intangible assets and goodwill to our total assets could increase significantly as we pursue various growth strategies. The value of these intangible assets and goodwill could be substantially impaired upon indications of impairment, with adverse effects on our financial condition and the value of our assets. For example, our financial performance for the years ended March 31, 2009 and 2010 was significantly impacted as a result of the impairments pertaining to our Germany operations.

**There are inherent uncertainties involved in estimates, judgments and assumptions used in the preparation of financial statements in accordance with IFRS. Any future changes in estimates, judgments and assumptions used or necessary revisions to prior estimates, judgments or assumptions or changes in accounting standards could lead to a restatement or revision to previously issued financial statements.**

The consolidated financial statements included in the periodic reports we file with the SEC are prepared in accordance with IFRS. The preparation of financial statements in accordance with IFRS involves making estimates, judgments and assumptions in areas such as valuation of inventories, sales returns, rebates and chargebacks provisions, determination of useful life of property, plant and equipment and intangible assets, assets and obligations relating to

employee benefits, business combinations and contingencies. Estimates, judgments and assumptions are inherently subject to change in the future and any necessary revisions to prior estimates, judgments or assumptions could lead to a restatement. Furthermore, although we have recorded reserves for litigation related contingencies based on estimates of probable future costs, such litigation related contingencies could result in substantial further costs. Also, any new or revised accounting standards may require adjustments to previously issued financial statements. Any such changes could result in corresponding changes to the amounts of liabilities, revenues, expenses and income. Any such changes could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or share price.



---

**Table of Contents**

**There are risks associated with executing on our strategy.**

There are risks associated with executing the strategies we adopt to achieve our core purpose as discussed in Item 4.B. below. Significant execution risks associated with our strategies include, but are not limited to:

developing and executing our complex product development, manufacturing and marketing strategies for North America and other key markets;

executing on our strategies for increasing our customer share and for key account management in our Active Pharmaceutical Ingredients ( API ) and Custom Pharmaceutical Services ( CPS ) businesses; and

executing our execution excellence and change management initiatives to ensure process safety, product quality and availability.

**Changes in Indian tax regulations may increase our tax liabilities and thus adversely affect our financial results.**

Currently, we are entitled to various tax benefits and exemptions under Indian tax laws, such as tax benefits on research and development spending and exemptions applicable to income derived from manufacturing facilities located in certain tax exempted zones. Any changes in these laws or their application may increase our tax liability and thus adversely affect our financial results.

The Union Budget, 2016 has proposed that the weighted deduction on research and development activities be reduced in a phased manner from 200% to 150% commencing April 1, 2017 and from 150% to 100% commencing April 1, 2020. Further, Special Economic Zone ( SEZ ) units commencing manufacture or production of article and things after April 1, 2020 will not be eligible for SEZ tax deductions.

India's Finance Act, 2015 amended the test of residence for foreign companies. While a non-resident company is generally taxed only on its Indian sourced income, a resident company is taxed on its global income. Under the amended rule, a company not formed under the laws of India would be considered a resident in India if its place of effective management in the previous year was in India. The term place of effective management (or PoEM) has been defined to mean a place where key management and commercial decisions that are necessary for the conduct of the business of an entity as a whole are in substance made. It is expected that final rules providing guidance on the interpretation and application of PoEM will be issued during the year ended March 31, 2017.

In India's Finance Act, 2012, the Government of India introduced a levy of service tax based on a negative list of services. Consequently, all services have become taxable, except notified exempted services. The Finance Act, 2015 increased the rate of service tax from 12.36% (inclusive of surcharge and cess) to a consolidated rate of 14% effective as of June 1, 2015. Furthermore, effective November 2015, the service tax of 14% was increased by an additional 0.5% cess called the Swatch Bharat Cess to a consolidated rate of 14.50%. Effective June 1, 2016, the Finance Act 2016 further increased the service tax rate to 15% through introduction of another 0.5% cess called the Krishi Kalyan Cess.

Further, the Union Budget, 2015 proposed to implement Goods and Service Tax ( GST ) from April 1, 2016. GST will put in place a state-of-the-art indirect tax system which will integrate State economies and boost overall growth. It is

proposed to subsume other taxes (such as central excise duty, service tax, octroi, value added tax, sales tax, and entry tax) into GST, thus avoiding the multiple layers of taxation that currently exist in India. A Constitution amendment bill approving the GST was approved by India's lower house of the Parliament (i.e. Lok Sabha) on May 6, 2015. This Constitution amendment bill is currently pending in the Upper house of the Parliament (i.e. Rajya Sabha), but it is expected that a number of issues (such as the elimination of a controversial proposed 1% additional tax and the introduction of a cap on the maximum GST rate) will need to be resolved before this Constitution amendment bill is likely to be finalized and approved.

Under the Finance Act, 2013, the effective rate of dividend distribution tax ( DDT ) was 16.995% inclusive of surcharge and cess. The Finance Act (No 2) 2014 made an amendment in section 115-O, which requires grossing up of the dividend amount distributed for computing DDT. Pursuant to the amendment, effective October 1, 2014, the effective rate of DDT increased from 16.995% to 19.994% inclusive of surcharge and cess, and as a result, dividend amounts receivable by our shareholders after taxes are reduced. Furthermore, as a result of the increase in rate of surcharge in the Finance Act, 2015, effective April 1, 2015, the effective rate of DDT increased from 19.994% to 20.3576%. If the effective rate of dividend distribution tax increases in the future, the dividend amount receivable by our shareholders after taxes may decrease further.

**We operate in jurisdictions that impose transfer pricing and other tax-related regulations on our intercompany arrangements, and any failure to comply could materially and adversely affect our profitability.**

## **Table of Contents**

We are required to comply with various transfer pricing regulations in India and other countries. Failure to comply with such regulations may impact our effective tax rates and consequently affect our net margins. Additionally, we operate in numerous countries and our failure to comply with the local and municipal tax regimes may result in additional taxes, penalties and enforcement actions from such authorities. Although our intercompany arrangements are based on accepted tax standards, tax authorities in various jurisdictions may disagree with and subsequently challenge the amount of profits taxed in such jurisdictions, which may increase our tax liabilities and could have a material adverse effect on the results of our operations. Further, the base erosion and profit shifting ( BEPS ) project undertaken by the Organization for Economic Cooperation and Development ( OECD ) contemplates changes to numerous international tax principles, as well as national tax incentives. It is hard to predict how the principles and recommendations developed by the OECD in the BEPS project will translate into specific national laws adversely impacting our tax liabilities, and therefore we cannot predict at this stage the magnitude of the effect of such rules on our financial results.

### **We enter into various agreements in the normal course of business which periodically incorporate provisions whereby we indemnify the other party to the agreement.**

In the normal course of business, we periodically enter into agreements with vendors, customers, alliance partners, innovators and others that incorporate terms for indemnification provisions. Our indemnification obligations under such agreements may be unlimited in duration and amount. We maintain insurance coverage that we believe will effectively mitigate our obligations under certain of these indemnification provisions (for example, in the case of outsourced clinical trials). However, should our obligations under an indemnification provision exceed our coverage or should coverage be denied, it could have a material adverse impact on our business, financial position and results of operations.

### **Current economic conditions may adversely affect our industry, financial position and results of operations.**

In recent years, the global economy has experienced volatility and an unfavorable economic environment, and these trends may continue in the future. Reduced consumer spending, reduced funding for national social security systems or shifting concentrations of payors and their preferences, may force our competitors and us to reduce prices. The growth of our business may be negatively affected by high unemployment levels and increases in co-pays, which may lead some patients to delay treatments, skip doses or use less effective treatments to reduce their costs. We have exposure to many different industries and counterparties, including our partners under our alliance, research and promotional services agreements, suppliers of raw materials, drug wholesalers and other customers, who may be unstable or may become unstable in the current economic environment. We run the risk of delayed payments or even non-payment by our customers, which consist principally of wholesalers, distributors, pharmacies, hospitals, clinics and government agencies.

Significant changes and volatility in the consumer environment and in the competitive landscape may make it increasingly difficult for us to predict our future revenues and earnings.

### **Risks from disruption to production, supply chain or operations from natural disasters could adversely affect our business and operations and cause our revenues to decline.**

If flooding, droughts, earthquakes, volcanic eruptions or other natural disasters were to directly damage, destroy or disrupt our manufacturing facilities, it could disrupt our operations, delay new production and shipments of existing inventory or result in costly repairs, replacements or other costs, all of which would negatively impact our business. A significant portion of our manufacturing facilities are situated around Hyderabad, India, a region that has experienced earthquakes, floods and droughts in the past.

Even if we take precautions to provide back-up support in the event of such a natural disaster, the disaster may nonetheless affect our facilities, harming production and ultimately our business. And, even if our manufacturing facilities are not directly damaged, a large natural disaster may result in disruptions in distribution channels or supply chains. The impact of such occurrences depends on the specific geographic circumstances but could be significant.

In addition, there is increasing concern that climate change is occurring and may have dramatic effects on human activity without aggressive remediation steps. A modest change in temperature may cause a rising number of natural disasters. We cannot predict the economic impact, if any, of natural disasters or climate change.

---

**Table of Contents**

**If the world economy is affected due to terrorism, wars or epidemics, it may adversely affect our business and results of operations.**

Several areas of the world, including India, have experienced terrorist acts and retaliatory operations in recent years. If the economy of our key markets (including but not limited to the United States, the United Kingdom, Germany, India, Venezuela and Russia) is affected by such acts, our business and results of operations may be adversely affected as a consequence.

In the last decade, Asia experienced outbreaks of avian influenza and Severe Acute Respiratory Syndrome, or SARS. In addition, in 2009 a rising death toll in Mexico from a new strain of Swine Flu led the World Health Organization to declare a public health emergency of international concern. In May 2015, the Pan American Health Organization issued an alert regarding the first confirmed Zika virus infection in Brazil, and since then it has spread across the Americas. In the United States, there have been reports of local mosquito-borne transmission of the Zika virus in Puerto Rico, the U.S. Virgin Islands, and American Samoa, and there have been reports of cases in the continental United States in returning travelers. If the economy of our key markets is affected by such outbreaks or other epidemics, our business and results of operations may be adversely affected as a consequence.

**Our principal shareholders have significant control over us and, if they take actions that are not in the best interests of our minority shareholders, the value of their investment in our ADSs may be harmed.**

Our full time directors and members of their immediate families, in the aggregate, beneficially owned 25.58% of our issued shares as at March 31, 2016. As a result, these people, acting in concert, are likely to have the ability to exercise significant control over most matters requiring approval by our shareholders, including the election and removal of directors and significant corporate transactions. This significant control by these directors and their family members could delay, defer or prevent a change in control, impede a merger, consolidation, takeover or other business combination involving us, or discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. As a result, the value of the equity shares and/or ADSs of our minority shareholders may be adversely affected or our minority shareholders might be deprived of a potential opportunity to sell their equity shares and/or ADSs at a premium.

**RISKS RELATING TO INVESTMENTS IN INDIAN COMPANIES**

We are an Indian company. Our headquarters are located in India, a substantial part of our operations are conducted in India and a significant part of our infrastructure and other assets are located in India. In addition, a substantial portion of our total revenues for the year ended March 31, 2016 continued to be derived from sales in India. As a result, the following additional risk factors apply that are not specific to our company or industry.

**We may be subjected to additional compliance and litigation risks as a result of introduction of the Companies Act, 2013 in India and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

As a company that is incorporated in India, we are governed by the rules and regulations covered under the Indian Companies Act, 1956. Significant amendments to the Companies Act were adopted in 2013 and 2014 and a majority of the provisions of the new Act (called the Companies Act, 2013) were implemented beginning in April, 2014. Some of the significant changes were in the areas of board and governance processes, boardroom responsibilities, disclosures, compulsory corporate social responsibility, audit matters, initiation of class action suits by shareholders or depositors, fraud reporting and whistle-blower mechanisms.

In addition, on September 2, 2015, the Securities and Exchange Board of India ( SEBI ) issued the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations ) that must be followed by all listed Indian public companies effective December 1, 2015. These Listing Regulations were intended to consolidate and streamline the provisions of the existing listing agreements for different segments of the capital markets (e.g., equity securities, debt securities, Indian depository receipts, etc.). The Listing Regulations have thus been structured to provide ease of reference by consolidating into one single document across various types of securities listed on the stock exchanges. Key features of the Listing Regulations include:

A framework has been prescribed for disclosure of material events and information by listed entities to the Indian stock exchanges. Certain events mentioned in the regulations are deemed material and disclosure is mandatory. Certain events are to be disclosed based on application of the guidelines for materiality as prescribed. The Board of Directors is required to frame a policy for determination of materiality and disclose the same on the website of the company.

## **Table of Contents**

Entities will be required to frame policies on preservation of documents, determination of material subsidiaries, risk management, code of conduct, remuneration of directors, key managerial personnel and other employees, board diversity, materiality of related party transactions and dealing with related party transactions and criteria for evaluation of directors.

Existing listed entities are required to sign the shortened version of the listing agreement with stock exchanges within six months of the issuance of the Listing Regulations.

However, certain provisions of the Companies Act, 2013 and the new Listing Regulations provisions are subject to varying interpretations and their application in practice may evolve over time as additional guidance is provided by regulatory and governing bodies. This may result in delays or continuing uncertainty regarding compliance matters and higher costs of compliance as a result of ongoing revisions.

### **If communal disturbances or riots erupt in India, or if regional hostilities increase, this would adversely affect the Indian economy, which our business depends upon.**

India has experienced communal disturbances, terrorist attacks and riots during recent years. For example, Mumbai, India's commercial capital, was the target of serial railway bombings in July 2006 as well as the 26/11 attacks on November 26, 2008. Hyderabad, the city in which we are headquartered, was also subjected to terrorist acts in May and August 2007 and more recently in February 2013, although none of our operations were impacted by these terrorist acts.

During the last several years, the state of Telangana, where our headquarters is located, experienced political disruption relating to a movement to bifurcate a part of the then existing undivided state of Andhra Pradesh into a new separate state of Telangana. In February 2014, the Indian Parliament approved such bifurcation and announced creation of a new state of Telangana with effect from June 2, 2014.

Due to civil disturbances and Bandhs (i.e., political protests in the form of worker strikes), several productive days were lost from forced or precautionary closures of our production units and offices during the agitation movement. We experienced such issues in 2009 and 2013 in Andhra Pradesh (now Telangana). If there are any such strikes, political protests or civil unrest in the future, our business and results of operations may be adversely affected as a consequence.

Additionally, India has from time to time experienced hostilities with neighboring countries. The hostilities have continued sporadically. Hostilities and tensions may occur in the future and on a wider scale. These hostilities and tensions could lead to political or economic instability in India and harm our business operations, our future financial performance and the price of our shares and our ADSs.

### **A slowdown in economic growth in India may adversely affect our business and results of operations.**

Our performance and the quality and growth of our business are necessarily dependent on the health of the overall Indian economy. The Indian economy has grown significantly over the past few years. Any future slowdown in the Indian economy could harm us, our customers and other contractual counterparties. In addition, the Indian economy is in a state of transition. The share of the services sector of the Indian economy is rising while that of the industrial, manufacturing and agricultural sector is declining. It is difficult to gauge the impact of these fundamental economic changes on our business.

**If wage costs or inflation rise in India, it may adversely affect our competitive advantages over higher cost countries and our profits may decline.**

Wage costs in India have historically been significantly lower than wage costs in developed countries and have been one of our competitive strengths. However, wage increases in India may increase our costs, reduce our profit margins and adversely affect our business and results of operations.

Due to various macro-economic factors, the rate of inflation has recently been highly volatile in India. According to the economic report released by the Department of Economic Affairs, Ministry of Finance in India, the annual inflation rate in India, as measured by the benchmark wholesale price index, Base 2004-05=100 was -0.85% for the year ended March 31, 2016 (as compared to -2.33% for the year ended March 31, 2015). This trend may continue to fluctuate and/or the rate of inflation may rise substantially. We may not be able to pass these inflationary costs on to our customers by increasing the price we charge for our products. If this occurs, our profits may decline.



## **Table of Contents**

### **Stringent labor laws may adversely affect our ability to have flexible human resource policies; labor union problems could negatively affect our production capacity and overall profitability.**

Labor laws in India are more stringent than in other parts of the world. These laws may restrict our ability to have human resource policies that would allow us to react swiftly to the needs of our business. Approximately 5% of our employees belong to a number of different labor unions. If we experience problems with our labor unions, our production capacity and overall profitability could be negatively affected.

## **OTHER RISKS RELATING TO OUR ADSS**

### **THAT ARE NOT SPECIFIC TO OUR COMPANY OR INDUSTRY**

#### **The market price of our ADSs may be volatile, and the value of your investment could materially decline.**

Investors who hold our ADSs may not be able to sell their ADSs at or above the price at which they purchased such ADSs. The price of our ADSs fluctuate from time to time, and we cannot predict the price of our ADSs at any given time. The risk factors described herein could cause the price of our ADSs to fluctuate materially. In addition, the stock market in general, including the market for generic and specialty pharmaceutical companies, has experienced price and volume fluctuations. These broad market and industry factors may materially harm the market price of our ADSs, regardless of our operating performance. In addition, the price of our ADSs may be affected by the valuations and recommendations of the analysts who cover us, and if our results do not meet the analysts' forecasts and expectations, the price of our ADSs could decline as a result of analysts lowering their valuations and recommendations or otherwise.

#### **Negative media coverage and public scrutiny may adversely affect the prices of our equity shares and ADSs.**

Media coverage, including social media coverage such as blogs, of our company has increased dramatically over the past several years. Any negative media coverage, regardless of the accuracy of such reporting, may have an adverse impact on our reputation and investor confidence, resulting in a decline in the share price of our equity shares and our ADSs.

#### **Indian law imposes certain restrictions that limit a holder's ability to transfer the equity shares obtained upon conversion of ADSs and repatriate the proceeds of such transfer, which may cause our ADSs to trade at a premium or discount to the market price of our equity shares.**

Under certain circumstances, the Reserve Bank of India must approve the sale of equity shares underlying ADSs by a non-resident of India to a resident of India. The Reserve Bank of India has given general permission to effect sales of existing shares or convertible debentures of an Indian company by a resident to a non-resident, subject to certain conditions, including the price at which the shares must be sold. Additionally, except under certain limited circumstances, if an investor seeks to convert the Indian rupee proceeds from a sale of equity shares in India into foreign currency and then repatriate that foreign currency from India, he or she will have to obtain an additional approval from the Reserve Bank of India for each such transaction. Required approval from the Reserve Bank of India or any other government agency may not be obtained on terms favorable to a non-resident investor or at all.

#### **There are limits and conditions to the deposit of shares into the ADS facility.**

Indian legal restrictions may limit the supply of our ADSs. The only way to add to the supply of our ADSs will be through a primary issuance because the depository is not permitted to accept deposits of our outstanding shares and

issue ADSs representing those shares. However, an investor in our ADSs who surrenders an ADS and withdraws our shares will be permitted to redeposit those shares in the depository facility in exchange for our ADSs. In addition, an investor who has purchased our shares in the Indian market will be able to deposit them in the ADS program, but only in a number that does not exceed the number of underlying shares that have been withdrawn from and not re-deposited into the depository facility. Moreover, there are restrictions on foreign institutional ownership of our equity shares as opposed to our ADSs.

**The persistently weak global economic and financial environment in many other countries, particularly emerging market countries in Asia, and increasing political and social instability could have a material adverse effect on our business and the price and liquidity of our shares and our ADSs.**

## **Table of Contents**

Many of the world's largest economies and financial institutions continue to be impacted by a weak ongoing global economic and financial environment, with some continuing to face financial difficulty, liquidity problems and limited availability of credit. We continue to see weak economic growth or a slowing of economic growth rates in certain emerging growth markets, such as China, Russia, Brazil and India. It is uncertain how long these effects will last, or whether economic and financial trends will worsen or improve. In addition, these issues may be further impacted by the unsettled political conditions currently existing in the United States and Europe, as well as the difficult conditions existing in parts of the Middle East and places such as Ukraine, as well as the ongoing refugee crisis, anti-immigrant activities, social unrest and fears of terrorism that have followed in many countries. Such uncertain times may have a material adverse effect on business and financial performance and, if circumstances worsen, our ability to raise capital at reasonable rates. For example, financial weakness in certain countries has increased pressures on those countries, and on payors in those countries, to force healthcare companies to decrease the prices at which we may sell them our products.

The Indian markets and the Indian economy are influenced by economic and market conditions in other countries, particularly emerging market countries in Asia. Although economic conditions are different in each country, investors reactions to developments in one country can have adverse effects on the securities of companies in other countries, including India. Any worldwide financial instability or any loss of investor confidence in the financial systems of Asian or other emerging markets could increase volatility in Indian financial markets or adversely affect the Indian economy in general. Either of these results could harm our business, our future financial performance and the price of our equity shares and ADSs.

**If U.S. investors in our ADSs are unable to exercise preemptive rights available to our non-U.S. shareholders due to the registration requirements of U.S. securities laws, the investment of such U.S. investors in our ADSs may be diluted.**

A company incorporated in India must offer its holders of shares preemptive rights to subscribe and pay for a proportionate number of shares to maintain their existing ownership percentages prior to the issuance of any shares, unless these rights have been waived by at least 75% of our shareholders present and voting at a shareholders' general meeting. U.S. investors in our ADSs may be unable to exercise preemptive rights for the shares underlying our ADSs unless a registration statement under the Securities Act of 1933 is effective with respect to the rights or an exemption from the registration requirements of the Securities Act is available. Our decision to file a registration statement will depend on the costs and potential liabilities associated with a registration statement as well as the perceived benefits of enabling U.S. investors in our ADSs to exercise their preemptive rights and any other factors we consider appropriate at the time. We might choose not to file a registration statement under these circumstances. If we issue any of these securities in the future, such securities may be issued to the depository, which may sell them in the securities markets in India for the benefit of the investors in our ADSs. There can be no assurances as to the value, if any, the depository would receive upon the sale of these securities. To the extent that U.S. investors in our ADSs are unable to exercise preemptive rights, their proportional interests in us would be reduced.

**Our equity shares and our ADSs may be subject to market price volatility, and the market price of our equity shares and ADSs may decline disproportionately in response to adverse developments that are unrelated to our operating performance.**

Market prices for the securities of Indian pharmaceutical companies, including our own, have historically been highly volatile, and the market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Factors such as the following can have an adverse effect on the market price of our ADSs and equity shares:

general market conditions,

speculative trading in our shares and ADSs, and

developments relating to our peer companies in the pharmaceutical industry.

**There may be less company information available in Indian securities markets than securities markets in developed countries.**

There is a difference between the level of regulation and monitoring of the Indian securities markets over the activities of investors, brokers and other participants, as compared to the level of regulation and monitoring of markets in the United States and other developed economies. The Securities and Exchange Board of India is responsible for improving disclosure and other regulatory standards for the Indian securities markets. The Securities and Exchange Board of India has issued regulations and guidelines on disclosure requirements, insider trading and other matters. There may, however, be less publicly available information about Indian companies than is regularly made available by public companies in developed countries, which could affect the market for our equity shares and ADSs.

---

**Table of Contents**

**Indian stock exchange closures, broker defaults, settlement delays, and Indian Government regulations on stock market operations could affect the market price and liquidity of our equity shares.**

The Indian securities markets are smaller than the securities markets in the United States and Europe and have experienced volatility from time to time. The regulation and monitoring of the Indian securities market and the activities of investors, brokers and other participants differ, in some cases significantly, from those in the United States and some European countries. Indian stock exchanges have at times experienced problems, including temporary exchange closures, broker defaults and settlement delays and if similar problems were to recur, they could affect the market price and liquidity of the securities of Indian companies, including our shares. Furthermore, any change in Indian Government regulations of stock markets could affect the market price and liquidity of our equity shares and ADSs.

**Sale of our equity shares may adversely affect the prices of our equity shares and ADSs.**

The Government of India has recently issued a notice of the implementation of the Depository Receipts Scheme, 2014, which permits liberalized rules for sponsored and unsponsored secondary market issue of depository receipts, subject to the existing sectorial cap on foreign investment. Once the regulations are fully implemented, an Indian company's equity shares can be freely issued to a depository for the purpose of issuing depository receipts through any mode permissible for the issue of such securities to other investors. This would enable us to more readily issue shares to the depository for our ADSs and conduct U.S. securities issuances of our ADSs, which would impact the share price and available float in Indian stock exchanges as well as the price and availability of our ADSs on the NYSE.

**ITEM 4. INFORMATION ON THE COMPANY**

***4.A. History and development of the company***

Dr. Reddy's Laboratories Limited was incorporated in India under the Companies Act, 1956, by its promoter and our former Chairman, the late Dr. K. Anji Reddy, as a Private Limited Company on February 24, 1984. We were converted to a Public Limited Company on December 6, 1985 and listed on the Indian Stock Exchanges in August 1986 and on the New York Stock Exchange on April 11, 2001. We are registered with the Registrar of Companies, Hyderabad, Telangana, India as Company No. 4507 (Company Identification No. L85195TG1984PLC004507). Our registered office is situated at 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India and the telephone number of our registered office is +91-40-49002900. The name and address of our registered agent in the United States is Dr. Reddy's Laboratories, Inc., 107 College Road East, Princeton, New Jersey 08540.

**Key business developments:**

***Receipt of warning letter from the U.S. FDA***

We received a warning letter dated November 5, 2015 from the U.S. FDA relating to cGMP deviations at our API manufacturing facilities at Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as violations at our oncology formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh previously raised in Form 483 observations following inspections of these sites by the U.S. FDA in November 2014, January 2015 and February-March 2015, respectively.

This has had an adverse impact on new product approvals from these sites, and we have taken steps to minimize the impact from these sites through site transfers of certain key products. We continue to develop and implement our corrective action plans relating to the warning letter.

The warning letter does not restrict production or shipment of our products from these facilities. However, unless and until we are able to correct outstanding issues to the U.S. FDA's satisfaction, the U.S. FDA may withhold approval of our new products and new drug applications, refuse admission of products manufactured at the facilities noted in the warning letter into the United States, and/or take additional regulatory or legal action against us. Any such further action could have a material and negative impact on our ongoing business and operations.

We submitted our response to the warning letter on December 7, 2015. Further, we provided updates on the progress of our corrective actions to the U.S. FDA in January 2016, March 2016 and May 2016.

We believe that we can resolve the issues raised by the U.S. FDA satisfactorily in a timely manner. We take the matters identified by U.S. FDA in the warning letter seriously, and will continue to work diligently to address the observations identified in the warning letter, and are concurrently continuing to refine and implement our corrective action plans relating to the warning letter.

*Venezuela operations*

Refer to Note 41 to our consolidated financial statements.

---

**Table of Contents**

***Acquisition of select portfolio of the established products business of UCB in India***

Refer to Note 6 to our consolidated financial statements.

***Product approval under section 505(b)(2) New Drug Applications from the U.S. Food and Drug Administration***

For our Proprietary Products segment, during the year ended March 31, 2016, we received U.S. FDA approval of our New Drug Applications (each, a NDA ) for two products and tentative approval of our NDA for one product, all under section 505(b)(2) of the Federal Food, Drug and Cosmetic Act:

In February, 2016, we received U.S. FDA approval for Sernivo™ (NDA - DFD-01), a corticosteroid delivered in a novel non-irritating spray platform, intended for the treatment of patients suffering from mild to moderate plaque psoriasis. We launched this product in the United States in June 2016;

In February, 2016, we received U.S. FDA tentative approval for Zenavod™ (NDA - DFD-09), a modified release oral doxycycline intended for the treatment of rosacea; and

In January, 2016, we received U.S. FDA approval for Zembrace™ SymTouch™ (NDA - DFN-11), a drug-device combination product intended to treat acute migraine episodes in certain patient populations who are inadequately managed with existing treatment regimens. We launched this product in the United States in April 2016.

***Asset purchase agreement with Teva Pharmaceutical Industries Ltd***

Refer to Note 45 to our consolidated financial statements.

***Product launches***

For a list of other products we launched in the United States during the year ended March 31, 2016, refer to Item 5.A Operating results .

**Principal capital expenditures:**

During the years ended March 31, 2016, 2015 and 2014, we invested Rs.11,933 million, Rs.9,167 million and Rs.9,996 million (net of sales of capital assets), respectively, in capital expenditures for manufacturing, research and development facilities and other assets. We believe that these investments will create the capacity to support our strategic growth agenda. As of March 31, 2016, we also had contractual commitments of Rs.5,065 million for capital expenditures. These commitments included Rs.4,872 million to be spent in India and Rs.193 million in other countries. We currently intend to finance our additional capital expansion plans entirely through our operating cash flows and through cash and other investments.

## **Table of Contents**

### **4.B. Business overview**

Established in 1984, we are an integrated global pharmaceutical company committed to providing affordable and innovative medicines through our three core business segments:

Global Generics;

Pharmaceutical Services and Active Ingredients (PSAI); and

Proprietary Products.

**Global Generics.** This segment consists of our business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of our biologics business.

**Pharmaceutical Services and Active Ingredients.** This segment includes our business of manufacturing and marketing active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are the principal ingredients for finished pharmaceutical products. Active pharmaceutical ingredients and intermediates become finished pharmaceutical products when the dosages are fixed in a form ready for human consumption such as a tablet, capsule or liquid using additional inactive ingredients. This segment also includes our contract research services business and our manufacture and sale of active pharmaceutical ingredients and steroids in accordance with specific customer requirements.

**Proprietary Products.** This segment consists of our business that focuses on the research, development, and manufacture of differentiated formulations and new chemical entities (NCEs). These novel products fall within the dermatology and neurology therapeutic areas and are marketed and sold through Promius Pharma, LLC.

**Others.** This includes the operations of our wholly-owned subsidiary, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with established pharmaceutical and biotechnology companies in early-stage collaborations, bringing drug candidates from hit generation through Investigational New Drug (IND) filing.

We have a strong presence in highly regulated markets such as the United States, the United Kingdom and Germany, as well as other key markets such as India, Russia, Venezuela, Romania, South Africa and certain countries of the former Soviet Union.

## **OUR STRATEGY**

Our core purpose is to accelerate access to affordable and innovative medicines because *Good Health Can't Wait*. Spiraling health care costs across the world have put many medicines out of the reach of millions of people who desperately need them. As a global pharmaceutical company, we take very seriously our responsibility to offer affordable alternatives to expensive medicines and help patients manage their disease better. To do this, we strive to fulfill the following five promises:



to bring expensive medicines within reach;

to address unmet patient needs by developing new products;

to help manage disease better to ease the burden on patients;

to equip our partners to succeed; and

to ensure that our products are always on the shelf.

The key elements of our strategy for achieving these promises include the following:

### **Strengths in Science and Technology**

Our strengths in science and technology range from synthetic organic chemistry, formulation development, biologics development and small molecule based drug discovery. Such expertise enables the creation of unique competitive advantages with an industry-leading intellectual property and technology-leveraged product portfolio.

### **Product Offerings**

Global Generics: Through our branded and unbranded drug products, we aim to offer affordable alternatives to highly-priced innovator brands, both directly and through key partnerships.

*Branded Generics*: We seek to have a portfolio that is strongly focused on delivering first-to-market, differentiated products to doctors and patients. Many of our brands hold significant market shares in the molecule and therapy areas where they are present. We have also entered into strategic partnerships with third parties to sell our products in markets where we have not established our own sales and distribution operations.

*Unbranded Generics*: We aim to ensure that our development capabilities remain strong and enable us to deliver products that are first to market, tough-to-make and technologically challenging.

## **Table of Contents**

Our biologics business seeks to accelerate access to bio-similar products globally through process development and relevant clinical research. We were the first company to launch a generic version of rituximab in 2007, and have launched 4 bio-similar products in India and other key markets.

Our vertical integration and process innovation helps to ensure that quality products are available to patients in need at all times.

**Pharmaceutical Services and Active Ingredients:** Our Pharmaceutical Services and Active Ingredients segment is comprised of our Active Pharmaceutical Ingredients ( API ) business and our Custom Pharmaceutical Services ( CPS ) business. Through our API and CPS businesses, we aim to offer technologically advanced product lines and niche product services through partnerships internally and externally.

Our product offerings in our API business are positioned to offer intellectual property and technology-advantaged products to enable launches ahead of others at competitive prices.

Through our CPS business, we aim to offer niche product service capabilities, technology platforms, and competitive cost structures to innovator and biotechnology companies.

**Proprietary Products:** Our Proprietary Products segment is comprised of our Differentiated Formulations business and our New Chemical Entity ( NCE ) research business in the therapeutic areas of dermatology and neurology.

*Differentiated Formulations:* Our Differentiated Formulations business works to improve patient outcomes by identifying unmet and under-met medical needs and addressing them through innovative products and services that are affordable and accessible. We also have an internal pipeline of differentiated products in dermatology and neurology products in various stages of development. In addition, we have the commercial portfolio of in-licensed dermatology products.

*New Chemical Entities (NCEs):* We are also focused in the discovery, development and commercialization of novel small molecule agents in therapeutic areas such as metabolic disorders, pain and inflammation.

## **Execution Excellence (Building Blocks)**

Execution excellence provides the framework to create sustainable customer value across all of our activities. We have been investing in the following to achieve this:

**Safety.** The concept of safety has been imbued in the operating culture throughout our organization. Specific initiatives are being carried out to increase safety awareness, to achieve a safe working environment, to avoid accidents and injuries, and to minimize the loss of manufacturing time.

Quality. We are fully dedicated to quality and have robust quality processes and systems in place at our developmental and manufacturing facilities to ensure that every product is safe and of high quality. In addition, we have integrated Quality by Design to build quality into all processes and use quality tools to minimize process risks.

Principles of the Theory of Constraints and Lean Manufacturing. Our supply chain and product development processes are designed on the principles of the Theory of Constraints and lean manufacturing. This results in a flexible supply chain that is able to increase availability of products to the customer with reduced cycle time and waste.

Leadership Development. We are focused on developing leaders, as well as enhancing leadership behavior, across our organization.

**Table of Contents****OUR PRINCIPAL AREAS OF OPERATIONS**

The following table shows our revenues and the percentage of total revenues of our business segments for the years ended March 31, 2016, 2015 and 2014, respectively:

Segment	For the year ended March 31,							
	2016		2015		2014			
	(Rs. in millions, U.S.\$ in millions)							
Global Generics	U.S.\$ 1,933	Rs. 128,062	83%	Rs. 119,397	81%	Rs. 104,483	79%	
Pharmaceutical Services and Active Ingredients	338	22,379	14%	25,456	17%	23,974	18%	
Proprietary Products	40	2,659	2%	2,172	1%	2,459	2%	
Others	24	1,608	1%	1,164	1%	1,254	1%	
<b>Total Revenue</b>	<b>U.S.\$ 2,335</b>	<b>Rs. 154,708</b>	<b>100%</b>	<b>Rs. 148,189</b>	<b>100%</b>	<b>Rs. 132,170</b>	<b>100%</b>	

Revenues by country and by therapeutic area for the years ended March 31, 2016, 2015 and 2014 are discussed in Note 5 to our consolidated financial statements.

**Global Generics Segment**

The production processes for finished dosages are similar, to a certain extent, regardless of whether the finished dosages are to be marketed to highly regulated or less regulated markets. In many cases, the processes share common and interchangeable facilities and employee bases, and use similar raw materials. However, differences remain between highly regulated and less regulated markets in terms of manufacturing, packaging and labeling requirements and the intensity of regulatory oversight, as well as the complexity of patent regimes. While the degree of regulation in certain markets may impact product development, we are observing increasing convergence of development needs throughout both highly regulated and less regulated markets. As a result, when we begin the development of a product, we may not necessarily target it at a particular market, but will instead target the product towards a cluster of markets that will include both highly regulated and less regulated markets.

Today, we are one of the leading generic pharmaceutical companies in the world. With the integration of all the markets where we are selling generic pharmaceuticals into our Global Generics segment, our front-end business strategies in various markets and our support services in India are increasingly being developed with a view to leverage our global infrastructure.

Our Global Generics segment's revenues were Rs.128,062 million for the year ended March 31, 2016, as compared to Rs.119,397 million for the year ended March 31, 2015. The revenue growth was largely led by this segment's operations in the United States, India, Germany and the United Kingdom. The following is a discussion of the key markets in our Global Generics segment.

***India***

Approximately 17% of our Global Generics segment's revenues in the year ended March 31, 2016 were derived from sales in the Indian market. In India, our key therapeutic categories include gastro-intestinal, cardiovascular, pain management and oncology. We are also increasing our presence in the niche areas of dermatology, urology and

nephrology.

As of March 31, 2016, we had a total of 296 branded products in India. Our top ten branded products together accounted for 31% of our revenues in India in the year ended March 31, 2016. According to IMS Health, in its moving annual total report for the 12-month period ended March 31, 2016, our secondary sales in India grew by 12.2%. In comparison, the Indian pharmaceutical market experienced growth of 14.4% during such period. IMS Health is a provider of market research to the Indian pharmaceutical industry. Strategic Marketing Solutions and Research Center Private Limited ( SMSRC ), a prescription market research firm, in its report measuring pharmaceutical prescriptions in India for the period from November 2015 to February 2016, ranked us 10th in terms of the number of prescriptions generated in India during such period.

#### Sales, marketing and distribution network

We generate demand for our products through our 5,662 sales representatives (which include representatives engaged by us on a contract basis through a service provider) and front line managers, who frequently visit doctors to detail our related product portfolio. They also visit various pharmacies to ensure that our brands are adequately stocked.

## Table of Contents

We sell our products primarily through clearing and forwarding agents to approximately 3,000 wholesalers who decide which brands to buy based on demand. The wholesalers pay for our products in an agreed credit period and in turn sell these products to retailers. Our clearing and forwarding agents are responsible for transporting our products to the wholesalers. We pay our clearing and forwarding agents on a commission basis. We have insurance policies that cover our products during shipment and storage at clearing and forwarding locations.

In April 2015, we entered into a definitive agreement with UCB India Private Limited and other UCB group companies (together referred to as "UCB") to acquire a select portfolio of established products business in the territories of India, Nepal, Sri Lanka and Maldives. The purchased business was acquired on a slump sale basis (an Indian tax law concept which refers to the transfer of a business as a going concern without values being assigned to individual assets and liabilities). The transaction includes approximately 350 employees engaged in operations of the acquired India business. The acquisition is expected to strengthen our presence in the areas of dermatology, respiratory and pediatric products. The total purchase consideration was Rs.8,000 million. The acquisition was closed on June 16, 2015.

## Competition

We compete with different companies in the Indian formulations market, depending upon therapeutic and product categories and, within each category, upon dosage strengths and drug delivery. On the basis of sales, we were the 12<sup>th</sup> largest pharmaceutical company in India, with a market share of 2.4%, according to IMS Health in its moving annual total report for the 12-month period ended March 31, 2016.

Some of the key observations on the performance of the Indian pharmaceutical market, as published by IMS Health in its moving annual total report for the 12-month period ended March 31, 2016, are as follows:

The Indian pharmaceutical market experienced growth of 14.4% for such period;

New products launched in the preceding 24 months accounted for 5% of total Indian pharmaceutical growth for such period;

The top 300 existing brands grew at a rate of 15.9%, which was 1.5% higher than the Indian pharmaceutical market's overall average, and together they account for 30.5% of the market's total sales; and

There was an increasing emergence of bio-similar products to address the needs of patients in the oncology therapeutic area.

Our principal competitors in the Indian market include Cipla Limited, GlaxoSmithKline Pharmaceuticals Limited, Cadila Healthcare Limited, Sun Pharmaceutical Industries Limited, Piramal Enterprises Ltd, Alkem Limited, Mankind Pharma Limited, Pfizer Limited, Abbott India, Lupin Limited, Aristo Pharma Limited, Intas Pharma, Sanofi India Limited and Emcure Pharmaceuticals Limited.

## Government regulations

The manufacturing and marketing of drugs, drug products and cosmetics in India is governed by many statutes, regulations and guidelines, including but not limited to the following:

The Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945;

The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954;

The Narcotic Drugs and Psychotropic Substances Act, 1985;

The Drugs (Price Control) Order, 1995 and 2013, read in conjunction with the Essential Commodities Act, 1955;

The Medicinal and Toilet Preparations (Excise Duties) Act, 1955; and

The National Pharmaceuticals Pricing Policy, 2012.

These statutes, regulations and guidelines govern the testing, manufacturing, packaging, labeling, storing, record-keeping, safety, approval, advertising, promotion, sale and distribution of pharmaceutical products.

Pursuant to the amendments in May 2005 to Schedule Y of the Drugs and Cosmetics Act, 1940, manufacturers of finished dosages are required to submit additional technical data to the Drugs Controller General of India in order to obtain a no-objection certificate for conducting clinical trials as well as to manufacture new drugs for marketing.

## **Table of Contents**

An approval is required from the Ministry of Health before a generic equivalent of an existing or referenced brand drug can be marketed. When processing a generics application, the Ministry of Health usually waives the requirement of conducting complete clinical studies, although it generally requires bio-availability and/or bio-equivalence studies.

Bio-availability indicates the rate and extent of absorption and levels of concentration of a drug product in the blood stream needed to produce a therapeutic effect. Bio-equivalence compares the bioavailability of one drug product with another, and when established, indicates that the rate of absorption and levels of concentration of the active drug substance in the body are equivalent for the generic drug with the previously approved drug. A generic application may be submitted for a drug on the basis that it is the equivalent of a previously approved drug. Before approving our generic products, the Ministry of Health also requires that our procedures and operations conform to current Good Manufacturing Practice ( cGMP ) regulations, relating to good manufacturing practices as defined by various countries. We must follow the cGMP regulations at all times during the manufacture of our products. We continue to spend significant time, money and effort in the areas of production and quality testing to help ensure full compliance with cGMP regulations.

The timing of final Ministry of Health approval of a generic application depends on various factors, including patent expiration dates, sufficiency of data and regulatory approvals.

On March 22, 2005, the Government of India passed the Patents (Amendment) Bill, 2005 (the 2005 Amendment ), introducing a product patent regime for food, chemicals and pharmaceuticals in India. The 2005 Amendment specifically provides that new medicines (patentability of which is not specifically excluded) for which a patent has been applied for in India on or after January 1, 1995 and for which a patent is granted cannot be manufactured or sold in India by anyone other than the patent holder and its assignees and licensees. This has resulted in a reduction of new product introductions in India for all Indian pharmaceutical companies engaged in the development and marketing of generic finished dosages and APIs. Processes for the manufacture of APIs and formulations were patentable in India even prior to the 2005 Amendment, so no additional impact results from patenting of such processes.

Under the present drug policy of the Government of India, certain drugs have been specified under the Drugs (Prices Control) Order, 2013 (the DPCO ) as subject to price control. The Government of India established the National Pharmaceutical Pricing Authority, 2012 ( NPPA ), to control pharmaceutical prices. Under the DPCO, the NPPA has the authority to fix the maximum selling price for specified products.

During the year ended March 31, 2013, the Department of Pharmaceuticals under the ministry of Chemicals and Fertilizers of the Government of India proposed the National Pharmaceuticals Pricing Policy, 2012, a revised national Pharmaceutical Pricing policy to apply price controls to 348 drugs listed in National List of Essential Medicines. Some of our formulation products are subject to these price controls.

On May 15, 2013, the Department of Pharmaceuticals released the DPCO governing the price control mechanism for 348 drugs listed in the National List of Essential Medicines. Under the DPCO, the prices of each of the drugs are determined based on the simple average of all drugs having market share of more than 1% by value. The individual drug price notifications for almost all of the products were released by the NPPA. Based on these notifications, we were adversely impacted by approximately 3% (the annualized impact is approximately 4%) of our annual revenues from sales of all of our formulation products in India during the year ended March 31, 2014.

Recently, there has been a series of proposals and announcements by the Government of India regarding price controls. First, in December 2015 a proposal was issued to list certain additional drugs on the National List of Essential Medicines. That was followed with an announcement on March 3, 2016 of a reduction in the maximum prices of various drugs, as a result of negative inflation as measured by India's Wholesale Price Index. Further, on March 10, 2016, the Department of Pharmaceuticals notified the Drugs (Prices Control) Amendment Order, 2016



( DPCAO 2016 ), which amended the DPCO and revised the National List of Essential Medicines. Under the DPCAO 2016, a total of 106 medicines were added to and 70 medicines were deleted from the National List of Essential Medicines, which now contains 376 drugs. The NPPA was in the process of notifying or re-notifying prices for these scheduled drugs as of March 31, 2016. The individual drug price notifications for a majority of the products have been released by the NPPA. Based on these notifications, we believe that we could be adversely impacted by approximately 3% to 5% of our annual revenues from sales of all of our products in India for the year ending on March 31, 2017.

Additionally, on March 12, 2016, the Department of Health and Family Welfare under the ministry of Health and Family Welfare of the Government of India banned 344 fixed dose combination drugs (i.e., two or more active drugs

## **Table of Contents**

combined in a fixed ratio into a single dosage). A number of pharmaceutical companies, including us, have filed a writ petition before the Delhi High Court challenging the ban. The Delhi High Court granted an interim stay on the ban notification. In the event that this notification comes into effect, it could adversely impact our revenues by approximately 0.7% on an annual basis. Further, it could adversely impact the Indian pharmaceutical industry by approximately 3.1% on an annual basis (as per AWACS, a provider of market research to the Indian pharmaceutical industry).

The NPPA has since notified changes to pricing of different products multiple times, which have impacted certain of our oncology and chronic condition products.

Such ongoing changes can disrupt the Indian branded pharmaceutical market and negatively impact the revenues and profitability of our Indian business and our company.

### ***Russia and other Countries of the former Soviet Union***

#### ***Russia***

Russia accounted for 8% of our Global Generics segment's revenues in the year ended March 31, 2016. IMS Health ranked us 17th in sales in Russia, with a market share of 1.7%, as of March 31, 2016 in its moving annual total report for the 12-months ended March 31, 2016. According to IMS Health, as per its moving annual total report for the 12 months ended March 31, 2016, our sales value growth and volume decrease were 5.6% and 3.9%, respectively, for the year ended March 31, 2016 as compared to the Russian pharmaceutical market value growth of 8.4% and volume decrease of 4.0%, respectively, for such period. We were the top ranked Indian pharmaceutical company in Russia for such period.

Our top four brands, Nise, Omez, Ketorol and Cetrine, accounted for 55% of our Global Generics segment's revenues in Russia for the year ended March 31, 2016. Omez (an anti-ulcerant product), Nise and Ketorol (both pain management products) and Cetrine (a respiratory product) were ranked as the 58th, 11th, 112th and 176th best-selling formulation brands, respectively, in the Russian market as of March 31, 2016 by IMS Health in its moving annual total retail segment report for the 12 months ended March 31, 2016.

Our strategy in Russia is to focus on the gastro-intestinal, pain management, anti-infectives, respiratory, oncology and cardiovascular therapeutic areas. Our focus is on building leading brands in these therapeutic areas in prescription, over-the-counter and hospital sales. Nise, Omez, Ketorol, Cetrine and Ciprolet continue to be brand leaders in their respective categories, as reported by IMS Health in its moving annual total report for the 12-months ended March 31, 2016.

Our Global Generics segment's revenues in Russia increased by 1% (in Russian rouble absolute currency terms) during the year ended March 31, 2016, which was driven by increased marketing and pharmacy chain activities for over-the-counter medicines. However, such revenue growth measured in Indian rupees was adversely impacted due to depreciation of the Russian rouble by approximately 27% as compared to the year ended March 31, 2015.

#### ***Other Countries of the former Soviet Union and Romania***

We operate in other countries of the former Soviet Union, including Ukraine, Kazakhstan, Belarus, Uzbekistan and Romania. For the year ended March 31, 2016, revenues from these countries accounted for approximately 3% of our total Global Generics segment's revenues.

During the year ended March 31, 2016, the Ukrainian hryvnia and the Kazakhstani tenge devalued significantly and adversely impacted our revenues from these markets.

Sales, marketing and distribution network

Our marketing and promotion efforts in our Russian prescription division is driven by a team of 268 medical representatives and 38 managers to detail our products to doctors in 77 cities in Russia.

Our Russian over-the-counter ( OTC ) division has 216 medical representatives and 31 managers and is focused on establishing a network of relationships with key pharmacy chains and individual pharmacies. Our Russian hospital division has 38 hospital specialists and 17 key account managers, and is focused on expanding our presence in hospitals and institutes.

In Russia, we generally extend credit only to customers after they have established a satisfactory history of payment with us. The credit ratings of these customers are based on turnover, payment record and the number of the customers branches or pharmacies, and are reviewed on a periodic basis. We review the credit terms offered to our key customers on a periodic basis and modify them to take into account the macro-economic scenario in Russia.

## Table of Contents

### Competition

Our principal competitors in the Russian market include Berlin Chemi AG, Gedeon Richter Limited, Krka d.d., Teva Pharmaceutical Industries Ltd., Lek-Sandoz Pharmaceuticals (an affiliate of Novartis Pharma A.G.), Ranbaxy Laboratories Limited, Nycomed International Management GmbH and Zentiva N.V. (an affiliate of Sanofi-Aventis S.A.).

### Government regulation

#### *Promotion of local industry*

In order to promote local industry, in October 2009 the Russian government announced the Strategy of Pharmaceutical Industry Development in the Russian Federation for the period up to the year 2020 (or the Pharma 2020 plan), which aims to develop the research, development and manufacturing of pharmaceutical products by Russia's domestic pharmaceutical industry. The goal of the Pharma 2020 plan is to reduce Russia's reliance on imported pharmaceutical products and increase Russia's self-sufficiency in that regard.

#### *Reference pricing regime*

During the year ended March 31, 2010, the Russian government announced a reference pricing regime, pursuant to which a price freeze on certain drugs categorized as essential was implemented effective as of April 2010. Pharmaceutical companies have had to register maximum import prices for approximately 5,000 drugs on a list of Essential and Vital Drugs (also known as the ZhNVLS). During the year ended March 31, 2011, the Russian government announced price re-registration in local currency (Russian roubles) for drugs categorized as essential and the new registered prices were effective as of December 10, 2010. Also, effective as of September 1, 2010, the price controls on certain drugs categorized as non-essential were removed by the Russian Ministry of Health.

For the past several years, the Russian Ministry of Industry and Trade has enacted and renewed short term government regulations under which local manufacturers (i.e., in Russia, Belarus and Kazakhstan) get a 15% price preference over non-local manufacturers in procurement tenders by the state.

#### *State Regulation of Prices for Vital and Essential Medicines*

Russia's Federal Law No. 34-FZ dated March 8, 2015 amends the Federal Law 61-FZ On Circulation of Medicines. The amendments create new rules for the registration, manufacture and quality control of medicines, including new rules for the calculation and registration of the maximum retail prices of vital and essential medicines established by the ZhNVLS. Most of the changes are effective commencing July 1, 2015, with certain changes effective starting in 2016 or 2017.

Calculation of the maximum sale price for medicines included in the ZhNVLS list shall be determined by the Government of the Russian Federation taking into account a variety of economic and/or social criteria. These amendments became effective from March 16, 2015. The updated EDL lists for 2015 approved by the Decree of the Government No. 2782-p dated December 30, 2014 became effective from March 1, 2015. These lists include the list of drugs for provision to specific groups of citizens, medicines prescribed by a decision of a medical commission of medical organizations, medical supplies from the 7 Nosologies program list, as well as the minimum range of medicines required for medical aid.

#### *Restrictions on access of foreign drugs*

The Russian Government approved the Priority Action Plan for sustainable economic and social stability development in 2015 (the Priority Action Plan ). The Priority Action Plan was signed by the Russian Prime Minister on January 27, 2015. The key areas that may impact the pharmaceutical industry in the Priority Action Plan are (i) supporting import substitution; (ii) optimization of budget costs and reduction of inefficient expenses; and (iii) particularly, in the public healthcare area, the following measures:

On February 2, 2015, the Russian Ministry of Health ( MoH ), Russian Federal Service on Tariffs and Russian Ministry of Economic Development ( MoED ) amended the Federal Law 61-FZ On Circulation of Medicines to provide the possibility of one-time indexation of prices for low-cost essential drugs;

On February 27, 2015, the Russian Ministry of Finance, MoH and MoED suggested improvements for public drugs supply; and

## Table of Contents

On February 15, 2015, the Russian Ministry of Industry and Trade enacted restrictions on access of foreign drugs to state procurement tenders, if two or more locally manufactured drugs participate in the relevant tender. The new regulation No. 1289 of the Russian Government came into effect on December 10, 2015 and affects medicines included in Russia's Vital and Essential Drugs List. However, the restrictions will not apply to purchases of drugs packaged in countries of the Eurasian Economic Union until December 31, 2016.

### *Interactions between healthcare professionals and medical product companies:*

During the year ended March 31, 2012, Russia introduced Federal Law # 323, titled "On the Foundations of Healthcare for Russian Citizens". Portions of this new law became effective on November 23, 2011 and the remainder became effective on January 1, 2012. This new law imposes stringent restrictions on interactions between (i) healthcare professionals, pharmacists, healthcare management organizations, opinion leaders (both governmental and from the private sector) and certain other parties (collectively referred to as "healthcare decision makers") and (ii) companies that produce or distribute drugs or medical equipment (collectively referred to as "medical product companies") and any representatives or intermediaries acting on their behalf (collectively referred to as "medical product representatives"). Some of the key provisions of this law are prohibitions on:

one-on-one meetings and communications between healthcare professionals and medical product representatives, except for participation in clinical trials, pharmacovigilance, group educational events and certain other limited exceptions approved by Russia's Healthcare Organization Administration;

the acceptance by a healthcare professional of compensation, gifts or entertainment paid by medical product representatives;

the agreement by a healthcare professional to prescribe or recommend a drug product or medical equipment;  
or

the engagement by a healthcare decision maker in a "conflict of interest" transaction with a medical product representative, unless approved by regulators pursuant to certain specified procedures.

At the end of 2013, the State Duma (i.e., the lower chamber of the Russian parliament) adopted a series of amendments to various healthcare related laws. Among other things, the "Law on Medicines" was amended to add regulations restricting interactions between medical product representatives with medical professionals in connection with events sponsored by medical product companies. Under these regulations, in the event that medical product companies wish to sponsor certain scientific, medical education or similar events, they are required to disclose the date, place and time of the event and the plans, programs and agendas for discussion. Disclosure is to be made by publishing appropriate information on their official websites not later than two months before the indicated events, and the same information shall also be sent to Russia's Federal Healthcare Service (Roszdravnadzor).

Liability for non-compliance with such restrictions extends to both the healthcare professional and the medical product representative. Except for requiring the disclosure of information on conflicts of interest, no specific liability has been currently prescribed for medical product companies.

On July 2, 2013, the Ministry of Health of the Government of Russia published an order on its website that binds physicians to prescribe medicinal products by International Nonproprietary Name (i.e., active substance) or by

combination list (which combines different International Nonproprietary Names in one treatment group).

*Russia signed the agreement on a common market for medicines within the Eurasian Economic Union*

The Eurasian Economic Union ( EEU ), whose member states are Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan, officially started functioning on January 1, 2015. Among other things, the member states of the EEU signed an international agreement establishing common principles and rules of functioning of the market for medicines within the EEU, which agreement was originally expected to be made effective from January 1, 2016. For these purposes, the member states are working on the necessary regulatory framework and EEU plans for its member states to sign 25 acts governing various stages of drugs circulation. According to the agreement, the market authorization for a particular medicine received in one EEU member state will be valid throughout the whole EEU territory.

#### Political Instability

There has been severe political instability in Ukraine following civilian riots and political unrest which began in November 2013, destabilization of the Ukrainian President's office in February 2014, and subsequent military action in the destabilized country operating under a temporary government.

## **Table of Contents**

As a result of ongoing conflict in the region, the United States and the European Union have imposed sanctions on certain designated individuals and companies in Ukraine and Russia. These sanctions were targeted at persons threatening the peace and security of Ukraine, senior officials of the Government of the Russian Federation and the energy, defense and financial services sectors of Russia, but they have had macroeconomic consequences beyond those persons and industries. In December 2014, the United States imposed further sanctions aimed at blocking new investments in the Crimea region of Ukraine which was annexed by Russia, and blocking trade between the United States or U.S. persons and Crimea. These sanctions also authorized the United States government to impose sanctions on any U.S. persons determined to be operating in the Crimea region of Ukraine, subject to certain authorizations for the export and reexport of certain agricultural commodities, medicine, medical supplies, and replacement parts to Crimea.

Political instability in the region has combined with low worldwide oil prices to significantly devalue the Russian rouble. In addition, the Ukrainian hryvnia experienced significant devaluation in 2014 and 2015. The possibility of additional sanctions implemented by the United States and/or the European Union against Russia or vice versa, continued political instability, civil strife, deteriorating macroeconomic conditions and actual or threatened military action in the region may result in serious economic challenges in Ukraine, Russia and the surrounding areas.

Among our operations, we are engaged in sales, distribution and marketing of pharmaceutical products in Russia and Ukraine, including the Crimea region, all through non-U.S. entities that sell to distributors. Our sales in Russia and Ukraine are not to any of the individuals, companies or sectors designated by the current sanctions, and our sales in the Crimea region accounted for approximately 0.06% of our total revenues for the year ended March 31, 2016. We do not believe that our business in Russia, Ukraine or the Crimea region violates any of the current sanctions. However, relevant regulators could take a view that is different from ours on the issue. We continue to monitor our subsidiaries activities in light of the restrictions imposed by these and any future sanctions.

### ***North America (the United States and Canada)***

During the year ended March 31, 2016, North America (the United States and Canada) accounted for 59% of our total Global Generics segment sales. In the United States, we sell generic drugs that are the chemical and therapeutic equivalents of reference branded drugs, typically sold under their generic chemical names at prices below those of their brand drug equivalents. Generic drugs are finished pharmaceutical products ready for consumption by the patient. These drugs are required to meet the U.S. FDA standards that are similar to those applicable to their brand-name equivalents and must receive regulatory approval prior to their sale.

Generic drugs may be manufactured and marketed only if relevant patents on their brand name equivalents and any additional government-mandated market exclusivity periods have expired, been challenged and invalidated, or otherwise validly circumvented.

Generic pharmaceutical sales have increased significantly in recent years, partly due to an increased awareness and acceptance among consumers, physicians and pharmacists that generic drugs are the equivalent of brand name drugs. Among the factors contributing to this increased awareness are the passage of legislation permitting or encouraging substitution and the publication by regulatory authorities of lists of equivalent drugs, which provide physicians and pharmacists with generic drug alternatives. In addition, various government agencies and many private managed care or insurance programs encourage the substitution of generic drugs for brand-name pharmaceuticals as a cost-savings measure in the purchase of, or reimbursement for, prescription drugs. We believe that these factors should lead to continued expansion of the generic pharmaceuticals market as a whole. We intend to capitalize on the opportunities resulting from this expansion of the market by leveraging our product development capabilities, manufacturing capacities inspected by various international regulatory agencies and access to our own APIs, which offer significant



supply chain efficiencies.

In April 2008, we acquired BASF's pharmaceutical contract manufacturing business and related facility in Shreveport, Louisiana, U.S.A. The acquisition included the relevant business, customer contracts, certain supplier contracts, related Abbreviated New Drug Applications (ANDAs) and New Drug Applications (NDAs), trademarks, as well as the manufacturing facility and assets owned by BASF in Shreveport, Louisiana. The facility is designed to manufacture solid, semi-solid and liquid dosage forms.

In March 2011, we acquired from GlaxoSmithKline plc and Glaxo Group Limited (collectively, GSK) a penicillin-based antibiotics manufacturing site in Bristol, Tennessee, U.S.A., the product rights for GSK's *Augmentin*<sup>®</sup> and *Amoxil*<sup>®</sup> brands of oral penicillin-based antibiotics in the United States (GSK retained the existing rights for these brands outside the United States), certain raw materials and finished goods inventory associated with *Augmentin*<sup>®</sup>, and rights to receive certain transitional services from GSK. The acquisition enabled us to enter the U.S. oral antibiotics market with a comprehensive product filing and a dedicated manufacturing site. Due to high competition in our antibiotics portfolio, with minimal or no margin for certain dosage strengths, we have restructured our antibiotics manufacturing operations during the year ended March 31, 2016, including a workforce reduction and the discontinuation of certain dosage strengths of *Amoxil*<sup>®</sup> and *Augmentin*<sup>®</sup>.

## Table of Contents

During the year ended March 31, 2016, we completed the transition and integration of the Habitrol® business (an over-the-counter Nicotine Replacement Therapy transdermal patch) that we acquired from Novartis Consumer Healthcare Inc. during the year ended March 31, 2015, including operational integration and customer onboarding. The business is now fully integrated into our company, and we are working to grow the franchise through expansion of distribution into new channels and through product innovation.

Through the coordinated efforts of our teams in the United States and India, we constantly seek to expand our pipeline of generic products. During the year ended March 31, 2016, we made 14 filings including 13 ANDA filings and 1 NDA filing under section 505(b)(2) of the Federal Food, Drug and Cosmetic Act (a 505(b)(2) NDA ) in the United States, including 10 Paragraph IV filings. During the year ended March 31, 2016, the U.S. FDA granted us 2 final ANDA approvals. As of March 31, 2016, we had filed a cumulative total of 233 ANDA in the United States, out of which 79 ANDAs were pending approval at the U.S. FDA, including 12 tentative approvals. As of March 31, 2016, we had also filed three NDAs under section 505(b)(2) of the Federal Food, Drug and Cosmetic Act in the United States, one of which is tentatively approved and awaits final approval. We have also filed two new Investigational New Drugs ( INDs ), our proposed biosimilars to rituximab and PEG-GCSF. For each of these two products, a Phase 1 clinical trial, under the applicable IND, is currently in progress.

During the year ended March 31, 2016, we in-licensed six ANDAs in the United States, of which two are Paragraph IV filings. As of March 31, 2016, we have in-licensed a cumulative total of eleven ANDAs in the United States, out of which eight were pending approval with the U.S. FDA.

Our Canada business generated revenues of Rs.478 million during the year ended March 31, 2016. This business includes revenues from certain profit sharing arrangements with distributors who market certain of our generic products.

## Sales, Marketing and Distribution Network

Dr. Reddy's Laboratories, Inc., our wholly-owned subsidiary in Princeton, New Jersey, United States, is primarily engaged in the marketing of our generic products in the United States. In early 2003, we commenced sales of generic products under our own label. We have our own sales and marketing team to market these generic products. Our key account representatives for generic products call on procurement buyers for chain drug stores, drug wholesalers and distributors, mass merchandisers, group purchasing organizations ( GPOs ) for hospitals, specialty distributors and pharmacy buying groups.

Our over-the-counter ( OTC ) division markets and distributes store brand OTC products. This division has successfully launched 10 products. OTC products include store brand generic equivalents of products that originally have prescription drug status and are switched to OTC drug status by the innovator upon U.S. FDA approval (sometimes called Rx-to-OTC switch products). Our OTC division services a broad range of customers, including drug retailers, mass merchandisers, food chains, drug wholesalers and distributors, and GPOs. For the year ended March 31, 2016, our OTC division generated Rs.11,200 million in revenues.

A significant portion of our revenue is derived from the sale of injectable products in the therapeutic areas of oncology, neurology and anti-allergy. During the years ended March 31, 2015 and 2014, we launched docetaxel, azacitidine, decitabine and zoledronic acid in the United States. We have also expanded our presence to drug wholesalers, GPOs, specialty distributors, integrated distribution networks ( IDNs ), clinics and hospitals to market these products.

In the year ended March 31, 2014, we started supplying products for private label customers for prescription products.

Competition

Revenues and gross profit derived from the sales of generic pharmaceutical products are affected by certain regulatory and competitive factors. As patents and regulatory exclusivity for brand name products expire, the first manufacturer to receive regulatory approval for generic equivalents of such products is generally able to achieve significant market penetration. As competing manufacturers receive regulatory approvals on similar products, market share, revenues and gross profit typically decline, in some cases significantly. Accordingly, the level of market share, revenues and gross profit attributable to a particular generic product is normally dependent upon the number of competitors and the timing of that product's regulatory approval and launch, in relation to competing approvals and launches. Consequently, we must continue

## Table of Contents

to develop and introduce new products in a timely and cost-effective manner to maintain our revenues and gross margins. In addition, the other competitive factors critical to this business include price, product quality, consistent and reliable product supplies, customer service and reputation. Our major competitors in the United States include Teva Pharmaceutical Industries Limited, Mylan Inc., Sandoz, a division of Novartis Pharma A.G., Endo Pharmaceuticals (including its subsidiary Par Pharmaceutical), Sun Pharmaceuticals Limited and Lupin Limited.

Continued consolidation of customer purchasing power through acquisitions, alliances and joint ventures (such as the Walgreens Boots Alliance Development, the proposed acquisition of Rite Aid by Walgreens, the Red Oak Sourcing joint venture between CVS and Cardinal Health, and the acquisitions of Omnicare and Target Pharmacy by CVS) has served to intensify the competition and drive down prices. Consolidation of manufacturers is also continuing and, at the same time, new manufacturers continue to enter the generic market in the United States, which may further lower our pricing power and adversely affect our revenues in that market.

Brand name manufacturers have devised numerous strategies to delay competition from lower cost generic versions of their products. One of these strategies is to change the dosage form or dosing regimen of the brand product prior to generic introduction, which may reduce the demand for the original dosage form as sought by a generic ANDA dossier applicant or create regulatory delays, sometimes significant, while the generic applicant, to the extent possible, amends its ANDA dossier to match the changes in the brand product. In many of these instances, the changes to the brand product may be protected by patent or exclusivities, further delaying generic introduction. Another strategy is the launch by the innovator or its licensee of an authorized generic during the 180-day generic exclusivity period, resulting in two generic products competing in the market rather than just the product that obtained the generic exclusivity. This may result in reduced revenues for the generic company which has been awarded the generic exclusivity period.

The U.S. market for OTC pharmaceutical products is highly competitive. Competition is based on a variety of factors, including price, quality, product mix, customer service, marketing support, and the reliability and flexibility of the supply chain for products. Our competition in store brand products in the United States consists of several publicly traded and privately owned companies, including large brand-name pharmaceutical companies. The competition is highly fragmented in terms of both geographic market coverage and product categories, such that a competitor generally does not compete across all product lines. In the store brand market, we compete directly with companies such as Perrigo that sell store brand OTC products. With the acquisition of Habitrol<sup>®</sup>, we now not only compete with store brands but also with large branded companies such as GlaxoSmithKline Consumer Care, which is an industry leader in the nicotine replacement therapy category. In addition, since our products are generic equivalents of innovator brands, we also compete against large brand-name pharmaceutical companies. The competitive landscape and market dynamics of the OTC market are rapidly evolving. Large brand-name pharmaceutical companies have begun to more aggressively pursue Rx-to-OTC switches in new categories, which could present opportunities for us and other companies that sell store brand products. At the same time, pricing pressures continue to increase with the entry of new competitors in the market. On key select molecules, the expectation is that competition in this area will continue to grow as newer categories experience Rx-to-OTC switches.

## Government regulations

### *U.S. REGULATORY ENVIRONMENT*

All pharmaceutical manufacturers that sell products in the United States are subject to extensive regulation by the U.S. federal government, principally pursuant to the Federal Food, Drug and Cosmetic Act, the Hatch-Waxman Act, the Generic Drug Enforcement Act and other federal government statutes and regulations. These regulations govern or influence the testing, manufacturing, packaging, labeling, storing, record keeping, safety, approval, advertising,

promotion, sale and distribution of products.

Our facilities and products are periodically inspected by the U.S. FDA, which has extensive enforcement powers over the activities of pharmaceutical manufacturers. Non-compliance with applicable requirements can result in fines, criminal penalties, civil injunction against shipment of products, recall and seizure of products, total or partial suspension of production, sale or import of products, refusal of the U.S. government to enter into supply contracts or to approve new drug applications and criminal prosecution. The U.S. FDA also has the authority to deny or revoke approvals of drug active pharmaceutical ingredients and dosage forms and the power to halt the operations of non-complying manufacturers. Any failure to comply with applicable U.S. FDA policies and regulations could have a material adverse effect on the operations in our generics business.

U.S. FDA approval of an ANDA is required before a generic equivalent of an existing or referenced brand drug can be marketed. The ANDA approval process is abbreviated because the U.S. FDA waives the requirement of conducting complete

## **Table of Contents**

clinical studies, although it generally requires bio-availability and/or bio-equivalence studies. An ANDA may be submitted for a drug on the basis that it is the equivalent of a previously approved drug or, in the case of a new dosage form, is suitable for use for the indications specified.

An ANDA applicant in the United States is required to review the patents of the innovator listed in the U.S. FDA publication entitled *Approved Drug Products with Therapeutic Equivalence Evaluations*, commonly known as the *Orange Book*, and make an appropriate certification. There are several different types of certifications that can be made. A Paragraph IV filing is made when the ANDA applicant believes its product or its manufacture, use or sales thereof does not infringe on the innovator's patents listed in the *Orange Book* or where the applicant believes that such patents are not valid or enforceable. The first generic company to file a Paragraph IV filing may be eligible to receive a six-month marketing exclusivity period starting from either the first commercial marketing of the drug by any of the first applicants or a decision of a court holding the patent that is the subject of the paragraph IV certification to be invalid or not infringed. A Paragraph III filing is made when the ANDA applicant does not intend to market its generic product until the patent expiration. A Paragraph II filing is made where the patent has already expired. A Paragraph I filing is made when there are no patents listed in the *Orange Book*. Another type of certification is made where a patent claims a method of use, and the ANDA applicant's proposed label does not claim that method of use. When an innovator has listed more than one patent in the *Orange Book*, the ANDA applicant must file separate certifications as to each patent.

Before approving a product, the FDA also requires that our procedures and operations conform to current Good Manufacturing Practice (cGMP) regulations, relating to good manufacturing practices as defined in the U.S. Code of Federal Regulations. We must follow cGMP regulations at all times during the manufacture of our products. We continue to spend significant time, money and effort in the areas of production and quality to help ensure full compliance with cGMP regulations.

The timing of final U.S. FDA approval of an ANDA depends on a variety of factors, including whether the applicant challenges any listed patents for the drug and whether the brand-name manufacturer is entitled to one or more statutory exclusivity periods, during which the U.S. FDA may be prohibited from accepting applications for, or approving, generic products. In certain circumstances, a regulatory exclusivity period can extend beyond the life of a patent, and thus block ANDAs from being approved on the patent expiration date. For example, in certain circumstances the U.S. FDA may extend the exclusivity of a product by six months past the date of patent expiration if the manufacturer undertakes studies on the effect of their product in children, a so-called pediatric extension.

The Medicare Prescription Drug, Improvement and Modernization Act of 2003 (the *Medicare Act of 2003*) modified certain provisions of the Hatch-Waxman Act. In particular, significant changes were made to provisions governing 180-day exclusivity and forfeiture thereof. The new statutory provisions governing 180-day exclusivity may or may not apply to an ANDA, depending on whether the first Paragraph IV certification submitted by any applicant for the drug was submitted prior to the enactment of the Medicare Amendments on December 8, 2003.

Where the first Paragraph IV certification was submitted on or after December 8, 2003, the new statutory provisions apply. Under these provisions, 180-day exclusivity is awarded to each ANDA applicant submitting a Paragraph IV certification for the same drug with regard to any patent on the first day that any ANDA applicant submits a Paragraph IV certification for the same drug. The 180-day exclusivity period begins on the date of first commercial marketing of the drug by any of the first applicants or a decision of a court holding the patent that is the subject of the paragraph IV certification to be invalid or not infringed. However, a first applicant may forfeit its exclusivity in a variety of ways, including, but not limited to (a) failure to obtain tentative approval within 30 months after the application is filed or (b) failure to market its drug by the later of two dates calculated as follows: (x) 75 days after approval or 30 months after submission of the ANDA, whichever comes first, or (y) 75 days after each patent for which the first applicant is

qualified for 180-day exclusivity is either (1) the subject of a final court decision holding that the patent is invalid, not infringed, or unenforceable or (2) withdrawn from listing with the U.S. FDA (court decisions qualify if either the first applicant or any applicant with a tentative approval is a party; a final court decision is a decision by a court of appeals or a decision by a district court that is

---

**Table of Contents**

not appealed). The foregoing is an abbreviated summary of certain provisions of the Medicare Act of 2003, and accordingly such act should be consulted for a complete understanding of both the provisions described above and other important provisions related to 180-day exclusivity and forfeiture thereof.

Where the first Paragraph IV certification was submitted prior to enactment of the Medicare Act of 2003, the statutory provisions governing 180-day exclusivity prior to the Medicare Act of 2003 still apply. The U.S. FDA interprets these statutory provisions to award 180-day exclusivity to each ANDA applicant submitting a Paragraph IV certification for the same drug on the same day with regard to the same patent on the first day that any ANDA applicant submits a Paragraph IV certification for the same drug with regard to the same patent. The 180-day exclusivity period begins on the date of first commercial marketing of the drug by any of the first applicants or on the date of a final court decision holding that the patent is invalid, not infringed, or unenforceable, whichever comes first. A final court decision is a decision by a court of appeals or a decision by a district court that is not appealed.

*Food and Drug Administration Safety and Innovation Act ( FDASIA ) and Generic Drug User Fee Agreement ( GDUFA )*

In 2012, the United States enacted the Food and Drug Administration Safety and Innovation Act ( FDASIA ), a landmark legislation intended to enhance the safety and security of the U.S. drug supply chain by imposing stricter oversight and by holding all drug manufacturers supplying products to the United States to the same U.S. FDA inspection standards. Specifically, prior to the passage of FDASIA, U.S. law required U.S. based manufacturers to be inspected by the U.S. FDA every two years but remained silent with respect to foreign manufacturers, causing some foreign manufacturers to go as many as nine years without a routine U.S. FDA current Good Manufacturing Practice ( cGMP ) inspection, according to the Government Accountability Office. FDASIA requires foreign manufacturers to have cGMP inspections at least every two years, or more frequently for manufacturers with high risk profiles.

FDASIA also includes the Generic Drug User Fee Agreement ( GDUFA ), a program to provide the U.S. FDA with additional funds through newly imposed user fees on generic and biosimilar products. These new fees are estimated to total approximately \$1.5 billion through 2018, and are intended to fund increases in the U.S. FDA's operations and staffing with a focus on three key aims:

*Safety* To ensure that industry participants, foreign or domestic, are held to consistent quality standards and are inspected with foreign and domestic parity using a risk-based approach.

*Access* To expedite the availability of generic drugs by bringing greater predictability to the review times for ANDAs, amendments and supplements and improving timeliness in the review process. For example, FDASIA is expected to decrease the review time for ANDAs by approximately two-thirds.

*Transparency* To enhance the U.S. FDA's visibility into the complex global supply environment by requiring the identification of facilities involved in the manufacture of drugs and associated active pharmaceutical ingredients, and improve the U.S. FDA's communications and feedback with industry.

The establishment of dedicated biosimilar fees should also help ensure that the U.S. FDA has appropriate resources for managing the introduction of biosimilar products on the U.S. market. Under GDUFA, 70% of the total fees will be derived from facility fees paid by finished dosage form manufacturers and active pharmaceutical ingredient facilities listed or referenced in a pending or approved generic drug application. The remaining 30% of the total fees will be



derived from application fees, including generic drug application fees, prior approval supplement fees and drug master file fees.

*U.S. FDA Proposed New Labeling Rule*

On November 13, 2013, the U.S. FDA proposed a new labeling rule which the agency believes will speed up the dissemination of new safety information about generic drugs to health professionals and patients by allowing generic drug manufacturers to use the same process as brand drug manufacturers to update safety information in the product labeling. Under the proposal, generic drug manufacturers would be able to independently update product labeling (also called prescribing information or package inserts) with newly-acquired safety information before the U.S. FDA's review of the change, in the same way brand drug manufacturers do today. Generic manufacturers would also be required to inform the brand name manufacturer about the change. The U.S. FDA would then evaluate whether the proposed change is justified and make an approval decision on the generic drug labeling change and the corresponding brand drug labeling change at the same time, so that brand and generic drug products would ultimately have the same U.S. FDA-approved prescribing information.

## **Table of Contents**

Currently, generic manufacturers must wait to update product safety information until the corresponding brand name product has received approval to update its safety information. Brand drug manufacturers are allowed to independently update and promptly distribute updated safety information by submitting a changes being effected ( CBE ) supplement to the U.S. FDA. Generic manufacturers must notify the U.S. FDA of new safety information, and wait for the U.S. FDA and the brand manufacturer to determine the updated labeling, which may result in a delay in getting new information to health care professionals and patients.

Under current law, generic and brand drug manufacturers are required to promptly review safety information about their drugs and comply with the U.S. FDA's reporting and recordkeeping requirements. When new information becomes available that causes the product labeling to be inaccurate, all drug manufacturers must take steps to update the labeling.

To enhance transparency while the U.S. FDA is reviewing the change and to make safety-related changes to drug labeling quickly available to health care professionals and the public, the U.S. FDA plans to create a web page where safety-related changes proposed by all drug manufacturers would be posted. Members of the public could subscribe to receive updates.

Because the current regulatory scheme only permits a generic manufacturer to use the CBE process to update its label if the branded drug manufacturer changes its label first, this can prevent generic manufacturers from complying with state law warning requirements. As a result, state product liability suits based on failure-to-warn and design defect claims against generics manufacturers have generally been held pre-empted by Federal law, and in June 2013 the United States Supreme Court upheld such pre-emption and immunity of generic manufacturers in *Mutual Pharmaceutical Co. v. Bartlett*.

If the U.S. FDA's proposed new rule is adopted, it may eliminate this pre-emption and increase our potential exposure to lawsuits relating to product safety, side effects and warnings on labels. This new potential exposure to lawsuits may also increase the risk that, in the future, we may not be able to obtain the type and amount of insurance coverage we desire at an acceptable price and self-insurance may become the sole commercially reasonable means available for managing the product liability risks of our business.

Comments on the proposed labeling rule were initially due on March 13, 2014. However, the U.S. FDA subsequently reopened the comment period from February 18, 2015 until April 27, 2015 in light of both the significant amount of interest in the proposal and the emergence of alternate proposals put forth and endorsed by the generic pharmaceutical industry. The U.S. FDA has announced that it will issue a final rule in April 2017.

### *Prescription Drug Marketing Act and Laws Regulating Payments to Healthcare Professionals*

The FDA also enforces the requirements of the Prescription Drug Marketing Act, which, among other things, imposes various requirements in connection with the distribution of product samples to physicians. Sales, marketing and scientific/educational grant programs must comply with the federal anti-kickback statute, the Medicare-Medicaid Anti-Fraud and Abuse Act, as amended, the False Claims Act, as amended, and similar state laws. Pricing and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990, as amended. We are also subject to Section 6002 of the Patient Protection and Affordable Care Act, commonly known as the Physician Payment Sunshine Act which regulates disclosure of payments to certain healthcare professionals and providers.

### *Patient Protection and Affordable Care Act*

In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the PPACA), were signed into law. The PPACA is one of the most significant healthcare reform measures in the United States in decades, and is expected to significantly impact the U.S. pharmaceutical industry. The PPACA imposes additional rebates, discounts and fees, mandates certain reporting and contains various other requirements that could adversely affect our business, including the following:

The PPACA imposes annual, non-deductible fees for entities that manufacture or import certain prescription drugs and biologics. This fee is calculated based upon each manufacturer's percentage share of total branded prescription drug and biologics sales to U.S. government programs (such as Medicare, Medicaid, Veterans Affairs and Public Health Service discount programs), and authorized generic products are generally treated as branded products. The manufacturer must have at least \$5 million in sales of branded prescription drugs or biologics in order to be subject to this fee.

## **Table of Contents**

The PPACA changed the computations used to determine Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program by redefining the average manufacturer's price ( AMP ), effective October 1, 2010, and by using 23.1% instead of 15.1% of AMP for most branded drugs and 13% instead of 11% of AMP for generic drugs, effective January 1, 2010.

The PPACA also increased the number of healthcare organizations eligible to participate in the Public Health Service pharmaceutical pricing program, which provides for government controlled prices that result in substantial discounts for participants.

The PPACA has pro-generic provisions that could increase competition in the generic pharmaceutical industry and therefore adversely impact our selling prices or costs and reduce our profit margins. Among other things, the PPACA creates an abbreviated pathway to U.S. FDA approval of biosimilar biological products and allows the first interchangeable bio-similar biological product 18 months of exclusivity, which could increase competition for our bio-similars business. Conversely, the PPACA has some anti-generic provisions that could adversely affect our bio-similars business, including provisions granting the innovator of a biological drug product 12 years of exclusive use before generic drugs can be approved based on being biosimilar.

The PPACA makes several important changes to the federal anti-kickback statute, false claims laws, and health care fraud statutes that may make it easier for the government or whistleblowers to pursue such fraud and abuse violations. In addition, the PPACA increases penalties for fraud and abuse violations. If our past, present or future operations are found to be in violation of any of the laws described above or other similar governmental regulations to which we are subject, we may be subject to the applicable penalty associated with the violation which could adversely affect our ability to operate our business and our financial results.

To further facilitate the government's efforts to coordinate and develop comparative clinical effectiveness research, the PPACA establishes a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in such research. The manner in which the comparative research results would be used by third-party payors is uncertain.

On June 28, 2010, the Departments of Health and Human Services, Labor, and the Treasury jointly issued interim final regulations to implement the provisions of the PPACA that prohibit the use of preexisting condition exclusions, eliminate lifetime and annual dollar limits on benefits, restrict contract rescissions, and provide patient protections. On June 20, 2014 the Departments of Health and Human Services, Labor, and the Treasury jointly issued final regulations clarifying the relationship between a group health plan's eligibility criteria and the PPACA's 90-day limit on waiting periods.

On January 27, 2012, The Centers for Medicare and Medicaid Services ( CMS ) issued its long awaited proposed rule implementing the Medicaid pricing and reimbursement provisions of the PPACA and related legislation. CMS accepted comments on this proposed rule through April 2, 2012.

On June 28, 2012, the U.S. Supreme Court ruled on certain challenged provisions of the PPACA. The U.S. Supreme Court generally upheld the constitutionality of the PPACA, including its individual mandate that requires most Americans to buy health insurance starting in 2014, and ruled that the Anti-Injunction Act did not bar the Court from reviewing that the PPACA provision. However, the U.S. Supreme Court invalidated the PPACA's provisions requiring

each state to expand its Medicaid program or lose all federal Medicaid funds. The Court did not invalidate the PPACA's expansion of Medicaid for states that voluntarily participate; it only held that a state's entire Medicaid funding cannot be withheld due to its failure to participate in the expansion.

On February 1, 2016, the CMS published in the Federal Register a Final Regulation with comment period to implement the Medicaid Drug Rebate Program. The Final Regulation was to clarify ambiguities in the ACA amendments. The key provisions covered under the Final Regulation included, without limitation, the following: (i) the adoption of a final definition of retail community pharmacy (RCP), (ii) the adoption of a rule permitting inhalation, infusion, instilled, implanted, or injectable drugs (5i drugs) to be deemed not to be generally dispensed through a RCP, and thus excluded from the calculation of their AMP, if 70% or more of its sales were to entities other than RCPs or wholesalers for drugs distributed to

## **Table of Contents**

RCPs (the prior threshold was 90%), (iii) the inclusion of authorized generics in calculations of AMP and best price, (iv) narrowing the regulatory definition for best price, (v) requiring additional Medicaid rebate payments for generic drugs, effective as of April 1, 2017, and (vi) clarification of the definition of bona fide service fees based on a four part test.

Pending full implementation of the PPACA, we are continuing to evaluate all potential scenarios surrounding its implementation and the corresponding impact on our financial condition, results of operations and cash flow.

### *Drug Quality and Security Act*

On November 28, 2013, the Drug Quality and Security Act was signed into law in the United States. The legislation introduces a federal track-and-trace system for medicines with serial numbers added to individual packs and (non-mixed) cases within four years of the legislation's adoption, and electronic tracing of production through the supply chain mandated within 10 years. It also strengthens licensure requirements for wholesale distributors and third-party logistics providers, and requires the U.S. FDA to maintain a database of wholesalers that will be available to the public through its website. The law also boosts oversight of compounding pharmacies that make drugs to order, and increases the powers of the U.S. FDA to oversee large-volume or outsourcing compounders without individual prescriptions.

### *Biologics Pathway*

The Biologics Price Competition and Innovation Act of 2009 ( BPCIA ) created a statutory pathway and abbreviated approval processes for the approval of biosimilar versions of brand-name biological products and a process to resolve patent disputes. On April 28, 2015, the U.S. FDA finalized three substantial draft guidance documents originally published in February 2012 that are intended to provide a roadmap for development of biosimilar products. On May 13, 2015, the U.S. FDA released another biosimilar guidance document. These guidance documents address quality considerations, scientific considerations and questions and answers regarding commonly posed issues.

### *Trans-Pacific Partnership*

The Trans-Pacific Partnership ( TPP ) free trade agreement was concluded in October 2015 by the United States, Australia, New Zealand, Peru, Chile, Mexico, Canada, Singapore, Brunei, Malaysia, Vietnam and Japan. The final text of the TPP agreement requires TPP-signatory countries to provide biopharmaceutical products with a minimum of either eight years of data exclusivity or five years of data exclusivity coupled with an additional three years of other measures that must deliver a comparable outcome in the market, recognizing that market circumstances also contribute to effective market protection to deliver a comparable outcome in the market. Notably, the TPP fails to explain what other measures or market circumstances will deliver a comparable outcome in the market. The TPP agreement only sets a minimum period for exclusivity and not a maximum, and so the United States will be permitted to maintain the current BPCIA rules granting biologics manufacturers 12 years of combined data and market exclusivity. The text of the TPP agreement must now be ratified and signed according to the procedures of each nation concerned.

### *Other matters*

#### *Civil Investigative Demand from the Office of the Attorney General, State of Texas*

On or about November 10, 2014, Dr. Reddy's Laboratories, Inc., one of our subsidiaries in the U.S., received a Civil Investigative Demand ( CID ) from the Office of the Attorney General, State of Texas (the Texas AG ) requesting

certain information, documents and data regarding sales and price reporting in the U.S. marketplace of certain products for the period of time between January 1, 1995 and the date of the CID. Compliance with the CID is ongoing, and we understand that the investigation is continuing.

*Subpeona duces tecum from the Office of the Attorney General, California*

On November 3, 2014, Dr. Reddy's Laboratories, Inc. received a subpoena duces tecum to appear before the Office of the Attorney General, California (the California AG ) and produce records and documents relating to the pricing of certain products. A set of five interrogatories related to pricing practices was served as well. Compliance with the subpoena is ongoing, and we understand that the investigation is continuing.

## **Table of Contents**

### *CANADA REGULATORY ENVIRONMENT*

In Canada, we are required to file product dossiers with the Health Canada for permission to market a generic pharmaceutical product. The regulatory authorities may inspect our manufacturing facility before approval of the dossier. As of March 31, 2016, we had filed a total of 24 Abbreviated New Drug Submissions ( ANDS ) in Canada, out of which 8 ANDS were pending approval and 2 were rejected.

### *Europe*

Our sales of generic medicines in Europe for the year ended March 31, 2016 were Rs.7,732 million, which accounted for approximately 6% of our Global Generics segment's sales.

In the European Union (the EU ), the manufacture and sale of pharmaceutical products is regulated in a manner substantially similar to that in the United States. Legal requirements generally prohibit the handling, manufacture, marketing and importation of any pharmaceutical product unless it is properly registered and manufactured in accordance with applicable law. The registration file relating to any particular product must contain scientific data related to product efficacy and safety, including results of clinical testing and references to medical publications, as well as detailed information regarding production methods and quality control. Regulatory authorities are authorized to suspend, restrict or cancel the registration of a product if it is found to be harmful or ineffective, or manufactured and marketed other than in accordance with registration conditions.

### **Sales, Marketing and Distribution Network**

#### *Germany*

In Germany, we sell a broad range of generic pharmaceutical products under the betapharm brand.

Over the last few years, the German pharmaceutical market has significantly changed. The healthcare reform known as the Statutory Health Insurance (SHI) Competition Strengthening Act or Wettbewerbsstärkungsgesetz ( GKV-WSG ) (an act to strengthen the competition in public health insurance), which was effective as of April 1, 2007, has significantly increased the power of insurance companies and statutory health insurance funds ( SHI funds ) to influence dispensing of medicines.

Pursuant to the GKV-WSG law, those pharmaceutical products covered by rebate contracts with insurance companies and SHI funds have to be prescribed by physicians and dispensed by pharmacies with priority. This has increased the power of insurance companies and SHI funds. As a result, many SHI funds have enacted tender (i.e., competitive bidding) processes to determine which pharmaceutical companies they will enter into rebate contracts with. This has resulted in more than 90% of generic products currently sold in German retail outlets being supplied through contracts procured in competitive bidding tenders, thereby causing significant pressure on product margins. In response to these market changes, betapharm underwent a comprehensive restructuring of its sales force, with a reduction of more than 200 employees since we acquired it in March 2006. In addition, we are participating in the tender opportunities by bidding at prices which meet our internal incremental profitability thresholds. In view of this, our success ratio in winning these tender awards has declined and, accordingly, the ratio of our tender based sales to our overall sales has significantly reduced over the past few years.

#### *United Kingdom and other Countries within Europe*



We market our generic products in the United Kingdom and other EU countries through our U.K. subsidiary, Dr. Reddy's Laboratories (U.K.) Limited. This subsidiary was formed in the year ended March 31, 2003 after our acquisition of Meridian Healthcare Limited, a United Kingdom based generic pharmaceutical company.

### Competition

Our key competitors within the German generics market include the Sandoz group of Novartis Pharma A.G. (including its Hexal, Sandoz and 1A Pharma subsidiaries), the Ratiopharm group of Teva Pharmaceutical Industries Ltd. (including its Ratiopharm, AbZ-Pharma and CT Arzneimittel subsidiaries), Winthrop Arzneimittel GmbH and the Stada group of Stada Arzneimittel AG (including its Stada and Aliud subsidiaries). In the rebate contracts with SHI funds, prices are one of the most important competitive factors.

According to British Generics Manufacturers Association, the United Kingdom is one of the largest markets for generic pharmaceuticals in Europe with high generic penetration 82% and is also one of the most price competitive markets due to a high degree of vertical integration and consolidation of buyers, as more than 65% of the retail pharmacies are owned by wholesalers or are part of retail chains, and low barriers of entry.

## Table of Contents

### Government regulations

#### *European Union Regulatory Environment*

The activities of pharmaceutical companies within the European Union are governed in particular by Directives 2001/83/EC and 2003/94/EC, as amended, and as implemented in national laws within the countries of the European Union. These Directives outline the legislative framework, including the legal basis of marketing authorization procedures, and quality standards including manufacture, patient information and pharmacovigilance activities.

Prior approval of a marketing authorization is required to supply products within the European Union. Such marketing authorizations may be restricted to one member state, cover a selection of member states or can be for the whole of the European Union, depending upon the form of registration procedure selected.

Generic or abridged applications omit full non-clinical and clinical data but contain limited non-clinical and clinical data, depending upon the legal basis of the application or to address a specific issue. In the case of a generic medicine application, the applicant is required to demonstrate that its generic product contains the same active pharmaceutical ingredients in the same dosage form for the same indication as the innovator product. Specific data is included in the application to demonstrate that the proposed generic product is interchangeable to the innovator product with respect to quality, safe usage and continued efficacy. European Union laws prevent regulatory authorities from accepting applications for approval of generics that rely on the safety and efficacy data of an innovator of a branded product until the expiration of the innovator's data exclusivity period (usually 8 years from the first marketing authorization in the European Union, depending on the circumstances). The applicant is also required to demonstrate bioequivalence with the EU reference product. Once all these criteria are met, a marketing authorization may be considered for grant.

Unlike in the United States, there is no equivalent regulatory mechanism within the European Union to incentivize challenge to any patent protection, nor is any period of market exclusivity conferred upon the first generic approval. In situations where the period of data exclusivity given to the innovator of a branded product expires before their patent expires, the launch of our product would then be delayed until patent expiration.

Our U.K. facilities are licensed and periodically inspected by the U.K. Medicines and Healthcare products Regulatory Agencies ( MHRA ) good manufacturing practice Inspectorate, which has extensive enforcement powers over the activities of pharmaceutical manufacturers. Non-compliance can result in product recall, plant closure or other penalties and restrictions. In addition, the U.K. MHRA Inspectorate has approved and periodically inspected our manufacturing facilities based in Hyderabad, Telangana, India for the manufacture of generic medicines for supply to Europe. The Regierung von Oberbayern, the district government of Upper Bavaria in Germany, has also inspected our plants in Hyderabad as well as Vishakapatnam.

All pharmaceutical companies that manufacture and market human medicinal products in Germany are subject to the applicable rules and regulations executed by the BfArM and the supervisory authorities of the respective federal state in Germany. All pharmaceutical companies in Germany are periodically inspected by the competent supervisory authority, which has extensive enforcement powers over the activities of pharmaceutical companies. Non-compliance can result in closure of the facility.

In Germany, the government has in recent years enacted a number of laws designed to limit pharmaceutical cost increases, including the GKV-WSG discussed above and the Economic Optimization of Pharmaceutical Care Act (also known as the AVWG ). During the fiscal year ended March 31, 2011, the German government introduced a new law entitled Act on the reorganization of the pharmaceutical market in the public health insurance (or *Arzneimittelmarktneuordnungsgesetz* , commonly referred to as AMNOG ), which affects reimbursement of drugs

within Germany's statutory health care system in order to further control the costs of medical care. The key elements of this law are as follows:

Historically, the pharmaceutical companies had been free to set the initial asking price for novel drugs in the German public health system, subject to certain mandatory rebates. Under this new law, a pharmaceutical company determines the price for a new drug or new therapeutic indication for the first year after launch, but must submit to the Joint Federal Committee (the Gemeinsamer Bundesausschuss or G-BA) a benefit/risk assessment dossier on the drug at or prior to its launch. The G-BA analyzes whether the drug shows an additional clinical benefit in comparison to a corresponding established drug (the appropriate comparator therapy).

**Table of Contents**

If an additional benefit is established, the pharmaceutical company must negotiate the price of the drug with the Federal Association of the health insurance funds. If no agreement is reached in the negotiation, then the price is determined pursuant to an arbitration procedure. There must be a minimum term of one year.

If no additional benefit is established, the drug is immediately included in a group of drugs with comparable pharmaceutical and therapeutic characteristics, for which maximum reimbursement prices have already been set. If this is not possible due to the drug's novelty, then the pharmaceutical company must negotiate a reimbursement price with the Federal Association of the health insurance funds that may not exceed the costs of the appropriate comparator therapy.

The prices determined pursuant to the above procedures also apply to private insurance agencies, privately insured persons and self-payers, although they may negotiate further discounts.

For drugs developed specifically to treat rare medical conditions that are designated as orphan drugs, the orphan drug will be presumed to have an additional benefit under certain circumstances.

A new regulation for packaging size had to be implemented in 2013. Standard sizes are now based upon the duration of therapies, instead of being based on fixed quantity. Three different types of package sizes are now allowed: N1-packages for treatment periods of 10 days; N2-packages for treatment periods of 30 days; and N3-packages for treatment periods of 100 days.

The law increases the choice to patients by the use of co-payment as an option for patients opting for a non-rebated generic drug.

In Germany, the German Drug Law (Arzneimittelgesetz) (AMG), which implements European Union requirements, is the primary regulation applicable to medicinal products. In 2012, the 16<sup>th</sup> Amendment to the AMG and related laws were enacted in order to implement European Directives into national laws. Among other things, the most important changes refer to pharmacovigilance, clinical trials, protection measures against counterfeited medicines and liberalization of German drug advertising law. These transpositions of European Union legislation into national law also took place in the United Kingdom.

The German Social Code's price freeze imposed on reimbursable drugs, which was due to expire at the end of 2013, was amended in 2013 and 2014 to extend the price freeze until December 31, 2017, although the continued price freeze will not apply to medicines subject to internal reference pricing.

New European pharmacovigilance legislation (Regulation (EU) No 1235/2010 and Directive 2010/84/EU) was implemented in July 2012. These new requirements are intended to improve patient safety, but will also increase our administrative burdens and therefore our costs. In 2015, the European Commission introduced pharmacovigilance service fees that industry pays for the simplification and maintenance of the European pharmacovigilance system, as well as fees for the assessment of aggregate safety reports and protocols and study reports mandated following a safety referral. The service fees payable for these reports are unpredictable, as the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicine Agency (EMA) can initiate a safety referral for any medicine or class

of medicines with a significant new safety concern at any time.

The International Standards for Identification of Medicinal Products ( IDMP ), comprised of five International Organization for Standardization ( ISO ) standards, were approved in 2012. These standards are designed to allow unambiguous identification of medicinal products across companies and regions in order to support and improve pharmacovigilance and other activities. In the European Union, these standards will become mandatory for medicinal product information by mid-2018.

The submission of medicinal product data to support pharmacovigilance has been required since 2012 in the European Union. The original European database for data regarding medicinal products, the Eudravigilance Medicinal Product Dictionary ( EVMPD ), was launched by the EMA at the end of 2001. It was designed to standardize the collection, reporting, coding, and evaluation of authorized and investigational medicinal product information. In 2012 it became mandatory for marketing-authorzation holders to supply information to the extended version of the EVMPD (xEVMPD or Article 57 database). However, this is an interim solution and contains only a fraction of the data that will have to be submitted to the IDMP-compliant database for each authorized product in the European Union.

---

**Table of Contents**

In order for us to support the maintenance of medicinal product data in the IDMP-compliant database, we will be required to invest in new systems and make significant changes to our processes and procedures.

Following implementation in the European Union, it is expected that the U.S. FDA will also implement these standards.

***Rest of the World markets of our Global Generics segment***

We refer to all markets of our Global Generics segment other than North America, Europe, Russia and other countries of the former Soviet Union and Romania and India as our Rest of the World markets. Our significant Rest of the World markets include Venezuela, South Africa and Australia. Our revenues from our Rest of the World markets were Rs.9,416 million in the year ended March 31, 2016, a decrease of 28% as compared to the year ended March 31, 2015. This decrease was primarily attributable to a reduction of our sales in Venezuela.

***Venezuela***

Venezuela accounted for 3.7% of our Global Generics segment's revenues in the year ended March 31, 2016. In comparison, Venezuela accounted for 7% of our Global Generics segment's revenues in the year ended March 31, 2015. This reduction in sales was primarily attributable to the ongoing economic crisis in the country and, correspondingly, our risk mitigation approach by way of moderating the supply of products to this country.

In February 2015, the Venezuelan government launched an overhaul of the exchange rate system and introduced a new exchange rate mechanism. The Marginal Currency System (known as SIMADI) was the third mechanism in this three-tier exchange rate regime and allowed for legal trading of the Venezuelan bolivar for foreign currency with fewer restrictions than other mechanisms in Venezuela (CENCOEX and SICAD). As per the then existing laws in Venezuela, payments towards the importation of pharmaceutical products qualified for the CENCOEX preferential rate of 6.3 VEF per U.S.\$1.00, and we were receiving approvals at such preferential rate.

In February, 2016, the Venezuelan government announced further changes to its foreign currency exchange mechanisms, including the devaluation of its official exchange rate. The following changes became effective as of March 10, 2016:

The CENCOEX preferential rate was replaced with a new DIPRO rate. The DIPRO rate is only available for purchases and sales of essential items such as food and medicine. Further, the preferential exchange rate was devalued from 6.3 VEF per U.S.\$1.00 to 10 VEF per U.S.\$1.00;

The SICAD exchange rate mechanism, which last auctioned U.S. Dollars for approximately 13 VEF per U.S.\$1.00, was eliminated; and

The SIMADI exchange rate mechanism was replaced with a new DICOM rate, which was 272.5 VEF per U.S.\$1.00 as at March 31, 2016. The DICOM rate governs all other transactions not covered by DIPRO and will fluctuate according to market supply and demand.

We have not received approvals from the Venezuelan government to repatriate any amounts at preferential rates beyond U.S.\$4 million already approved and received during the year ended March 31, 2016. We believe that in the

interim, it is appropriate to use the DICOM rate (i.e., 272.5 VEF per U.S.\$1.00) instead of the preferential rate of VEF 10 per U.S.\$1.00 for translating the monetary assets and liabilities of our Venezuelan subsidiary as at March 31, 2016. Accordingly, we recorded foreign exchange loss of Rs.4,621 million under finance expenses in the income statement during the year ended March 31, 2016.

Notwithstanding this ongoing uncertainty, we continue to actively engage with the Venezuelan Government and seek approval to repatriate funds at preferential rates so that we may continue to provide affordable medicine to fulfill the needs of people of their country.

## Table of Contents

### *GSK Alliance*

We have a strategic partnership with GlaxoSmithKline plc ( GSK ) to develop and market select products across emerging markets outside India. The products are manufactured by us, and licensed and supplied to GSK in markets such as Latin America, Africa, the Middle East and Asia Pacific, excluding India.

During the year ended March 31, 2016, as part of our company strategy and in light of our strong portfolio of products, we have decided to expand into select new markets. To supplement our own entry and growth in these markets, we have reached an agreement with GSK to take back the marketing rights for key products in these markets. To enable this, both the parties have agreed to terminate the old agreement.

### *Collaboration agreement with Merck Serono*

On June 6, 2012, we entered into a collaboration agreement with the biosimilars division of Merck KGaA, Darmstadt, Germany, formerly known as Merck Serono (hereinafter, Merck KGaA ), to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The arrangement covers co-development, manufacturing and commercialization of the compounds around the globe, with some specific country exceptions. During the year ended March 31, 2016, the collaboration agreement was amended to rearrange and realign the development of compounds, territory rights and royalty payments. Both parties will undertake commercialization based on their respective regional rights as defined in the agreement. We will lead and support early product development towards or including Phase I development. Merck KGaA will carry out manufacturing of the compounds and will lead further development for its territories. In our exclusive and co-exclusive territories, we will carry out our own development, wherever applicable, for commercialization. As before, we will continue to receive royalty payments upon commercialization by Merck KGaA in its territories.

During the three months ended December 31, 2015, we received from Merck KGaA certain amounts relating to its share of development costs and other amounts linked to the achievement of milestones for the development of compounds under the collaboration agreement, as amended.

### Global Generics Manufacturing and Raw Materials

Manufacturing for our Global Generics segment entails converting active pharmaceutical ingredients ( API ) into finished dosages. As of March 31, 2016, we had thirteen manufacturing facilities within this segment. Eleven of these facilities are located in India and two are located in the United States (Shreveport, Louisiana; and Bristol, Tennessee). In addition, we also have one packaging facility in the United Kingdom. All of the facilities are designed in accordance with and are compliant with current Good Manufacturing Practice ( cGMP ) requirements and are used for the manufacture of tablets, hard gelatin capsules, injections, liquids and creams for sale in India as well as other markets. All of our manufacturing sites laboratories and facilities are designed and maintained to meet increasingly stringent requirements of safety and quality. All of our sites outside of India are approved by the respective regulatory bodies in the jurisdictions where they are located.

We manufacture most of our finished products at these facilities and also use contract manufacturing arrangements as we determine necessary. For each of our products, we continue to identify, upgrade and develop alternate vendors as part of risk mitigation and continual improvement.

The ingredients for the manufacture of the finished products are sourced from in-house API manufacturing facilities and from vendors, both local and non-local. Each of these vendors undergo a thorough assessment as part of the vendor qualification process before they qualify as an approved source. We attempt to identify more than one supplier



in each drug application or make plans for alternate vendor development from time to time, considering the supplier's history and future product requirements. Arrangements with international raw material suppliers are subject to, among other things, respective country regulations, various import duties and other government clearances.

The prices of our raw materials generally fluctuate in line with commodity cycles. Raw material expense forms the largest portion of our cost of revenues. We evaluate and manage our commodity price risk exposure through our operating procedures and sourcing policies.

The logistics services for storage and distribution in the United States, Germany, Venezuela, Russia, the United Kingdom, South Africa and Australia are outsourced to a third party service provider.

We manufacture formulations in various dosage forms including tablets, capsules, injections, liquids and creams. These dosage forms are then packaged, quarantined and subject to stringent quality tests, to assure product quality before release into the market. We manufacture our key brands for our Indian markets at our facilities in Baddi, Himachal Pradesh, to take advantage of certain fiscal benefits offered by the Government of India, which includes partial exemption from income taxes for a specified period.

**Table of Contents**

All pharmaceutical manufacturers that sell products in any country are subject to regulations issued by the Ministry of Health (or its equivalent) of the respective country. These regulations govern, or influence the testing, manufacturing, packaging, labeling, storing, record-keeping, safety, approval, advertising, promotion, sale and distribution of products. Our facilities and products are periodically inspected by various regulatory authorities such as the U.S. FDA, the U.K. MHRA, the German BfARM, the South African Medicines Control Council, the Brazilian ANVISA, the Romanian National Medicines Agency, Ukrainian State Pharmacological Center, the local World Health Organization and Drug Control Authority of India, all of which have extensive enforcement powers over the activities of pharmaceutical manufacturers operating within their jurisdiction.

In November 2015, we received a warning letter from the U.S. FDA relating to violations at our oncology formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh. Refer to Item 4.A. History and development of the company - Key business developments for further details.

*Changes in OctoPlus N.V. operations*

In the year ended March 31, 2013, we acquired Netherlands-based specialty pharmaceutical company OctoPlus N.V. ( OctoPlus ). OctoPlus has developed significant in-house expertise in the development and creation of micro-spheres and liposomes using certain polymer based technologies that enhance and enable controlled-release of the subject API into the human body. OctoPlus is well-known in the market for formulating complex injectables using polylactic-co-glycolic acid ( PLGA ) technology, which requires significant expertise and experience. In addition, OctoPlus also uses its own patented PolyActive technology in specific project based injectables.

OctoPlus was previously engaged in our internal drug development projects as well as providing pharmaceutical development services to external customers. During the year ended March 31, 2015, we decided to significantly increase the utilization of OctoPlus's technical know-how and its time and effort on internal drug development projects, and to scale-down its external pharmaceutical development services.

**Pharmaceutical Services and Active Ingredients ( PSAI ) segment**

Our Pharmaceutical Services and Active Ingredients ( PSAI ) segment includes our business of manufacturing and marketing active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are the principal ingredients for finished pharmaceutical products. Active pharmaceutical ingredients and intermediates become finished pharmaceutical products when the dosages are fixed in a form ready for human consumption, such as a tablet, capsule or liquid using additional inactive ingredients. This segment also includes our contract research services business and our manufacture and sale of steroids in accordance with specific customer requirements.

Our PSAI segment's revenues for the year ended March 31, 2016 were Rs.22,379 million, a decline of 12% as compared to the year ended March 31, 2015. Our PSAI segment accounted for 14% of our total revenues for the year ended March 31, 2016.

During the year ended March 31, 2016, we filed 50 Drug Master Files ( DMFs ) worldwide, of which 8 were filed in the United States, 3 were filed in Europe and 39 were filed in other countries. Cumulatively, our total DMFs filed worldwide as of March 31, 2016 were 768, including 218 DMFs filed in the United States.

We produce and market more than 100 different APIs for numerous markets. Our PSAI segment's API business is operated independently from our Global Generics segment and, in addition to supplying API to our Global Generics segment, our PSAI segment sells API to third parties for use in manufacturing generic products, subject to any patent rights of other third parties. We export API to more than 80 countries, and our principal overseas markets in this

business segment include North America (the United States and Canada) and Europe. Our PSAI segment's API business also manufactures and supplies the API requirements of our pharmaceutical services business. The research and development group within our API business contributes to our business by creating intellectual property (principally with respect to novel and non-infringing manufacturing processes and intermediates), providing research intended to reduce the cost of production of our products and developing new products.

The pharmaceutical services (contract research and manufacturing) arm of our PSAI segment was established in 2001 to leverage our strength in process chemistry to serve the niche segment of Innovator pharmaceutical and fine chemicals industry. Over the years, our business strategy in this area has evolved to focus on the marketing of process development and manufacturing services. Our objective is to be the preferred partner for innovator pharmaceutical companies, providing a

## Table of Contents

complete range of services that are necessary to take their innovations to the market speedily and more efficiently. The focus is to leverage our skills in process development, analytical development, formulation development and Current Good Manufacturing Practice ( cGMP ) to serve various needs of innovator pharmaceutical companies. We have positioned our PSAI segment s Custom Pharmaceutical Services business to be the partner of choice for large and emerging innovator companies across the globe, with service offerings spanning the entire value chain of pharmaceutical services.

### Sales, Marketing and Distribution

*Developed Markets.* Our PSAI segment s principal overseas markets are the United States and Europe. Our PSAI segment s sales to these markets were Rs.12,365 million for the year ended March 31, 2016, and accounted for 55% of our PSAI segment s revenues for the year ended March 31, 2016. In the United States and Europe, the patent protection for a large number of high value branded pharmaceutical products expired in years ended March 31, 2011, 2012 and 2013 and this opened the market to generic products that sourced their API from our PSAI segment. However, during the years ended March 31, 2014, 2015 and 2016, such expirations were much less frequent, which resulted in a decrease in new opportunities in these markets for the customers of our PSAI segment. We market our products through our subsidiaries in the United States and Europe. These subsidiaries are engaged in all aspects of marketing activity and support our customers pursuit of regulatory approval for their products, focusing on building long-term relationships with the customers.

*Other Key Markets.* India is an important market for our PSAI segment, with total sales of Rs.2,618 million, and it accounted for 12% of the PSAI segment s revenues in the year ended March 31, 2016. In India, we market our API products to Indian and multinational companies, many of whom are also our competitors in our Global Generics segment. The market in India is highly competitive, with severe pricing pressure and competition from lower cost foreign imports in several products.

Our PSAI segment s sales to all of the other markets (excluding the United States, Europe and India) were Rs.7,396 million for the year ended March 31, 2016 and accounted for 33% of our PSAI segment s revenues for the year. Our PSAI segment s other key markets include Brazil, Mexico, South Korea and Japan. While we work through our agents in these markets, our zonal marketing managers also interact directly with our key customers in order to service their requirements.

Our focus is on building relationships with top customers in each of these markets and partnering with them in product launches by providing timely technical and analytical support.

For our custom pharmaceutical services line of business, we have focused business development teams dedicated to our key geographies of North America (the United States and Canada), the European Union and Asia Pacific. These teams target large and emerging innovator companies to build long-term business relationships focused on catering to their outsourcing needs.

Going forward, we expect our PSAI segment to show growth on account of our investments in newer technologies and platforms. We are also pursuing a partnership model to enable our customers to reach more markets faster and efficiently by leveraging our cost leadership and presence across the globe.

### PSAI Manufacturing and Raw Materials

The infrastructure for our PSAI segment consists of eight U.S. FDA-inspected plants (six of which are in India, one of which is in Mexico, and one of which is in Mirfield, United Kingdom) and three technology development centers (two

of which are in Hyderabad, India and one of which is in Cambridge, United Kingdom). In addition, we have also set up a new manufacturing facility which is part of a Special Economic Zone located in Devunipalavalasa, Srikakulam, Andhra Pradesh, India.

*India.* All of our facilities in India are located in the states of Andhra Pradesh and Telangana. We have the flexibility to produce quantities that range from a few kilograms to several metric tons. The manufacturing process consumes a wide variety of raw materials that we obtain from sources that comply with the requirements of regulatory authorities in the markets to which we supply our products. We procure raw materials on the basis of our requirement planning cycles. We utilize a broad base of suppliers in order to minimize risk arising from dependence on a single supplier. We also source several APIs from third party suppliers for resale. During the year ended March 31, 2016, approximately 6% of our total API revenues resulted from sales of API procured from third-party suppliers. We maintain stringent quality controls when procuring materials from third-party suppliers.

## Table of Contents

In November 2015, we received a warning letter from the U.S. FDA relating to cGMP deviations at our API manufacturing facilities at Srikakulam, Andhra Pradesh and Miryalaguda, Telangana. Refer to Item 4.A. History and development of the company - Key business developments for further details.

The prices of our raw materials generally fluctuate in line with commodity cycles although the prices of raw materials used in our API business are generally more volatile. Raw material expense forms the largest portion of our cost of revenues. We evaluate and manage our commodity price risk exposure through our operating procedures and sourcing policies.

*Mexico.* Our manufacturing plant in Cuernavaca, Mexico (the Mexico facility) was acquired from Roche during the year ended March 31, 2006. In addition to manufacturing the active pharmaceutical ingredients naproxen and naproxen sodium and a range of intermediates, the Mexico facility synthesizes steroids for use in pharmaceutical and veterinary products.

The Dowpharma Small Molecules business, which we acquired from The Dow Chemical Company in April 2008, continues to offer niche capabilities, such as biocatalysis, chemocatalysis and hydroformulation, to provide cost effective solutions for chiral molecules. The non-exclusive license to Dow's Pfēnex Expression Technology for biocatalysis development, also acquired as part of the acquisition, continues to offer us opportunities to provide technology leveraged manufacturing services to innovators, including major global pharmaceutical companies.

For our contract research services, we have well-resourced synthetic organic chemistry laboratories, analytical laboratories and kilo laboratories at our technology development centers at Miyapur and Jeedimetla in Hyderabad, India. Our chemists and engineers understand cGMP manufacturing and regulatory requirements for synthesis, manufacture and formulation of a NCE from the pre-clinical stage to commercialization. To complete the full value chain in development services, we also provide formulation development services. We have facilities for pre-formulation and formulation development, analytical development, clinical trial supplies, pilot scale and product regulatory support. Larger quantities of APIs are sourced from API plants in India and Mexico.

Our contract research and manufacturing business is uniquely positioned in the market where it utilizes assets (both in terms of physical assets and technical know-how) of a vertically integrated pharmaceutical company and combines this with the service model which we built over the last few years.

## Competition

The global API market can broadly be divided into regulated and less regulated markets. The less regulated markets offer low entry barriers in terms of regulatory requirements and intellectual property rights. The regulated markets, like the United States and Europe, have high entry barriers in terms of intellectual property rights and regulatory requirements, including facility approvals. As a result, there is a premium for quality and regulatory compliance along with relatively greater stability for both volumes and prices. As an API supplier, we compete with a number of manufacturers within and outside India, which vary in size. Our main competitors in this segment are Divis Laboratories Limited, Aurobindo Pharma Limited, Cipla Limited, Mylan Laboratories Limited, Sun Pharmaceutical Industries Limited and MSN Laboratories Limited, all based or operating in India. In addition, we experience competition from European and Chinese manufacturers, as well as from Teva Pharmaceuticals Industries Limited, based in Israel.

With respect to our custom pharmaceuticals business, we believe that contract manufacturing is a significant opportunity for Indian pharmaceutical companies, based on their strengths of a skilled workforce and a low-cost manufacturing infrastructure. Key competitors in India include Divis Laboratories Limited, Dishman

Pharmaceuticals & Chemicals Limited, Jubilant Organosys Limited and Nicholas Piramal India Limited. Key competitors from outside India include Lonza Group, Koninklijke DSM N.V., Albany Molecular Research, Inc., Patheon, Inc. and Cardinal Health, Inc. We distinguish ourselves from our key competitors by offering a wider range of cost effective services spanning the entire pharmaceutical value chain. Growth in contract manufacturing is likely to be driven by increasing outsourcing of late-stage and off-patent molecules by large pharmaceutical companies to compete with generics. We expect India to emerge as an alliance and outsourcing destination of choice for global pharmaceutical companies.

#### Government regulations

All pharmaceutical companies that manufacture and market products in India are subject to various national and state laws and regulations, which principally include the Drugs and Cosmetics Act, 1940, the Drugs (Prices Control) Order, 1995, various environmental laws, labor laws and other government statutes and regulations. These regulations govern the testing, manufacturing, packaging, labeling, storing, record-keeping, safety, approval, advertising, promotion, sale and distribution of pharmaceutical products.

## **Table of Contents**

In India, manufacturing licenses for drugs and pharmaceuticals are generally issued by state drug authorities. Under the Drugs and Cosmetics Act, 1940, the state drug administration agencies are empowered to issue manufacturing licenses for drugs if they are approved for marketing in India by the Drug Controller General of India ( DCGI ). Prior to granting licenses for any new drugs or combinations of new drugs, the DCGI clearance has to be obtained in accordance with the Drugs and Cosmetics Act, 1940.

We submit a DMF for active pharmaceutical ingredients to be commercialized in the United States. Any drug product for which an ANDA is being filed must have a DMF in place with respect to a particular supplier supplying the underlying API. The manufacturing facilities are inspected by the U.S. FDA to assess compliance with current Good Manufacturing Practice regulations ( cGMP ). The manufacturing facilities and production procedures utilized at the manufacturing facilities must meet U.S. FDA standards before products may be exported to the United States. Eight of our manufacturing facilities are inspected and approved by the U.S. FDA. For European markets, we submit a European DMF and where applicable, obtain a certificate of suitability from the European Directorate for the Quality of Medicines.

## **Proprietary Products Segment**

Our Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations and new chemical entities ( NCEs ). These novel products fall within the dermatology and neurology therapeutic areas and are marketed and sold through Promius Pharma, LLC.

We continue to leverage our semi-virtual research and development model to expand our portfolio of specialty formulation products. Our efforts primarily focus on repurposing or improving the clinical properties of already approved and well-characterized active pharmaceutical ingredients ( API ) for application in the dermatologic and neurologic disease areas. We achieve this by utilizing internal resources as well as efficiently collaborating with leading technology and platform based companies and service providers, tapping into their expertise areas across different phases of the development process. We continue to progress towards building a diversified portfolio with a sustainable mix of branded proprietary formulations generated through research and development with significantly reduced fixed costs.

Our research and development efforts have a unique medicines-to-molecules approach to product development. In this approach, we identify areas of medical need and then leverage in an integrated manner the disciplines of biology, chemistry, drug delivery, clinical development, regulatory and commercial positioning to develop differentiated formulations.

Our research and development model is both in-house and virtual (i.e., operations are outsourced, subject to our supervision of strategic and project management functions), and follows these core principles:

develop creative research and development investment models and partnerships to access external innovation focused on leveraging, rather than replicating, unique core competencies;

select assets based on potential for early risk mitigation, both with respect to product development and commercialization; and



leverage knowledge and presence in emerging markets (India and other developing countries) to maximize cost advantages.

Our principal research laboratory is based in Hyderabad, India. As of March 31, 2016, we employed a total of 166 scientists, including 37 scientists who hold Ph.D. degrees and four with M.D. degrees. We pursue an integrated research strategy through a mix of translational, formulation and analytical research at our laboratories. We focus on discovery of new molecular targets, design of assays to screen promising molecules and development of novel formulations of currently marketed drugs or combinations thereof to address unmet medical needs.

While we conduct clinical development of candidate drugs ourselves, we continue to seek licensing and development opportunities with third parties to further expand our product pipeline. Our goal is to balance the development of our own product candidates with in-licensing of promising compounds that complement our product offering. We also pursue licensing and joint development of some of our lead compounds with companies looking to enhance their own product portfolio.

### Pipeline Status

As of March 31, 2016, we had 19 active product development programs in our pipeline. During January and February 2016, we received U.S. FDA approval of our New Drug Applications (each, a NDA ) for two products and tentative approval of our NDA for one product, all under section 505(b)(2) of the Federal Food, Drug and Cosmetic Act.

**Table of Contents**

The details of our products in Phase III, for which an NDA has been filed as of March 31, 2016 or which are approved by U.S. FDA during the year ended March 31, 2016 are as follows:

<b>Compound</b>	<b>DFN-02 (previously DFP-02)</b>	<b>DFD-01 (Sernivo )</b>	<b>DFD-06</b>
<b>Therapeutic Area</b>	Migraine	Psoriasis	Psoriasis
<b>Indication</b>	Acute treatment of migraines, with or without aura in adults.	Treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.	Treatment of moderate plaque psoriasis in patients 18 years of age or older.
<b>Significant developments during the period</b>	Pivotal bioequivalence studies were completed. Patient safety study initiated.	Phase III studies have been completed and NDA was filed with the U.S. FDA in April 2015. Phase IV studies are under way.	Nonclinical activities are in progress, Phase II studies have been completed and Phase III studies have been initiated. Registration batches have been made.
<b>Significant patents associated with the compound</b>	<p>Patents (including those granted to the development partner) expiring as follows:</p> <p>U.S.A. - 2026;</p> <p>Australia and New Zealand - 2029; and</p> <p>South Africa - 2030.</p> <p>Further, patent applications are pending in certain other countries along with the U.S.A.</p>	A patent is granted in Japan, and patents are accepted in U.S.A and Europe, and some patent applications are pending in U.S.A.	Patent applications are pending in the U.S.A.
<b>Current status/ expected NDA filing*</b>	Phase III / Submission of NDA to U.S. FDA planned for 2018	U.S. FDA approval of NDA granted in February 2016 and the product launched in June 2016.	Phase III / Submission of NDA to U.S. FDA planned for December 2016.

**Table of Contents**

[Continued from prior table, first column repeated]

<b>Compound</b>	<b>DFN-11 (Zembrace )</b>	<b>DFD-09 (Zenavod )</b>
<b>Therapeutic Area</b>	Migraine	Dermatology
<b>Indication</b>	Acute treatment of migraine with or without aura in adults.	Treatment of inflammatory lesions (papules and pustules) of rosacea in adult patients.
<b>Significant developments during the period</b>	Successful completion of three bioequivalence studies.	Successful completion of bioequivalence studies.
<b>Significant patents associated with the compound</b>	Patent application is pending in the U.S.A. and PCT application was filed.	Patent applications pending in the U.S.A. and PCT application was filed.
<b>Current status/expected NDA filing*</b>	U.S. FDA approval of NDA granted in January 2016 and product launched in April 2016.	Tentative approval of NDA granted by U.S. FDA in February 2016; subject to an automatic stay of final approval for up to 30 months pending a patent infringement process under the Drug Price Competition and Patent Term Restoration Act.

[Continued from prior table, first column repeated]

<b>Compound</b>	<b>DFD-10</b>	<b>DFD-11 (Xeglyze )</b>
<b>Therapeutic Area</b>	Acne	Dermatology
<b>Indication</b>	Treatment of acne in patients 12 years of age or older.	Treatment of head lice in patients 6 months of age or older.
<b>Significant developments during the period</b>	Two pivotal bioequivalence studies completed.	NDA filed by Hatchtech in September 2015; ownership assumed by us in December 2015.
<b>Significant patents associated with the compound</b>	Patent application is pending in the U.S.A. and a PCT application was filed.	Two patents were granted in the U.S.A., with estimated expiration in 2026 and 2028. Patents are granted in Australia, Canada, China, India, Japan, and New Zealand. Some patent applications are pending in certain countries, including the U.S.A.
<b>Current status/expected NDA filing*</b>	Submission of NDA to U.S. FDA planned for July 2016.	NDA submitted to U.S. FDA. PDUFA Date** of September, 2016.

\*\* The final U.S. FDA decision to approve or not to approve a new product occurs on the Prescription Drug User Fee Act ( PDUFA ) meeting date.

**Table of Contents**

[Continued from prior table, first column repeated]

<b>Compound</b>	<b>XP 23829</b>	<b>E7777</b>
<b>Therapeutic Area</b>	Psoriasis	Skin Cancer
<b>Indication</b>	Treatment of plaque psoriasis in patients 12 years of age or older.	Treatment of Cutaneous T Cell Lymphoma.
<b>Significant developments during the period</b>	This is a NCE program in-licensed from Xenoport; Phase II completed.	This is an anti-cancer biologic agent in-licensed from EISAI limited.
<b>Significant patents associated with the compound</b>	Two patents were granted, with estimated expiration in 2029. Patents were also granted in Australia, China, Europe, Japan and Russia with estimated expiration in 2029. There are also other patent applications pending in the U.S.A. and some other countries.	One Patent was granted with estimated expiration in June, 2017.
<b>Current status/expected NDA filing*</b>	Phase III completed / Submission of NDA to U.S. FDA planned for 2018.	Phase II in process / Submission of NDA to U.S. FDA planned for 2019.

\* The timelines for expected filing may change due to various factors, including outcome of Phase III studies, completion of Integrated Summary of Safety/Integrated Summary of Effectiveness ( ISS/ISE ), outcome of stability data and internal reprioritization of portfolio.

*Patents.* Our Proprietary Products segment had the following patent applications filed and patents granted as of March 31, 2016:

<b>Category</b>	<b>USPTO<sup>(1)</sup></b>				
	<b>(# Filed)</b>	<b>USPTO<sup>(1)</sup> (# Granted)</b>	<b>PCT<sup>(2)</sup> (# Filed)</b>	<b>India (# Filed)</b>	<b>India (# Granted)</b>
Anti-diabetic	85	17	62	117	45
Anti-cancer	18	11	14	45	15
Anti-bacterial	8	7	10	22	4
Anti-inflammation/cardiovascular	47	26	35	26	3
Anti-ulcerant	1	1		1	
Miscellaneous	15	6	4	26	8
Differentiated formulations	27	4	15	24	
<b>TOTAL</b>	<b>201</b>	<b>72</b>	<b>140</b>	<b>261</b>	<b>75</b>

- (1) USPTO means the United States Patent and Trademark Office.
- (2) PCT means the Patent Cooperation Treaty, an international treaty that facilitates foreign patent filings for residents of member countries when obtaining patents in other member countries.

*Stages of Testing Development.* The stages of testing required before a pharmaceutical product can be marketed in the United States are generally as follows:

**Stage of**

**Development**

**Description**

Nonclinical	Animal studies and laboratory tests to evaluate safety and efficacy, demonstrate activity of a product candidate and identify its chemical and physical properties.
Phase I	Clinical studies to test safety and pharmacokinetic profile of a drug in normal human subjects.
Phase II	Clinical studies conducted with groups of patients to determine preliminary efficacy, dosage and expanded evidence of safety.
Phase III	Larger scale clinical studies conducted in patients to provide sufficient data for statistical proof of efficacy and safety.

## Table of Contents

For ethical, scientific and legal reasons, animal studies are required in the discovery and safety evaluation of new medicines. Nonclinical tests assess the potential safety and efficacy of a product candidate in animal models. The results of these studies must be submitted to the U.S. FDA as part of an Investigational New Drug ( IND ) application before human testing may proceed.

U.S. law further requires that studies conducted to support approval for product marketing be adequate and well controlled. In general, this means that either a placebo or a product already approved for the treatment of the disease or condition under study must be used as a reference control. Studies must also be conducted in compliance with good clinical practice requirements, and adverse event and other reporting requirements must be followed.

The clinical trial process can take five to ten years or more to complete, and there can be no assurance that the data collected in compliance with good clinical practice regulations will demonstrate that the product is safe or effective, or, in the case of a biologic product, pure and potent, or will provide sufficient data to support U.S. FDA approval of the product. The U.S. FDA may place clinical trials on hold at any point in this process if, among other reasons, it concludes that clinical subjects are being exposed to an unacceptable health risk. Trials may also be terminated by Institutional Review Boards ( IRBs ) or Ethics Committees ( ECs ), which must review and approve all research involving human subjects. Side effects or adverse events that are reported during clinical trials can delay, impede, or prevent marketing authorization.

## Competition

The pharmaceutical and biotechnology industries are highly competitive. We face intense competition from organizations such as large pharmaceutical companies, biotechnology companies and academic and research organizations. The major pharmaceutical organizations competing with us have greater capital resources, larger overall research and development staff and facilities and considerably more experience in drug development. Biotechnology companies competing with us may have these advantages as well.

In addition to competition from collaborators and investors, these companies and institutions also compete with us in recruiting and retaining highly qualified scientific and management personnel.

## Government regulations

Virtually all pharmaceutical and biologics products that we or our collaborative partners develop will require regulatory approval by governmental agencies prior to commercialization. The nature and extent to which these regulations apply varies depending on the nature of the products and also vary from country to country. In particular, human pharmaceutical products are subject to rigorous nonclinical and clinical testing and other approval procedures by the relevant regulatory agency. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary widely from country to country.

In India, under the Drugs and Cosmetics Act, 1940, the regulation of the manufacture, sale and distribution of drugs is primarily the concern of the state authorities while the Central Drug Control Administration is responsible for approval of new drugs, clinical trials in the country, establishing the standards for drugs, control over the quality of imported drugs, coordination of the activities of state drug control organizations and providing expert advice with a view of bringing about the uniformity in the enforcement of the Drugs and Cosmetics Act, 1940.

In order to market a drug in the United States, we or our partners will be subject to regulatory requirements governing human clinical trials, marketing approval and post-marketing activities for pharmaceutical products and biologics. Various federal, and in some cases state, statutes and regulations also govern or influence the manufacturing, safety,

labeling, storage, record-keeping and marketing of these products. The process of obtaining these approvals and the subsequent compliance with applicable statutes and regulations is time consuming and requires substantial resources, and the approval outcome is uncertain.

Generally, in order to gain U.S. FDA approval, a company first must conduct nonclinical studies in the laboratory and in animal models to gain preliminary information on a compound's activity and to identify any safety problems. Nonclinical studies must be conducted in accordance with U.S. FDA regulations. The results of these studies are submitted as part of an IND application that the U.S. FDA must review before human clinical trials of an investigational drug can start. If the U.S. FDA does not respond with any questions, a drug developer can commence clinical trials thirty days after the submission of an IND.

In order to eventually commercialize any products, we or our collaborator first will be required to sponsor and file an IND and will be responsible for initiating and overseeing the clinical studies to demonstrate the safety and efficacy that is necessary to obtain U.S. FDA marketing approval. Clinical trials are normally done in three phases and generally take several years to complete. The clinical trials have to be designed taking into account the applicable U.S. FDA guidelines. Furthermore, the U.S. FDA may suspend clinical trials at any time if the U.S. FDA believes that the subjects participating in trials are being exposed to unacceptable risks or if the U.S. FDA finds deficiencies in the conduct of the trials or other problems with our product under development.



## **Table of Contents**

After completion of clinical trials of a new product, U.S. FDA marketing approval must be obtained. If the product is classified as a new pharmaceutical, we or our collaborator will be required to file a New Drug Application ( NDA ), and receive approval before commercial marketing of the drug. The testing and approval processes require substantial time and effort. NDAs submitted to the U.S. FDA can take several years to obtain approval and the U.S. FDA is not obligated to grant approval at all.

Even if U.S. FDA regulatory clearances are obtained, a marketed product is subject to continual review. If and when the U.S. FDA approves any of our or our collaborators' products under development, the manufacture and marketing of these products will be subject to continuing regulation, including compliance with cGMP, adverse event reporting requirements and prohibitions on promoting a product for unapproved uses. Later discovery of previously unknown problems or failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Various federal and, in some cases, state statutes and regulations also govern or influence the manufacturing, safety, labeling, storage, record keeping and marketing of pharmaceutical products.

Our research and development processes involve the controlled use of hazardous materials and controlled substances. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these materials and waste products.

### ***Promius Pharma LLC***

Promius Pharma LLC ( Promius Pharma ) is our subsidiary based in Princeton, New Jersey in the United States focusing on our U.S. Specialty Business, which is engaged in the development and sales of branded specialty products in the therapeutic areas of dermatology and neurology.

Promius Pharma has a portfolio of in-licensed patented dermatology products. It also has an internal pipeline of dermatology products that are in different stages of development. Promius Pharma's current portfolio contains innovative products for the treatment of seborrheic dermatitis, acne and steroid responsive dermatoses. It has commercialized six products: EpiCeram<sup>®</sup>, a skin barrier emulsion for the treatment of atopic dermatitis; Scytera<sup>®</sup>, a foam for the treatment of psoriasis; Promiseb<sup>®</sup>, a cream for the treatment of seborrheic dermatitis; Cloderin<sup>®</sup> (clocortolone pivalate 0.1%), a cream used for treating corticosteroid-responsive dermatoses; Trianex<sup>®</sup>, a cream for the treatment of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Zembrace SymTouch (subcutaneous sumatriptan 3mg), an autoinjector for treatment of migraine headaches; and Sernivo (betamethasone propionate, 0.05%), a spray for the treatment of mild to moderate plaque psoriasis. Promius Pharma also markets and promotes Zenatane (isotretinoin).

Promius Pharma leverages our research, development and manufacturing facilities in Hyderabad, India. Promius Pharma also works with various third party research organizations in conducting product development, nonclinical and clinical studies. Manufacturing is also outsourced to reputable contract manufacturing organizations in the United States and Europe. Both of Promius Pharma's commercial groups - dermatology and neurology - have the support of teams spanning marketing, sales operations, and medical affairs. The dermatology team includes 72 marketing and sales employees targeting dermatologists, and the neurology team includes 59 marketing and sales employees targeting primary care physicians and neurologists who treat migraine headaches.

### **Seasonality**

Certain parts of our business are affected by seasonality, primarily our Global Generics segment's business in India and Russia. The seasonal impact of these particular businesses may affect a quarterly comparison within any fiscal

year. However, there is generally no significant seasonality impact on a year to year basis.

**4.C. *Organizational structure***

Dr. Reddy's Laboratories Limited is the parent company in our group. Refer to Note 46 of our consolidated financial statements for a list of our subsidiaries, associates and joint ventures.

**Table of Contents****4.D. Property, plant and equipment**

The following table sets forth current information relating to our principal facilities:

Sl. No.	Location	Approximate Area (Square feet)	Built up Area (Square feet)	Certifications	Installed Capacity	Actual Production
<b>Within India</b>						
1	API Hyderabad Plant 1, Telangana, India <sup>(21)</sup>	734,013	411,657	U.S. FDA and EUGMP	4,767 <sup>(8)(11)</sup>	2,726 <sup>(8)(11)</sup>
2	API Hyderabad Plant 2, Telangana, India <sup>(21)</sup>	725,274	401,271	U.S. FDA and EUGMP	See above <sup>(11)</sup>	See above <sup>(11)</sup>
3	API Hyderabad Plant 3, Telangana, India <sup>(21)</sup>	715,610	333,681	U.S. FDA and EUGMP	See above <sup>(11)</sup>	See above <sup>(11)</sup>
4	API Hyderabad Plant 4, Telangana, India <sup>(21)</sup>	189,343	150,002	U.S. FDA and EUGMP	See above <sup>(11)</sup>	See above <sup>(11)</sup>
5	API Nalgonda Plant, Telangana, India <sup>(21)(24)</sup>	3,402,907	631,320	U.S. FDA and EUGMP	See above <sup>(11)</sup>	See above <sup>(11)</sup>
6	API Srikakulam Plant, Andhra Pradesh, India <sup>(21)(24)</sup>	4,047,595	1,618,579	U.S. FDA and EUGMP	See above <sup>(11)</sup>	See above <sup>(11)</sup>
7	API Srikakulam Plant (SEZ), Andhra Pradesh, India <sup>(22)</sup>	11,001,863	414,351		N/A	N/A
8	Technology Development Centre Hyderabad 1, Telangana, India <sup>(23)</sup>	113,256	96,445	ISO 27001: 2005 Information Security Management System	N/A	N/A
9	Technology Development Centre Hyderabad 2, Telangana, India <sup>(23)</sup>	68,825	23,538	ISO 27001: 2005 Information Security Management System	N/A	N/A
10	Formulations Hyderabad Plant 1, Telangana, India <sup>(22)</sup>	217,729	195,348	(2)	8,160 <sup>(6)(13)(15)</sup>	4,898 <sup>(6)(13)</sup>
11	Formulations Hyderabad Plant 2, Telangana, India <sup>(22)</sup>	3,202,862	987,765	(3)	See above <sup>(13)</sup>	See above <sup>(13)</sup>
12	Formulations Yanam Plant, Pondicherry, India <sup>(22)</sup>	457,000	63,738		See above <sup>(13)</sup>	See above <sup>(13)</sup>
13	Formulations Baddi Plant 1, Himachal Pradesh, India <sup>(22)</sup>	728,234	304,185	(19)	See above <sup>(13)</sup>	See above <sup>(13)</sup>
14	Formulations Baddi Plant 2, Himachal Pradesh, India <sup>(22)</sup>	381,342	222,119		See above <sup>(13)</sup>	See above <sup>(13)</sup>
15		789,727	213,002	(2)	125,122 <sup>(9)(14)</sup>	47,077 <sup>(9)</sup>

Edgar Filing: DR REDDYS LABORATORIES LTD - Form 20-F

	Biologics Hyderabad, Telangana, India <sup>(22)</sup>					
16	Formulations Hyderabad Plant 3, Telangana, India <sup>(22)</sup>	1,539,098	906,030	(4)	11,600 <sup>(6)(10)</sup>	5,509 <sup>(6)</sup>
17	Formulations Srikakulam Plant 1 (SEZ), Andhra Pradesh, India <sup>(17)(22)</sup>	878,054	644,997	U.S. FDA	960 <sup>(6)</sup>	455
18	Formulations Srikakulam Plant 2 (SEZ), Andhra Pradesh, India <sup>(17)(22)</sup>	328,912	200,082		N/A	N/A
19	Formulations Visakhapatnam Plant 1 (SEZ), Andhra Pradesh, India <sup>(22)(25)</sup>	581,880	209,542	U.S. FDA and BfARM, Germany	127 <sup>(6)(7)</sup>	4 <sup>(6)</sup>
20	Formulations Visakhapatnam Plant 2 (SEZ), Andhra Pradesh, India <sup>(22)</sup>	528,529	278,038		N/A	N/A
21	ADTL Hyderabad, Telangana, India <sup>(7)</sup>	187,308	114,512		N/A	N/A
22	ADTL Bengaluru, Karnataka, India <sup>(7)</sup>	718,716	271,799		N/A	N/A
	Outside India					
23	API Cuernavaca Plant, Mexico <sup>(23)</sup>	2,361,840	689,719	(1)	3,500 <sup>(8)</sup>	2,201 <sup>(8)</sup>
24	API Mirfield Plant, United Kingdom <sup>(23)</sup>	1,785,960	653,400	(20)	(12)	(12)
25	API Middleburgh Plant, New York, United States <sup>(5)(22)</sup>	292,000	26,000		50-100 <sup>(16)</sup>	N/A
26	Technology Development Centre, Cambridge, United Kingdom <sup>(5)(21)</sup>	32,966	32,966		N/A	N/A
27	Technology Development Centre, OctoPlus B.V., Leiden, the Netherlands <sup>(5)(21)</sup>	56,500	18,700	EUGMP	2 <sup>(7)(8)</sup>	0.07 <sup>(7)(8)</sup>
28	Formulations Beverley Plant, East Yorkshire, United Kingdom <sup>(22)</sup>	81,000	32,500	U.K. MHRA cGMP	700 <sup>(6)(14)(15)</sup>	400 <sup>(6)(15)</sup>
29	Formulations Shreveport Plant, Louisiana, United States <sup>(22)</sup>	1,817,123	335,000	U.S. FDA	5,875 <sup>(6)(10)</sup>	3,470 <sup>(6)</sup>
30	Formulations Bristol Plant, TN, United States <sup>(22)</sup>	1,742,400	390,000	U.S. FDA	2,460 <sup>(6)(7)</sup>	20 <sup>(6)</sup>

**Table of Contents**

- (1) U.S. FDA; European Directorate for the Quality of Medicines & HealthCare ( EDQM ); Ministry of Health, Labour and Welfare, Japan; Secretaría de Salud, Mexico; Ministry of Health, Romania; Korean Ministry of Food and Drug Safety and Health Canada.
  - (2) National Medicines Agency, Romania; Ministry of Health, Ukraine; National Center of Drugs, Medical Products and Medical Equipment Examination, Kazakhstan; World Health Organization, cGMP.
  - (3) Medicine Control Council, Republic of South Africa; The State Company for Marketing Drugs and Medical Appliances, Ministry of Health, Iraq; Ministry of Health, Muscat; Ministry of Health, State of Bahrain; Ministry of Health, Kuwait; National Medicines Agency, Romania; Ministry of Health, Ukraine; World Health Organization, cGMP; Medicines and Health Care Products Regulatory Agencies ( MHRA ), U.K., British Retail Consortium; BfARM, Germany; National Center of Drugs, Medical Products and Medical Equipment Examination, Kazakhstan.
  - (4) U.S. FDA; Medicines and Healthcare Products Regulatory Agency, U.K.; Medicines Control Council, South Africa; ANVISA, Brazil; Environmental Management System ISO 14001; Occupational Health and Safety Management System OHSAS 18001; Quality Management System-ISO 9001:2000; BfARM, Germany; China Food and Drug Administration, China; Turkish Drug and Medical Institution, Turkey; Therapeutic Goods Administration, Australia; Ministry of Healthcare, Ukraine; National Center of Drugs, Medical Products and Medical Equipment Examination, Kazakhstan and WHO.
  - (5) Leased facilities.
  - (6) Million units.
  - (7) On a single shift basis.
  - (8) Tons.
  - (9) Grams.
  - (10) Three shift basis
  - (11) Represents the aggregate capacity and production for the facilities serially numbered from 1 to 6 in this table.
  - (12) Capacity and production at this facility is not separately tracked.
  - (13) Represents the aggregate capacity and production for the facilities serially numbered from 10 to 14 in this table.
  - (14) Installed capacity is variable and subject to changes in product mix, and utilization of manufacturing facilities given the nature of production.
  - (15) On a two shift basis.
  - (16) Kilograms.
  - (17) This facility is part of our PSAI segment s Special Economic Zone ( SEZ ) in Devunipalavalasa, Srikakulam, Andhra Pradesh, India.
  - (18) Includes facilities of our Integrated Product Development Organization ( IPDO ), Leadership Academy and Global Distribution Centre located at our Bachupally Campus in Hyderabad, Telangana, India.
  - (19) WHO-GMP, National Center of Drugs, Medical Products and Medical Equipment Examination, Kazakhstan, Ministry of Healthcare, Ukraine.
  - (20) ISO 9001:2008, MHRA (UK), U.S. FDA and Korean FDA (Travopost).
  - (21) This facility is used by our Global Generics and PSAI segments.
  - (22) This facility is used by our Global Generics segment.
  - (23) This facility is used by our PSAI segment.
  - (24) In November 2015, we received a warning letter from the U.S. FDA relating to cGMP deviations at this facility.
  - (25) In November 2015, we received a warning letter from the U.S. FDA relating to cGMP violations at this facility.
- Except for as indicated in the notes above, we own all of our facilities. All properties identified above, including leased properties, are either used for manufacturing and packaging of pharmaceutical products or for research and development activities. In addition, we have sales, marketing and administrative offices, some of which are owned and some others are leased properties. We believe that our facilities are optimally utilized.



## **Table of Contents**

### **Global Generics**

During the year ended March 31, 2013, we expanded our biosimilars facility in Hyderabad, Telangana, India to meet growing demand in emerging markets.

During the year ended March 31, 2014, we set up a new manufacturing facility in a Special Economic Zone in Duvvada, Visakhapatnam, Andhra Pradesh, India for the manufacture of parenteral (injectable form) products. This will help us meet the demand for such products in some of our key markets, including the United States.

During the year ended March 31, 2015, we obtained approvals from the U.S. FDA for products to be manufactured from a recently commissioned oral solid dosage form facility in a Special Economic Zone in Devunipalavalasa, Srikakulam, Andhra Pradesh, India. The new plant is intended for the manufacture of new molecules, and certain high volume products of our Global Generics segment. Further, during the year March 31, 2016, we began manufacturing products from this plant.

### **Pharmaceutical Services and Active Ingredients**

During the year ended March 31, 2013, we set up a new manufacturing facility in a Special Economic Zone located in Devunipalavalasa, Srikakulam, Andhra Pradesh, India. We have filed some of our new DMFs from this location. This plant is adjacent to an existing plant, in a newly acquired area of approximately 250 acres under a Pharmaceutical-Sector specific Special Economic Zone for fiscal benefits. This location also houses our Global Generics segment's recently commissioned oral solid dosage form facility. The formal governmental approval for designating the property as a Special Economic Zone has been obtained.

### **Material plans to construct, expand and improve facilities**

As of March 31, 2016, we had capital work-in-progress of Rs.7,550 million and capital commitments of Rs.5,065 million for expansion of our manufacturing and research facilities, primarily relating to facilities located in India and the United States. We currently intend to finance our additional expansion plans entirely through our operating cash flows and through cash and other investments. A majority of these projects are expected to be completed during the fiscal years ending March 31, 2017 and March 31, 2018.

### **Environmental laws and regulations**

We are subject to significant national and state environmental laws and regulations which govern the discharge, emission, storage, handling and disposal of a variety of substances that may be used in or result from our operations at the above facilities. Non-compliance with the applicable laws and regulations may subject us to penalties and may also result in the closure of our facilities.

### **ITEM 4A. UNRESOLVED STAFF COMMENTS**

None.

**Table of Contents**

**ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS**

**Overview**

We are an integrated global pharmaceutical company committed to providing affordable and innovative medicines. We derive our revenues from the sale of finished dosage forms, active pharmaceutical ingredients and intermediates, development and manufacturing services provided to innovator pharmaceutical and biotechnology companies, and license fees from marketing authorizations for our products.

The Chief Operating Decision Maker ( CODM ) evaluates our performance and allocates resources based on an analysis of various performance indicators by reportable segments. The CODM reviews revenue and gross profit as the performance indicator for all of the operating segments, and does not review the total assets and liabilities of an operating segment.

Our reportable operating segments are as follows:

Global Generics;

Pharmaceutical Services and Active Ingredients ( PSAI ); and

Proprietary Products.

**Global Generics.** This segment consists of our business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of our biologics business.

**Pharmaceutical Services and Active Ingredients.** This segment includes our business of manufacturing and marketing active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are the principal ingredients for finished pharmaceutical products. Active pharmaceutical ingredients and intermediates become finished pharmaceutical products when the dosages are fixed in a form ready for human consumption such as a tablet, capsule or liquid using additional inactive ingredients. This segment also includes our contract research services business and our manufacture and sale of active pharmaceutical ingredients and steroids in accordance with the specific customer requirements.

**Proprietary Products.** This segment consists of our business that focuses on the research, development, and manufacture of differentiated formulations and new chemical entities ( NCEs ). These novel products fall within the dermatology and neurology therapeutic areas and are marketed and sold through Promius Pharma, LLC.

**Others.** This includes the operations of our wholly-owned subsidiary, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with established pharmaceutical and biotechnology companies in early-stage collaborations, bringing drug candidates from hit generation through Investigational New Drug ( IND ) filing.



The measurement of each segment's revenues, expenses and assets is consistent with the accounting policies that are used in preparation of our consolidated financial statements.

## **Table of Contents**

### **Critical Accounting Policies**

Critical accounting policies are defined as those that in our view are the most important to the portrayal of our financial condition and results and that require the most exercise of management's judgment. We consider the policies discussed under the following paragraphs to be critical for an understanding of our financial statements. Our significant accounting policies and application of these are discussed in detail in Notes 2 and 3 to our consolidated financial statements.

### **Accounting estimates and judgments**

While preparing financial statements in conformity with IFRS, we make certain estimates and assumptions that require difficult, subjective and complex judgments. These judgments affect the application of accounting policies and the reported amount of assets, liabilities, income and expenses, disclosure of contingent liabilities at the statement of financial position date and the reported amount of income and expenses for the reporting period. Financial reporting results rely on our estimate of the effect of certain matters that are inherently uncertain. Future events rarely develop exactly as forecast and the best estimates require adjustments, as actual results may differ from these estimates under different assumptions or conditions. We continually evaluate these estimates and assumptions based on the most recently available information.

Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In particular, information about significant areas of estimation uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements are as below:

Assessment of functional currency;

Financial instruments;

Business combinations;

Useful lives of property, plant and equipment and intangible assets;

Valuation of inventories;

Measurement of recoverable amounts of cash-generating units;

Assets and obligations relating to employee benefits;

Provisions;

Sales returns, rebates and chargeback provisions;

Evaluation of recoverability of deferred tax assets; and

Contingencies.

**Revenue**

*Sale of goods*

Revenue is recognized when the significant risks and rewards of ownership have been transferred to the buyer, recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, there is no continuing management involvement with the goods and the amount of revenue can be measured reliably. Revenue from the sale of goods includes excise duty and is measured at the fair value of the consideration received or receivable, net of returns, sales tax and applicable trade discounts and allowances. Revenue includes shipping and handling costs billed to the customer.

Revenue from sales of generic products in India is recognized upon delivery of products to distributors by our clearing and forwarding agents. Significant risks and rewards in respect of ownership of generic products are transferred by us when the goods are delivered to distributors from clearing and forwarding agents. Clearing and forwarding agents are generally compensated on a commission basis as a percentage of sales made by them. Revenue from sales of active pharmaceutical ingredients and intermediates in India is recognized on delivery of products to customers (generally formulation manufacturers) from our factories. Revenue from export sales and other sales outside of India is recognized when the significant risks and rewards of ownership of products are transferred to the customers, which occurs upon delivery of the products to the customers unless the terms of the applicable contract provide for specific revenue generating activities to be completed, in which case revenue is recognized once all such activities are completed.

---

**Table of Contents***Profit share revenues*

From time to time, we enter into marketing arrangements with certain business partners for the sale of our products in certain markets. Under such arrangements, we sell our products to the business partners at a non-refundable base purchase price agreed upon in the arrangement, and we are also entitled to a profit share which is over and above the base purchase price. The profit share is typically dependent on the business partner's ultimate net sale proceeds or net profits, subject to any reductions or adjustments that are required by the terms of the arrangement. Such arrangements typically require the business partner to provide confirmation of units sold and net sales or net profit computations for the products covered under the arrangement.

Revenue in an amount equal to the base purchase price is recognized in these transactions upon delivery of products to the business partners. An additional amount representing the profit share component is recognized as revenue in the period which corresponds to the ultimate sales of the products made by business partners only when the collectability of the profit share becomes probable and a reliable measurement of the profit share is available. Otherwise, recognition is deferred to a subsequent period pending satisfaction of such collectability and measurability requirements. In measuring the amount of profit share revenue to be recognized for each period, we use all available information and evidence, including any confirmations from the business partner of the profit share amount owed to us, to the extent made available before the date our Board of Directors authorizes the issuance of our financial statements for the applicable period.

*Milestone payments and out licensing arrangements*

Revenues include amounts derived from product out-licensing agreements. These arrangements typically consist of an initial up-front payment upon inception of the license and subsequent payments dependent on achieving certain milestones in accordance with the terms prescribed in the agreement. Non-refundable up-front license fees received in connection with product out-licensing agreements are deferred and recognized over the period in which we have continuing performance obligations. Milestone payments which are contingent on achieving certain clinical milestones are recognized as revenues either on achievement of such milestones, if the milestones are considered substantive, or over the period we have continuing performance obligations, if the milestones are not considered substantive. If milestone payments are creditable against future royalty payments, the milestones are deferred and released over the period in which the royalties are anticipated to be paid.

*Provision for chargeback, rebates, sales returns and discounts*

In our U.S. Generics business, our gross revenues are significantly reduced by chargebacks, rebates, sales returns, discounts, shelf stock adjustments, Medicaid payments and similar gross-to-net adjustments. Each of such adjustments are discussed in detail below.

*Chargebacks:* Chargebacks are issued to wholesalers for the difference between our invoice price to the wholesaler and the contract price through which the product is resold in the retail part of the supply chain. The information that we consider for establishing a chargeback accrual includes the historical average chargeback rate over a period of time, current contract prices with wholesalers and other customers, and estimated inventory holding by the wholesaler. With this methodology, we believe that the results are more realistic and closest to the potential chargeback claims that may be received in the future period relating to inventory on which a claim is yet to be received as at the end of the reporting period. In addition, as part of our book closure process, a chargeback validation is performed in which we track and reconcile the volume

of inventory sold for which we should carry an appropriate provision for chargeback. We procure the inventory holding statements and data through an electronic data interface with our wholesalers (representing approximately 90% of the total value of chargebacks outstanding at every reporting date) as part of this reconciliation. On the basis of this volume reconciliation, chargeback accrual is validated. For the chargeback rate computation, we consider different contract prices for each product across our customer base. This chargeback rate is adjusted (if necessary) on a periodic basis for expected future price reductions.

*Shelf Stock Adjustments:* Shelf stock adjustments are credits issued to customers to reflect decreases in the selling price of products sold by us, and are accrued when the prices of certain products decline as a result of increased competition upon the expiration of limited competition or exclusivity periods. These credits are customary in the pharmaceutical industry, and are intended to reduce the customer inventory cost to better reflect the current market prices. The determination to grant a shelf stock adjustment to a customer is based on the terms of the applicable contract, which may or may not specifically limit the age of the stock on which a credit would be offered.

*Rebates:* Rebates (direct and indirect) are generally provided to customers as an incentive to stock and sell our products. Rebate amounts are based on a customer's purchases made during an applicable period. Rebates are paid to

---

**Table of Contents**

wholesalers, chain drug stores, health maintenance organizations or pharmacy buying groups under a contract with us. We determine our estimates of rebate accruals primarily based on the contracts entered into with our wholesalers and other direct customers and the information received from them for secondary sales made by them. For direct rebates, liability is accrued whenever we invoice to direct customers. For indirect rebates, the accruals are based on a representative weighted average percentage of the contracted rebate amount applied to inventory sold and delivered by us to wholesalers or other direct customers.

*Sales Return Allowances:* We account for sales returns by recording a provision based on our estimate of expected sales returns. We deal in various products and operate in various markets. Accordingly, our estimate of sales returns is determined primarily by our experience in these markets. In respect of established products, we determine an estimate of sales returns provision primarily based on historical experience of such sales returns. Additionally, other factors that we consider in determining the estimate include levels of inventory in the distribution channel, estimated shelf life, product discontinuances, price changes of competitive products, and introduction of competitive new products, to the extent each of these factors impact our business and markets. We consider all of these factors and adjust the sales return provision to reflect our actual experience. With respect to new products introduced by us, those have historically been either extensions of an existing product line where we have historical experience or in a general therapeutic category where established products exist and are sold either by us or our competitors.

We have not yet introduced products in a new therapeutic category where the sales returns experience of such products by us or our competitors (as we understand based on industry publications) is not known. The amount of sales returns for our newly launched products have not historically differed significantly from sales returns experience of the then current products marketed by us or our competitors (as we understand based on industry publications). Accordingly, we do not expect sales returns for new products to be significantly different from expected sales returns of current products. We evaluate sales returns of all our products at the end of each reporting period and record necessary adjustments, if any.

*Medicaid Payments:* We estimate the portion of our sales that may get dispensed to customers covered under Medicaid programs based on the proportion of units sold in the previous two quarters for which a Medicaid claim could be received as compared to the total number of units sold in the previous two quarters. The proportion is based on an analysis of the actual Medicaid claims received for the preceding four quarters. In addition, we also apply the same percentage on the derived estimated inventory sold and delivered by us to our wholesalers and other direct customers to arrive at the potential volume of products on which a Medicaid claim could be received. We use this approach because we believe that it corresponds to the approximate six month time period it takes for us to receive claims from the various Medicaid programs. After estimating the number of units on which a Medicaid claim is to be paid, we use the latest available Medicaid reimbursement rate per unit to calculate the Medicaid accrual. In the case of new products, accruals are done based on specific inputs from our marketing team or data from the publications of IMS Health.

*Cash Discounts:* We offer cash discounts to our customers, generally at 2% of the gross sales price, as an incentive for paying within invoice terms, which generally range from 45 to 90 days. Accruals for such cash discounts do not involve any significant variables, and the estimates are based on the gross sales price and agreed cash discount percentage at the time of invoicing.

We believe our estimation processes are reasonable methods of determining accruals for the gross-to-net adjustments. Chargeback accrual accounts for the highest element among the gross-to-net adjustments, and constituted

approximately 69% of such gross-to-net adjustments for our U.S. Generics business for the year ended March 31, 2016. For the purpose of the following discussion, we are therefore restricting our explanations to this specific element. While chargeback accruals depend on multiple variables, the most pertinent variables are our estimates of inventories on which a chargeback claim is yet to be received and the unit price at which the chargeback will be processed. To determine the chargeback accrual applicable for a reporting period, we perform the following procedures to calculate these two variables:

- a) *Estimated inventory* Inventory volumes on which a chargeback claim that is expected to be received in the future are determined using the validation process and methodology described above (see Chargebacks above). When such a validation process is performed, we note that the difference represents an immaterial variation. Therefore, we believe that our estimation process in regard to this variable is reasonable.

**Table of Contents**

- b) *Unit pricing rate* At any point in time, inventory volumes on which we carry our chargeback accrual represents up to 1.1 months of sales volumes. Therefore, the sensitivity of price changes on our chargeback accrual only relates to such volumes. Assuming that the chargebacks were processed within such period, we analyzed the impact of changes of prices for the periods beginning April 1, 2015, 2014 and 2013, respectively, and ended March 31, 2016, 2015 and 2014, respectively, on our estimated inventory levels computed based on the methodology described above (see Chargebacks above). We note that the impact on net sales on account of such price variation was negligible.

In view of this, we believe that the calculations are not subject to a level of uncertainty that warrants a probability-based approach. Accordingly, we believe that we have been reasonable in our estimates for future chargeback claims and that the amounts of reversals or adjustments made in the current period pertaining to the previous year's accruals are immaterial. Further, this data is not determinable except on occurrence of specific instances or events during a period, which warrant an adjustment to be made for such accruals.

A roll-forward for each major accrual for our U.S. Generics operations is presented below for our fiscal years ended March 31, 2014, 2015 and 2016:

Particulars	Chargebacks	Rebates	Medicaid	Sales Returns
	<i>(All values in U.S. \$millions)</i>			
Beginning Balance: April 1, 2013	167	113	12	20
Current provisions relating to sales in current year	1,029	355	17	24
Provisions and adjustments relating to sales in prior years	*	2	0	
Credits and payments**	(1,070)	(340)	(14)	(16)
<b>Ending Balance: March 31, 2014</b>	<b>126</b>	<b>130</b>	<b>15</b>	<b>28</b>
Beginning Balance: April 1, 2014	126	130	15	28
Current provisions relating to sales in current year <sup>(1)</sup>	1,939	635	24	32
Provisions and adjustments relating to sales in prior years	*		0	
Credits and payments**	(1,871)	(543)	(22)	(20)
<b>Ending Balance: March 31, 2015</b>	<b>194</b>	<b>222</b>	<b>17</b>	<b>40</b>
Beginning Balance: April 1, 2015	194	222	17	40
Current provisions relating to sales in current year <sup>(2)</sup>	2,208	767	23	32
Provisions and adjustments relating to sales in prior years	*			
Credits and payments**	(2,193)	(732)	(26)	(27)
<b>Ending Balance: March 31, 2016</b>	<b>209</b>	<b>257</b>	<b>14</b>	<b>45</b>



- \* Currently, we do not separately track provisions and adjustments, in each case to the extent relating to prior years for chargebacks. However, the adjustments are expected to be non-material. The volumes used to calculate the closing balance of chargebacks represent up to 1.1 months equivalent of sales, which corresponds to the pending chargeback claims yet to be processed.
- \*\* Currently, we do not separately track the credits and payments, in each case to the extent relating to prior years for chargebacks, rebates, medicaid payments or sales returns.
- (1) Chargebacks and rebates provisions for the year ended March 31, 2015 and payments for the year ended March 31, 2015 were each higher as compared to the year ended March 31, 2014, primarily as a result of customer consolidation (such as the Walgreens Boots Alliance Development, the Red Oak Sourcing joint venture between CVS and Cardinal Health, and the McKesson expanded distribution agreements with Rite Aid and Omnicare). Such customer consolidation has led to an increase in the difference between our invoice price to the wholesaler and the contract price through which the product is resold in the retail part of the supply chain, as well as an increase in rebates offered to retail customers.
- (2) Chargebacks and rebates provisions for the year ended March 31, 2016 and payments for the year ended March 31, 2016 were each higher as compared to the year ended March 31, 2015, primarily as a result of product mix changes and the addition of new products.

The estimates of gross-to-net adjustments for our operations in India and other countries outside of the U.S. relate mainly to sales return allowances in all such operations, and certain rebates to healthcare insurance providers are specific to our

## **Table of Contents**

German operations. The pattern of such sales return allowances is generally consistent with our gross sales. In Germany, the rebates to healthcare insurance providers mentioned above are contractually fixed in nature and do not involve significant estimations by us.

Our overall provision for sales returns as at March 31, 2016 was Rs.4,421 million, as compared to a provision of Rs.3,905 million as at March 31, 2015. This increase in our provision was primarily attributable to a higher allowance for returns provision created for the year ended March 31, 2016 due to higher sales recorded for the year ended March 31, 2016 and higher anticipated sales returns, based on our historical experience and recent trends in actual sales returns, in the markets in which we operate. For further information regarding our sales return provisions, refer to Note 21 to our consolidated financial statements.

### *Services*

Revenue from services rendered, which primarily relate to contract research, is recognized in the consolidated income statement as the underlying services are performed. Upfront non-refundable payments received under these arrangements are deferred and recognized as revenue over the expected period over which the related services are expected to be performed.

### ***Financial instruments***

#### **Non-derivative financial instruments**

Non-derivative financial instruments consist of investments in mutual funds, equity securities, trade and other receivables, cash and cash equivalents, loans and borrowings, trade and other payables and certain other assets and liabilities.

Non-derivative financial instruments are recognized initially at fair value plus any directly attributable transaction costs, except for those instruments that are designated as being fair value through profit and loss upon initial recognition. Subsequent to initial recognition, non-derivative financial instruments are measured as described below.

#### *Cash and cash equivalents*

Cash and cash equivalents consist of cash on hand, demand deposits and short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value. For this purpose, short-term means investments having maturity of three months or less from the date of investment. Bank overdrafts that are repayable on demand and form an integral part of our cash management are included as a component of cash and cash equivalents for the purpose of the statement of cash flows.

#### *Other investments*

Other investments consist of term deposits with original maturities of more than three months, mutual funds and equity securities.

Investments in mutual funds and equity securities are classified as available-for-sale financial assets. Subsequent to initial recognition, they are measured at fair value and changes therein, other than impairment losses, are recognized in other comprehensive income/(loss) and presented within equity. When an investment is derecognized, the cumulative gain or loss in equity is transferred to the consolidated income statement.

*Trade payables*

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if payment is expected within one year or within the normal operating cycle of the business.

*Trade receivables*

Trade receivables are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Trade receivables are classified as current assets if the collection is expected within one year or within the normal operating cycle of the business.

*Debt instruments and other financial liabilities*

We initially recognize debt instruments issued on the date that they originate. All other financial liabilities are recognized initially on the trade date, which is the date we become a party to the contractual provisions of the instrument. These are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, these financial liabilities are measured at amortized cost using the effective interest method.

## Table of Contents

### *Others*

Other non-derivative financial instruments are measured at amortized cost using the effective interest method, less any impairment losses.

### Derivative financial instruments

We are exposed to exchange rate risks which arise from our foreign exchange revenues, expenses and borrowings primarily in U.S. dollars, U.K. pounds sterling, Russian roubles, Venezuelan bolivars and Euros, and foreign currency debt in U.S. dollars, Russian roubles and Euros.

We use derivative financial instruments, including foreign exchange forward contracts, option contracts and currency swap contracts, to mitigate our risk of changes in foreign currency exchange rates and interest rates. We also use non-derivative financial instruments as part of our foreign currency exposure risk mitigation strategy.

### *Hedges of highly probable forecasted transactions*

We classify our derivative financial instruments that hedge foreign currency risk associated with highly probable forecasted transactions as cash flow hedges and measure them at fair value. The effective portion of such cash flow hedges is recorded in our hedging reserve, as a component of equity, and re-classified to the consolidated income statement as revenue in the period corresponding to the occurrence of the forecasted transactions. The ineffective portion of such cash flow hedges is recorded in the consolidated income statement as finance costs immediately.

We also designate certain non-derivative financial liabilities, such as foreign currency borrowings from banks, as hedging instruments for hedge of foreign currency risk associated with highly probable forecasted transactions. Accordingly, we apply cash flow hedge accounting to such relationships. Remeasurement gain/loss on such non-derivative financial liabilities is recorded in our hedging reserve, as a component of equity, and reclassified to the consolidated income statement as revenue in the period corresponding to the occurrence of the forecasted transactions.

Upon initial designation of a hedging instrument, we formally document the relationship between the hedging instrument and hedged item, including the risk management objectives and strategy in undertaking the hedge transaction and the hedged risk, together with the methods that will be used to assess the effectiveness of the hedging relationship. We make an assessment, both at the inception of the hedge relationship as well as on an ongoing basis, of whether the hedging instruments are expected to be highly effective in offsetting the changes in the fair value or cash flows of the respective hedged items attributable to the hedged risk, and whether the actual results of each hedge are within a range of 80%-125% relative to the gain or loss on the hedged items. For cash flow hedges to be highly effective, a forecast transaction that is the subject of the hedge must be highly probable and must present an exposure to variations in cash flows that could ultimately affect profit or loss.

If the hedging instrument no longer meets the criteria for hedge accounting, expires or is sold, terminated or exercised, then hedge accounting is discontinued prospectively. The cumulative gain or loss previously recognized in other comprehensive income/(loss), remains there until the forecast transaction occurs. If the forecast transaction is no longer expected to occur, then the balance in other comprehensive income/(loss) is recognized immediately in the consolidated income statement.

### *Hedges of recognized assets and liabilities*

Changes in the fair value of derivative financial instruments (such as forward contracts and option contracts) that economically hedge monetary assets and liabilities in foreign currencies, and for which no hedge accounting is applied, are recognized in the consolidated income statement. The changes in fair value of such derivative financial instruments, as well as the foreign exchange gains and losses relating to the monetary items, are recognized as part of net finance income/(expense) in the consolidated income statement.

*Hedges of changes in the interest rates*

Consistent with our risk management policy, we use interest rate swaps to mitigate the risk of changes in interest rates. We do not use such instruments for trading or speculative purposes.

## **Table of Contents**

### *De-recognition of financial assets and liabilities*

We derecognize a financial asset when the contractual right to the cash flows from that asset expires, or we transfer the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. If we retain substantially all the risks and rewards of ownership of a transferred financial asset, we continue to recognize the financial asset and also recognize a collateralized borrowing, at amortized cost, for the proceeds received.

We derecognize a financial liability when its contractual obligations are discharged, cancelled or expired. The difference between the carrying amount of the derecognized financial liability and the consideration paid is recognized as profit or loss.

### *Offsetting financial assets and liabilities*

Financial assets and liabilities are offset and the net amount presented in the statement of financial position when, and only when, we have a legal right and ability to offset the amounts and intend either to settle on a net basis or to realize the asset and settle the liability simultaneously.

### ***Foreign currency***

#### *Functional currency*

The consolidated financial statements are presented in Indian rupees, which is the functional currency of our parent company, DRL. Functional currency of an entity is the currency of the primary economic environment in which the entity operates.

In respect of all non-Indian subsidiaries that operate as marketing arms of our parent company in their respective countries/regions, the functional currency has been determined to be the functional currency of our parent company (i.e., the Indian rupee). The operations of these subsidiaries are largely restricted to the import of finished goods from our parent company in India, sale of these products in the foreign country and making of import payments to our parent company. The cash flows realized from sale of goods are available for making import payments to our parent company and cash is paid to our parent company on a regular basis. The costs incurred by these subsidiaries are primarily the cost of goods imported from our parent company. The financing of these subsidiaries is done directly or indirectly by our parent company.

In respect of subsidiaries whose operations are self-contained and integrated within their respective countries/regions, the functional currency has been determined to be the local currency of those countries/regions.

#### *Foreign currency transactions and foreign operations*

Transactions in foreign currencies are translated to the respective functional currencies of entities within our company group at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated into the functional currency at the exchange rate at that date. Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction. Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition during the period or in previous financial statements are recognized in profit or loss in the period in which they arise.

When several exchange rates are available, the rate used is that at which the future cash flows represented by the transaction or balance could have been settled if those cash flows had occurred at the measurement date. In such circumstances, we consider all the relevant facts and circumstances in determining the most appropriate rate to use for the purpose of translation, including practical difficulties, uncertainties or delays associated with applying a foreign currency at a particular rate.

Foreign exchange gains and losses arising from a monetary item receivable from a foreign operation, the settlement of which is neither planned nor likely in the foreseeable future, are considered to form part of the net investment in the foreign operation and are recognized in other comprehensive income/(loss) and presented within equity as a part of foreign currency translation reserve ( FCTR ).

In case of foreign operations whose functional currency is different from Indian rupees (our parent company's functional currency), the assets and liabilities of such foreign operations, including goodwill and fair value adjustments arising upon acquisition, are translated to the reporting currency at exchange rates at the reporting date. The income and expenses of such

## **Table of Contents**

foreign operations are translated to the reporting currency at the monthly average exchange rates prevailing during the year. Resulting foreign currency differences are recognized in other comprehensive income/(loss) and presented within equity as part of FCTR. When a foreign operation is disposed of, in part or in full, the relevant amount in the FCTR is transferred to the consolidated income statement.

### ***Business combinations***

We use the acquisition method of accounting to account for any business combination that occurred on or after April 1, 2009. A business consists of inputs and processes applied to those inputs that have the ability to create outputs. It is not clear in all circumstances whether the acquired set of activities and assets constitutes a business or not. In such situations, we use our judgment and take into consideration various factors such as the industry, the structure of the entity's operations and the stage of development, in determining whether the acquired set of activities and assets constitutes a business. Further, determining whether a particular set of assets and activities is a business is based on whether the integrated set is capable of being conducted and managed as a business by a market participant. The acquisition date is the date on which control is transferred to the acquirer. Judgment is applied in determining the acquisition date and determining whether control is transferred from one party to another. Control exists when we are exposed to, or have rights to, variable returns from our involvement with the entity and have the ability to affect, those returns through power over the entity. In assessing control, potential voting rights are considered only if the rights are substantive.

We measure goodwill as of the applicable acquisition date at the fair value of the consideration transferred, including the recognized amount of any non-controlling interest in the acquiree, less the net recognized amount of the identifiable assets acquired and liabilities assumed. When the fair value of the net identifiable assets acquired and liabilities assumed exceeds the consideration transferred, a bargain purchase gain is recognized immediately in the consolidated income statement. Consideration transferred includes the fair values of the assets transferred, liabilities incurred by us to the previous owners of the acquiree, and equity interests issued by us. Consideration transferred also includes the fair value of any contingent consideration. Consideration transferred does not include amounts related to settlement of pre-existing relationships. Any goodwill that arises on account of such business combination is tested annually for impairment.

Any contingent consideration is measured at fair value at the date of acquisition. If an obligation to pay contingent consideration that meets the definition of a financial instrument is classified as equity, then it is not remeasured and settlement is accounted for within equity. Otherwise, other contingent consideration is remeasured at fair value at each reporting date, and subsequent changes in the fair value of the contingent consideration are recorded in the consolidated income statement.

A contingent liability of the acquiree is assumed in a business combination only if such a liability represents a present obligation and arises from a past event, and its fair value can be measured reliably. On an acquisition-by-acquisition basis, we recognize any non-controlling interest in the acquiree either at fair value or at the non-controlling interest's proportionate share of the acquiree's net assets. Transaction costs incurred by us in connection with a business combination, such as finder's fees, legal fees, due diligence fees and other professional and consulting fees, are expensed as incurred.

Acquisitions of non-controlling interests are accounted for as transactions with equity holders in their capacity as equity holders. The difference between any consideration paid and the relevant share acquired of the carrying value of net assets of the subsidiary is recorded in equity.

### ***Property, plant and equipment***



*Recognition and measurement*

Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses, if any. Cost includes expenditures that are directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials and other costs directly attributable to bringing the asset to a working condition for its intended use. Borrowing costs that are directly attributable to the construction or production of a qualifying asset are capitalized as part of the cost of that asset.

When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

Gains and losses upon disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognized net within other (income)/expense, net in the consolidated income statement.

The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to us and its cost can be measured reliably. The costs of repairs and maintenance are recognized in the consolidated income statement as incurred.

**Table of Contents**

Items of property, plant and equipment acquired through exchange of non-monetary assets are measured at fair value, unless the exchange transaction lacks commercial substance or the fair value of either the asset received or asset given up is not reliably measurable, in which case the asset exchanged is recorded at the carrying amount of the asset given up.

*Depreciation*

Depreciation is recognized in the consolidated income statement on a straight line basis over the estimated useful lives of property, plant and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives. The depreciation expense is included in the costs of the functions using the asset. Land is not depreciated.

Leasehold improvements are depreciated over period of the lease agreement or the useful life, whichever is shorter.

Depreciation methods, useful lives and residual values are reviewed at each reporting date. The estimated useful lives are as follows:

Buildings	
- Factory and administrative buildings	20 - 50 years
- Ancillary structures	3 - 15 years
Plant and equipment	3 - 15 years
Furniture, fixtures and office equipment	4 - 10 years
Vehicles	4 - 5 years
Computer equipment	3 - 5 years

Software for internal use, which is primarily acquired from third-party vendors and which is an integral part of a tangible asset, including consultancy charges for implementing the software, is capitalized as part of the related tangible asset. Subsequent costs associated with maintaining such software are recognized as expense as incurred. The capitalized costs are amortized over the estimated useful life of the software or the remaining useful life of the tangible fixed asset, whichever is lower.

Advances paid towards the acquisition of property, plant and equipment outstanding at each reporting date and the cost of property, plant and equipment not ready to use before such date are disclosed under capital work-in-progress. Assets not ready for use are not depreciated.

***Goodwill and other intangible assets****Goodwill*

Goodwill represents the excess of consideration transferred, together with the amount of non-controlling interest in the acquiree, over the fair value of our share of identifiable net assets acquired.

Goodwill is measured at cost less accumulated impairment losses. In respect of equity accounted investees, the carrying amount of goodwill is included in the carrying amount of the investment, and any impairment loss on such an investment is not allocated to any asset, including goodwill, that forms part of the carrying value of the equity accounted investee.

*Other intangible assets*

Other intangible assets that are acquired by us, which have finite useful lives, are measured at cost less accumulated amortization and accumulated impairment losses.

Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate.

*Research and development*

Expenditures on research activities undertaken with the prospect of gaining new scientific or technical knowledge and understanding are recognized in profit or loss when incurred.

Expenditures on development activities involving a plan or design for the production of new or substantially improved products and processes are capitalized only if:

development costs can be measured reliably;

the product or process is technically and commercially feasible;

future economic benefits are probable; and

we intend to and have sufficient resources to complete development and to use or sell the asset.

Our internal drug development expenditures are capitalized only if they meet the recognition criteria as mentioned above. Where regulatory and other uncertainties are such that the criteria are not met, the expenditures are recognized in profit or loss

---

**Table of Contents**

as incurred. This is almost invariably the case prior to approval of the drug by the relevant regulatory authority. However, where the recognition criteria are met, intangible assets are capitalized and amortized on a straight-line basis over their useful economic lives from product launch. As of March 31, 2016, no internal drug development expenditure amounts have met the recognition criteria. The expenditures to be capitalized include the cost of materials and other costs directly attributable to preparing the asset for its intended use. Other development expenditures are recognized in profit or loss as incurred.

In conducting our research and development activities related to new chemical entities ( NCEs ), we seek to optimize our expenditures and to limit our risk exposures. Most of our current research and development projects related to NCEs are at an early discovery/development phase. These early development stage exploratory projects are numerous and are characterized by uncertainty with respect to timing and cost of completion. At such time as a research and development project related to NCE progresses into the more costly clinical study phases, where the costs can be tracked separately, such project is considered to be significant if:

- a) it is expected to account for more than 10% of our total research and development costs; and
- b) the costs and efforts to develop the project can be reasonably estimated and the product resulting from the project has a high probability of launch.

Historically, none of our development projects related to NCEs have met the significance thresholds listed above.

A substantial portion of our current research and development activities relates to the development of bio-equivalent products, which do not require full scale clinical trials to be conducted prior to the filing by us of applications with regulatory authorities to allow the marketing and sale of such products. Our total research and development costs for the year ended March 31, 2016 were Rs.17,834 million, which was approximately 12% of our total revenue for the year. The amounts spent on research and development related to our bio-equivalent products for the years ended March 31, 2016, 2015 and 2014 represented approximately 65%, 60%, and 62%, respectively, of our total research and development expenditures.

For each of our bio-equivalent generic product research and development projects, the timing and cost of completion varies depending on numerous factors, including, among others: the intellectual property patented by the innovator for the applicable product; the patent regimes of the countries in which we seek to market the product; our development strategy for such product; the complexity of the molecule for such product; and the time required to address any development challenges that arise during the development process. For any particular bio-equivalent generic product, these factors and other product launch requirements may vary across the numerous geographies in which we seek to market the product. In addition, bio-equivalent research and development projects often may relate to a number of different therapeutic areas. At any particular point of time, we tend to have a very high number of bio-equivalent generic product research and development projects ongoing simultaneously, in various developmental stages, with the exact number of such active projects changing regularly. As a result, we believe it would be impractical for us to state the exact number of ongoing projects and the estimated timing or cost to complete such projects.

Payments to third parties that generally take the form of up-front payments and milestones for in-licensed products, compounds and intellectual property are capitalized. Our criteria for capitalization of such assets are consistent with the guidance given in paragraph 25 of International Accounting Standard 38, Intangible Assets ( IAS 38 ) (i.e., receipt of economic benefits out of the separately purchased transaction is considered to be probable).

Acquired research and development intangible assets, which are under development and have accordingly not yet obtained marketing approval, are recognized as In-Process Research and Development ( IPR&D ) assets. IPR&D assets are not amortized, but evaluated for potential impairment on an annual basis or when there are indications that the carrying value may not be recoverable. Any impairment charge on such IPR&D assets is recorded in the consolidated income statement under Research and Development expenses .

Subsequent expenditure on an in-process research or development project acquired separately or in a business combination, and recognized as an intangible asset, is:

recognized as an expense when incurred, if it is research expenditure;

recognized as an expense when incurred, if it is development expenditure that does not satisfy the criteria for recognition as an intangible asset in paragraph 57 of IAS 38; and

added to the carrying amount of the acquired in-process research or development project, if it is development expenditure that satisfies the recognition criteria in paragraph 57 of IAS 38.

## **Table of Contents**

Intangible assets relating to products in development, other intangible assets not available for use and intangible assets having indefinite useful life are subject to impairment testing at each reporting date. All other intangible assets are tested for impairment when there are indications that the carrying value may not be recoverable. All impairment losses are recognized immediately in the consolidated income statement.

### *Amortization*

Amortization is recognized in the consolidated income statement on a straight-line basis over the estimated useful lives of intangible assets or on any other basis that reflects the pattern in which the asset's future economic benefits are expected to be consumed by the entity. Intangible assets that are not available for use are amortized from the date they are available for use. In determining the useful life we consider the following factors:

technical, technological, commercial or other types of obsolescence;

expected actions by competitors or potential competitors;

typical product life cycles for the asset and public information on estimates of useful lives of similar assets that are used in a similar way; and

the period of control over the asset and legal or similar limits on the use of the asset.

### ***Impairment***

#### *Financial assets*

A financial asset is assessed at each reporting date to determine whether there is any objective evidence that it is impaired. A financial asset is considered to be impaired if objective evidence indicates that one or more events have had a negative effect on the estimated future cash flows of that asset.

An impairment loss in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows, discounted at the original effective interest rate. An impairment loss in respect of an available-for-sale financial asset is calculated by reference to its fair value.

Significant financial assets are tested for impairment on an individual basis.

All impairment losses are recognized in the consolidated income statement. When the fair value of available-for-sale financial assets declines below acquisition cost and there is objective evidence that the asset is impaired, the cumulative loss that has been recognized in other comprehensive income is transferred to the statement of income. An impairment loss may be reversed in subsequent periods if the indicators for the impairment no longer exist. Such reversals are recognized in other comprehensive income.

#### *Non-financial assets*

The carrying amounts of our non-financial assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated. For goodwill and intangible assets that have indefinite lives or that are not yet available for use, an impairment test is performed each year at March 31.

The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or the cash-generating unit. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the cash-generating unit).

In the circumstances where the asset specific discount rate is not directly available from the market, we use surrogates to estimate the discount rate. For this purpose, we take into consideration the following rates:

the weighted average cost of capital determined using techniques such as the Capital Asset Pricing Model;

our incremental borrowing rate; and

other market borrowing rates.

However, these rates are adjusted:

to reflect the way that the market would assess the specific risks associated with the asset's estimated cash flows; and

## **Table of Contents**

to exclude the risks that are not relevant to the asset's estimated cash flows or for which the estimated cash flows have been adjusted.

Consideration is given to risks such as country risk, currency risk and price risk.

The goodwill acquired in a business combination is, for the purpose of impairment testing, allocated to cash-generating units that are expected to benefit from the synergies of the combination.

An impairment loss is recognized if the carrying amount of an asset or its cash-generating unit exceeds its estimated recoverable amount. Impairment losses are recognized in the consolidated income statement. Impairment losses recognized in respect of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to the units and then to reduce the carrying amount of the other assets in the unit on a pro-rata basis.

An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss for an asset other than goodwill is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss for an asset other than goodwill is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. Goodwill that forms part of the carrying amount of an investment in an associate is not recognized separately, and therefore is not tested for impairment separately. Instead, the entire amount of the investment in an associate is tested for impairment as a single asset when there is objective evidence that the investment in an associate may be impaired.

## ***Income tax***

Income tax expense consists of current and deferred tax. Income tax expense is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years.

Deferred tax is recognized using the balance sheet method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit; differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future; and taxable temporary differences arising upon the initial recognition of goodwill. Deferred tax is measured at the tax rates that are expected to be applied to the temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.

A deferred tax asset is recognized to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

Any deferred tax asset or liability arising from deductible or taxable temporary differences in respect of unrealized inter-company profit or loss on inventories held by us in different tax jurisdictions is recognized using the tax rate of the jurisdiction in which such inventories are held. Withholding tax arising out of payment of dividends to



shareholders under the Indian Income tax regulations is not considered as tax expense for us and all such taxes are recognized in the statement of changes in equity as part of the associated dividend payment.

***Inventories***

Inventories consist of raw materials, stores and spares, work in progress and finished goods, and are measured at the lower of cost and net realizable value. The cost of all categories of inventories is based on the weighted average method. Cost includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. In the case of finished goods and work in progress, cost includes an appropriate share of overheads based on normal operating capacity. Stores and spares consists of packing materials, engineering spares (such as machinery spare parts) and consumables (such as lubricants, cotton waste and oils) that are used in operating machines or consumed as indirect materials in the manufacturing process.

Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

## **Table of Contents**

The factors that we consider in determining the allowance for slow moving, obsolete and other non-saleable inventory includes estimated shelf life, planned product discontinuances, price changes, aging of inventory and introduction of competitive new products, to the extent each of these factors impact our business and markets. We consider all of these factors and adjust the inventory provision to reflect our actual experience on a periodic basis.

### ***Litigations***

We are involved in disputes, lawsuits, claims, governmental and/or regulatory inspections, inquiries, investigations and proceedings, including patent and commercial matters that arise from time to time in the ordinary course of business. Most of the claims involve complex issues. We assess the need to make a provision for a liability for such claims and record a provision when we determine that a loss related to a matter is both probable and reasonably estimable.

Because litigation and other contingencies are inherently unpredictable, our assessment can involve judgments about future events. Often, these issues are subject to uncertainties and therefore the probability of a loss, if any, being sustained and an estimate of the amount of any loss are difficult to ascertain. This is due to a number of factors, including: the stage of the proceedings (in many cases trial dates have not been set) and the overall length and extent of pre-trial discovery; the entitlement of the parties to an action to appeal a decision; clarity as to theories of liability; damages and governing law; uncertainties in timing of litigation; and the possible need for further legal proceedings to establish the appropriate amount of damages, if any. We also believe that disclosure of the amount of damages sought by plaintiffs, if that is known, would not be meaningful with respect to those legal proceedings.

Consequently, for a majority of these claims, it is not possible to make a reasonable estimate of the expected financial effect, if any, that will result from ultimate resolution of the proceedings. In such circumstances, we disclose information with respect to the nature and facts of the case.

### ***Other provisions***

We recognize a provision if, as a result of a past event, we have a present legal or constructive obligation that can be estimated reliably, and it is probable (i.e., more likely than not) that an outflow of economic benefits will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

### ***Restructuring***

A provision for restructuring is recognized when we have approved a detailed and formal restructuring plan, and the restructuring either has commenced or has been announced publicly. Future operating costs are not provided.

### ***Onerous contracts***

A provision for onerous contracts is recognized when the expected benefits to be derived by us from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, we recognize any impairment loss on the assets associated with that contract.

*Reimbursement rights*

Expected reimbursements for expenditures required to settle a provision are recognized only when receipt of such reimbursements is virtually certain. Such reimbursements are recognized as a separate asset in the statement of financial position, with a corresponding credit to the specific expense for which the provision has been made.

Table of ContentsRecent Accounting Pronouncements

Refer to Note 3(s) to our consolidated financial statements.

**5.A. Operating results****Income Statement Data**

	For the year ended March 31,			
	2016	2016	2015	2014
	(Rs. in millions, U.S.\$ in millions)			
	<i>Convenience translation into U.S.\$</i>			
<b>Revenues</b>	U.S.\$ 2,335	Rs. 154,708	Rs. 148,189	Rs. 132,170
Cost of revenues	942	62,427	62,786	56,369
<b>Gross profit</b>	<b>1,393</b>	<b>92,281</b>	<b>85,403</b>	<b>75,801</b>
Selling, general and administrative expenses	690	45,702	42,585	38,783
Research and development expenses	269	17,834	17,449	12,402
Other (income)/expense, net	(13)	(874)	(917)	(1,416)
<b>Results from operating activities</b>	<b>447</b>	<b>29,619</b>	<b>26,286</b>	<b>26,032</b>
Finance (expense)/income, net	(41)	(2,708)	1,682	400
Share of profit of equity accounted investees, net of tax	3	229	195	174
<b>Profit before tax</b>	<b>410</b>	<b>27,140</b>	<b>28,163</b>	<b>26,606</b>
Tax expense	(108)	(7,127)	(5,984)	(5,094)
<b>Profit for the year</b>	<b>U.S.\$ 302</b>	<b>Rs. 20,013</b>	<b>Rs. 22,179</b>	<b>Rs. 21,512</b>

The following table sets forth, for the periods indicated, financial data as percentages of total revenues and the increase (or decrease) by item as a percentage of the amount over the comparable period in the previous years.

	Percentage of Sales			Percentage Increase/(Decrease)	
	For the year ended March 31,			2015 to	2014 to
	2016	2015	2014	2016	2015
Revenues	100.0%	100.0%	100.0%	4.4%	12.1%
<b>Gross profit</b>	<b>59.6%</b>	<b>57.6%</b>	<b>57.4%</b>	<b>8.1%</b>	<b>12.7%</b>
Selling, general, and administrative expenses	29.5%	28.7%	29.3%	7.3%	9.8%
Research and development expenses	11.5%	11.8%	9.4%	2.2%	40.7%
Other (income)/expense, net	(0.6%)	(0.6%)	(1.1%)	(4.7%)	(35.3%)
<b>Results from operating activities</b>	<b>19.1%</b>	<b>17.7%</b>	<b>19.8%</b>	<b>12.7%</b>	<b>1.0%</b>
Finance (expense)/income, net	(1.8%)	1.1%	0.3%	(261.1%)	320.4%
Share of profit of equity accounted investees, net of tax	0.1%	0.1%	0.1%	17.7%	12.1%
<b>Profit before taxes</b>	<b>17.5%</b>	<b>19.0%</b>	<b>20.1%</b>	<b>(3.6%)</b>	<b>5.9%</b>

Tax expense	(4.6%)	(4.0%)	(3.9%)	19.1%	17.5%
<b>Profit for the year</b>	<b>12.9%</b>	<b>15.0%</b>	<b>16.3%</b>	<b>(9.8%)</b>	<b>3.1%</b>

**Table of Contents**

The following table sets forth, for the periods indicated, our consolidated revenues by segment:

	For the year ended March 31,					
	2016		2015		2014	
	(Rs. in millions)					
	Revenues	Revenues (Segment % of Total)	Revenues	Revenues (Segment % of Total)	Revenues	Revenues (Segment % of Total)
Global Generics	Rs. 128,062	83%	Rs. 119,397	81%	Rs. 104,483	79%
Pharmaceutical Services and Active Ingredients	22,379	14%	25,456	17%	23,974	18%
Proprietary Products	2,659	2%	2,172	1%	2,459	2%
Others	1,608	1%	1,164	1%	1,254	1%
<b>Total</b>	<b>Rs. 154,708</b>	<b>100%</b>	<b>Rs. 148,189</b>	<b>100%</b>	<b>Rs. 132,170</b>	<b>100%</b>

**Fiscal Year Ended March 31, 2016 compared to Fiscal Year Ended March 31, 2015****Revenues**

Our overall consolidated revenues were Rs.154,708 million for the year ended March 31, 2016, an increase of 4% as compared to Rs.148,189 million for the year ended March 31, 2015. Revenue growth for the year ended March 31, 2016 was largely driven by our Global Generics segment's operations in the United States, India and Europe markets

The following table sets forth, for the periods indicated, our consolidated revenues by geography:

	For the year ended March 31,					
	2016		2015		2014	
	(Rs. in millions)					
	Revenues	% of Total Revenue*	Revenues	% of Total Revenue*	Revenues	% of Total Revenue*
<b>Global Generics</b>	<b>Rs. 128,062</b>	<b>83%</b>	<b>Rs. 119,397</b>	<b>81%</b>	<b>Rs. 104,483</b>	<b>79%</b>
North America (the United States and Canada)	75,445	59%	63,564	53%	54,622	52%
Europe	7,732	6%	6,481	5%	6,110	6%
India	21,293	17%	17,870	15%	15,713	15%
Russia and other countries of the former Soviet Union	14,176	11%	18,425	16%	20,679	20%
Others	9,416	7%	13,057	11%	7,359	7%
<b>Pharmaceutical Services and Active Ingredients</b>	<b>Rs. 22,379</b>	<b>14%</b>	<b>Rs. 25,456</b>	<b>17%</b>	<b>Rs. 23,974</b>	<b>18%</b>
	3,052	14%	4,605	18%	3,820	16%

North America (the United States and Canada)

Europe	9,313	42%	10,507	41%	9,058	38%
India	2,618	12%	3,288	13%	3,787	16%
Others	7,396	32%	7,056	28%	7,309	30%
<i>Proprietary Products and Others</i>	<b>Rs. 4,267</b>	<b>3%</b>	<b>Rs. 3,336</b>	<b>2%</b>	<b>Rs. 3,713</b>	<b>3%</b>
<b>Total</b>	<b>Rs. 154,708</b>	<b>100%</b>	<b>Rs. 148,189</b>	<b>100%</b>	<b>Rs. 132,170</b>	<b>100%</b>

\* This represents the segment's revenue from sales in the respective geography as a percentage of the total segment's revenue.

During the year ended March 31, 2016, the U.S. dollar appreciated by approximately 7% against the Indian rupee, while the Euro and the Russian rouble depreciated by approximately 7% and 27%, respectively against the Indian rupee as compared to the year ended March 31, 2015. These changes in exchange rates increased our reported revenues because of the increase in Indian rupee realization from sales in U.S. dollars, partially offset by the decrease in Indian rupee realization from sales in Euros and Russian roubles. However, our higher realization for the U.S. dollar was offset by net losses realized on cash flow hedges undertaken by us to hedge the foreign currency risk associated with highly probable forecasted sales transactions.

**Table of Contents**

**Segment analysis**

***Global Generics***

Revenues from our Global Generics segment were Rs.128,062 million for the year ended March 31, 2016, an increase of 7% as compared to Rs.119,397 million for the year ended March 31, 2015. The revenue growth was largely led by this segment's operations in the United States, India and Europe.

After taking into account the impact of exchange rate fluctuations of the Indian rupee against multiple currencies in the markets in which we operate, the foregoing increase in revenues of this segment was attributable to the following factors:

an increase of approximately 4% resulting from the introduction of new products during the year ended March 31, 2016;

a decrease of approximately 8% resulting from the net impact of decreases in sales prices of products; and

an increase of approximately 11% resulting from increased sales volumes of existing products (including the annualized impact of products launched during the year ended March 31, 2015).

The following is a discussion of the key markets in our Global Generics segment:

*North America (the United States and Canada):* Our Global Generics segment's revenues from North America (the United States and Canada) were Rs.75,445 million for the year ended March 31, 2016, an increase of 19% as compared to the year ended March 31, 2015. In U.S. dollar absolute currency terms (i.e., U.S. dollars without taking into account the effect of currency exchange rates), such revenues increased by 12% for the year ended March 31, 2016 as compared to the year ended March 31, 2015.

This revenue growth was largely attributable to the following:

revenues from new products launched during the year ended March 31, 2016, such as esomeprazole, memantine and pramipexole;

a gain in market share of certain of our existing products, such as valganciclovir, Habitrol®, isotretinoin 30mg, metoprolol, decitabine injection, and sumatriptan injection; and

the foregoing was partially offset by lower realization from certain of our existing products due to price decreases.

The following table sets forth products that we launched in the United States during the year ended March 31, 2016:



<b>Product</b>	<b>Innovator s Brand</b>	<b>Innovator</b>
Esomeprazole DR	Nexium®	AstraZeneca
Pramipexole ER	Mirapex®	Boehringer Ingelheim
Memantine	Namenda®	Eli Lilly
Pravastatin	Pravachol®	Bristol Myers Squibb

During the year ended March 31, 2016, we made 14 filings in the United States, including 13 ANDA filings and one NDA filing under section 505(b)(2) of the Federal Food, Drug and Cosmetic Act (a 505(b)(2) NDA ). As of March 31, 2016 our cumulative filings in the United States were 236 including 233 ANDA filings and three 505(b)(2) NDA filings. As of March 31, 2016, we had 82 filings pending approval at the U.S. FDA including 79 ANDA filings and three 505(b)(2) NDA filings, of which 52 are Paragraph IV filings, and we believe we are the first to file with respect to 18 of these filings.

*India:* Our revenues from India for the year ended March 31, 2016 were Rs.21,293 million, an increase of 19% as compared to the year ended March 31, 2015. This growth was largely attributable to the increase in sales volumes across our key brands and revenues from new brands launched during the year ended March 31, 2016. The products that we acquired from UCB accounted for approximately 7% of the revenue growth for our India business. According to IMS Health in its Moving Annual Total report for the year ended March 31, 2016, our secondary sales in India grew by 12.2% during such period, as compared to the Indian pharmaceutical market s growth of 14.4% during such period. During the year ended March 31, 2016, we launched 17 new brands in India.

*Emerging Markets:* Our revenues from our Emerging Markets (which is comprised of Russia, other countries of the former Soviet Union, Romania, and certain other countries from our Rest of the World markets, primarily Venezuela, South Africa and Australia) for the year ended March 31, 2016 were Rs.23,591 million, a decrease of 25% as compared to the year ended March 31, 2015. The reasons for this decrease are set forth below in the separate discussions of these geographies.

*Russia:* Our Global Generics segment s revenues from Russia were Rs.10,640 million for the year ended March 31, 2016, a decrease of 29% as compared to the year ended March 31, 2015. In Russian rouble absolute currency terms (i.e.,

**Table of Contents**

Russian roubles without taking into account the effect of currency exchange rates), such revenues increased by 1% for the year ended March 31, 2016 as compared to the year ended March 31, 2015. Our over-the-counter ( OTC ) division's revenues from Russia for the year ended March 31, 2016 were 39% of our total revenues from Russia, and we intend to further strengthen our OTC sales by continuous branding initiatives.

According to IMS Health, as per its report for the year ended March 31, 2016, our sales value (in Russian roubles) growth and volume growth from Russia, as compared to the Russian pharmaceutical market sales value (in Russian roubles) growth and volume growth for the year ended March 31, 2016 was as follows:

	Year ended March 31, 2016			
	Dr. Reddy's		Russian pharmaceutical market	
	Sales value	Volume	Sales value	Volume
Prescription (Rx)	2.61%	(4.92%)	10.25%	(1.07%)
Over-the-counter (OTC)	10.88%	(1.02%)	6.73%	(5.09%)
Total (Rx + OTC)	5.60%	(3.92%)	8.36%	(3.96%)

As per the above referenced IMS Health report, our volume-based market shares in Russia for the years ended March 31, 2016 and 2015 were as follows:

	Year ended March 31,	
	2016	2015
Prescription (Rx)	4.50%	4.68%
Over-the-counter (OTC)	0.66%	0.63%
Total (Rx + OTC)	1.77%	1.77%

*Other countries of the former Soviet Union and Romania:* Our revenues from other countries of the former Soviet Union and Romania for the year ended March 31, 2016 were Rs.3,536 million, an increase of 1% over the year ended March 31, 2015. This increase was largely on account of an increase in sales volumes in Romania and Ukraine, partially offset by depreciation of the Ukrainian hryvnia against the Indian rupee. During the year ended March 31, 2016, the Ukrainian hryvnia depreciated by approximately 34% as compared to the year ended March 31, 2015.

*Rest of the World Markets:* We refer to all markets of this segment other than North America, Europe, Russia and other countries of the former Soviet Union, Romania and India as our Rest of the World markets. Our revenues from our Rest of the World markets were Rs.9,416 million for the year ended March 31, 2016, a decrease of 28% as compared to the year ended March 31, 2015. The decrease was largely led by decreased revenues in Venezuela primarily due to reduction in the sales volume of our existing products. Our sales in Venezuela were Rs.4,666 million for the year ended March 31, 2016, as compared to Rs.8,335 million for the year ended March 31, 2015. This reduction in sales was primarily attributable to the ongoing economic crisis in the country and, correspondingly, our risk mitigation approach by way of moderating the supply of products to this country.

*Europe:* Our Global Generics segment's revenues from Europe were Rs.7,732 million for the year ended March 31, 2016, an increase of 19% as compared to the year ended March 31, 2015. This growth was led by revenues from new products launched during the year ended March 31, 2015.



**Table of Contents****Pharmaceutical Services and Active Ingredients ( PSAI )**

Our PSAI segment's revenues for the year ended March 31, 2016 were Rs.22,379 million, a decrease of 12% as compared to the year ended March 31, 2015. After taking into account the impact of the exchange rate fluctuations of the Indian rupee against multiple currencies in the markets in which we operate, this decrease was largely attributable to:

decreased sales of active pharmaceutical ingredients for the year ended March 31, 2016, primarily attributable to decreased sales volumes and sales prices of existing products, which decreased our PSAI segment's revenues by approximately 13%; and

increased customer orders in our pharmaceutical development services for certain products provided to innovator companies, which increased our PSAI segment's revenues by approximately 1%.

During the year ended March 31, 2016, we filed 50 Drug Master Files ( DMFs ) worldwide. Cumulatively, our total worldwide DMFs as of March 31, 2016 were 768, including 218 DMFs in the United States.

**Gross Profit**

Our total gross profit was Rs.92,281 million for the year ended March 31, 2016, representing 59.6% of our total revenues for this period, as compared to Rs.85,403 million for the year ended March 31, 2015, representing 57.6% of our total revenues for such period.

The following table sets forth, for the periods indicated, our gross profit by segment:

	For the year ended March 31,					
	2016		2015		2014	
	(Rs. in millions)					
	Gross Profit (% of Segment Revenue)		Gross Profit (% of Segment Revenue)		Gross Profit (% of Segment Revenue)	
	Gross Profit	Segment Revenue)	Gross Profit	Segment Revenue)	Gross Profit	Segment Revenue)
Global Generics	Rs. 84,427	66%	Rs. 77,569	65%	Rs. 68,544	66%
Pharmaceutical Services and Active Ingredients	4,931	22%	5,709	22%	4,848	20%
Proprietary Products	2,217	83%	1,796	83%	2,210	90%
Others	706	44%	329	28%	199	16%
<b>Total</b>	<b>Rs. 92,281</b>	<b>60%</b>	<b>Rs. 85,403</b>	<b>58%</b>	<b>Rs. 75,801</b>	<b>57%</b>

After taking into account the impact of the exchange rate fluctuations of the Indian rupee against multiple currencies in the markets in which we operate, the gross profits from our Global Generics segment increased to 65.9% for the year ended March 31, 2016 from 65.0% for the year ended March 31, 2015. This increase was largely attributable to

the impact of changes in our existing business mix (i.e., an increase in the proportion of sales of higher gross margin products and a decrease in the proportion of sales of lower gross margin products).

The gross profits from our PSAI segment decreased to 22.0% for the year ended March 31, 2016, from 22.4% for the year ended March 31, 2015. This decrease was primarily due to a decrease in sales of products with higher gross profit margins during the year ended March 31, 2016.

**Selling, general and administrative expenses**

Our selling, general and administrative expenses were Rs.45,702 million for the year ended March 31, 2016, an increase of 7% as compared to Rs.42,585 million for the year ended March 31, 2015. After taking into account the impact of exchange rate fluctuations of the Indian rupee against multiple currencies in the markets in which we operate, this increase was largely attributable to the following:

increased costs due to the ongoing remediation activities related to the warning letter received from the U.S. FDA for three of our manufacturing facilities in India, which increased our selling, general and administrative expenses by approximately 5%;

## **Table of Contents**

increased personnel costs, due to annual raises and new recruitments, which increased our selling, general and administrative expenses by approximately 3%;

increased amortization, primarily due to our acquisition of the Habitrol® brand in December 2014 and acquisition of a select portfolio of products business of UCB in June 2015, which increased our selling, general and administrative expenses by approximately 2%;

for the year ended March 31, 2016 we had recorded impairment losses of Rs.61 million, as compared to impairment losses of Rs.509 million recorded for the year ended March 31, 2015, which resulted in an approximately 1% difference in selling, general and administrative expenses between the two periods; and

decreased sales and marketing costs, which decreased our selling, general and administrative expenses by approximately 1%.

As a proportion of our total revenues, our selling, general and administrative expenses increased to 29.5% for the year ended March 31, 2016 from 28.7% for the year ended March 31, 2015.

### **Research and development expenses**

Our research and development expenses were Rs.17,834 million for the year ended March 31, 2016, an increase of 2% as compared to Rs.17,449 million for the year ended March 31, 2015. This increase was in accordance with our strategy to expand our research and development efforts in complex formulations, differentiated formulations and biosimilar compounds. Approximately 65% of our research and development expenses for the year ended March 31, 2016 were incurred for the development of bio-equivalent products, and the other 35% was dedicated to innovative and bio-pharmaceutical research.

### **Other (income)/expense, net**

Our net other income was Rs.874 million for the year ended March 31, 2016, as compared to net other income of Rs.917 million for the year ended March 31, 2015.

### **Finance (expense)/income, net**

Our net finance expense was Rs.2,708 million for the year ended March 31, 2016, as compared to net finance income of Rs.1,682 million for the year ended March 31, 2015. The increase in net finance expense was attributable to:

net foreign exchange gain of Rs.488 million (excluding the impact of our Venezuela operations described below) for the year ended March 31, 2016, as compared to net foreign exchange gain of Rs.1,801 million for the year ended March 31, 2015;

foreign exchange losses related to our Venezuela operations of Rs.4,621 million for the year ended March 31, 2016, as compared to such losses of Rs.843 million for the year ended March 31, 2015. Refer to Note 41 to our consolidated financial statements for further details;

net interest income of Rs.573 million for the year ended March 31, 2016, as compared to net interest expense of Rs.31 million for the year ended March 31, 2015; and

profit on sale of investments of Rs.852 million for the year ended March 31, 2016, as compared to profit on sale of investments of Rs.755 million for the year ended March 31, 2015.

**Profit before tax**

As a result of the above, profit before taxes was Rs.27,140 million for the year ended March 31, 2016, a decrease of 4% as compared to Rs.28,163 million for the year ended March 31, 2015.

**Tax expense**

Our consolidated weighted average tax rate for the year ended March 31, 2016 was 26%, as compared to 21% for the year ended March 31, 2015. Income tax expense was Rs.7,127 million for the year ended March 31, 2016, as compared to income tax expense of Rs.5,984 million for the year ended March 31, 2015.

The increase in our effective tax rate for the year ended March 31, 2016 was primarily attributable to the following:

non-deductible losses related to our Venezuela operations, which resulted in an increase in our effective tax rate by approximately 3.8% (refer to Note 41 of our consolidated financial statements for further details);

**Table of Contents**

deferred tax expense on undistributed earnings of a subsidiary outside India, which resulted in an increase in our effective tax rate by approximately 1.9%;

an increase in the effective tax rate by approximately 1.8% due to non-recognition of certain deferred tax assets, as we believe that availability of taxable profits against which the temporary differences can be utilized is not probable;

recognition of a previously unrecognized deferred tax asset pertaining to a jurisdiction outside of India, which resulted in a decrease in our effective tax rate by approximately 1.1%; and

an increase in weighted deduction on eligible research and development expenditure in India during the year ended March 31, 2016, as compared to the year ended March 31, 2015, has resulted in a decrease in the effective tax rate by 1.8%. The rate of weighted deduction on our eligible research and development expenditure was equal to 200% for the years ended March 31, 2016 and 2015, respectively.

**Profit for the period**

As a result of the above, our net result was a net profit of Rs.20,013 million for the year ended March 31, 2016, as compared to a net profit of Rs.22,179 million for the year ended March 31, 2015.



**Table of Contents****Fiscal Year Ended March 31, 2015 compared to Fiscal Year Ended March 31, 2014****Revenues**

Our overall consolidated revenues were Rs.148,189 million for the year ended March 31, 2015, an increase of 12% as compared to Rs.132,170 million for the year ended March 31, 2014. Revenue growth for the year ended March 31, 2015 was largely driven by our Global Generics segment's operations in the United States, India and our Rest of the World markets (i.e., all markets other than North America, Europe, Russia and other countries of the former Soviet Union, and India), primarily Venezuela.

The following table sets forth, for the periods indicated, our consolidated revenues by geography:

	For the year ended March 31,					
	2015		2014		2013	
	Revenues	% of Total Revenue*	Revenues	% of Total Revenue*	Revenues	% of Total Revenue*
	(Rs. in millions)					
<b>Global Generics</b>	<b>Rs. 119,397</b>	<b>81%</b>	<b>Rs. 104,483</b>	<b>79%</b>	<b>Rs. 82,516</b>	<b>71%</b>
North America (the United States and Canada)	63,564	53%	54,622	52%	37,799	46%
Europe	6,481	5%	6,110	6%	7,011	8%
India	17,870	15%	15,713	15%	14,560	18%
Russia and other countries of the former Soviet Union	18,425	16%	20,679	20%	17,613	21%
Others	13,057	11%	7,359	7%	5,533	7%
<b>Pharmaceutical Services and Active Ingredients</b>	<b>Rs. 25,456</b>	<b>17%</b>	<b>Rs. 23,974</b>	<b>18%</b>	<b>Rs. 30,702</b>	<b>26%</b>
North America (the United States and Canada)	4,605	18%	3,820	16%	5,744	19%
Europe	10,507	41%	9,058	38%	12,007	39%
India	3,288	13%	3,787	16%	4,638	15%
Others	7,056	28%	7,309	30%	8,313	27%
<b>Proprietary Products and Others</b>	<b>Rs. 3,336</b>	<b>2%</b>	<b>Rs. 3,713</b>	<b>3%</b>	<b>Rs. 3,048</b>	<b>3%</b>
<b>Total</b>	<b>Rs. 148,189</b>	<b>100%</b>	<b>Rs. 132,170</b>	<b>100%</b>	<b>Rs. 116,266</b>	<b>100%</b>

\* This represents the segment's revenue from sales in the respective geography as a percentage of the total segment's revenue.

During the year ended March 31, 2015, the Indian rupee depreciated by approximately 1.1% against the U.S. dollar, while the Euro and the Russian rouble depreciated by approximately 4.5% and 22.3%, respectively, against the Indian rupee as compared to the year ended March 31, 2014. These changes in exchange rates reduced our reported revenues because of the decrease in Indian rupee realization from sales in Euros and Russian roubles. However, our lower

realization for the Russian rouble was partially offset by net gains realized on cash flow hedges undertaken by us to hedge the foreign currency risk associated with highly probable forecasted sales transactions. Accordingly, on a net basis, our realizations of Russian rouble denominated revenues reported in Indian rupees were lower by 19% for the year ended March 31, 2015, as compared to our revenues for the year ended March 31, 2014 adjusted for gains on such cash flow hedges, on account of the depreciation of the Russian rouble.

## **Segment analysis**

### ***Global Generics***

Revenues from our Global Generics segment were Rs.119,397 million for the year ended March 31, 2015, an increase of 14% as compared to Rs.104,483 million for the year ended March 31, 2014. The revenue growth was largely led by this segment's operations in the United States, India and Venezuela.

**Table of Contents**

After taking into account the impact of exchange rate fluctuations of the Indian rupee against multiple currencies in the markets in which we operate, the foregoing increase in revenues of this segment was attributable to the following factors:

an increase of approximately 7% resulting from the introduction of new products during the year ended March 31, 2015;

a decrease of approximately 13% resulting from the net impact of decreases in sales prices of products; and

an increase of approximately 20% resulting from increased sales volumes of existing products (including the annualized impact of products launched during the year ended March 31, 2014).

The following is a discussion of the key markets in our Global Generics segment:

*North America (the United States and Canada):* Our Global Generics segment's revenues from North America (the United States and Canada) were Rs.63,564 million for the year ended March 31, 2015, an increase of 16% as compared to the year ended March 31, 2014. In U.S. dollar absolute currency terms (i.e., U.S. dollars without taking into account the effect of currency exchange rates), such revenues increased by 15% for the year ended March 31, 2015 as compared to the year ended March 31, 2014.

This revenue growth was largely attributable to the following:

revenues from new products launched during the year ended March 31, 2015, such as valganciclovir, sirolimus and Habitrol®;

a gain in market share of certain of our existing products, such as divalproex sodium ER, azacitidine, decitabine, and ziprasidone; and

the foregoing was partially offset by lower realization from certain of our existing products due to price decreases.

The following table sets forth products that we launched in the United States during the year ended March 31, 2015:

<b>Product</b>	<b>Innovator's Brand</b>	<b>Innovator</b>
eszopiclone	Lunesta®	Sepracor
fenofibrate capsules	Antara®	Ethypharm
paricalcitol	Zemplar®	Abbott
duloxetine delayed release capsules	Cymbalta®	Eli Lilly
levalbuterol hydrochloride	Xopenex®	Sunovion Pharmaceuticals

sirolimus	Rapamune®	Pfizer
docetaxel	Taxotere®	Sanofi
fexofenadine pseudophedrine HCL OTC	Allegra D12®	Sanofi
fluconazole	Diflucan®	Pfizer
valganciclovir	Valcyte®	Roche
isotretinoin 30 mg	Zenatane®	Roche

Furthermore, during the year ended March 31, 2015, we acquired from Novartis Consumer Health Inc. the title and rights to its Habitrol® brand (an over-the-counter nicotine replacement therapy transdermal patch) and related U.S. marketing rights, and we began marketing the product in the United States.

During the year ended March 31, 2015, we made 13 new ANDA filings, and as of March 31, 2015 our cumulative ANDA filings were 220. As of March 31, 2015, we had 68 ANDAs pending approval at the U.S. FDA, of which 43 are Paragraph IV filings, and we believe we are the first to file with respect to 13 of these filings.

*India:* Our revenues from India for the year ended March 31, 2015 were Rs.17,870 million, an increase of 14% as compared to the year ended March 31, 2014. This growth was largely attributable to the increase in sales volumes across our key brands and revenues from new brands launched during the year ended March 31, 2015. According to IMS Health in its Moving Annual Total report for the year ended March 31, 2015, our secondary sales in India grew by 13.1% during such period, as compared to the India pharmaceutical market's growth of 12.1% during such period. During the year ended March 31, 2015, we launched 18 new brands in India such as DOXT-SL™, Melgain®, Xalibo™, and Resof (sofosbuvir).

**Table of Contents**

Furthermore, in April 2015, we entered into a definitive agreement with UCB India Private Limited and other UCB group companies (together referred to as UCB) to acquire a select portfolio of established products business in the territories of India, Nepal, Sri Lanka and Maldives for a total purchase consideration of Rs.8,000 million. The purchased business was acquired on a slump sale basis (an Indian tax law concept which refers to the transfer of a business as a going concern without values being assigned to individual assets and liabilities). The transaction includes approximately 350 employees engaged in the operations of the acquired India business. The acquisition is expected to strengthen our presence in the areas of dermatology, respiratory and pediatric products. The acquired business had revenues of approximately Rs.1,500 million for the year ended December 31, 2014. The transaction was closed on June 16, 2015 and we began marketing of these products.

*Emerging Markets:* Our revenues from our Emerging Markets (which is comprised of Russia, other countries of the former Soviet Union, and certain other countries from our Rest of the World markets, primarily Venezuela, South Africa and Australia) for the year ended March 31, 2015 were Rs.31,482 million, an increase of 12% as compared to the year ended March 31, 2014. The reasons for this growth are set forth below in the separate discussions of these geographies.

*Russia:* Our Global Generics segment's revenues from Russia were Rs.14,922 million for the year ended March 31, 2015, a decrease of 9% as compared to the year ended March 31, 2014. In Russian rouble absolute currency terms (i.e., Russian roubles without taking into account the effect of currency exchange rates), such revenues increased by 13% for the year ended March 31, 2015 as compared to the year ended March 31, 2014. Our over-the-counter (OTC) division's revenues from Russia for the year ended March 31, 2015 were 36% of our total revenues from Russia, and we intend to further strengthen our OTC sales by continuous branding initiatives.

According to IMS Health, as per its report for the year ended March 31, 2015, our sales value (in Russian roubles) growth and volume growth from Russia, as compared to the Russian pharmaceutical market sales value (in Russian roubles) growth and volume growth for the year ended March 31, 2015 was as follows:

	Year ended March 31, 2015			
	Dr. Reddy's		Russian pharmaceutical market	
	Sales value	Volume	Sales value	Volume
Prescription (Rx)	6.62%	-5.67%	12.29%	0.27%
Over-the-counter (OTC)	16.86%	7.28%	12.30%	-1.84%
Total (Rx + OTC)	10.10%	-2.66%	12.29%	-1.26%

As per the above referenced IMS Health report, our volume-based market shares in Russia for the years ended March 31, 2015 and 2014 were as follows:

	Year ended March 31,	
	2015	2014
Prescription (Rx)	4.68%	4.97%
Over-the-counter (OTC)	0.63%	0.58%
Total (Rx + OTC)	1.77%	1.80%

*Other countries of the former Soviet Union and Romania:* Our revenues from other countries of the former Soviet Union for the year ended March 31, 2015 were Rs.3,504 million, a decrease of 19% over the year ended March 31,

2014. This decline was largely on account of a decrease in sales volumes in Ukraine, primarily on account of the geo-political situation in Ukraine coupled with depreciation of the Ukrainian hryvnia against the Indian rupee. During the year ended March 31, 2015, the Ukrainian hryvnia depreciated by approximately 41% as compared to the year ended March 31, 2014.

*Rest of the World Markets:* We refer to all markets of this segment other than North America, Europe, Russia and other countries of the former Soviet Union and India as our Rest of the World markets. Our revenues from our Rest of the World markets were Rs.13,056 million for the year ended March 31, 2015, an increase of 77% as compared to the year ended March 31, 2014. The growth was largely led by increased revenues in Venezuela attributable to new marketing initiatives for prescription products. Our sales in Venezuela were Rs.8,335 million for the year ended March 31, 2015.

*Europe:* Our Global Generics segment's revenues from Europe were Rs.6,481 million for the year ended March 31, 2015, an increase of 6% as compared to the year ended March 31, 2014. This growth was led by revenues from new products launched during the year ended March 31, 2015.

**Table of Contents****Pharmaceutical Services and Active Ingredients ( PSAI )**

Our PSAI segment's revenues for the year ended March 31, 2015 were Rs.25,456 million, an increase of 6% as compared to the year ended March 31, 2014. After taking into account the impact of the exchange rate fluctuations of the Indian rupee against multiple currencies in the markets in which we operate, this increase was largely attributable to:

increased sales of active pharmaceutical ingredients for the year ended March 31, 2015, primarily attributable to certain key products such as capecitabine and epoxide, partially offset by the net impact of changes in sales prices of existing products, all of which increased our PSAI segment's revenues by approximately 5%; and

increased customer orders in our pharmaceutical development services for certain products provided to innovator companies, which increased our PSAI segment's revenues by approximately 1%.

During the year ended March 31, 2015, we filed 77 Drug Master Files ( DMFs ) worldwide. Cumulatively, our total worldwide DMFs as of March 31, 2015 were 735, including 219 DMFs in the United States.

**Gross Profit**

Our total gross profit was Rs.85,403 million for the year ended March 31, 2015, representing 57.6% of our total revenues for this period, as compared to Rs.75,801 million for the year ended March 31, 2014, representing 57.4% of our total revenues for such period.

The following table sets forth, for the periods indicated, our gross profit by segment:

	For the year ended March 31,					
	2015		2014		2013	
	(Rs. in millions)		(Rs. in millions)		(Rs. in millions)	
	Gross Profit (% of Segment Revenue)	Gross Profit (% of Segment Revenue)	Gross Profit (% of Segment Revenue)	Gross Profit (% of Segment Revenue)	Gross Profit (% of Segment Revenue)	Gross Profit (% of Segment Revenue)
Global Generics	Rs. 77,569	65%	Rs. 68,544	66%	Rs. 48,687	59%
Pharmaceutical Services and Active Ingredients	5,709	22%	4,848	20%	9,970	32%
Proprietary Products	1,796	83%	2,210	90%	1,358	90%
Others	329	28%	199	16%	564	37%
<b>Total</b>	<b>Rs. 85,403</b>	<b>58%</b>	<b>Rs. 75,801</b>	<b>57%</b>	<b>Rs. 60,579</b>	<b>52%</b>

After taking into account the impact of the exchange rate fluctuations of the Indian rupee against multiple currencies in the markets in which we operate, the gross profits from our Global Generics segment decreased to 65.0% for the year ended March 31, 2015 from 65.6% for the year ended March 31, 2014. This decrease was largely attributable to

the impact of changes in our existing business mix (i.e., a decrease in the proportion of sales of higher gross margin products and an increase in the proportion of sales of lower gross margin products).

The gross profits from our PSAI segment increased to 22.4% for the year ended March 31, 2015, from 20.2% for the year ended March 31, 2014. This increase was primarily due to an increase in sales of products with higher gross profit margins during the year ended March 31, 2015.

#### **Selling, general and administrative expenses**

Our selling, general and administrative expenses were Rs.42,585 million for the year ended March 31, 2015, an increase of 10% as compared to Rs.38,783 million for the year ended March 31, 2014. After taking into account the impact of exchange rate fluctuations of the Indian rupee against multiple currencies in the markets in which we operate, this increase was largely attributable to the following:

increased personnel costs, due to annual raises and new recruitments, which increased our selling, general and administrative expenses by approximately 4%;

for the year ended March 31, 2015 we had recorded impairment losses of Rs.509 million, as compared to a reversal of impairment losses of Rs.497 million recorded for the year ended March 31, 2014, which resulted in an approximately 3% difference in selling, general and administrative expenses between the two periods; and



## **Table of Contents**

increased sales and marketing costs, which increased our selling, general and administrative expenses by approximately 1%.

As a proportion of our total revenues, our selling, general and administrative expenses decreased to 28.7% for the year ended March 31, 2015 from 29.3% for the year ended March 31, 2014.

### **Research and development expenses**

Our research and development expenses were Rs.17,449 million for the year ended March 31, 2015, an increase of 41% as compared to Rs.12,402 million for the year ended March 31, 2014. This increase was in accordance with our strategy to expand our research and development efforts in complex formulations, differentiated formulations and biosimilar compounds. Approximately 60% of our research and development expenses for the year ended March 31, 2015 were spent towards the development of bio-equivalent products and the other 40% was dedicated to innovative and bio-pharmaceutical research.

Furthermore, consequent to our decision to discontinue the further development of certain In-Process Research and Development assets pertaining to our Proprietary Products segment, we recorded Rs.95 million as impairment loss for the year ended March 31, 2015 under research and development expenses.

### **Other (income)/expense, net**

Our net other income was Rs.917 million for the year ended March 31, 2015, as compared to net other income of Rs.1,416 million for the year ended March 31, 2014. Our net other income for the year ended March 31, 2014 included Rs.415 million from the resolution of litigation associated with the sale of one of our generic products in North America.

### **Finance (expense)/income, net**

Our net finance income was Rs.1,682 million for the year ended March 31, 2015, as compared to net finance income of Rs.400 million for the year ended March 31, 2014. The increase in net finance income was attributable to:

net foreign exchange gain of Rs.1,801 million (excluding the impact of Venezuela currency exchange loss described below) for the year ended March 31, 2015, as compared to net foreign exchange gain of Rs.372 million for the year ended March 31, 2014;

foreign exchange loss of Rs.843 million for the year ended March 31, 2015 on translation of certain monetary assets and liabilities of our Venezuelan subsidiary. Refer to Note 41 to our consolidated financial statements for further details;

net interest expense of Rs.31 million for the year ended March 31, 2015, as compared to net interest expense of Rs.189 million for the year ended March 31, 2014; and

profit on sale of investments of Rs.755 million for the year ended March 31, 2015, as compared to profit on sale of investments of Rs.213 million for the year ended March 31, 2014.

**Profit before tax**

As a result of the above, profit before income taxes was Rs.28,163 million for the year ended March 31, 2015, an increase of 6% as compared to Rs.26,606 million for the year ended March 31, 2014.

**Tax expense**

Our consolidated weighted average tax rate for the year ended March 31, 2015 was 21.2%, as compared to 19.1% for the year ended March 31, 2014. Income tax expense was Rs.5,984 million for the year ended March 31, 2015, as compared to income tax expense of Rs.5,094 million for the year ended March 31, 2014. The effective tax rate for the period ended March 31, 2014 was lower primarily as a result of a favorable order from the Income Tax Appellate Tribunal, Hyderabad, India on a previously litigated tax matter relating to the deductibility of share-based payment expenses.

**Profit for the period**

As a result of the above, our net result was a net profit of Rs.22,179 million for the year ended March 31, 2015, as compared to a net profit of Rs.21,512 million for the year ended March 31, 2014.

**Table of Contents****Fiscal Year Ended March 31, 2014 compared to Fiscal Year Ended March 31, 2013****Revenues**

Our overall consolidated revenues were Rs.132,170 million for the year ended March 31, 2014, an increase of 14% as compared to Rs.116,266 million for the year ended March 31, 2013. Revenue growth for the year ended March 31, 2014 was largely driven by our Global Generics segment's operations in the United States and our Emerging Markets (which is comprised of Russia, other countries of the former Soviet Union, and certain other countries from our Rest of the World markets, primarily South Africa, Venezuela and Australia).

The following table sets forth, for the periods indicated, our consolidated revenues by geography:

	For the year ended March 31,					
	2014		2013		2012	
	Revenues	% of Total Revenue *	Revenues	% of Total Revenue *	Revenues	% of Total Revenue *
	(Rs. in millions)					
<b>Global Generics</b>	<b>Rs. 104,483</b>	<b>79%</b>	<b>Rs. 82,516</b>	<b>71%</b>	<b>Rs. 70,243</b>	<b>72%</b>
North America (the United States and Canada)	54,622	52%	37,799	46%	31,889	45%
Europe	6,110	6%	7,011	8%	7,632	11%
India	15,713	15%	14,560	18%	12,931	18%
Russia and other countries of the former Soviet Union	20,679	20%	17,613	21%	13,887	20%
Rest of the World	7,359	7%	5,533	7%	3,904	6%
<b>Pharmaceutical Services and Active Ingredients</b>	<b>Rs. 23,974</b>	<b>18%</b>	<b>Rs. 30,702</b>	<b>26%</b>	<b>Rs. 23,812</b>	<b>25%</b>
North America (the United States and Canada)	3,820	16%	5,744	19%	4,272	18%
Europe	9,058	38%	12,007	39%	8,424	35%
India	3,787	16%	4,638	15%	3,586	15%
Rest of the World	7,309	30%	8,313	27%	7,531	32%
<b>Proprietary Products and Others</b>	<b>Rs. 3,713</b>	<b>3%</b>	<b>Rs. 3,048</b>	<b>3%</b>	<b>Rs. 2,682</b>	<b>3%</b>
<b>Total</b>	<b>Rs. 132,170</b>	<b>100%</b>	<b>Rs. 116,266</b>	<b>100%</b>	<b>Rs. 96,737</b>	<b>100%</b>

\* This represents the segment's revenue from sales in the respective geography as a percentage of the total segment's revenue.

During the year ended March 31, 2014, the Indian rupee depreciated by approximately 10%, 14%, and 4% against the U.S. dollar, the Euro and the Russian rouble, respectively, as compared to the year ended March 31, 2013. This change in the exchange rates resulted in higher reported revenues because of the increase in Indian rupee realization from sales in U.S. dollars, Euros and Russian roubles. However, our higher realization for the U.S. dollar was partially offset by net losses incurred on cash flow hedges undertaken by us to hedge the foreign currency risk associated with highly probable forecasted sales transactions. Accordingly, on a net basis, our realizations of U.S. dollar denominated revenues reported in Indian rupees were higher by 15% for the year ended March 31, 2014, as compared to our revenues for the year ended March 31, 2013 adjusted for losses on such cash flow hedges, on account of depreciation of the Indian rupee.

Our provision for sales returns as at March 31, 2014 was Rs.2,504 million, as compared to a provision of Rs.1,904 million as at March 31, 2013. This increase in our provision was primarily due to higher sales recorded for the year ended March 31, 2014. Consistent with our accounting policy for creating provisions for sales returns (discussed in Note 3(1) of our consolidated financial statements), we periodically assess the adequacy of our allowance for sales returns based on the criteria discussed in our Critical Accounting Policies, as well as sales returns actually processed during the year. For further information regarding our sales return provisions, see Notes 3(1) and 21 to our consolidated financial statements.

### **Segment analysis**

#### ***Global Generics***

Revenues from our Global Generics segment were Rs.104,483 million for the year ended March 31, 2014, an increase of 27% as compared to Rs.82,516 million for the year ended March 31, 2013. North America (the United States and Canada), India and our Emerging Markets (which is comprised of Russia, other countries of the former Soviet Union, and certain other countries from our Rest of the World markets, primarily South Africa, Venezuela and Australia), contributed approximately 93% of the revenues of this segment for the year ended March 31, 2014.

**Table of Contents**

After taking into account the favorable impact of depreciation of the Indian rupee against multiple currencies in the markets in which we operate, the foregoing increase in revenues of this segment was attributable to the following factors:

an increase of approximately 20% resulting from the introduction of new products during the year ended March 31, 2014;

an increase of approximately 3% resulting from the net impact of increases in sales prices of products; and

an increase of approximately 4% resulting from increased sales volumes of existing products;

**North America (the United States and Canada):** Our Global Generics segment's revenues from North America (the United States and Canada) for the year ended March 31, 2014 were Rs.54,622 million, an increase of 45% as compared to our revenues of Rs.37,799 million for the year ended March 31, 2013. In U.S. dollar absolute currency terms (i.e., U.S. dollars without taking into account the effect of currency exchange rates), this segment's revenues from such geography grew by 25% in the year ended March 31, 2014 as compared to the year ended March 31, 2013. This growth was largely attributable to the following:

Revenues from 9 new products launched in the year ended March 31, 2014. The following table sets forth, for the year ended March 31, 2014, products that we launched in the United States:

<b>Product</b>	<b>Innovator's Brand</b>	<b>Innovator</b>
Zoledronic acid (5mg/100ml)	Reclast®	Novartis AG
Lamotrigine Extended Release	Lamictal® XR	GlaxoSmithKline
Azacitidine	Vidaza®	Celgene Corporation
Divalproex Extended Release	Depakote® ER	GlaxoSmithKline
Donepezil 23 mg	Aricept® 23 mg	Eisai Inc.
Decitabine	Dacogen®	Eisai Inc.
Amlodipine besylate and atorvastatin calcium	Caduet®	Pfizer Inc.
Sumatriptan Auto Injector	Imitrex STATdose Pen®	Pfizer Inc.
Moxifloxacin	Avelox®	Bayer AG

Market share expansion in our existing key products, such as metoprolol succinate and atorvastatin.

During the year ended March 31, 2014, we made 13 U.S. filings, which includes one NDA filing under section 505(b)(2) and 12 ANDA filings, bringing our cumulative ANDA filings to 209. We now have 62 ANDAs pending approval at the U.S. FDA, out of which 39 are Paragraph IV filings and we believe 9 to have first to file status. We have also received a tentative approval for one of our NDAs filed under section 505(b)(2).

A significant portion of our Global Generics segment's revenue growth in North America (the United States and Canada) for the year ended March 31, 2014 was on account of sales from launches of new products.

**India:** Our revenues from India in the year ended March 31, 2014 were Rs.15,713 million, an increase of 8% as compared to the year ended March 31, 2013. During the year ended March 31, 2014, the Government of India released drug price notifications for a majority of the 348 products listed in the National List of Essential Medicines that are subject to price controls under the Drugs (Price Control) Order, 2013. The reduced prices from these price controls adversely impacted the revenues from our India business by approximately 3% (the annualized impact is approximately 4%) for the year ended March 31, 2014.

Despite the adverse impact of the aforesaid reduction in prices, growth was largely driven by an increase in sales volumes across our key brands, as well as revenues from 11 new products launched during the year ended March 31, 2014. According to IMS Health, as per its moving annual total report for the 12 months ended March 31, 2014, our sales value grew by 12.2% for the year ended March 31, 2014. In comparison, the Indian pharmaceutical market grew by 9.9% during such period.

Bio-similar products are one of the key contributors to our revenues from India, and represented approximately 7% of our revenues from India for the year ended March 31, 2014.

**Emerging Markets:** Our revenues from our Emerging Markets (which is comprised of Russia, other countries of the former Soviet Union, and certain other countries from our Rest of the World markets, primarily South Africa, Venezuela and Australia), for the year ended March 31, 2014 were Rs.28,038 million, an increase of 21% over the year ended March 31, 2013. The reasons for this growth are set forth below in the separate discussions of these geographies.

**Table of Contents**

**Russia:** Our revenues from Russia for the year ended March 31, 2014 were Rs.16,333 million, an increase of 16% over the year ended March 31, 2013. In Russian rouble absolute currency terms (i.e., Russian roubles without taking into account the effect of currency exchange rates), such revenues grew by 11% in the year ended March 31, 2014 as compared to the year ended March 31, 2013. The growth was largely driven by an increase in sales across our key brands (such as Nise, Omez, Ketorol, Senade and Cetrine) as well as new product launches. According to IMS Health, as per its moving annual total report for the 12 months ended March 31, 2014, our sales value and volume growths for the year ended March 31, 2014 were 7.7% and 4.1%, respectively, as compared to the Russian pharmaceutical market value growth and volume decrease of 1.9% and 5.0%, respectively. During the same period, our volume market share increased from 1.64% to 1.80%, according to IMS Health. Our sales of OTC products have grown significantly, and accounted for 34% of the total sales made by us in Russia for the year ended March 31, 2014. We intend to further increase our OTC sales by various branding and other marketing initiatives. According to IMS Health, in the year ended March 31, 2014, we have improved our rank by five positions in the OTC segment as compared to the year ended March 31, 2013. As per IMS Health's moving annual total report for the 12 months ended March 31, 2014, our OTC sales value and volume growths in Russia for the year ended March 31, 2014 were 18.8% and 16.8%, respectively, as compared to the Russian OTC pharmaceutical market value growth and volume decrease of 1.4% and 6.0%, respectively.

**Other countries of the former Soviet Union and Romania:** Our revenues from other countries of the former Soviet Union for the year ended March 31, 2014 were Rs.4,346 million, an increase of 22% over the year ended March 31, 2013. This growth was largely led by increased revenues resulting from higher prices from sales in Ukraine and increased sales volumes from sales in Uzbekistan, Belarus and Kazakhstan. This growth also benefitted from the depreciation of the Indian rupee against the U.S. dollar and the Ukrainian hryvnia.

**Rest of the World Markets:** We refer to all markets of this segment other than North America, Europe, Russia and other countries of the former Soviet Union and India as our Rest of the World markets. Our revenues from our Rest of the World markets were Rs.7,359 million in the year ended March 31, 2014, an increase of 33% as compared to the year ended March 31, 2013. The growth was largely led by increased revenues resulting from higher prices and increased sales volumes from South Africa and Venezuela, and was partially offset by the impact of devaluation of the Venezuelan bolivar from VEF 4.3 per U.S. dollar to VEF 6.3 per U.S. dollar.

***Pharmaceutical Services and Active Ingredients ( PSAI )***

Our Pharmaceutical Services and Active Ingredients ( PSAI ) segment's revenues for the year ended March 31, 2014 were Rs.23,974 million, a decrease of 22% as compared to the year ended March 31, 2013. After taking into account the favorable impact of depreciation of the Indian rupee against multiple currencies in the markets in which we operate, such decrease was largely attributable to:

decreased sales of active pharmaceutical ingredients, as some of our key customers lost market share during the year, coupled with lower sales from launch molecules (i.e., API sales to customers to support their generic product launches related to impending patent expirations) to our customers in the year ended March 31, 2014, which decreased our PSAI segment's revenues by 16%; and

decreased customer orders in our pharmaceutical development services for certain products provided to innovator companies which decreased our PSAI segment's revenues by 6%.

In the year ended March 31, 2014, our PSAI segment filed 61 Drug Master Files ( DMFs ) worldwide, of which 12 were filed in the United States, 13 were filed in Europe and 36 were filed in other countries. Cumulatively, our total DMFs filed worldwide as of March 31, 2014 were 631, including 196 DMFs filed in the United States.

**Gross Profit**

Our total gross profit was Rs.75,801 million in the year ended March 31, 2014, representing 57.4% of our total revenues for this period, as compared to Rs.60,579 million in the year ended March 31, 2013, representing 52.1% of our total revenues for this period.



**Table of Contents**

The following table sets forth, for the periods indicated, our gross profit by segment:

	For the year ended March 31,					
	2014		2013		2012	
	Gross Profit	% of Segment Revenue	Gross Profit	% of Segment Revenue	Gross Profit	% of Segment Revenue
	(Rs. in millions)					
Global Generics	Rs. 68,544	66%	Rs. 48,687	59%	Rs. 44,263	63%
Pharmaceutical Services and Active Ingredients	4,848	20%	9,970	32%	7,508	32%
Proprietary Products	2,210	90%	1,358	90%	903	84%
Others	199	16%	564	37%	631	39%
<b>Total</b>	<b>Rs. 75,801</b>	<b>57%</b>	<b>Rs. 60,579</b>	<b>52%</b>	<b>Rs. 53,305</b>	<b>55%</b>

After taking into account the favorable impact of depreciation of the Indian rupee against multiple currencies in the markets in which we operate, the gross profits from our Global Generics segment increased from 59.0% in the year ended March 31, 2013 to 65.6% in the year ended March 31, 2014, on account of:

the favorable impact of changes in our existing business mix (i.e., an increase in the proportion of sales of higher gross margin products and a decrease in the proportion of sales of lower gross margin products) primarily attributable to an increased proportion of sales from new product launches with better margins; and

higher price realizations from existing products, primarily due to the favorable impact of the depreciation of the Indian rupee against the U.S. Dollar.

The gross profits from our PSAI segment decreased from 32.5% for the year ended March 31, 2013 to 20.2% for the year ended March 31, 2014, due to the following:

the unfavorable impact of changes in our existing business mix (i.e., a decrease in the proportion of sales of higher gross margin products and an increase in the proportion of sales of lower gross margin products) primarily on account of lower sales from launch molecules (i.e., API sales to customers to support their generic product launches related to impending patent expirations) to our customers during the year; and

increased pricing pressures on key products.

**Selling, general and administrative expenses**

Our selling, general and administrative expenses for the year ended March 31, 2014 were Rs.38,783 million, an increase of 13% as compared to Rs.34,272 million for the year ended March 31, 2013. After taking into account the unfavorable impact of depreciation of the Indian rupee against multiple currencies in the markets in which we operate,

this increase was largely attributable to the following:

increased personnel costs, due to annual raises and new recruitments, which increased our selling, general and administrative expenses by 5.2%;

increased sales and marketing costs, due to expenditures towards select brand building activities in Emerging Markets (which is comprised of Russia, other countries of the former Soviet Union, and certain other countries from our Rest of the World markets, primarily South Africa, Venezuela and Australia), which increased our selling, general and administrative expenses by 4.8%; and

increased legal and professional services cost, which increased our selling, general and administrative expenses by 2.0%.

As a proportion of our total revenues, our selling, general and administrative expenses have marginally decreased from 29.5% for the year ended March 31, 2013 to 29.3% for the year ended March 31, 2014.

### **Research and development expenses**

Our research and development expenses in the year ended March 31, 2014 were Rs.12,402 million, an increase of 62% as compared to Rs.7,674 million in the year ended March 31, 2013. This increase was in accordance with our strategy to expand our research and development efforts in complex formulations, differentiated formulations and biosimilar compounds. Our research and development expenditures accounted for 9.4% of our total revenues in the year ended March 31, 2014, as compared to 6.6% in the year ended March 31, 2013. Approximately 62% of our research and development expenses for the year ended March 31, 2014 were spent towards the development of bio-equivalent products and the other 38% was dedicated to innovative and bio-pharmaceutical research.

### **Reversal of impairment losses**

Consequent to the increase in expected cash flows of some of the products forming part of the product related intangibles pertaining to our Global Generics segment, we estimated the recoverable amount of such intangible assets and assessed that the impairment loss recorded in an earlier period should be reversed. Accordingly, a reversal of impairment loss

## **Table of Contents**

of Rs.497 million for such product related intangibles was recorded for the year ended March 31, 2014 under Selling, general and administrative expenses in the consolidated income statement. The expected cash flows increased primarily due to various market dynamics, such as reduced competition and favorable pricing position.

### **Other income, net**

Our net other income was Rs.1,416 million for the year ended March 31, 2014, as compared to a net other income of Rs.2,479 million for the year ended March 31, 2013. The decrease in net other income by Rs.1,063 million was largely attributable to the following:

during March 2013, we entered into an agreement with Nordion Inc. (formerly known as MDS Inc.) to settle our ongoing litigation for alleged breach of service obligations by Nordion Inc. during the years 2000 to 2004. As part of the settlement, we received a one-time settlement amount of Rs.1,220 million (U.S.\$22.5 million) from Nordion Inc., out of which Rs.108 million (U.S.\$2 million) was towards reimbursement of research and development cost and was recorded as reduction in such cost. The balance of Rs.1,112 million (U.S.\$20.5 million) was compensation for lost profits and was recorded as part of other income; and

other income for the year ended March 31, 2014 includes Rs.415 million (CAD6.75 million) from the resolution of litigation associated with the sale of one of our generic products in North America.

### **Finance income, net**

Our net finance income was Rs.400 million for the year ended March 31, 2014, as compared to net finance income of Rs.460 million for the year ended March 31, 2013. The decrease in net finance income by Rs.60 million was largely attributable to an increase in our net interest expense, which was Rs.189 million for the year ended March 31, 2014 as compared to Rs.118 million for the year ended March 31, 2013.

### **Profit before income taxes**

As a result of the above, profit before income taxes was Rs.26,606 million for the year ended March 31, 2014, an increase of 23% as compared to Rs.21,676 million for the year ended March 31, 2013.

### **Income tax expense**

Our consolidated weighted average tax rates for the years ended March 31, 2014 and 2013 were 19.1% and 22.6%, respectively. Income tax expense was Rs.5,094 million for the year ended March 31, 2014, as compared to income tax expense of Rs.4,900 million for the year ended March 31, 2013. The decrease in effective tax rate by 3.5% for the year ended March 31, 2014 was primarily attributable to the following:

a decrease in the effective tax rate by approximately 3.2% as a result of a favorable order from the Income Tax Appellate Tribunal, Hyderabad, India over a previously litigated tax matter;

a decrease in the effective tax rate by approximately 0.9% on account of impairment losses and reversal of impairment losses; and

a decrease in the effective tax rate by approximately 1.6% due to increased research and development expenditures which were eligible for weighted tax deduction. This decrease was largely offset by an increase in the effective tax rate on account of unrecognized deferred tax assets, primarily pertaining to OctoPlus N.V., Dr. Reddy's Laboratories New York, Inc. and Dr. Reddy's Srl.

### **Profit for the period**

As a result of the above, our net result was a net profit of Rs.21,512 million in the year ended March 31, 2014, as compared to a net profit of Rs.16,776 million in the year ended March 31, 2013.

### **5.B. Liquidity and capital resources**

#### **Liquidity**

We have primarily financed our operations through cash flows generated from operations and a mix of long-term and short-term borrowings. Our principal liquidity and capital needs are for making investments, the purchase of property, plant and equipment, regular business operations and research and development.

**Table of Contents**

Our principal sources of short-term liquidity are internally generated funds and short-term borrowings, which we believe are sufficient to meet our working capital requirements. Through our subsidiary in Switzerland, we borrowed U.S.\$220 million during the year ended March 31, 2012, which was required to be repaid in eight quarterly installments beginning December 2014. During the year ended March 31, 2016, we repaid the entire outstanding loan amount (including a prepayment of U.S.\$110 million), and our subsidiary in Switzerland further borrowed U.S.\$82.5 million of new short-term borrowings (refer to Note 18 to our consolidated financial statements for further details). Further, we also borrowed U.S.\$150 million during the year ended March 31, 2014, which is to be repaid in five quarterly installments beginning February 2018. These loans were borrowed primarily to repay some of our then existing short term borrowings and to meet anticipated capital expenditures over the near term. As part of our growth strategy, we continue to review opportunities to acquire companies, complementary technologies or product rights.

The following table summarizes our statements of cash flows for the periods presented:

	<b>For the year ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
	<b>(Rs. in millions)</b>		
<b>Net cash provided by/(used in):</b>			
Operating activities	Rs. 41,247	Rs. 25,033	Rs. 19,463
Investing activities	(20,423)	(22,904)	(16,620)
Financing activities	(17,001)	(4,118)	(217)
Net increase/(decrease) in cash and cash equivalents	3,823	(1,989)	2,626
Effect of exchange rate changes on cash	(4,296)	(1,068)	771

In addition to cash, inventory and our balance of accounts receivable, our unused sources of liquidity included Rs.14,771 million in available credit under revolving credit facilities with banks as of March 31, 2016. We had no other material unused sources of liquidity as of March 31, 2016.

*Cash Flow from Operating Activities*

The net result of our operating activities was a net cash inflow of Rs.41,247 million for the year ended March 31, 2016, as compared to a net cash inflow of Rs.25,033 million for the year ended March 31, 2015, which resulted in an increase in our net cash inflow by Rs.16,214 million during the year ended March 31, 2016 as compared to the year ended March 31, 2015.

Increases in working capital accounted for net cash outflows of Rs.188 million and Rs.15,040 million during the years ended March 31, 2016 and 2015, respectively. This lower increase in working capital requirements during the year ended March 31, 2016, as compared to the year ended March 31, 2015, resulted in a significant increase in our net cash provided by operating activities during the year ended March 31, 2016 as compared to the year ended March 31, 2015. The increase in working capital requirements during the year ended March 31, 2015 primarily resulted from an increase in our trade receivables by Rs.10,905 million and an increase in our inventories by Rs.5,447 million. The increase in our trade receivables was primarily due to an increase in the proportion of sales made to customers with longer credit periods in the United States. The increase in our inventories was primarily to support the increased sales of our existing products as well as launches of new products.

For the years ended March 31, 2016 and 2015, our earnings before interest expense/income, profit/loss on sale of investments, tax expense, impairment loss, depreciation and amortization ( Adjusted EBITDA ) were Rs.36,253 million

and Rs.36,168 million, respectively.

The net result of our operating activities was a cash inflow of Rs.25,033 million for the year ended March 31, 2015, as compared to a cash inflow of Rs.19,463 million for the year ended March 31, 2014.

The net cash provided by our operating activities increased by Rs.5,570 million for the year ended March 31, 2015, as compared to the year ended March 31, 2014. This increase was primarily due to our improved business performance for the year ended March 31, 2015, resulting in Adjusted EBITDA of Rs.36,168 million, as compared to Rs.33,187 million for the year ended March 31, 2014.

Our days sales outstanding ( DSO ) as at March 31, 2016, December 31, 2015, March 31, 2015 and March 31, 2014, computed based on the sales for the three months ended March 31, 2016, December 31, 2015, March 31, 2015 and March 31, 2014, were 99 days, 97 days, 95 days and 86 days, respectively. The increase in our DSO was primarily due to an increase in the proportion of sales made to customers with longer credit periods in the United States.

**Table of Contents**

*Cash Flow from Investing Activities*

Our investing activities resulted in a net cash outflow of Rs.20,423 million and Rs.22,904 million for the years ended March 31, 2016 and 2015, respectively. This decrease in net cash outflow of Rs.2,481 million was primarily due to:

Rs.7,936 million paid to UCB India Private Limited and other UCB group companies for the acquisition of a select portfolio of products business during the year ended March 31, 2016 (refer to Note 6 to our consolidated financial statements for further details);

Rs.1,158 million paid to Alchemia Limited for the purchase of worldwide, exclusive intellectual property rights to fondaparinux sodium during the year ended March 31, 2016 (refer to Note 38 to our consolidated financial statements for further details);

Rs.5,097 million paid for acquisition from Novartis Consumer Health Inc. of the title and rights to its Habitrol® brand (an over-the-counter nicotine replacement therapy transdermal patch) and related U.S. marketing rights during the year ended March 31, 2015 (refer to Note 39 to our consolidated financial statements for further details);

our net investments in mutual funds and time deposits having an original maturity of more than three months decreased by Rs.9,311 million for the year ended March 31, 2016 as compared to the year ended March 31, 2015; and

a net increase in amounts spent on property, plant and equipment by Rs.2,678 million during the year ended March 31, 2016 as compared to the year ended March 31, 2015.

Our net cash used in investing activities was Rs.22,904 million for the year ended March 31, 2015, as compared to Rs.16,620 million for the year ended March 31, 2014.

Our net cash used in investing activities increased by Rs.6,284 million for the year ended March 31, 2015, as compared to the year ended March 31, 2014, primarily due to the following reasons:

our net investments in mutual funds and time deposits having an original maturity of more than three months increased by Rs.1,200 million for the year ended March 31, 2015 as compared to the year ended March 31, 2014; and

our payment of Rs.5,097 million for the acquisition from Novartis Consumer Health Inc. of the title and rights to its Habitrol® brand (an over-the-counter nicotine replacement therapy transdermal patch) and related U.S. marketing rights during the year ended March 31, 2015.

*Cash Flows from Financing Activities*

Our financing activities resulted in a net cash outflow of Rs.17,001 million and Rs.4,118 million for the years ended March 31, 2016 and 2015, respectively.

During the year ended March 31, 2016, we repaid long term borrowings of Rs.11,706 million, which primarily consisted of the repayment of all long term borrowings by our subsidiaries in Switzerland and the United Kingdom (refer to Note 18 to our consolidated financial statements for further details). Furthermore, we also paid dividends (including dividend distribution taxes) of Rs.4,106 million and repaid short term loans of Rs.273 million during the year ended March 31, 2016.

In comparison, during the year ended March 31, 2015, we had a cash inflow on account of net short term borrowing proceeds of Rs.4,068 million, we repaid two installments amounting to Rs.3,452 million (U.S.\$55 million) due under the loan agreement by our Swiss subsidiary, and we paid dividends (including corporate dividend tax) of Rs.3,587 million.

Our net cash outflows from financing activities were Rs.4,118 million for the year ended March 31, 2015, as compared to Rs.217 million for the year ended March 31, 2014.

During the year ended March 31, 2014, we redeemed our 9.25% unsecured, non-convertible, redeemable debentures (sometimes referred to as our bonus debentures ) for an aggregate payment of Rs.5,078 million, representing their face value and we borrowed Rs.9,391 million (U.S.\$150 million) pursuant to a long term loan arrangement for the purpose of our ongoing capital investments and paid dividends (including corporate dividend tax) of Rs.2,985 million.



**Table of Contents****Principal obligations**

The following table summarizes our principal debt obligations (excluding capital lease obligations) outstanding as of March 31, 2016:

Financial Contractual Obligations	Total	Payments due by period		
		Less than 1 year	1-5 years	More than 5 years
		(Rs. in millions)		
Short-term borrowings from banks	Rs. 22,718	Rs. 22,718	Rs.	Rs.
Long term debt in foreign currency	9,938		9,938	
<b>Total obligations</b>	<b>Rs. 32,656</b>	<b>Rs. 22,718</b>	<b>Rs. 9,938</b>	<b>Rs.</b>

**Annual rate of interest***Short term borrowings*

As at March 31, 2016					
	Outstanding balance	Currency	Interest rate	Average amount outstanding	Maximum amount outstanding
			(All amounts in Rs. millions)		
Packing credit borrowings	Rs. 20,896	USD	LIBOR + (5) to 15 bps	Rs. 20,477	Rs. 22,459
		EURO	LIBOR + 5 to 7.5 bps		
		RUB	10.65% to 11.57%		
Other foreign currency borrowings	1,822	USD	LIBOR + 40 bps	3,552	5,364
Other rupee borrowings		INR	10%	813	1,000

As at March 31, 2015					
	Outstanding balance	Currency	Interest rate	Average amount outstanding	Maximum amount outstanding
			(All amounts in Rs. millions)		
Packing credit borrowings	Rs. 20,857	USD	LIBOR + 10 to 40 bps	Rs. 12,878	Rs. 21,220
		EURO	LIBOR + 7.5 to 20 bps		
		RUB	9.80% to 22.30%		
Other foreign currency borrowings				4,049	5,941
Other rupee borrowings	1,000	INR	10%	1,000	1,000

The maturities of our short-term borrowings from banks vary from one month to twelve months. Our objective in determining the borrowing maturity is to ensure a balance between flexibility, cost and the continuing availability of funds.

*Long term borrowings*

	<b>As at March 31,</b>			
	<b>2016</b>		<b>2015</b>	
	<b>Currency</b>	<b>Interest Rate</b>	<b>Currency</b>	<b>Interest Rate</b>
Foreign currency borrowings	USD	LIBOR + 125 bps	USD	LIBOR + 100 to 125 bps
			GBP	LIBOR + 130 bps

Subject to obtaining certain regulatory approvals, there are no legal or economic restrictions on the transfer of funds between us and our subsidiaries or for the transfer of funds in the form of cash dividends, loans or advances. However, transfers of funds from Venezuela are subject to certain exchange control regulations. Refer to Note 41 of our consolidated financial statements for further details.

Cash and cash equivalents are primarily held in Indian rupees, U.S. dollars, U.K. pounds sterling, Euros, Russian roubles, Venezuela bolivars and Swiss francs.

As of March 31, 2016 and 2015, we had committed to spend Rs.5,065 million and Rs.4,173 million, respectively, under agreements to purchase property, plant and equipment. This amount is net of capital advances paid in respect of such purchases. These commitments will be funded through the cash flows generated from operations as well as cash flows from our long term borrowings.

---

**Table of Contents*****5.C. Research and development, patents and licenses, etc.*****Research and Development**

Our research and development activities can be classified into several categories, which run parallel to the activities in our principal areas of operations:

*Global Generics*, where our research and development activities are directed at the development of product formulations, process validation, bioequivalence testing and other data needed to prepare a growing list of drugs that are equivalent to numerous brand name products for sale in the highly regulated markets of the United States and Europe as well as emerging markets. Global Generics also includes our biologics business, where research and development activities are directed at the development of biologics products for the emerging as well as highly regulated markets. Our new biologics research and development facility caters to the highest development standards, including cGMP, Good Laboratory Practices and bio-safety level IIA.

*Pharmaceutical Services and Active Ingredients*, where our research and development activities concentrate on development of chemical processes for the synthesis of active pharmaceutical ingredients and intermediates ( API ) for use in our Global Generics segment and for sales in the emerging and developed markets to third parties. Our research and development activities also support our custom pharmaceutical line of business, where we continue to leverage the strength of our process chemistry and finished dosage development expertise to target innovator as well as emerging pharmaceutical companies. The research and development is directed toward providing services to support the entire pharmaceutical value chain, from discovery all the way to the market.

*Proprietary Products*, where we focus on the research, development, and manufacture of differentiated formulations and new chemical entities ( NCEs ). These novel products fall within the dermatology and neurology therapeutic areas.

In the years ended March 31, 2016, 2015 and 2014, we expended Rs. 17,834 million, Rs. 17,449 million and Rs. 12,402 million, respectively, on research and development activities. The increase in research and development expenditure was in line with our strategy to expand our research and development efforts in complex formulations, differentiated formulations and bio-similar compounds.

**Patents, Trademarks and Licenses**

We have filed and been issued numerous patents in our principal areas of operations: Global Generics, Pharmaceutical Services and Active Ingredients and Proprietary Products. We expect to continue to file patent applications seeking to protect our innovations and novel processes in several countries, including the United States. Any existing or future patents issued to or licensed by us may not provide us with any competitive advantages for our products or may even be challenged, invalidated or circumvented by our competitors. In addition, such patent rights may not prevent our competitors from developing, using or commercializing products that are similar or functionally equivalent to our products. As of March 31, 2016, we had filed more than 1,417 trademarks with the Registrar of Trademarks in India. We have also filed registration applications for non-U.S. trademarks in other countries in which we do business. We market several products under licenses in several countries where we operate.

***5.D. Trend Information***

Please see Item 5: Operating and Financial Review and Prospects and Item 4. Information on the Company for trend information.

***5.E. Off-balance sheet arrangements***

None.

**Table of Contents****5.F. Tabular Disclosure of Contractual Obligations**

The following summarizes our contractual obligations as of March 31, 2016 and the effect such obligations are expected to have on our liquidity and cash flows in future periods.

<b>Contractual Obligations</b>	<b>Total</b>	<b>Payments due by period</b>			
		<b>(Rs. in millions)</b>			
		<b>Less than 1 year</b>	<b>2-3 years</b>	<b>4-5 years</b>	<b>More than 5 years</b>
<i>Operating lease obligations</i>	Rs. 2,244	Rs. 396	Rs. 672	Rs. 513	Rs. 663
<i>Capital lease obligations</i>	857	110	160	112	475
<i>Purchase obligations</i>					
<i>Agreements to purchase property, plant and equipment and other capital commitments<sup>(1)</sup></i>	5,065	5,065			
<i>Short term debt obligations</i>	22,718	22,718			
<i>Long term debt obligations</i>	9,938		9,938		
<i>Estimated interest payable on long-term debt<sup>(2)</sup></i>	402	170	232		
<i>Post-retirement benefits obligations<sup>(3)</sup></i>	1,781	179	346	354	902
<b>Total contractual obligations</b>	<b>Rs. 43,005</b>	<b>Rs. 28,638</b>	<b>Rs. 11,348</b>	<b>Rs. 979</b>	<b>Rs. 2,040</b>

(1) These amounts are net of capital advances paid in respect of such purchases and are expected to be funded from internally generated funds and proceeds from long term borrowings.

(2) Disclosure of estimated interest payments for future periods is only with respect to our long term debt obligations, as the projected interest payments with respect to our short term borrowings and other obligations cannot be reasonably estimated because they are subject to fluctuation in actual utilization of borrowings depending on our daily funding requirements. The estimated interest costs are based on March 31, 2016 applicable benchmark rates and are subject to fluctuation in the future.

(3) Post-retirement benefits obligations in the More than 5 years column are estimated for a maximum of 10 years.

**5.G. Safe harbor**

See page 3 under heading Forward-Looking and Cautionary Statement .

**Table of Contents****ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES****6. A. Directors and senior management**

The list of our directors and executive officers and their respective age and position as of March 31, 2016 was as follows:

<b>Directors Name<sup>(1)</sup></b>	<b>Age (in yrs.)</b>	<b>Position</b>
Mr. Satish Reddy <sup>(2)(3)</sup>	49	Chairman
Mr. G.V. Prasad <sup>(2)(4)</sup>	56	Co-Chairman, Managing Director and Chief Executive Officer
Mr. Anupam Puri	70	Director
Ms. Kalpana Morparia	67	Director
Dr. Omkar Goswami	59	Director
Mr. Ravi Bhoothalingam	70	Director
Dr. Bruce L.A. Carter	72	Director
Dr. Ashok S. Ganguly	81	Director
Mr. Sridar Iyengar	68	Director

(1) Except for Mr. Satish Reddy and Mr. G.V. Prasad, all of the directors are independent directors under the corporate governance rules of the New York Stock Exchange.

(2) Full-time director.

(3) Brother-in-law of Mr. G.V. Prasad.

(4) Brother-in-law of Mr. Satish Reddy.

Our Board of Directors appointed Mr. Bharat Narotam Doshi (aged 67 years) and Mr. Hans Peter Hastler (aged 60 years) as independent directors, effective May 11, 2016 and June 17, 2016, respectively.

**Executive Officers**

Our policy is to classify our officers as executive officers if they have membership on our Management Council. Our Management Council consists of various business and functional heads and is our senior management organization. As of March 31, 2016, the Management Council consisted of:

<b>Name and Designation</b>	<b>Education/Degrees</b>		<b>Experience in years</b>	<b>Date of commencement of employment</b>	<b>Particulars of last employment</b>
	<b>Held</b>	<b>Age</b>			
Satish Reddy <sup>(1)</sup> Chairman	B. Tech., M.S. (Medicinal Chemistry)	49	24	January 18, 1993	Director, Globe Organics Limited
G.V. Prasad <sup>(2)</sup> Co-Chairman, Managing Director and Chief	B. E. (Chem. Eng.), M.S. (Incl. Admn.)	56	32	June 30, 1990	Promoter Director, Benzex Labs Private Limited

## Executive Officer

Abhijit Mukherjee <sup>(3)</sup>	B. Tech. (Chem.)	58	36	January 15, 2003	President, Atul Limited
Chief Operating Officer					
Alok Sonig	B.E., MBA	44	21	June 11, 2012	Vice President and Head of Global Commercial Excellence, Strategy and Business Model Innovation, Bristol Myers Squibb
Executive Vice President and Head - North America Generics					
Dr. Amit Biswas	B. Tech. (Chem.), Masters (Polymer Science), Ph.D.	56	28	July 12, 2011	Senior Vice President, Reliance Industries Limited
Executive Vice President and Head - Integrated Product Development Organization					
Dr. Cartikeya Reddy	B. Tech, M.S., Ph.D.	46	25	July 20, 2004	Senior Engineer, Genetech Inc.
Executive Vice President and Head-Biologics					

**Table of Contents**

<b>Name and Designation</b>	<b>Education/Degrees Held</b>	<b>Age</b>	<b>Experience in years</b>	<b>Date of commencement of employment</b>	<b>Particulars of last employment</b>
Dr. KVS Ram Rao Sr. Vice President and Head-PSAI Commercial Organization	B.Tech., M.E., Ph. D.(Chem Eng)	53	23	April 3, 2000	Head of Technical Services, Jubilant Life Sciences
M.V. Ramana Executive Vice President and Head Branded Markets (India & Emerging Countries)	MBA	48	24	October 15, 1992	
Dr. Raghav Chari Executive Vice President and Head- Proprietary Products	M.S. (Physics), Ph.D.	46	19	September 25, 2006	Head Corporate Strategy, NPS Pharmaceuticals Limited
Dr. S. Chandrasekhar President and Global Head of Human Resources	MBA., Ph.D.	59	37	August 12, 2013	Vice President and Head of Human Resources, IBM India.
Samiran Das Executive Vice President and Head- Global Manufacturing Operations	B. Tech (Mechanical.)	56	34	June 15, 2011	Executive Director, PepsiCo India.
Saumen Chakraborty President and Chief Financial Officer and Global Head of Information Technology and Business Process Excellence	B.Sc. (H), MBA (IIM)	55	32	July 2, 2001	Vice President, Tecumseh Products India Private Limited

(1) Brother-in-law of Mr. G.V. Prasad.

(2) Brother-in-law of Mr. Satish Reddy

In April 2016, Mr. Ganadhish Kamat (aged 53 years), joined the Company as Executive Vice President and Global Head Quality. He will be a member of our Management Council. Mr. Kamat received his M.Pharm degree from Mumbai University and has approximately 31 years of experience in the pharmaceutical industry. During his long career he has worked in leadership roles in a number of different organizations such as Sandoz, Intas Pharma and Ranbaxy. He was last employed with Lupin Limited as Executive Vice President Corporate Quality.



There was no arrangement or understanding with major shareholders, customers, suppliers or others pursuant to which any director or executive officer referred to above was selected as a director or member of our Management Council.

### **Biographies Directors**

*Mr. Satish Reddy* is a member of our Board of Directors and serves as our Chairman of the Board. Prior to May 2014, he held the titles of Vice Chairman and Managing Director. He has a Master of Science degree in Medicinal Chemistry from Purdue University, Indiana in the United States of America and a Bachelor of Technology degree in Chemical Engineering from Osmania University, Hyderabad. He was a member of the Drugs Technical Advisory Board of India, the Chairman of the Andhra Pradesh Chapter of the Confederation of Indian Industries ( CII ) and head of its National Committee on Pharmaceuticals. He was the President of the Indian Pharmaceutical Alliance, a premier industry association of leading research-based Indian companies. He also chairs the Life Sciences Skill Development Council under The National Skill Development Corporation ( NSDC ), an organization, working in partnership with various stakeholders groups, to serve and address the skill shortfalls in the Life Sciences Sectors across India. In May 2015, the Ministry of Labour and Employment, Government of India, nominated Mr. Reddy as Chairman of the Board of Governors of the National Safety Council. In addition to positions held in our subsidiaries and joint ventures, he is also a Director of Green Park Hotels and Resorts Limited, Dr. Reddy s Holdings Limited, Stamlo Hotels Limited, Araku Originals Limited, Dr. Reddy s Research Foundation, Dr. Reddy s Institute of Life Sciences, Young President s Organisation Hyderabad Chapter, Cipro Estates Private Limited, KAR Therapeutics & Estates Private Limited, Quin Estates Private Limited, Satish Reddy Estates Private Limited, Molecular Connections Private Limited, Dr. Reddy s Trust Services Private Limited, KAR Holdings (Singapore) Private Limited, Singapore, KAREUS Therapeutics (Singapore) Private Limited, Singapore and KAREUS Therapeutics, SA, Switzerland.

---

**Table of Contents**

*Mr. G.V. Prasad* is a member of our Board of Directors and serves as our Co-Chairman, Managing Director and Chief Executive Officer. Prior to May 2014, he held the titles of Chairman and Chief Executive Officer. He was the Managing Director of Cheminor Drugs Limited prior to its merger with us. He has a Bachelor of Engineering degree in Chemical Engineering from Illinois Institute of Technology, Chicago in the United States of America, and an M.S. in Industrial Administration from Purdue University, Indiana in United States of America. He has been involved with the Andhra Pradesh chapter of the Worldwide Fund for nature and the Acumen Fund, a non-profit venture that uses entrepreneurial approaches to eliminate global poverty. Mr. Prasad was recognized as India's Best CEO in the Large Company category by Business Today in 2014, and as India Business Leader of the Year by CNBC Asia in 2015. In addition to positions held in our subsidiaries and joint ventures, he is a Director of Green Park Hotels and Resorts Limited, Dr. Reddy's Holdings Limited, Stamlo Hotels Limited, Dr. Reddy's Institute of Life Sciences, Dr. Reddy's Research Foundation, International Foundation for Research and Education, Molecular Connections Private Limited, Dr. Reddy's Trust Services Private Limited, Vijaya Productions Private Limited, Indian School of Business and the Acumen Fund in the United States of America. He also serves as a member of the Board of Governors of the Indian Institute of Technology, Hyderabad.

*Mr. Anupam Puri* has been a member of our Board of Directors since 2002. He retired from McKinsey and Company in late 2000. He was a Director and played a variety of other leadership roles during his 30-year career there. Before joining McKinsey and Company, he was Advisor for Industrial Development to the President of Algeria, and consultant to General Electric's Center for Advanced Studies. He holds a Bachelor of Arts degree in Economics from St. Stephen's College, Delhi University, and Master of Arts and M. Phil. degrees from Oxford University. He is also on the Board of Directors of Mahindra and Mahindra Limited, Tech Mahindra Limited, Mumbai Mantra Media Limited and our wholly owned subsidiary Dr. Reddy's Laboratories Inc. in the United States of America.

*Dr. Omkar Goswami* has been a member of our Board of Directors since 2000. He is a founder and Chairman of CERG Advisory Private Limited, a corporate advisory and economic research and consulting company. He was a senior consultant and chief economist at the Confederation of Indian Industry for six years. He has also served as editor of Business India, associate professor at the Indian Statistical Institute, Delhi, and as an honorary advisor to the Ministry of Finance. He holds a Bachelor of Economics degree from St. Xavier's College, Calcutta University, a Master of Economics degree from the Delhi School of Economics, Delhi University and a Ph.D. degree from Oxford University. He is also a Director on the Boards of Crompton Greaves Limited, Ambuja Cements Limited, Cairn India Limited, Godrej Consumer Products Limited, Infosys BPO Limited, Bajaj Finance Limited, Max Healthcare Institute Limited, IDFC Financial Holding Company Limited, Hindustan Construction Company Limited and DSP Black Rock Investment Managers Private Limited.

*Mr. Ravi Bhoothalingam* has been a member of our Board of Directors since 2000. He has served as the President of The Oberoi Group and was responsible for its worldwide operations. He has also served as the Head of Personnel at BAT Plc, Managing Director of VST Industries Limited, and as a Director of ITC Limited. He holds a Bachelor of Science degree in Physics from St. Stephens College, Delhi and a Master of Experimental Psychology degree from Gonville and Caius College, Cambridge University. He is also a Director on the Board of Sona Koyo Steering Systems Limited.

*Ms. Kalpana Morparia* has been a member of our Board of Directors since 2007. Ms. Morparia is Chief Executive Officer of J.P. Morgan, South and Southeast Asia. Ms. Morparia is a member of J.P. Morgan's Asia Pacific Management Committee. Prior to becoming Chief Executive Officer of J.P. Morgan, South and Southeast Asia, Ms. Morparia served as Chief Executive Officer of J.P. Morgan India and Vice Chair on the Board of ICICI Group. She was a Joint Managing Director of ICICI Group from 2001 to 2007. Ms. Morparia has also served as Chief Strategy and Communications Officer - ICICI Group. Ms. Morparia had been with the ICICI Group since 1975. A graduate in law from Bombay University, Ms. Morparia has served on several committees constituted by the

Government of India. Ms. Morparia was named one of The 50 Most Powerful Women in International Business by Fortune magazine in 2008 and one of the 25 most powerful women in Indian business by Business Today, a leading Indian business journal, in the years 2004, 2005, 2006 and 2008. Ms. Morparia was also named one of the The 100 Most Powerful Women by Forbes Magazine in 2006. She also serves on the Board of Bennett, Coleman and Co. Limited, Hindustan Unilever Limited, J.P. Morgan Services India Private Limited, J.P. Morgan Asset Management India Private Limited and Philip Morris International Inc. in the United States of America. She also serves as a member on the Board of Governors of Bharati Foundation.

*Dr. Bruce L.A. Carter* has been a member of our Board of Directors since 2008. Dr. Carter was the Chairman of the Board and the former Chief Executive Officer of ZymoGenetics, Inc. in Seattle, Washington, in the United States of America. Dr. Carter was appointed as Chairman of the Board of ZymoGenetics in April 2005. From April, 1998 to January, 2009, he served as Chief Executive Officer of ZymoGenetics. Dr. Carter first joined ZymoGenetics in 1986 as Vice President of Research and Development. In 1988, Novo Nordisk acquired ZymoGenetics and, in 1994, Dr. Carter was promoted to

**Table of Contents**

Corporate Executive Vice President and Chief Scientific Officer for Novo Nordisk A/S, the then parent company of ZymoGenetics. Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk in 2000. Dr. Carter held various positions of increasing responsibility at G.D. Searle and Co., Ltd. from 1982 to 1986 and was a Lecturer at Trinity College, University of Dublin from 1975 to 1982. Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London. Dr. Carter is also on the Board of Directors of TB Alliance, New York Xencor Inc. and Enanta Pharmaceutical Inc. in the United States of America and our wholly-owned subsidiary Aurigene Discovery Technologies Limited.

*Dr. Ashok S. Ganguly* has been a member of our Board of Directors since 2009. Dr. Ashok Ganguly is the Chairman of ABP Private Ltd. (formerly Ananda Bazar Patrika Group), and was a Director on the Central Board of the Reserve Bank of India from 2001 to 2009. Dr. Ganguly's principal professional career spanned 35 years with Unilever Plc/NV. He was the Chairman of Hindustan Lever Ltd. from 1980 to 1990 and a member of the Unilever Board of Directors from 1990 to 1997 with responsibility for world-wide research and technology. He is a former member of the Board of British Airways Plc (1996-2005). He has served on several public bodies, the principal among them being as a member of the Science Advisory Council to the Prime Minister of India (1985-1989) and the U.K. Advisory Board of Research Councils (1991-1994). Currently, he is a member of the Prime Minister's Council on Trade and Industry, Investment Commission and the India-U.S.A. CEO Council, set up by the Prime Minister of India and the President of the United States of America. He is also a member of the National Knowledge Commission to the Prime Minister. He is a recipient of the Padma Bhushan as well as the Padma Vibhushan, two of India's prestigious civilian honors. At present he serves as a member of the Rajya Sabha, the upper house of the Parliament of India. Dr. Ganguly also serves as a Director of Wipro Limited and ABP Private Limited.

*Mr. Sridar Iyengar* has been a member of our Board of Directors since 2011. Mr. Sridar Iyengar is an independent mentor investor in early stage start-up companies. For more than 35 years, he has worked in the United Kingdom, the United States and India with a large number of companies, advising them on strategy and other issues. Mr. Iyengar is the former President of Foundation for Democratic Reforms in India, a U.S. based non-profit organization. He is also an advisor to several venture and private equity funds in India. Earlier, he was a senior partner with KPMG in the United States and the United Kingdom and served for 3 years as the Chairman and CEO of KPMG's operations in India. Mr. Iyengar holds a Bachelor of Commerce (Hons.) degree from Calcutta University and he is a Fellow of the Institute of Chartered Accountants in England and Wales. Mr. Iyengar is also on the Board of Directors of Rediff.com India Limited, Mahindra Holidays and Resorts India Limited, CL Educate Limited, ICICI Venture Funds Management Company Limited, Cleartrip Private Limited, CL Media Private Limited, AverQ Inc., Rediff Holdings Inc. in the United States of America, Cleartrip Inc. in the Cayman Islands, Holiday Club Resorts OY, Finland and our wholly owned subsidiary Dr. Reddy's Laboratories S.A. in Switzerland. He is also a member of the governing board of Janaagraha Center for Citizenship and Democracy.

**Biographies - Executive Officers**

*Mr. Abhijit Mukherjee* is the Chief Operating Officer of our company. Before joining us, he worked with Atul Limited for 10 years, where he held numerous positions of increasing responsibility. In his last assignment there he was President, Bulk Chemicals and Intermediates Business, and Managing Director, Atul Products Limited. He started his career as a management trainee in Hindustan Lever Limited (HLL) and worked at that company for 13 years, including three years in a Unilever company. He was primarily involved in technical assignments in the aroma chemicals business in HLL and Unilever and also in detergents and sulphonation plants of HLL. He holds a degree in Chemical Engineering from the Indian Institute of Technology in Kharagpur, India.

*Mr. Alok Sonig* is the Executive Vice President and head of North America Generics. He joined us in June 2012 and has over 21 years of experience in healthcare, technology and consumer marketing. Prior to joining us, he worked with Bristol Myers Squibb in Princeton, New Jersey, U.S.A., as Vice President and Head of Global Commercial Excellence, Strategy and Business Model Innovation. Mr. Sonig holds a Bachelor s of Engineering from Punjab Engineering College in India and an MBA from American University, Washington, D.C.

*Dr. Amit Biswas* is the Executive Vice President and Head of Integrated Product Development ( IPDO ). He joined us on July 12, 2011 and has 28 years of diverse and rich international experience, spanning academic and industrial research, product development, technical service and management of research and technology in the areas of commodity plastics, engineering polymers, high performance fibers, industrial/automotive coatings and alternate energy technologies. He previously worked with companies such as DuPont (USA), ICI India and GE Advanced Materials. Prior to joining us, he worked with Reliance Industries Limited as Senior Vice President, Technology Services and Emerging Technologies-Reliance Technology Group and was responsible for design and implementation of Research and Technology Management processes, Business Transformation and Change Management, and interfacing with private/public institutions on Alternate Energy Technologies. He is a Master Black Belt in Six Sigma (GE Certification). He was also a member of various councils, including National Chemical Laboratory (Pune) Research Council, Indian Institute of Chemical Technology (Hyderabad)

## Table of Contents

Research Council, Indian Institute of Technology Bombay Advisory Council and currently is a member of All India CII Technology Council. He was made an Adjunct Professor at the Centre for Research in Nano-technology and Science at the Indian Institute of Technology in Bombay, India. He has 44 international publications, 3 book chapters and 4 patents. He holds a Ph.D. and Masters in Polymer Science from Case Western Reserve University, Ohio, U.S.A. and a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Bombay, India.

*Dr. Cartikeya Reddy* is the Executive Vice President and head of our Biologics division, which focuses on the development of biosimilar molecules for the Indian and global markets. Prior to joining us in 2004, Dr. Reddy worked with Genentech Inc., where he was a Group Leader in the area of Cell Culture Process Development. Before that, he was with the Biotechnology Division of Bayer Corporation, where he successfully led teams in the areas of Bioprocess Development and pilot scale manufacturing. Mr. Reddy holds a Master of Science degree and Ph.D. in Chemical Engineering from the University of Illinois, Urbana-Champaign, and was a Visiting Scholar at the Massachusetts Institute of Technology in Cambridge, Massachusetts, United States of America. He also graduated with a Bachelor of Technology degree in Chemical Engineering from the Indian Institute of Technology in Chennai, India.

*Dr. KVS Ram Rao* is the Senior Vice President and Head of PSAI Commercial Organization. He joined us in 2000 and has over 23 years of experience in New Product Development-API and Global Oncology. In his current role, he is responsible for our PSAI commercial organization managing sales, strategy, business development and new product management. Prior to joining us, Dr. Ram Rao worked at Jubilant Life Sciences where he headed the Technical Services Division and Gujarat Heavy Chemicals Limited where he was the Head of Research and Development. He holds a Ph.D. and a Masters degree in Chemical Engineering from the Indian Institute of Science ( IISc ), Bangalore along with a Bachelors Degree in Chemical Engineering from Osmania University, Hyderabad, India. He also holds a Diploma in Project Management from Narsee Monjee Institute of Management Studies ( NMIMS ), India.

*Mr. M.V. Ramana* is the Executive Vice President and Head of Branded Markets (India and Emerging countries). He joined us on October 15, 1992 as a Management Trainee in the International Marketing division of our Branded Formulations business. In his 24 year tenure, he has handled various critical assignments including setting up the businesses in several countries across Asia, Latin America, Africa and the Middle East. Mr. Ramana is also a frequent speaker at various international forums in the pharmaceutical and generics industry. He holds a MBA degree from Osmania University, Hyderabad, India and has done the ISB-Kellogg management development program.

*Dr. Raghav Chari* is the Executive Vice President and Head of Proprietary Products, and is responsible for developing a viable portfolio of products across our key specialty therapeutic areas, New Chemical Entities and Differentiated Formulations businesses. Dr. Chari joined us in 2006 as Vice President- Corporate Development for our New Chemical Entities and Specialty business and has helped shape our Proprietary Products business strategy while developing strong alliance platforms. He started his career with McKinsey and Company, where he spent several years as an Associate, Engagement Manager and finally Associate Principal in McKinsey's Pharmaceuticals and Medical Products practice. After McKinsey, he took leadership roles in strategy and business development with several smaller biotech companies. Prior to joining us, he was the head of the Corporate Strategy function at NPS Pharmaceuticals. Dr. Chari is a graduate in Mathematics and Physics from the California Institute of Technology and holds a Ph.D. in Theoretical Physics from Princeton University.

*Dr. S. Chandrasekhar* is the President and Global Head of our Human Resources ( HR ). He joined us in August 2013 and leads a wide range of HR initiatives in leadership development and coaching, talent development, employee engagement and organization design to integrate, grow and transform the organization globally in order to enable our enterprise to meet our business objectives. He has over 37 years of experience across India's leading firms in public and private sectors engaged in multiple industries such as steel, manufacturing, telecom, information technology

services and consulting. He is also among the first few Indians who have been accredited by the International Coach Federation – the world’s leading coach certification body – in the professional practice of executive coaching. Prior to joining us, Dr. Chandrasekhar worked with IBM, India as Vice President and Head of Human Resources for the India/South Asia region. At IBM, he was a key member of the India Leadership Team and a Director on the Board of IBM India Private Limited. Dr. Chandrasekhar holds an MBA from Leeds Business School, United Kingdom and a Ph. D in Organizational Behavior from Andhra University, India.

*Mr. Samiran Das* is the Executive Vice President and Head of Global Manufacturing Operations. He joined us on June 15, 2011 and has diverse and rich experience in manufacturing across multiple sectors. Prior to joining us, he worked with Pepsico India as Executive Director, Technical Operations for Pepsico’s beverage business in the India region and was responsible for supply strategy and implementation, manufacturing footprint and expansion, quality assurance, safety, development of co-packing network, procurement and new product commercialization, and supply chain validation. At Pepsico, he was a member of the Regional Executive Committee and the Division Operations Leadership Council, with active involvement in Corporate Governance and Corporate Social Responsibility activities. Before that, he worked with companies like Union Carbide, ICI India, Hindustan Unilever, Godrej Pillsbury, Frito Lay India and D1-BP Fuel Crops India in different roles. He holds a Bachelors degree in Mechanical Engineering from the Indian Institute of Technology, Delhi, India.

---

**Table of Contents**

*Mr. Saumen Chakraborty* is the President and Chief Financial Officer. In this role, he is responsible for managing our global finance functions including, among others, Accounts and Controlling, Taxation, Compliance, Secretarial, Investor Relations and Treasury. In addition, Mr. Chakraborty is also responsible for our Information Technology ( IT ) and Business Process Excellence ( BPE ) functions. As the Chief Financial Officer, Mr. Chakraborty was recognized as the Best CFO for Healthy Balance Sheet management India's Best CFO with Exemplary at BW Businessworld-YES Bank Best CFO Awards 2015-16, CFO of the year by International Market Assessment ( IMA ), All Round Performance in the 5th Annual Business Today in 2014 Yes Bank Best CFO Awards event. Mr. Chakraborty joined us in 2001 as Global Chief of Human Resources. He later took over as Chief Financial Officer in 2006 and then became our President Corporate and Global Generics Operations in early 2009. In 2010 he was appointed as President and Global Head of Quality, Human Resources and Information Technology and focused on the integration of people practices, processes and information across the organization. He has 32 years of experience in strategic and operational aspects of management. Prior to joining us, he held various line management, human resources and other positions, including Senior Manager (Finance and Accounts) in the Eicher Group and Vice President (Operations) in Tecumseh Products Company. Saumen is also a member of the National Leadership Committee of CII. He has been on the Board of the AHRD and various joint ventures/subsidiaries of our Company. He graduated with honors as the valedictorian of his class from Visva-Bharati University in Physics and holds degree in Management from the Indian Institute of Management, Ahmedabad, Gujarat, India.

**6.B. Compensation**
**Directors compensation**

*Full-Time Directors:* The compensation of our Chairman of the Board (who formerly held the title of Vice Chairman and Managing Director) and our Co-Chairman, Managing Director and Chief Executive Officer (who formerly held the titles of Chairman and Chief Executive Officer) (who we refer to as our full-time directors ) is divided into salary, commission and benefits. They are not eligible to participate in our stock option plans. The Nomination, Governance and Compensation Committee of the Board of Directors initially recommends the compensation for full-time directors. If the Board of Directors (the Board ) approves the recommendation, it is then submitted to the shareholders for approval at the general shareholders meeting along with the proposal for their appointment or re-appointment.

Our Chairman of the Board and our Co-Chairman, Managing Director and Chief Executive Officer are each entitled to receive a maximum commission of up to 0.75% of our net profit (as defined under the Indian Companies Act, 2013) for the fiscal year. The Nomination, Governance and Compensation Committee, which is entirely composed of independent directors, recommends the commission for our Chairman of the Board and our Co-Chairman, Managing Director and Chief Executive Officer within the limits of 0.75% and 0.75%, respectively, of our net profits (as defined under the Indian Companies Act, 2013) for each fiscal year.

*Non-Full Time Directors:* In the year ended March 31, 2016, none of our non-full time directors were paid any sum as attendance fees. Non-full time directors are eligible to receive a commission on our net profit (as defined under the Indian Companies Act) for each fiscal year. Our shareholders have approved a maximum commission of up to 0.5% of the net profits (as defined under the Indian Companies Act) for each fiscal year for all non-full time directors in a year. The Board determines the entitlement of each of the non-full time directors to commission within the overall limit. The non-full time directors were not granted stock options under the Dr. Reddy's Employees Stock Option Scheme, 2002 or Dr. Reddy's Employees ADR Stock Option Scheme, 2007 in the year ended March 31, 2016.

For the year ended March 31, 2016, the directors were entitled to the following amounts as compensation:



Name of Directors	(Amounts Rs. in millions)			Total
	Commission	Salary	Perquisites	
Mr. Satish Reddy	Rs. 76.50	Rs. 6.32	Rs. 5.21	Rs. 88.03
Mr. G.V. Prasad	108.00	8.33	2.89	119.22
Mr. Anupam Puri	11.12			11.12
Dr. J.P. Moreau*	4.89			4.89
Ms. Kalpana Morparia	11.05			11.05
Dr. Omkar Goswami	9.71			9.71
Mr. Ravi Bhoothalingam	10.05			10.05
Dr. Bruce L.A. Carter	10.12			10.12
Dr. Ashok S. Ganguly	10.38			10.38
Mr. Sridar Iyengar	10.45			10.45

\* Term ended on July 31, 2015.

**Table of Contents****Executive officers compensation**

The initial compensation to all our executive officers is determined through appointment letters issued at the time of employment. The appointment letter provides the initial amount of salary and benefits the executive officer will receive as well as a confidentiality provision and a non-compete provision applicable during the course of the executive officer's employment with us. We provide salary, certain perquisites, retirement benefits, stock options and variable pay to our executive officers. The Nomination, Governance and Compensation Committee of the Board reviews the compensation of executive officers on a periodic basis.

All of our employees at the managerial and staff levels are eligible to participate in a variable pay program, which consists of performance bonuses based on the performance of their function or business unit, and a profit sharing plan through which part of our profits can be shared with our employees. Our variable pay program is aimed at rewarding the individual based on performance of such individual, their business unit/function and our company as a whole, with significantly higher rewards for superior performances.

We also have two employee stock option schemes: the Dr. Reddy's Employees Stock Option Scheme, 2002 and the Dr. Reddy's Employees ADR Stock Option Scheme, 2007. The stock option schemes are applicable to all of our employees including directors and employees and directors of our subsidiaries. The stock option schemes are not applicable to promoter directors, promoter employees, non-full time directors (independent directors) and persons holding 2% or more of our outstanding share capital. The Nomination, Governance and Compensation Committee of the Board of Directors awards options pursuant to the stock option schemes based on the employee's performance appraisal. Some employees have also been granted options upon joining us.

Compensation for executive officers who are full time directors is summarized in the table under Directors compensation above. The following table presents the annual compensation paid or payable to other executive officers for services rendered to us for the year ended March 31, 2016 and stock options issued to all of our other executive officers during the year ended March 31, 2016:

**Compensation for Executive Officers**

Name	Compensation <sup>(1)(3)</sup>	
	(Rs. in millions)	No. of Options <sup>(2)</sup>
Abhijit Mukherjee	50.3	4,500
Alok Sonig	45.7	3,000
Dr. Cartikeya Reddy	23.9	2,800
Saumen Chakraborty	32.1	3,000
Dr. Raghav Chari	45.2	3,000
M.V. Ramana	26.0	3,000
Samiran Das	23.8	2,500
Dr. Amit Biswas	23.5	2,500
Dr. K.V.S. Ram Rao	21.2	2,000
Dr. S. Chandrasekhar	22.7	2,500
Umang Vohra (until September 25, 2015)	17.9	3,000

- (1) These compensation amounts do not include share based payment expense arising from stock options. However, the number of options granted during the year are mentioned separately in the above table.
- (2) The options vest 25% each year on various dates beginning in the year ended March 31, 2017 and ending in the year ended March 31, 2020 subject to the employee being in continued service on the date of vesting. The options expire after five years from the date of vesting. Each of the options has an exercise price of Rs.5 and results in the issuance of one equity share upon its exercise.
- (3) These compensation amounts do not include Rs.169 million accrued towards a long term incentive plan for the services rendered by our executive officers for the year ended March 31, 2016 (refer to Note 19 to our consolidated financial statements for further details).

**Table of Contents****Retirement benefits:**

We provide the following benefit plans to our employees:

*Gratuity benefits:* In accordance with applicable Indian laws, we provide for gratuity, a defined benefit plan (the Gratuity Plan ) covering certain categories of employees of the parent company. The Gratuity Plan provides a lump sum payment to vested employees, at retirement or termination of employment, at an amount based on the respective employee's last drawn salary and the years of employment with us. Effective September 1, 1999, we established the Dr. Reddy's Laboratories Gratuity Fund (the Gratuity Fund ). Liability with regard to the Gratuity Plan is determined by an actuarial valuation, based upon which we make contributions to the Gratuity Fund. Trustees administer the contributions made to the Gratuity Fund. The amounts contributed to the Gratuity Fund are primarily invested in Indian Government bonds and corporate debt securities. A small portion of the fund is also invested in equity securities of Indian companies.

The net periodic gratuity benefit cost recognized by us towards the aforesaid Gratuity Plan was Rs.179 million and Rs.155 million for the years ended March 31, 2016 and 2015, respectively.

*Superannuation benefits:* Our senior officers participate in superannuation, a defined contribution plan administered by the Life Insurance Corporation of India. We make annual contributions based on a specified percentage of each covered employee's salary. We have no further obligations under the plan beyond our annual contributions. We contributed Rs.71 million and Rs.68 million to the superannuation plan during the years ended March 31, 2016 and 2015, respectively.

*Provident fund benefits.* In India, certain employees receive benefits from a provident fund, a defined contribution plan. Both the employee and employer each make monthly contributions to the plan equal to 12% of the covered employee's basic salary. We have no further obligations under the plan beyond our monthly contributions. We contributed Rs.574 million and Rs.492 million to the provident fund plan during the years ended March 31, 2016 and 2015, respectively.

*401(k) retirement savings plans.* In the United States, we sponsor a defined contribution 401(k) retirement savings plan for all eligible employees who meet minimum age and service requirements. We contributed Rs.204 million and Rs.195 million to this 401(k) retirement savings plan for the years ended March 31, 2016 and 2015, respectively.

*National Insurance contributions.* In the United Kingdom, certain social security benefits (such as pension, unemployment and disability) are funded by employers and employees through mandatory National Insurance contributions. We sponsor a defined contribution plan for such National Insurance contributions. The contribution amounts are determined based upon the employee's base salary. We have no further obligations under the plan beyond our monthly contributions. We contributed Rs.156 million and Rs.151 million to the U.K. National Insurance scheme during the years ended March 31, 2016 and 2015, respectively.

*Pension.* All employees of Industrias Quimicas Falcon de Mexico, SA de CV ( Falcon ), our subsidiary in Mexico, are governed by a defined benefit pension plan. The pension plan provides a payment to vested employees at retirement or termination of employment. Liabilities in respect of the pension plan are determined by an actuarial valuation, based on which we make contributions to the pension plan fund. This fund is administered by a third party who is provided guidance by a technical committee formed by senior employees of Falcon.

The net periodic cost recognized under the Falcon pension plan was Rs.25 million and Rs.22 million during the years ended March 31, 2016 and 2015, respectively.

*Compensated leave of absence.* Our current policies permit certain categories of employees to accumulate and carry forward a portion of their unutilized compensated absences and utilize them in future periods or receive cash in lieu thereof in accordance with the terms of such policies. We measure the expected cost of accumulating compensated absences as the additional amount that we expect to pay as a result of the unused entitlement that has accumulated at the statement of financial position date. Such measurement is based on actuarial valuation as at the statements of financial position date carried out by a qualified actuary. Towards this benefit, we recorded a total liability of Rs.792 million and Rs.616 million as at March 31, 2016 and 2015, respectively.

*Long term incentive plan.* Certain senior management employees of our company participate in a long term incentive plan which is aimed at rewarding the individual based on the performance of such individual, their business unit/function and our company as a whole, with significantly higher rewards for superior performances. The total liability recorded by us towards this benefit was Rs.881 million as of March 31, 2016.

### **6.C. Board practices**

Our Articles of Association require us to have a minimum of three and a maximum of fifteen directors. As of March 31, 2016, we had nine directors on our Board, of which seven were non-full time independent directors.

The Companies Act, 2013 and our Articles of Association require that at least two-thirds of our directors be subject to re-election by our shareholders in rotation and that, at every annual general meeting, one-third of the directors who are subject to re-election must retire from the Board. However, if eligible for re-election, they may be re-elected by our shareholders at the annual general meeting.

**Table of Contents**

Due to India's adoption of the Companies Act, 2013, effective as of April 1, 2014, non-full time independent directors are no longer required to retire from the Board by rotation. As a result, at annual general meetings held after April 1, 2014, our non-full time independent directors are excluded from the calculation of the two-thirds directors who are subject to re-election by our shareholders in rotation.

The Ministry of Corporate Affairs, Government of India, by a circular dated June 9, 2014, stated that all non-full time independent directors (including existing non-full time independent directors) are required to be appointed expressly under the provisions of the Companies Act, 2013 before March 31, 2015. Accordingly, all of our non-full time independent directors were re-appointed by our shareholders at the July, 2014 annual general meeting.

The terms of each of our directors and their expected expiration dates are provided in the table below:

Name	Expiration of	Term of Office	Term of Office	Period of Service
	Current			
Mr. G.V. Prasad <sup>(1)(4)</sup>	January 29, 2021	5 years	30 years	
Mr. Satish Reddy <sup>(1)</sup>	September 30, 2017	5 years	23 years	
Mr. Anupam Puri <sup>(2)(3)</sup>	July 31, 2018	4 years	14 years	
Ms. Kalpana Morparia <sup>(2)(3)</sup>	July 31, 2019	5 years	9 years	
Dr. Omkar Goswami <sup>(2)(3)</sup>	July 31, 2019	5 years	15.5 years	
Mr. Ravi Bhoothalingam <sup>(2)(3)</sup>	July 31, 2016	2 years	15.5 years	
Dr. Bruce L.A. Carter <sup>(2)(3)</sup>	July 31, 2019	5 years	8 years	
Dr. Ashok S. Ganguly <sup>(2)(3)</sup>	July 31, 2017	3 years	6.5 years	
Mr. Sridar Iyengar <sup>(2)(3)</sup>	July 31, 2019	5 years	5 years	

(1) Full time director.

(2) Non-full time independent director.

(3) All of the non-full time independent directors were appointed at our annual general meeting on July 31, 2014, under the provisions of the Companies Act, 2013 for a term stated in the above table. This appointment of our non-full time independent directors was to comply with the circular dated June 9, 2014 issued by the Ministry of Corporate Affairs, Government of India requiring us to appoint all of our non-full time independent directors specifically under the provisions of the Companies Act, 2013.

(4) Reappointed by the Board of Directors at their meeting held on October 29, 2015 for a further period of five years effective as of January 30, 2016 (expiring January 29, 2021), subject to approval by our shareholders at their next Annual General Meeting scheduled on July 27, 2016.

As a result of the above, a proposal to vary the terms of appointment so that only our full time directors are subject to retirement by rotation was approved by our shareholders at the July 2014 annual general meeting. Accordingly, our full time directors are now subject to retirement by rotation. The directors are not eligible for any termination benefit on the termination of their tenure with us. As a result of the above, Mr. Satish Reddy shall retire by rotation and the proposal to reappoint him is being placed before our shareholders at the July 2016 annual general meeting.

## Table of Contents

### **Committees of the Board**

Committees appointed by the Board focus on specific areas and take decisions within the authority delegated to them.

The Committees also make specific recommendations to the Board on various matters from time-to-time. All decisions and recommendations of the Committees are placed before the Board for information or approval. We had eight Board-level Committees as of March 31, 2016:

Audit Committee.

Nomination, Governance and Compensation Committee.

Science, Technology and Operations Committee.

Risk Management Committee.

Stakeholders Relationship Committee.

Management Committee.

Investment Committee.

Corporate Social Responsibility Committee.

We have adopted charters for our Audit Committee, Nomination, Governance and Compensation Committee, Science, Technology and Operations Committee, Risk Management Committee, Shareholders Grievance Committee and Corporate Social Responsibility Committee, formalizing the applicable committee's procedures and duties. Each of these charters is available on our website at <http://drreddys.com/investors/governance/committees-of-the-board.aspx>.

**Audit Committee.** Our management is primarily responsible for our internal controls and financial reporting process. Our independent registered public accounting firm is responsible for performing independent audits of our financial statements in accordance with the standards of the Public Company Accounting Oversight Board (United States) and for issuing reports based on such audits. The Board of Directors has entrusted the Audit Committee to supervise these processes and thus ensure accurate and timely disclosures that maintain the transparency, integrity and quality of financial controls and reporting.

The Audit Committee consists of the following four non-full time, independent directors:

Mr. Sridar Iyengar (Chairman);

Dr. Omkar Goswami;

Ms. Kalpana Morparia; and

Mr. Ravi Bhoothalingam.

Our Company Secretary is the Secretary of the Audit Committee. This Committee met five times during the year ended March 31, 2016. Our independent registered public accounting firm was generally present at all Audit Committee meetings during the year.

The primary responsibilities of the Audit Committee are to:

Supervise our financial reporting process;

Review our quarterly and annual financial results, along with related public disclosures and filings, before providing them to the Board;

Review the adequacy of our internal controls, including the plan, scope and performance of our internal audit function;

Discuss with management our major policies with respect to risk assessment and risk management.

Hold discussions with external auditors on the nature, scope and process of audits and any views that they have about our financial control and reporting processes;

Ensure compliance with accounting standards and with listing requirements with respect to the financial statements;

Recommend the appointment and removal of external auditors and their remuneration;

Recommend the appointment of cost auditors;

Review the independence of auditors;

Ensure that adequate safeguards have been taken for legal compliance both for us and for our subsidiaries;



Review the financial statements of our subsidiary companies, in particular investments made by them;

Review and approval of related party transactions;

Review the functioning of whistle blower mechanism;

Review the implementation of applicable provisions of the Sarbanes-Oxley Act, 2002;

Scrutinize our inter-company loans and investments;

**Table of Contents**

Value our undertakings and assets, wherever it is necessary;

Evaluation of internal financial controls; and

Review any findings of investigations related to suspected fraud committed against us.

***Nomination, Governance and Compensation Committee.*** The primary functions of the Nomination, Governance and Compensation Committee are to:

Examine the structure, composition and functioning of the Board, and recommend changes, as necessary, to improve the Board's effectiveness;

Formulate policies on remuneration of Directors, key managerial personnel and other employees and on Board diversity

Formulate criteria for evaluation of Independent Directors and the Board;

Assess our policies and processes in key areas of corporate governance, other than those explicitly assigned to other Board Committees, with a view to ensuring that we are at the forefront of good governance practices; and

Regularly examine ways to strengthen our organizational health, by improving the hiring, retention, motivation, development, deployment and behavior of management and other employees. In this context, the Committee also reviews the framework and processes for motivating and rewarding performance at all levels of the organization, reviews the resulting compensation awards, and makes appropriate proposals for Board approval. In particular, it recommends all forms of compensation to be granted to our Directors, executive officers and key managerial personnel.

The Nomination, Governance and Compensation Committee also administers our Employee Stock Option Schemes.

The Nomination, Governance and Compensation Committee consists of the following non-full time, independent directors:

Dr. Ashok S. Ganguly (Chairman);

Mr. Anupam Puri;

Ms. Kalpana Morparia; and

Mr. Ravi Bhoothalingam.

The corporate officer heading our Human Resources function serves as the Secretary of the Committee. The Nomination, Governance and Compensation Committee met three times during the year ended March 31, 2016.

***Science, Technology and Operations Committee.*** The primary functions of the Science, Technology and Operations Committee are to:

Advise our Board and management on scientific, medical and technical matters and operations involving our development and discovery programs (generic and proprietary), including major internal projects, business development opportunities, interaction with academic and other outside research organizations;

Assist our Board and management in staying abreast of novel scientific and technologies developments and innovations, anticipating emerging concepts and trends in therapeutic research and development, and making well-informed choices in committing our resources;

Assist our Board and management in creating valuable intellectual property;

Review the status of non-infringement patent challenges; and

Assist our Board and management in building and nurturing science in our organization in line with our business strategy.

The Science, Technology and Operations Committee consists of the following non-full time, independent directors:

Dr. Bruce L.A. Carter (Chairman);

Mr. Anupam Puri;

Dr. Ashok S. Ganguly; and

Dr. J.P. Moreau (term ended on July 31, 2015).

The corporate officers heading our Integrated Product Development Operations, Proprietary Products and Biologics functions serve as the Secretary of the Committee with regard to their respective businesses. The Science, Technology and Operations Committee met four times during the year ended March 31, 2016.

**Table of Contents**

***Risk Management Committee.*** The primary function of the Risk Management Committee is to:

Discuss with senior management our enterprise risk management and provide oversight as may be needed;

Ensure that it is apprised of our more significant risks, along with the risk management steps implemented to ensure effective enterprise risk management; and

Review risk disclosure statements in any public documents or disclosures, where applicable.

The Risk Management Committee consists of the following non-full time, independent directors:

Dr. Omkar Goswami (Chairman);

Dr. J.P. Moreau (term ended on July 31, 2015);

Dr. Bruce L.A. Carter; and

Mr. Sridar Iyengar.

Our Chief Financial Officer is the Secretary of the Risk Management Committee. This Committee met three times during the year ended March 31, 2016.

***Corporate Social Responsibility ( CSR ) Committee.*** The primary function of the Corporate Social Responsibility Committee is to:

Formulate, review and recommend to the Board a corporate social responsibility policy indicating the activities to be undertaken by us as specified in Schedule VII of the Companies Act, 2013.

Recommend the amount of expenditures to be incurred in connection with our corporate social responsibility initiatives;

Provide guidance on our corporate social responsibility initiatives and monitoring their progress; and

Monitor implementation and adherence to our corporate social responsibility policy from time to time.

The Corporate Social Responsibility Committee consists of the following directors:

Mr. Ravi Bhoothalingam (Chairman);

Mr. G.V. Prasad; and

Mr. Satish Reddy.

Our corporate officer heading our Corporate Social Responsibility function serves as the Secretary of the Corporate Social Responsibility Committee. This Committee met three times during the year ended March 31, 2016.

**Stakeholders Relationship Committee.** Effective May 13, 2014, the name of our Shareholders Grievance Committee has been changed to Stakeholders Relationship Committee in accordance with the provisions of Section 178 of the Indian Companies Act, 2013. The primary function of the Stakeholders Relationship Committee is to:

Review investor complaints and their redress;

Review queries received from investors;

Review work done by our share transfer agent; and

Review corporate actions related to our security holders.

The Stakeholders Relationship Committee consists of the following directors:

Ms. Kalpana Morparia (Chairperson);

Mr. Ravi Bhoothalingam;

Mr. G.V. Prasad; and

Mr. Satish Reddy.

Our Company Secretary is the Secretary of the Stakeholders Relationship Committee. This Committee met four times during the year ended March 31, 2016.

**Table of Contents****6.D. Employees**

The following table sets forth the number of our employees as at March 31, 2016, 2015 and 2014.

	As at March 31, 2016				Total
	India	North America	Europe	Rest of World	
Manufacturing <sup>(1)</sup>	10,584	352	169	259	11,364
Sales and marketing <sup>(2)</sup>	5,625	141	33	1,388	7,187
Research and development <sup>(3)</sup>	2,298	49	120	50	2,517
Others <sup>(4)</sup>	724	105	65	213	1,107
<b>Total</b>	<b>19,231</b>	<b>647</b>	<b>387</b>	<b>1,910</b>	<b>22,175</b>

	As at March 31, 2015				Total
	India	North America	Europe	Rest of World	
Manufacturing <sup>(1)</sup>	9,442	420	155	285	10,302
Sales and marketing <sup>(2)</sup>	4,953	137	35	1,375	6,500
Research and development <sup>(3)</sup>	2,202	45	120	46	2,413
Others <sup>(4)</sup>	727	104	94	233	1,158
<b>Total</b>	<b>17,324</b>	<b>706</b>	<b>404</b>	<b>1,939</b>	<b>20,373</b>

	As at March 31, 2014				Total
	India	North America	Europe	Rest of World	
Manufacturing <sup>(1)</sup>	8,160	417	169	132	8,878
Sales and marketing <sup>(2)</sup>	4,162	133	83	1,233	5,611
Research and development <sup>(3)</sup>	1,940	28	70	41	2,079
Others <sup>(4)</sup>	1,131	100	113	509	1,853
<b>Total</b>	<b>15,393</b>	<b>678</b>	<b>435</b>	<b>1,915</b>	<b>18,421</b>

(1) Includes quality, technical services and warehouse.

(2) Includes business development.

(3) Includes employees engaged in contract research services provided to other companies.

(4) Includes shared services, corporate business development and the intellectual property management team.

We did not experience any significant work stoppages in the years ended March 31, 2016 and 2015, and we consider our relationship with our employees and labor unions to be good. Approximately 4% of our employees belong to labor unions.



**Table of Contents****6.E. Share ownership**

The following table sets forth, as of March 31, 2016 for each of our directors and executive officers, the total number of our equity shares and options owned by them:

Name	No. of Shares Held <sup>(1), (2)</sup>	% of Outstanding Capital	No. of Options Held <sup>(5)</sup>	Vesting and Expiration Date (See note no.)
G.V. Prasad <sup>(3)</sup>	1,365,840	0.80%		
Satish Reddy <sup>(3)</sup>	1,205,832	0.71%		
Anupam Puri (ADRs) <sup>(3)</sup>	18,302	0.01%		
Dr. Omkar Goswami <sup>(3)</sup>	22,800	0.01%		
Kalpana Morparia <sup>(3)</sup>	10,800	0.01%		
Ravi Bhoothalingam <sup>(3)</sup>	22,800	0.01%		
Dr. Bruce L.A. Carter (ADRs) <sup>(3)</sup>	7,800	0.00%		
Dr. Ashok S. Ganguly <sup>(3)</sup>	4,800	0.00%		
Sridar Iyengar <sup>(3)</sup>				
Abhijit Mukherjee	21,986	0.01%	13,125	(4)
Dr. Cartikeya Reddy			8,175	(4)
Saumen Chakraborty	31,500	0.02%	8,625	(4)
Dr. Raghav Chari (ADRs)	4,275	0.00%	8,375	(4)
M.V. Ramana	13,846	0.01%	12,150	(4)
Samiran Das	1,825	0.00%	8,975	(4)
Dr. Amit Biswas	5,350	0.00%	7,250	(4)
Alok Sonig	1,050	0.00%	9,350	(4)
Dr. K. V. S. Ram Rao	7,575	0.00%	5,175	(4)
Dr. S. Chandrasekhar			4,375	(4)

(1) Shares held in their individual name only.

(2) All shares have voting rights.

(3) Not eligible for grant of stock options.

(4) The options vest on various dates between the year ending March 31, 2016 and the year ending March 31, 2020.

(5) The options expire after five years from the date of vesting. Each of the options has an exercise price of Rs.5 and results in the issuance of one equity share upon its exercise.

**Employee Stock Incentive Plans**

We have adopted a number of stock option incentive plans covering either our ordinary shares or our ADSs, and we are currently operating under the Dr. Reddy's Employees Stock Option Plan-2002 and the Dr. Reddy's Employees ADR Stock Option Plan-2007. During the year ended March 31, 2016, options to purchase ordinary shares and ADSs were awarded to various of our executive officers and other employees under these two plans as follows: an aggregate of 142,408 options were granted having an average exercise price of Rs.5 per share or ADS and no options were granted at a fair market value based exercise price. Each option granted had an expiration date of five years from the



vesting date, and each grant provided for time-based vesting in 25% increments over four years. As of March 31, 2016, options were outstanding under these two plans for an aggregate of 519,391 shares and ADSs with an average exercise price of Rs.5 per share.

For the years ended March 31, 2016 and 2015, Rs.471 million and Rs.498 million, respectively, have been recorded as employee share-based payment expense under all of our employee stock incentive plans. As of March 31, 2016, there was Rs.437 million of total unrecognized compensation cost related to unvested stock options. This cost is expected to be recognized over a weighted-average period of 3.10 years. For further information regarding our options and stock option incentive plans, see Note 20 to our consolidated financial statements.

**Table of Contents****ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS****7.A. Major shareholders**

All of our equity shares have the same voting rights. As of March 31, 2016, a total of 25.58% of our equity shares were held by the following parties:

Mr. G.V. Prasad (Co-Chairman, Managing Director and Chief Executive Officer);

Mr. Satish Reddy (Chairman of the Board);

Mrs. K. Samrajyam, mother of Mr. Satish Reddy, and Mrs. G. Anuradha, wife of Mr. G.V. Prasad (hereafter collectively referred as the Family Members ); and

Dr. Reddy s Holdings Limited (formerly known as Dr. Reddy s Holdings Private Limited), a company in which the APS Trust owns 83.11% of the equity and the remainder is held by Mr. G.V. Prasad HUF, Mr. Satish Reddy individually and as HUF and the Family Members. Mr. G.V. Prasad, Mr. Satish Reddy, Mrs. G. Anuradha, Mrs. Deepti Reddy and their bloodline descendents are the beneficiaries of the APS Trust. Mr. G.V. Prasad, Mr. Satish Reddy, Mrs. G. Anuradha and Mrs. Deepti Reddy are the sole members of the Board of Directors of Dr. Reddy s Holdings Limited. Mr. G.V. Prasad and Mr. Satish Reddy are the sole trustees of the APS trust.

The following table sets forth information regarding the beneficial ownership of our shares by the foregoing persons as of March 31, 2016:

<b>Name</b>	<b>Equity Shares Beneficially Owned<sup>(1)</sup></b>	
	<b>Number of Shares</b>	<b>Percentage of Shares</b>
Dr. Reddy s Holdings Limited <sup>(3)</sup>	39,961,234	23.42%
Mr. G.V. Prasad <sup>(2)</sup>	1,365,840	0.80%
Mr. Satish Reddy <sup>(2)</sup>	1,205,832	0.71%
Family Members	1,116,856	0.65%
<b>Subtotal</b>	<b>43,649,762</b>	<b>25.58%</b>
Others/public float	126,957,891	74.42%
<b>Total number of shares outstanding</b>	<b>170,607,653</b>	<b>100.00%</b>

<sup>(1)</sup> Beneficial ownership is determined in accordance with rules of the U.S. Securities and Exchange Commission, which provides that shares are beneficially owned by any person who has voting or

investment power with respect to the shares. All information with respect to the beneficial ownership of any principal shareholder has been furnished by that shareholder and, unless otherwise indicated below, we believe that persons named in the table have sole voting and sole investment power with respect to all shares shown as beneficially owned, subject to community property laws where applicable.

- (2) The APS Trust owns approximately 83.11% of the equity of Dr. Reddy's Holdings Limited, and thus may be deemed to beneficially own all of the equity shares directly held by Dr. Reddy's Holdings Limited. Mr. G.V. Prasad and Mr. K. Satish Reddy are the sole trustees of the APS Trust. Accordingly, each of Mr. G.V. Prasad and Mr. K. Satish Reddy may be deemed to beneficially own all of the equity shares directly held by Dr. Reddy's Holdings Limited. Each of Mr. G.V. Prasad and Mr. K. Satish Reddy has disclaimed such beneficial ownership pursuant to Rule 13d-4.

In addition, the Deed of Family Settlement of the APS Trust provides for the parties thereto to exercise all rights, including voting rights, with respect to their personally held equity shares in accordance with the directions of the board of trustees of the APS Trust. As a result, each of Mr. Satish Reddy and Mr. G.V. Prasad may be deemed to beneficially own all of the equity shares directly held by each other or by any of the other parties to such Deed of Family Settlement. Based on the Amendment No. 1 to Schedule 13D filed with the U.S. Securities and Exchange Commission on February 3, 2016, such equity shares held by other parties to the Deed of Family Settlement consisted of, in each case as of December 31, 2015, an aggregate of 1,115,360 equity shares directly held by Mrs. K. Samrajyam (mother of Mr. Satish Reddy) and 1,496 equity shares directly held by Mrs. G. Anuradha (wife of Mr. G.V. Prasad). Each of Mr. G.V. Prasad and Mr. K. Satish Reddy has disclaimed all such beneficial ownership pursuant to Rule 13d-4.

As otherwise stated above and to the best of our knowledge, we are not owned or controlled directly or indirectly by any government or by any other corporation or by any other natural or legal persons. We are not aware of any arrangement, the consummation of which may at a subsequent date result in a change in our control.

**Table of Contents**

The following shareholders held more than 5% of our equity shares as of:

Name	March 31, 2016		March 31, 2015		March 31, 2014	
	No. of equity shares held	% of equity shares held	No. of equity shares held	% of equity shares held	No. of equity shares held	% of equity shares held
Dr. Reddy s Holdings Limited*	39,961,234	23.42%	39,729,284	23.32%	39,729,284	23.35%
First State Investments Management (UK) Limited, First State Investments International Limited and their associates**	15,181,101	8.90%	14,389,390	8.45%	14,056,799	8.26%
Oppenheimer Funds Distributor, Inc. and its associates***	8,731,914	5.12%	7,661,494	4.50%	0	0.00%

\* Each of the APS Trust, Mr. G.V. Prasad and Mr. K. Satish Reddy may be deemed to beneficially own all of the equity shares directly held by Dr. Reddy s Holdings Limited, as described in footnote (2) to the table on the preceding page.

\*\* Based on information provided to us by First State Investments Management (UK) Limited, as of March 31, 2016, they held an additional 2.41% of the aggregate shares of our Company in the form of ADSs in addition to the equity shares listed above.

\*\*\* Based on information provided to us by Oppenheimer Funds Distributor, Inc., as of March 31, 2016, they held an additional 0.02% of the aggregate shares of our Company in the form of ADSs in addition to the equity shares listed above.

As of March 31, 2016, we had 170,607,653 outstanding equity shares. As of March 31, 2016, there were 109,791 record holders of our equity shares listed and traded on the Indian stock exchanges. Our American Depositary Shares ( ADSs ) are listed on the New York Stock Exchange. One ADS represents one equity share of Rs.5 par value per share. As of March 31, 2016, 16.75% of our issued and outstanding equity shares were held by ADS holders. On March 31, 2016 we had approximately 66 registered shareholders and 16,438 beneficial shareholders of record in the United States.

**7.B. Related party transactions**

Refer to Note 29 of our consolidated financial statements.

**7.C. Interests of experts and counsel**

Not applicable.

**Table of Contents**

**ITEM 8. FINANCIAL INFORMATION**

**8.A. Consolidated statements and other financial information**

The following financial statements and auditors' report appear under Item 18 of this Annual Report on Form 20-F and are incorporated herein by reference:

Report of Independent Registered Public Accounting Firm

Consolidated statement of financial position as of March 31, 2016 and 2015

Consolidated income statement for the years ended March 31, 2016, 2015 and 2014

Consolidated statement of comprehensive income for the years ended March 31, 2016, 2015 and 2014

Consolidated statement of changes in equity for the years ended March 31, 2016, 2015 and 2014

Consolidated statement of cash flows for the years ended March 31, 2016, 2015 and 2014

Notes to the consolidated financial statements

Our financial statements included in this Annual Report on Form 20-F have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. The financial statements included herein are for our three most recent fiscal years.

**Amount of Export Sales**

For the year ended March 31, 2016, our export revenues (i.e., revenues from all geographies other than India) were Rs.130,795 million, and accounted for 85% of our total revenues.

**Legal Proceedings**

Refer to Note 43 of our consolidated financial statements.

**Dividend Policy**

In the years ended March 31, 2014, 2015 and 2016, we paid cash dividends of Rs.15, Rs.18 and Rs.20 respectively, per equity share. Every year our Board of Directors recommends the amount of dividends to be paid to shareholders, if any, based upon conditions then existing, including our earnings, financial condition, capital requirements and other factors. In our Board of Directors' meeting held on May 12, 2016, the Board of Directors proposed a dividend per share of Rs.20 and aggregating to Rs.3,405 million plus an additional amount of Rs.693 million, which is intended to

equal the applicable dividend tax, all of which is subject to the approval of our shareholders.

Holders of our ADSs are entitled to receive dividends payable on equity shares represented by such ADSs. Cash dividends on equity shares represented by our ADSs are paid to the depositary in Indian rupees and are converted by the depositary into U.S. dollars and distributed, net of depositary fees, taxes, if any, and expenses, to the holders of such ADSs.

### ***Bonus Debentures***

On March 31, 2010, our Board of Directors approved a scheme for the issuance ( in-kind , i.e., for no cash consideration) to our shareholders of 9.25% unsecured, non-convertible, redeemable debentures (sometimes referred to as our bonus debentures ), to be effected by way of capitalization of our retained earnings. The scheme was subject to the successful receipt of necessary approvals of our shareholders, the High Court of Andhra Pradesh, India and other identified regulatory authorities as mentioned in the scheme. All necessary approvals to effectuate the scheme, including that of the High Court, were received during the year ended March 31, 2011. Accordingly, on March 24, 2011, we issued these bonus debentures to our shareholders. These bonus debentures matured on March 24, 2014 and were redeemed by us for cash in an amount equal to their face value of Rs. 5 each, along with the third and final interest payment thereon. The aggregate principal payment for all such bonus debentures on March 24, 2014 was Rs.5,078 million.

### ***8.B. Significant changes***

Refer to note 45 to our consolidated financial statements.

**Table of Contents****ITEM 9. THE OFFER AND LISTING****9.A. Offer and listing details***Information Regarding Price History*

The following tables set forth the price history for our shares on the BSE Limited (formerly known as the Bombay Stock Exchange Limited) ( BSE ) and for our ADSs on the New York Stock Exchange ( NYSE ).

Year	BSE		NYSE	
	Price Per Equity Share <sup>(1)</sup>		Price Per ADS <sup>(1)</sup>	
	High (Rs.)	Low (Rs.)	High (U.S.\$)	Low (U.S.\$)
<b>Ended March 31,</b>				
2012	1,770.80	1,387.00	39.37	28.75
2013	1,968.60	1,528.00	36.73	27.28
2014	2,939.80	1,766.30	47.93	31.32
2015	3,662.00	2,250.00	59.02	38.23
2016	4,382.95	2,750.00	68.00	40.68

Quarter Ended	BSE		NYSE	
	Price Per Equity Share <sup>(1)</sup>		Price Per ADS <sup>(1)</sup>	
	High (Rs.)	Low (Rs.)	High (U.S.\$)	Low (U.S.\$)
June 30, 2014	2,783.00	2,250.00	46.24	38.23
September 30, 2014	3,353.85	2,598.10	53.67	43.03
December 31, 2014	3,662.00	2,883.40	59.02	45.67
March 31, 2015	3,570.00	3,010.00	58.25	47.52
June 30, 2015	3,808.75	3,250.15	60.85	51.25
September 30, 2015	4,337.00	3,502.45	68.00	55.48
December 31, 2015	4,382.95	2,950.50	68.00	43.41
March 31, 2016	3,280.00	2,750.00	49.4	40.68

Month Ended	BSE		NYSE	
	Price Per Equity Share <sup>(1)</sup>		Price Per ADS <sup>(1)</sup>	
	High (Rs.)	Low (Rs.)	High (U.S.\$)	Low (U.S.\$)
October 31, 2015	4,382.95	4,080.00	68.00	62.38
November 30, 2015	4,375.30	3,049.75	66.68	46.06
December 31, 2015	3,265.00	2,950.50	48.79	43.41
January 31, 2016	3,122.90	2,750.00	46.29	40.68
February 29, 2016	3,151.85	2,814.80	45.86	41.34
March 31, 2016	3,280.00	2,891.95	49.40	43.73

(1) Source: www.bseindia.com and www.nyse.com, respectively.

**9.B. Plan of distribution**

Not applicable.

**9.C. Markets**

*Markets on Which Our Shares Trade*

Our equity shares are traded on the BSE Limited (formerly known as the Bombay Stock Exchange Limited) ( BSE ) and National Stock Exchange of India Limited ( NSE ), or collectively, the Indian Stock Exchanges. Our American Depositary Shares (or ADSs ), as evidenced by American Depositary Receipts (or ADRs ), are traded in the United States on the New York Stock Exchange ( NYSE ), under the ticker symbol RDY. Each ADS represents one equity share. Our ADSs began trading on the NYSE on April 11, 2001. Our shareholders approved the delisting of our shares from the Hyderabad Stock Exchange Limited, The Stock Exchange, Ahmedabad, The Madras Stock Exchange Limited and The Calcutta Stock Exchange Association Limited at the general shareholders meeting held on August 25, 2003.

**9.D. Selling shareholders**

Not applicable.

**9.E. Dilution**

Not applicable.



**Table of Contents**

**9.F. Expenses of the issue**

Not applicable.

**ITEM 10. ADDITIONAL INFORMATION**

**10.A. Share capital**

Not applicable.

**10.B. Memorandum and articles of association**

Dr. Reddy's Laboratories Limited was incorporated under the Indian Companies Act, 1956. We are registered with the Registrar of Companies, Hyderabad, Telangana, India, with Company Identification No. L85195AP1984PLC004507. Our company's registration number changed to L85195TG1984PLC004507 effective as of June 2, 2014.

Our registered office is located at 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India and the telephone number of our registered office is +91-40-49002900. The summary of our Articles of Association and Memorandum of Association that is included in our registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (the SEC) on April 11, 2001, together with copies of the Articles of Association and Memorandum of Association that are included in our registration statement on Form F-1, are incorporated herein by reference.

The Memorandum and Articles of Association were amended at the 17th Annual General Meeting held on September 24, 2001, 18th Annual General Meeting held on August 26, 2002, the 20th Annual General Meeting held on July 28, 2004 and the 22nd Annual General Meeting held on July 28, 2006. A full description of these amendments was given in the Form 20-F filed with the SEC on September 30, 2003, September 30, 2004 and October 2, 2006, which description is incorporated herein by reference. The Memorandum and Articles of Association were amended at the 22nd Annual General Meeting held on July 28, 2006 to increase the authorized share capital in connection with the stock split effected in the form of a stock dividend that occurred on August 30, 2006.

The Memorandum and Articles of Association were further amended in accordance with the terms of an Order of the High Court of Judicature, Andhra Pradesh, dated June 12, 2009 to effect an increase in our parent company's authorized share capital pursuant to the amalgamation of Perlecan Pharma Private Limited into our parent company. In a related order dated June 12, 2009, the High Court concluded that there was no need to have a shareholders meeting in order to affect such amendment.

The Memorandum and Articles of Association were further amended in accordance with the terms of an Order of the High Court of Judicature, Andhra Pradesh, dated July 19, 2010 to provide for the capitalization or utilization of undistributed profit or retained earnings or security premium account or any other reserve or fund of ours with the approval of our shareholders in connection with our bonus debentures.

The Memorandum and Articles of Association were amended by adopting a new set of Articles of Association which replaced and superseded in its entirety the existing Articles of Association of the Company. This was primarily done to align the Articles of Association with the new Companies Act, 2013 and the rules thereunder. This amendment was approved by our shareholders on September 17, 2015. The new Articles of Association were furnished to the SEC on a Form 6-K on September 25, 2015.

**10.C. *Material contracts***

Other than the contracts entered into in the ordinary course of business, there are no material contracts to which we or any of our direct and indirect subsidiaries is a party for the two years immediately preceding the date of this Form 20-F.

**10.D. *Exchange controls***

Foreign investment in Indian securities, whether in the form of foreign direct investment or in the form of portfolio investment, is governed by the Foreign Exchange Management Act, 1999, as amended ( FEMA ), and the rules, regulations

## **Table of Contents**

and notifications issued thereunder. Set forth below is a summary of the restrictions on transfers applicable to both foreign direct investments and portfolio investments, including the requirements under Indian law applicable to the issuance and transfer of ADSs.

### **Foreign Direct Investment**

The Foreign Direct Investment Policy under the Reserve Bank of India's (RBI) Automatic Route enables Indian companies (other than those specifically excluded thereunder) to issue shares to persons who reside outside of India without prior permission from the RBI, except in cases where there are ceilings of investments in certain industry sectors and subject to certain conditions.

The Department of Industrial Policy and Promotion, a part of the Ministry of Commerce and Industry, issued detailed guidelines in January 1997 for consideration of foreign direct investment proposals by the Foreign Investment Promotion Board (the Guidelines). The basic objective of the Guidelines is to improve the transparency and objectivity of the Foreign Investment Promotion Board's consideration of proposals. However, since these are administrative guidelines and have not been codified as either law or regulations, they are not legally binding with respect to any recommendation made by the Foreign Investment Promotion Board or with respect to any decision taken by the Government of India in cases involving foreign direct investment.

Under the Guidelines, sector specific guidelines for foreign direct investment and the levels of permitted equity participation have been established. In February 2000, the Department of Industrial Policy and Promotion issued a notification that foreign ownership of up to 50%, 51%, 74% or 100%, depending on the category of industry, would be allowed without prior permission of the Foreign Investment Promotion Board and, in certain cases, without prior permission of the RBI. Over a period of time, the Government of India has relaxed the restrictions on foreign investment, including the revision of the investment cap from 26% to 49% in the insurance sector and 74% subject to RBI guidelines for setting up branches/subsidiaries of foreign banks in the private banking sector.

In May 1994, the Government of India announced that purchases by foreign investors of ADSs, as evidenced by ADRs, and foreign currency convertible bonds of Indian companies would be treated as foreign direct investment in the equity issued by Indian companies for such offerings. Therefore, offerings that involve the issuance of equity that results in Foreign Direct Investors holding more than the stipulated percentage of direct foreign investments (which depends on the category of industry) would require approval from the Foreign Investment Promotion Board.

In addition, offerings by Indian companies of any such securities to foreign investors require Foreign Investment Promotion Board approval, whether or not the stipulated percentage limit would be reached if the proceeds will be used for investment in specified industries.

For investments in the pharmaceutical sector, the Foreign Direct Investment limit is 100%. However, unlike Foreign Direct Investments in new pharmaceutical projects (sometimes called greenfield investments), Foreign Direct Investments in existing Indian pharmaceutical companies (sometimes called brownfield investments) are nonetheless subject to approval by the Foreign Investment Promotion Board (which can incorporate conditions for its approval at the time of grant). Thus, foreign ownership of up to 100% of our equity shares would be allowed but would require certain approvals.

### **Portfolio Investment Scheme**

Under Indian law, persons or entities residing outside of India cannot acquire securities of an Indian company listed on a stock exchange (Portfolio Investments) unless such non-residents are (a) persons of Indian nationality or origin

residing outside of India (also known as Non-Resident Indians or NRIs ) or (b) registered Foreign Institutional Investors ( FIIs ) or Foreign Portfolio Investors ( FPIs ).

*Portfolio Investments by NRIs*

A variety of methods for investing in shares of Indian companies are available to NRIs. These methods allow NRIs to make Portfolio Investments in existing shares and other securities of Indian companies on a basis not generally available to other foreign investors.

*Portfolio Investments by FIIs*

In September 1992, the Government of India issued guidelines that enable FIIs, including institutions such as pension funds, investment trusts, asset management companies, nominee companies and incorporated/institutional portfolio managers,

**Table of Contents**

to invest in all of the securities traded on the primary and secondary markets in India. Under the guidelines, FIIs are required to obtain an initial registration from the Securities and Exchange Board of India ( SEBI ), and a general permission from the RBI to engage in transactions regulated under the Foreign Exchange Management Act. FIIs must also comply with the provisions of the SEBI (Foreign Institutional Investors Regulations) 1995. When it receives the initial registration, the FII also obtains general permission from the RBI to engage in transactions regulated under the Foreign Exchange Management Act. Together, the initial registration and the RBI's general permission enable the registered FII to: (i) buy (subject to the ownership restrictions discussed below) and sell unrestricted securities issued by Indian companies; (ii) realize capital gains on investments made through the initial amount invested in India; (iii) participate in rights offerings for shares; (iv) appoint a domestic custodian for custody of investments held; and (v) repatriate the capital, capital gains, dividends, interest income and any other compensation received pursuant to rights offerings of shares. The current policy with respect to purchase or sale of securities of an Indian company by an FII is in Schedule 2 and Regulation 5(2) of the Foreign Exchange Management (Transfer or Issue of Securities by a Person Resident Outside India) Regulations, 2000.

*Portfolio Investments by FPIs*

Effective June 1, 2014, the regime permitting Portfolio Investments by FIIs has been replaced with the SEBI (Foreign Portfolio Investors) Regulations, 2014 (the FPI Regulations ), a new regime permitting Portfolio Investments by Foreign Portfolio Investors ( FPIs ). FPIs are subject to ownership limits in Portfolio Investments, as further described below, and only certain categories of FPIs may invest or deal in offshore derivative instruments (defined under the FPI Regulations as any instrument which is issued overseas by a FPI against underlying securities held by it that are listed or proposed to be listed on any recognized stock exchange in India). FPIs are required to be registered with the designated depository participant on behalf of SEBI subject to compliance with Know Your Customer rules.

Certain FIIs may continue to remain eligible to make Portfolio Investments for a limited time under the transition rules. Any FII or Qualified Foreign Investor ( QFI ) who holds a valid certificate of registration will be deemed to be a FPI until the expiration of three years from the date on which fees have been paid per the Securities and Exchange Board of India (Foreign Institutional Investors) Regulations, 1995. All existing FIIs and sub accounts, subject to payment of conversion fees specified in the FPI Regulations, may continue to buy, sell or otherwise deal in securities subject to the provisions of the FPI Regulations, until the earlier of (i) expiration of its registration as a FII or sub-account, or (ii) obtaining a certificate of registration as a FPI. Effective as of June 1, 2015, a QFI must obtain a certificate of registration as a FPI in order to be eligible to buy, sell or otherwise deal in securities.

Subject to compliance with the FPI Regulations, a FPI may issue or otherwise deal in offshore derivative instruments (defined under the FPI Regulations as any instrument, by whatever name called, which is issued overseas by a FPI against securities held by it that are listed or proposed to be listed on any recognized stock exchange in India, as its underlying) directly or indirectly, only in the event (i) such offshore derivative instruments are issued only to persons who are regulated by an appropriate regulatory authority; and (ii) such offshore derivative instruments are issued after compliance with know your client norms. Offshore derivative instruments may not be dealt with by Category III FPIs, or by unregulated broad based funds which are classified as Category II FPIs by virtue of their investment manager being appropriately regulated. A FPI is also required to ensure that no further issue or transfer of any offshore derivative instrument is made by or on behalf of it to any persons that are not regulated by an appropriate foreign regulatory authority.

In furtherance of the FPI Regulations, the RBI amended relevant provisions of Foreign Exchange Management (Transfer or Issue of Security by a Person Resident outside India) Regulations, 2000 by a notification dated March 13, 2014. The portfolio investor registered in accordance with the FPI Regulations would be called a Registered Foreign Portfolio Investor (or RFPI ). Accordingly, a RFPI may purchase and sell shares and convertible debentures of an

Indian company through a registered broker as well as purchase shares and convertible debentures offered to the public under the FPI Regulations. Further, a RFPI may sell shares or convertible debentures so acquired (i) in an open offer in accordance with the Securities Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; or (ii) in an open offer in accordance with the Securities Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; or (iii) through buyback of shares by a listed Indian company in accordance with the Securities Exchange Board of India (Buy-back of Securities) Regulations, 1998. A RFPI may also acquire shares or convertible debentures (i) in any bid for, or acquisition of securities in response to an offer for disinvestment of shares made by the central government or any state government of India; or (ii) in any transaction in securities pursuant to an agreement entered into with merchant banker in the process of market making or subscribing to unsubscribed portion of the issue in accordance with Chapter XB of the SEBI (ICDR) Regulations, 2009.

---

**Table of Contents**

**Ownership restrictions**

The SEBI and the RBI regulations restrict portfolio investments in Indian companies by FIIs, NRIs, RFPIs and OCBs, all of which we refer to as foreign portfolio investors. Under current Indian law, FIIs or FPIs may in the aggregate hold not more than 24.0% of the equity shares of an Indian company, and NRIs in the aggregate may hold not more than 10.0% of the shares of an publicly traded Indian company through portfolio investments. The 24.0% limit referred to above can be increased to sectoral cap/statutory limits as applicable if a resolution is passed by the board of directors of the company followed by a special resolution passed by the shareholders of the company to that effect. The 10.0% limit referred to above may be increased to 24.0% if the shareholders of the company pass a special resolution to that effect. No single FII or FPI may hold more than 10.0% of the shares of an Indian company and no single NRI may hold more than 5.0% of the shares of an Indian company. If multiple entities have at least 50% overlap in their ownership (direct or ultimate beneficial owners), then such entities shall be treated as part of the same group and the above percentage of FPI investment limit shall apply to the entire group as if they were a single FPI.

Our shareholders have passed a resolution enhancing the limits of portfolio investment by FIIs in the aggregate to 49%. NRIs in the aggregate may hold not more than 10.0% of our equity shares through portfolio investments. Holders of ADSs are not subject to the rules governing FIIs or FPIs unless they convert their ADSs into equity shares.

As of March 31, 2016, FIIs held 36.00% of our equity shares and NRIs held 1.22% of our equity shares.

In September 2011, the Securities and Exchange Board of India ( SEBI ) enacted the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (the 2011 Takeover Code ), which replaces the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Under the 2011 Takeover Code, upon acquisition of shares or voting rights in a publicly listed Indian company (the target company ) such that the aggregate shareholding of the acquirer (meaning a person who directly or indirectly, acquires or agrees to acquire shares or voting rights in the target company, or acquires or agrees to acquire control over the target company, either alone or together with any persons acting in concert), is 5% or more of the shares of the target company, the acquirer is required to, within two working days of such acquisition, disclose the aggregate shareholding and voting rights in the target company to the target company and to the stock exchanges in which the shares of the target company are listed.

Furthermore, an acquirer who, together with persons acting in concert with such acquirer, holds shares or voting rights entitling them to 5% or more of the shares or voting rights in a target company must disclose every sale or acquisition of shares representing 2% or more of the shares or voting rights of the target company to the target company and to the stock exchanges in which the shares of the target company are listed within two working days of such acquisition or sale or receipt of intimation of allotment of such shares.

Every acquirer, who together with persons acting in concert with such acquirer, holds shares or voting rights entitling such acquirer to exercise 25% or more of the voting rights in a target company, has to disclose to the target company and to stock exchanges in which the shares of the target company are listed, their aggregate shareholding and voting rights as of the thirty-first day of March, in such target company within seven working days from the end of the financial year of that company.

The acquisition of shares or voting rights that entitles the acquirer to exercise 25% or more of the voting rights in or control over the target company triggers a requirement for the acquirer to make an open offer to acquire additional shares representing at least 26% of the total shares of the target company for an offer price determined as per the provisions of the 2011 Takeover Code. The acquirer is required to make a public announcement for an open offer on

the date on which it is agreed to acquire such shares or voting rights. Such open offer shall only be for such number of shares as is required to adhere to the maximum permitted non-public shareholding.

Since we are a listed company in India, the provisions of the 2011 Takeover Code will apply to us and to any person acquiring our ADSs, equity shares or voting rights in our company.

Pursuant to the 2011 Takeover Code, we must report to the Indian stock exchanges on which our equity shares are listed, any disclosures made to us under 2011 Takeover Code.

Holders of ADSs may be required to comply with such notification and disclosure obligations pursuant to the provisions of the Deposit Agreement entered into by such holders, our company and the depository of our ADRs.



## **Table of Contents**

### **Subsequent transfer of shares**

A person resident outside India holding the shares or debentures of an Indian company may transfer the shares or debentures so held by him, in compliance with the conditions specified in the relevant Schedule of Foreign Exchange Management (Transfer or Issue of Security by a Person Resident outside India) Regulations, 2000 (the Foreign Exchange Management Regulations ) as follows:

- (i) A person resident outside India, not being a NRI or an OCB, may transfer by way of sale or gift, the shares or convertible debentures held by him or it to any person resident outside India;
- (ii) A NRI may transfer by way of sale or gift, the shares or convertible debentures held by that person to another NRI; provided that the person to whom the shares are being transferred has obtained prior permission of the Government of India to acquire the shares if he has a previous venture or tie up in India through an investment in shares or debentures or a technical collaboration or a trade mark agreement or investment by whatever name called in the same field or allied field in which the Indian company whose shares are being transferred is engaged. Provided further that the restriction in clauses (i) and (ii) shall not apply to the transfer of shares to international financial institutions such as Asian Development Bank ( ADB ), International Finance Corporation ( IFC ), Commonwealth Development Corporation ( CDC ), Deutsche Entwicklungs Gessellschaft ( DEG ) and transfer of shares of an Indian company engaged in the Information Technology sector.

However, a transfer of shares from a NRI to a non-resident (who is not a not a NRI or OCB) requires the prior approval of the Reserve Bank of India.

- (iii) A person resident outside India holding the shares or convertible debentures of an Indian company in accordance with the Foreign Exchange Management Regulations, (a) may transfer such shares or convertible debentures to a person resident in India by way of gift; or (b) may sell such shares or convertible debentures on a recognized Stock Exchange in India through a registered broker.

Restrictions for subsequent transfers of shares of Indian companies between residents and non-residents (other than OCBs) were relaxed significantly as of October 2004. As a result, for a transfer between a resident and a non-resident of securities of an Indian company, no prior approval of either the RBI or the Government of India is required, as long as certain conditions are met.

### **ADS guidelines**

Shares of Indian companies represented by ADSs may be approved for issuance to foreign investors by the Government of India under the Issue of Foreign Currency Convertible Bonds and Ordinary Shares (Through Depositary Receipt Mechanism) Scheme, 1993 (the 1993 Scheme ), as modified from time to time, promulgated by the Government of India. The 1993 Scheme is in addition but without prejudice to the other policies or facilities, as described below, relating to investments in Indian companies by foreign investors. The issuance of ADSs pursuant to the 1993 Scheme also affords to holders of the ADSs the benefits of Section 115AC of the Income Tax Act, 1961 for purpose of the application of Indian tax laws. In March 2001, the RBI issued a notification permitting, subject to certain conditions, two-way fungibility of ADSs. This notification provides that ADSs converted into Indian shares can be converted back into ADSs, subject to compliance with certain requirements and the limits of sectoral caps.

The Ministry of Finance, Government of India, has enacted The Depository Receipts Scheme, 2014 (the Depository Receipts Scheme ) effective as of December 15, 2014. In order to facilitate the issuance of depository receipts by Indian companies outside India, the Depository Receipts Scheme repeals the former provisions dealing with depository receipts in the Foreign Currency Convertible Bonds and Ordinary Shares (Through Depository Receipt Mechanism) Scheme, 1993. The Depository Receipts Scheme now governs the issue or transfer of permissible securities to a foreign depository by eligible persons and defines the rights and duties of a foreign depository and obligations of a domestic custodian. While the Depository Receipts Scheme has not been fully implemented yet, below is a brief summary of some of the key provisions.

There are certain relaxations provided under the Depository Receipts Scheme subject to prior approval of the Ministry of Finance. For example, a registered broker is permitted to purchase shares of an Indian company on behalf of a person resident outside of India for the purpose of converting those shares into ADSs. However, such conversion is subject to compliance with the provisions of the Depository Receipts Scheme and the periodic guidelines issued by the regulatory authorities. Therefore depository receipts converted into Indian shares may be converted back into depository receipts, subject to certain limits of sectorial caps.

## **Table of Contents**

Under the Depository Receipts Scheme, a foreign depository may take instructions from depository receipts holders to exercise the voting rights with respect to the underlying equity securities. Additionally, a domestic custodian has been defined to include a custodian of securities, an Indian depository, a depository participant or a bank having permission from SEBI to provide services as custodian. Further, the Depository Receipts Scheme provides that the aggregate of permissible securities which may be issued or transferred to foreign depositories for issue of depository receipts, along with permissible securities already held by persons resident outside India, shall not exceed the limit on foreign holding of such permissible securities under the Foreign Exchange Management Act, 1999.

The Department of Economic Affairs, Ministry of Finance made amendments to certain provisions of the Securities Contracts (Regulation) Rules, 1957 vide Securities Contracts (Regulation) (Amendment) Rules, 2015, on February 25, 2015. An amended definition of public shareholding has introduced to define equity shares of the Company held by the public to include shares underlying depository receipts if the holder of such depository receipts has the right to issue voting instruction and such depository receipts are listed on an international stock exchange in accordance with the Depository Receipts Scheme. The final regulations regarding the implementation of these amendments to Clause 35 and 40A of the Listing Agreement with Indian stock exchanges have not yet been released.

## **Fungibility of ADSs**

A registered broker in India can purchase shares of an Indian company that issued ADSs, on behalf of a person residing outside India, for the purposes of converting the shares into ADSs.

The Depository Receipts Scheme states that the aggregate of permissible securities which may be issued or transferred to foreign depositories for issue of depository receipts, along with permissible securities already held by persons resident outside India, shall not exceed the limit on foreign holding of such permissible securities under the Foreign Exchange Management Act, 1999. However, the Depository Receipts Scheme has not yet been fully implemented.

## **Transfer of ADSs**

A person resident outside India may transfer ADSs held in an Indian company to another person resident outside India without any permission. A person resident in India is not permitted to hold ADSs of an Indian company, except in connection with the exercise of stock options.

Shareholders resident outside India who intend to sell or otherwise transfer equity shares within India should seek the advice of Indian counsel to understand the requirements applicable at that time.

The RBI placed various restrictions on the eligibility of OCBs to make investments in Indian companies in AP (DIR) Series Circular No. 14 dated September 16, 2003. For further information on these restrictions, the circular is available on [www.rbi.org.in](http://www.rbi.org.in) for review.

## **10.E. Taxation**

### **Indian Taxation**

*General.* The following summary is based on the law and practice of the Income-tax Act, 1961 (the Income-tax Act), including the special tax regime contained in Sections 115AC and 115ACA of the Income-tax Act read with the Issue of Foreign Currency Convertible Bonds and Ordinary Shares (through Depository Receipt Mechanism) Scheme, 1993 (collectively, the Income-tax Act Scheme), as amended on January 19, 2000. The Income-tax Act is amended every year by the Finance Act of the relevant year. Some or all of the tax consequences of Sections 115AC and 115ACA

may be amended or changed by future amendments to the Income-tax Act.

We believe this information is materially complete as of the date hereof. However, this summary is not intended to constitute an authoritative analysis of the individual tax consequences to non-resident holders or employees under Indian law for the acquisition, ownership and sale of ADSs and equity shares.

**EACH PROSPECTIVE INVESTOR SHOULD CONSULT TAX ADVISORS WITH RESPECT TO TAXATION IN INDIA OR THEIR RESPECTIVE LOCATIONS ON ACQUISITION, OWNERSHIP OR DISPOSING OF EQUITY SHARES OR ADSS.**

---

**Table of Contents**

*Residence.* For purposes of the Income-tax Act, an individual is considered to be a resident of India during any fiscal year (i.e., April 1 to March 31) if he or she is in India in that year for:

a period or periods of at least 182 days; or

at least 60 days and, within the four preceding fiscal years has been in India for a period or periods amounting to at least 365 days.

The period of 60 days referred to above shall be 182 days in case of a citizen of India or a Person of Indian Origin living outside India for the purpose of employment outside India who is visiting India.

A company is a resident of India under the Income-tax Act if it is formed or registered in India or the control and the management of its affairs is situated wholly in India. Individuals and companies that are not residents of India would be treated as non-residents for purposes of the Income-tax Act.

*Taxation of Distributions.*

- a) As per Section 10(34) of the Income-tax Act, dividends paid by Indian companies to their shareholders are not subject to tax in the hands of the shareholders, except as discussed in paragraph (b) below. For periods prior to March 31, 2013, Indian companies were liable to pay a dividend distribution tax ( DDT ) at the rate of 16.22%, inclusive of applicable surcharges and a special levy called the Education and Higher Education Cess (hereinafter, the education cess ). Effective April 1, 2013, the Finance Act, 2013 increased the surcharge on the DDT from 5% to 10%, which resulted in an increase in the effective rate of DDT from 16.22% to 16.995%. The Finance Act (No 2) 2014 amended section 115-O, which requires grossing up of the dividend amount distributed for purposes of computing DDT. Pursuant to the amendment, effective October 1, 2014, the effective rate of DDT increased from 16.995% to 19.994%, inclusive of surcharge and cess, and as a result, dividend amounts receivable by our shareholders after taxes are reduced. Furthermore, as a result of the increase in rate of surcharge in the Finance Act, 2015, effective April 1, 2015, the effective rate of DDT has further increased from 19.994% to 20.3576%.
- b) Dividends received by resident individuals, HUFs or firms exceeding Rs.1,000,000 are taxable at a 10% rate. This tax will not be withheld by the company paying the dividend and has to be paid by the shareholder receiving such dividend.
- c) Any distributions of additional ADSs or equity shares by way of bonus shares (i.e., stock dividends) to resident or non- resident holders will not be subject to Indian tax.

*Taxation of Capital Gains.* The following is a brief summary of capital gains taxation of non-resident holders and resident employees relating to the sale of ADSs and equity shares received upon redemption of ADSs. The relevant provisions are contained mainly in sections 10(36), 10(38), 45, 47(viia), 111A, 115AC and 115ACA, of the Income-tax Act, in conjunction with the Income- tax Scheme. *You should consult your own tax advisor concerning the tax consequences of your particular situation.*

A non-resident investor transferring our ADS or equity shares, outside India to a non-resident investor, will not be liable for income taxes arising from capital gains on such ADS or equity shares under the provisions of the Income-tax Act in certain circumstances. Equity shares (including equity shares issuable on the conversion of the ADSs) held by the non-resident investor for a period of more than 12 months are treated as long-term capital assets. If the equity shares are held for a period of less than 12 months from the date of conversion of the ADSs, the capital gains arising on the sale thereof is to be treated as short-term capital gains.

Capital gains are taxed as follows:

gains from a sale of ADSs outside India by a non-resident to another non-resident are not taxable in India;

long-term capital gains realized by a resident and an employee from the transfer of the ADSs will be subject to tax at the rate of 10%, plus the applicable surcharge and education cess; short-term capital gains on such a transfer will be taxed at graduated rates with a maximum of 30%, plus the applicable surcharge and education cess;

long-term capital gains realized by a non-resident upon the sale of equity shares obtained from the conversion of ADSs are subject to tax at a rate of 10%, excluding the applicable surcharge and education cess; and short-term capital gains on such a transfer will be taxed at the rate of tax applicable to the seller; and

**Table of Contents**

long-term capital gain realized by a non-resident upon the sale of equity shares obtained from the conversion of ADSs is exempt from tax and any short term capital gain is taxed at 15%, excluding the applicable surcharge and education cess, if the sale of such equity shares is settled on a recognized stock exchange and securities transaction tax ( STT ) is paid on such sale.

As per the Finance Act, 2015, the rate of surcharge for Indian companies having total taxable income exceeding Rs.10,000,000 but not exceeding Rs.100,000,000 is 7% and in the case of Indian companies whose total taxable income is greater than Rs.100,000,000, the applicable surcharge is 12%. For foreign companies, the rate of surcharge is 2% if the total taxable income exceeds Rs.10,000,000 but does not exceed Rs.100,000,000 and it is 5% if the total taxable income of the foreign company exceeds Rs.100,000,000.

The Finance Act, 2016 has increased the surcharge for individuals having income exceeding Rs.10,000,000 from 12% to 15%.

All assesseees, including individuals, whose advance tax payable is Rs.10,000 or more during the year are required to pay advance tax in four installments as follows:

<b>Due Date of Installment</b>	<b>Amount Payable</b>
On or before June 15	Not less than 15% of such advance tax.
On or before September 15	Not less than 45% of such advance tax, as reduced by the amounts (if any) paid in earlier installments.
On or before December 15	Not less than 75% of such advance tax, as reduced by the amounts (if any) paid in earlier installments.
On or before March 15	The whole amount of such advance tax, as reduced by the amounts (if any) paid in earlier installments.

As per Section 10(38) of the Income-tax Act, long term capital gains arising from the transfer of equity shares on or after October 1, 2004 in a company completed through a recognized stock exchange in India and on which sale the STT has been paid are exempt from Indian tax.

As per Section 111A of the Income-tax Act, short term capital gains arising from the transfer of equity shares on or after October 1, 2004 in a company completed through a recognized stock exchange in India are subject to tax at a rate of 15%, plus applicable surcharge and education cess.

As per the Finance Act, 2004, as modified by the Finance Act, 2008 and the Finance Act, 2013, in a sale and purchase of securities entered into through a recognized stock exchange, a Securities Transaction Tax ( STT ) may be imposed upon one or both of the parties as follows:

With respect to a sale and purchase of equity shares (i) both the buyer and seller are required to pay a STT at the rate of 0.1% of the transaction value of the securities, if the transaction is a delivery based transaction (i.e., the transaction involves actual delivery or transfer of shares); or (ii) the seller of the shares is required to pay a STT at the rate of 0.025% of the transaction value of the securities, if the transaction is a non-delivery based transaction (i.e., the transaction is settled without taking delivery of the shares).

With respect to a sale and purchase of an option with respect to securities (i) upon the sale of the option, the seller is required to pay a STT at the rate of 0.05% of the option premium; and (ii) upon exercise of the option, the buyer is required to pay a STT at the rate of 0.125% of the settlement price.

With respect to a sale and purchase of futures with respect to securities, the seller is required to pay a STT at the rate of 0.01% of the transaction value.

The applicable provisions of the Income Tax Act, in the case of non-residents, may offset the above taxes, except the STT. The capital gains tax is computed by applying the appropriate tax rates to the difference between the sale price and the purchase price of the equity shares or ADSs. Under the Income-tax Scheme, the purchase price of equity shares in an Indian listed company received in exchange for ADSs will be the market price of the underlying shares on the date that the Depository gives notice to the custodian of the delivery of the equity shares in exchange for the corresponding ADSs, or the stepped up basis purchase price. The market price will be the price of the equity shares prevailing on the Stock Exchange, Mumbai or the National Stock Exchange. There is no corresponding provision under the Income-tax Act in relation to the stepped up basis for the purchase price of equity shares. However, the tax department in India has not denied this benefit. In the event that the tax department denies this benefit, the original purchase price of ADSs would be considered the purchase price for computing the capital gains tax.



---

**Table of Contents**

According to the Income-tax Scheme, a non-resident holder's holding period for the purposes of determining the applicable Indian capital gains tax rate relating to equity shares received in exchange for ADSs commences on the date of the notice of the redemption by the Depository to the custodian. However, the Income-tax Scheme does not address this issue in the case of resident employees, and it is therefore unclear as to when the holding period for the purposes of determining capital gains tax commences for such a resident employee.

It is unclear as to whether section 115AC of the Income Tax Act and the rest of the Income-tax Scheme are applicable to a non-resident who acquires equity shares outside India from a non-resident holder of equity shares after receipt of the equity shares upon redemption of the ADSs.

It is unclear as to whether capital gains derived from the sale of subscription rights or other rights by a non-resident holder not entitled to an exemption under a tax treaty will be subject to Indian capital gains tax. If such subscription rights or other rights are deemed by the Indian tax authorities to be situated within India, the gains realized on the sale of such subscription rights or other rights will be subject to Indian taxation. The capital gains realized on the sale of such subscription rights or other rights, which will generally be in the nature of short-term capital gains, will be subject to tax (i) at variable rates with a maximum rate of 40%, excluding the prevailing surcharge and education cess, in the case of a foreign company and (ii) at the rate of 30% excluding the prevailing surcharge and education cess in the case of resident employees.

*Withholding Tax on Capital Gains.* Any gain realized by a non-resident or resident employee on the sale of equity shares is subject to Indian capital gains tax, which, in the case of a non-resident is to be withheld at the source by the buyer. However, as per the provisions of Section 196D(2) of the Income-tax Act, no withholding tax is required to be deducted from any income by way of capital gains arising to FIIs (as defined in Section 115AD of the Act) on the transfer of securities (as defined in Section 115AD of the Act).

*Buy-back of Securities.* Indian companies are not subject to any tax on the buy-back of their shares. However, the shareholders are taxed on any resulting gains. We are required to deduct tax at the source according to the capital gains tax liability of a non-resident shareholder. Furthermore, in the case of a buy-back of unlisted securities as per section 115QA of the Finance Act 2013, unlisted domestic companies are subject to tax on the buy-back of their securities. However, section 10(34A) of the Finance Act 2013 exempts shareholders from the gain, if any, arising from such transaction.

*Stamp Duty and Transfer Tax.* Upon issuance of the equity shares underlying our ADSs, we are required to pay a stamp duty of Rs.0.3 per share certificate evidencing such underlying equity shares. A transfer of ADSs is not subject to Indian stamp duty. A sale of equity shares in physical form by a non-resident holder is also subject to Indian stamp duty at the rate of 0.25% of the market value of the equity shares on the trade date, although customarily such duty is borne by the transferee. Shares must be traded in dematerialized form. The issuance or transfer of shares in dematerialized form is currently not subject to stamp duty.

*Wealth Tax:* Wealth Tax has been abolished with effect from April 1, 2015.

*Gift Tax and Estate Duty.* Currently, there are no gift taxes or estate duties. These taxes and duties could be restored in future. Non-resident holders are advised to consult their own tax advisors regarding this issue.

*Service Tax.* Brokerage fees or commissions paid to stockbrokers in connection with the sale or purchase of shares is subject to a service tax of 12.36%. The stockbroker is responsible for collecting the service tax from the shareholder and paying it to the relevant authority. Effective June 1, 2015, the Finance Act 2015 increased the rate of service tax from 12.36% (inclusive of surcharge and cess) to a consolidated rate of 14%. Furthermore, effective November 2015,

the service tax of 14% was increased by an additional 0.5% cess called the Swatch Bharat Cess to a consolidated rate of 14.50%. Effective June 1, 2016, the Finance Act 2016 further increased the service tax rate to 15% through introduction of another 0.5% cess called the Krishi Kalyan Cess .

### **United States Federal Taxation**

The following is a summary of the material U.S. federal income and estate tax consequences that may be relevant with respect to the acquisition, ownership and disposition of equity shares or ADSs and is for general information only. This summary addresses the U.S. federal income and estate tax considerations of holders that are U.S. holders. U.S. holders are beneficial holders of equity shares or ADSs who are (i) citizens or residents of the United States, (ii) corporations (or other entities treated as corporations for U.S. federal tax purposes) created in or organized in the United States or under the laws of the United States or any state thereof or any political subdivision thereof or therein, (iii) estates, the income of which is

---

**Table of Contents**

subject to U.S. federal income taxation regardless of its source, and (iv) trusts having a valid election to be treated as U.S. persons in effect under U.S. Treasury Regulations or for which a U.S. court exercises primary supervision and a U.S. person has the authority to control all substantial decisions.

This summary is limited to U.S. holders who will hold equity shares or ADSs as capital assets (generally, property held for investment). In addition, this summary is limited to U.S. holders who are not residents in India for purposes of the Convention between the Government of the United States of America and the Government of the Republic of India for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion With Respect to Taxes on Income. If a partnership, including any entity treated as a partnership for U.S. federal income tax purposes, holds the equity shares or ADSs, the tax treatment of a partner will generally depend upon the status of the partner and upon the activities of the partnership. A partner in a partnership holding equity shares or ADSs should consult his, her or its own tax advisor regarding the tax treatment of an investment in the equity shares or ADSs.

This summary does not address tax considerations applicable to holders that may be subject to special tax rules, such as banks, insurance companies, certain financial institutions, regulated investment companies, real estate investment trusts, broker dealers, traders in securities that elect to use the mark to-market method of accounting, United States expatriates, persons liable for alternative minimum tax, persons holding ADSs or equity shares through partnerships or other pass-through entities, persons that have a functional currency other than the U.S. dollars, tax-exempt entities, persons that will hold equity shares or ADSs as a position in a straddle or as part of a hedging or conversion transaction for tax purposes or holders of 10% or more, by voting power or value, of our shares. This summary is based on the U.S. Internal Revenue Code of 1986, as amended and as in effect on the date of this Annual Report on Form 20-F and on United States Treasury Regulations in effect or, in some cases, proposed, as of the date of this Annual Report on Form 20-F, as well as judicial and administrative interpretations thereof available on or before such date, and is based in part on the assumption that each obligation in the deposit agreement and any related agreement will be performed in accordance with its terms. All of the foregoing is subject to change, which change could apply retroactively, or the Internal Revenue Service may interpret existing authorities differently, any of which could affect the tax consequences described below. This summary does not address the U.S. federal tax laws other than income or estate tax, and does not address U.S. state or local or non-U.S. tax laws.

**EACH PROSPECTIVE INVESTOR SHOULD CONSULT HIS, HER OR ITS OWN TAX ADVISOR WITH RESPECT TO THE U.S. FEDERAL, STATE, LOCAL AND NON-U.S. TAX CONSEQUENCES OF ACQUIRING, OWNING OR DISPOSING OF EQUITY SHARES OR ADSS.**

*Ownership of ADSs.* For U.S. federal income tax purposes, holders of ADSs will generally be treated as the holders of equity shares represented by such ADSs. Accordingly, the conversion of ADSs into equity shares will not be subject to United States federal income tax.

*Dividends.* Subject to the passive foreign investment company rules described below, except for ADSs or equity shares, if any, distributed pro rata to all of our shareholders, including holders of ADSs, the gross amount of any distributions of cash or property with respect to ADSs or equity shares (before reduction for any Indian withholding taxes) will generally be included in income by a U.S. holder as foreign source dividend income at the time of receipt, which in the case of a U.S. holder of ADSs generally should be the date of receipt by the Depositary, to the extent such distributions are made from our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Such dividends will not be eligible for the dividends received deduction generally allowed to corporate U.S. holders in respect of dividends received from other United States corporations. To the extent, if any, that the amount of any distribution by us exceeds our current and accumulated earnings and profits (as determined under U.S. federal income tax principles) such excess will be treated first as a tax-free return of capital to the extent of the U.S. holder's tax basis in the equity shares or ADSs, and thereafter as capital gain.

With respect to certain non-corporate U.S. holders, subject to certain limitations, including certain limitations based on taxable income and filing status, qualifying dividends paid to non-corporate U.S. holders, including individuals, may be eligible for a reduced rate of taxation if we are deemed to be a qualified foreign corporation for United States federal income tax purposes and certain holding period requirements are met (including the requirement that the non-corporate U.S. holder holds the ADSs for more than 60 days during the 121-day period beginning 60 days before the ex-dividend date). A qualified foreign corporation includes a foreign corporation if (1) its shares (or, according to legislative history, its ADSs) are readily tradable on an established securities market in the United States or (2) it is eligible for the benefits under a comprehensive income tax treaty with the United States. In addition, a corporation is not a qualified foreign corporation if it is a passive foreign investment company (as discussed below) for either its taxable year in which the dividend is paid or the preceding taxable year. Our ADSs are traded on the New York Stock Exchange, an established securities market in the United States as identified by Internal Revenue Service guidance. Due to the absence of specific statutory provisions addressing ADSs, however, there can be no assurance that we are a qualified foreign corporation solely as a result of our listing on the New York Stock Exchange. Nonetheless, we may be eligible for benefits under the comprehensive income tax treaty between India and the United States.

---

**Table of Contents**

EACH U.S. HOLDER SHOULD CONSULT ITS OWNS TAX ADVISOR REGARDING THE TREATMENT OF DIVIDENDS AND SUCH HOLDER'S ELIGIBILITY FOR REDUCED RATE OF TAXATION UNDER THE LAW IN EFFECT FOR THE YEAR OF THE DIVIDEND.

Qualifying dividends will generally be taxed at a maximum income tax rate of 15% except for U.S. Holders who are subject to tax on their income at the income tax rate 39.6%. Qualifying dividends received by U.S. Holders whose income tax rate is 39.6% will be subject to tax at the rate of 20% on such qualifying dividends. Further, qualifying dividends received by U.S Holders whose income tax rate is 15% or lower will be subject to tax at the rate of 0% on such qualifying dividends. Each U.S. holder should consult its own tax advisor regarding the treatment of dividends and such holder's eligibility for a reduced rate of taxation.

Subject to certain conditions and limitations, any Indian withholding tax imposed upon distributions paid to a U.S. holder with respect to ADSs or equity shares may be eligible for credit against the U.S. holder's federal income tax liability. Alternatively, a U.S. holder may claim a deduction for such amount, but only for a year in which a U.S. holder does not claim a credit with respect to any foreign income taxes. The overall limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. For this purpose, distributions on ADSs or equity shares generally will be foreign source income, and will be passive category income or general category income for purposes of computing the United States foreign tax credit allowable to a U.S. holder. The rules governing the foreign tax credit are complex. You are urged to consult your tax advisors regarding the availability of the foreign tax credit under your particular circumstances.

If dividends are paid in Indian rupees, the amount of the dividend distribution included in the income of a U.S. holder will be in the U.S. dollar value of the payments made in Indian rupees, determined at a spot exchange rate between Indian rupees and U.S. dollars applicable to the date such dividend is included in the income of the U.S. holder, regardless of whether the payment is in fact converted into U.S. dollars. Generally, gain or loss, if any, resulting from currency exchange fluctuations during the period from the date the dividend is paid to the date such payment is converted into U.S. dollars will be treated as U.S. source ordinary income or loss. You are urged to consult your tax advisors regarding the taxation of currency gain or loss.

*Sale or exchange of equity shares or ADSs.* Subject to the passive foreign investment company rules described below, a U.S. holder generally will recognize gain or loss on the sale or exchange of equity shares or ADSs equal to the difference between the amount realized on such sale or exchange and the U.S. holder's adjusted tax basis in the equity shares or ADSs, as the case may be. Such gain or loss will be capital gain or loss, and will be long-term capital gain or loss if the equity shares or ADSs, as the case may be, were held for more than one year (currently long-term capital gains are taxed at maximum of 20%). Gain or loss, if any, recognized by a U.S. holder generally will be treated as U.S. source passive category income or loss for U.S. foreign tax credit purposes. In the case of capital losses, a U.S. holder is eligible to claim a capital loss deduction subject to significant limitations. If a U.S. holder is unable to claim these losses on its, his or her U.S. Federal Tax Return, the U.S. holder may be eligible to carryover the amount of the unused capital loss to future years, subject to additional limitations provided under U.S. tax regulations. Capital gains realized by a U.S. holder upon the sale of equity shares (but not ADSs) may be subject to certain tax in India. See Taxation-Indian Taxation-Taxation of Capital Gains. Due to limitations on foreign tax credits, however, a U.S. holder may not be able to utilize any such taxes as a credit against the U.S. holder's federal income tax liability.

*Estate taxes.* An individual U.S. holder who is a citizen or resident of the United States for U.S. federal estate tax purposes may have the value of the equity shares or ADSs held by such holder included in his or her gross estate for U.S. federal estate tax purposes. An individual holder who actually pays Indian estate tax with respect to the equity shares will, however, be entitled to credit the amount of such tax against his or her U.S. federal estate tax liability, subject to a number of conditions and limitations.

*Additional Tax on Investment Income.* U.S. holders that are individuals, estates or trusts and whose income exceeds certain thresholds will be subject to a 3.8% Medicare contribution tax on unearned income, including, among other things, dividends on, and capital gains from the sale or other taxable disposition of, equity shares or ADSs, subject to certain limitations and exceptions.

*Backup withholding tax and information reporting requirements.* Any dividends paid on, or proceeds from a sale of, equity shares or ADSs to or by a U.S. holder may be subject to U.S. information reporting, and a backup withholding tax

---

**Table of Contents**

(currently at a rate of 28%) may apply unless the holder establishes that he, she or it is an exempt recipient or provides a U.S. taxpayer identification number and certifies under penalty of perjury that such number is correct and that such holder is not subject to backup withholding and otherwise complies with any applicable backup withholding requirements. Any amount withheld under the backup withholding rules will be allowed as a refund or credit against the holder's U.S. federal income tax liability, provided that the required information is timely furnished to the Internal Revenue Service.

Certain U.S. holders are required to report information with respect to their investment in equity shares or ADSs not held through a custodial account with a U.S. financial institution on Internal Revenue Service Form 8938, which must be attached to the U.S. holder's annual income tax return. Investors who fail to report required information could become subject to substantial penalties. In addition, a U.S. holder should consider the possible obligation to file online a FinCEN Form 114 Foreign Bank and Financial Accounts Report as a result of holding ordinary shares or ADSs. Each U.S. holder should consult its tax advisor concerning its obligation to file new Internal Revenue Service Form 8938 and/or FinCEN Form 114.

*Passive foreign investment company.* A non-U.S. corporation will be classified as a passive foreign investment company for U.S. Federal income tax purposes if either:

75% or more of its gross income for the taxable year is passive income; or

on average for the taxable year, 50% or more of the total value of its assets produce or are held for the production of passive income

We do not believe that we satisfy either of the tests for passive foreign investment company status for the current fiscal year ended March 31, 2016. Because this determination is made on an annual basis and depends on a variety of factors (including the value of the ADS), no assurance can be given that we will not be considered a passive foreign investment company in future taxable years. If we were to be a passive foreign investment company for any taxable year, U.S. Holders would be required to:

pay an interest charge together with tax calculated at ordinary income rates on excess distributions, as the term is defined in relevant provisions of the U.S. tax laws, and on any gain on a sale or other disposition of ADSs or equity shares;

if an election is made to be a qualified electing fund (as the term is defined in relevant provisions of the U.S. tax laws), include in their taxable income their pro rata share of undistributed amounts of our income; or

if the equity shares are marketable and a mark-to-market election is made, to mark-to-market the equity shares each taxable year and recognize ordinary gain and, to the extent of prior ordinary gain, recognize ordinary loss for the increase or decrease in market value for such taxable year.

If we are treated as a passive foreign investment company, we do not plan to provide information necessary for the U.S. Holder to make a qualified electing fund election.

In addition, certain information reporting obligations (i.e., filing Internal Revenue Service Form 8621) may apply to U.S Holders if we are determined to be a passive foreign investment company.

THE ABOVE SUMMARY IS NOT INTENDED TO CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSEQUENCES RELATING TO THE OWNERSHIP OF EQUITY SHARES OR ADSS. YOU SHOULD CONSULT YOUR OWN TAX ADVISOR CONCERNING THE TAX CONSEQUENCES TO YOU BASED ON YOUR PARTICULAR SITUATION.

**10.F. *Dividends and paying agents***

Not applicable.

**10.G. *Statements by experts***

Not applicable.



**Table of Contents**

**10.H. Documents on display**

This report and other information filed or to be filed by us can be inspected and copied at the public reference facilities maintained by the SEC at Room 1200, 450 Fifth Street, Washington, DC, U.S.A. These reports and other information may also be accessed via the SEC's website at [www.sec.gov](http://www.sec.gov).

Additionally, documents referred to in this Form 20-F may be inspected at our corporate office, which is located at 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India

**10.I. Subsidiary information**

Not applicable.

**Table of Contents****ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Market risk is the risk of loss of future earnings or fair values or future cash flows that may result from a change in the price of a financial instrument. The value of a financial instrument may change as a result of changes in the interest rates, foreign currency exchange rates and other market changes that affect market risk sensitive instruments. Market risk is attributable to all market risk sensitive financial instruments including foreign currency receivables and payables and long term debt. We are exposed to market risk primarily related to foreign exchange rate risk, interest rate risk and the market value of our investments. Thus, our exposure to market risk is a function of investing and borrowing activities and revenue generating and operating activities in foreign currency. The objective of market risk management is to avoid excessive exposure in our foreign currency revenues and costs.

Our Board of Directors and its Audit Committee are responsible for overseeing our risk assessment and management policies. Our major market risks of foreign exchange, interest rate and counter-party risk are managed centrally by our group treasury department, which evaluates and exercises independent control over the entire process of market risk management.

We have a written treasury policy, and we do regular reconciliations of our positions with our counter-parties. In addition, internal audits of the treasury function are performed at regular intervals.

**Components of Market Risk*****Foreign Exchange Rate Risk***

Our foreign exchange risk arises from our foreign operations, foreign currency revenues and expenses (primarily in U.S. dollars, Russian roubles, Venezuelan bolivars, British pound sterling and Euros) and foreign currency borrowings in U.S. dollars, Russian roubles and Euros. A significant portion of our revenues are in these foreign currencies, while a significant portion of our costs are in Indian rupees. As a result, if the value of the Indian rupee appreciates relative to these foreign currencies, our revenues measured in Indian rupees may decrease. The exchange rate between the Indian rupee and these foreign currencies has changed substantially in recent periods and may continue to fluctuate substantially in the future. Consequently, we use both derivative and non-derivative financial instruments, such as foreign exchange forward contracts, option contracts, currency swap contracts and foreign currency financial liabilities, to mitigate the risk of changes in foreign currency exchange rates in respect of our highly probable forecasted transactions and recognized assets and liabilities. We do not use derivative financial instruments for trading or speculative purposes.

We had the following derivative financial instruments to hedge the foreign exchange rate risk as of March 31, 2016:

Category	Instrument	Currency	Cross Currency	Amounts in millions	Buy/Sell
Hedges of recognized assets and liabilities	Forward contract	U.S.\$	INR	U.S.\$ 97.0	Sell
	Forward contract	U.S.\$	RON	U.S.\$ 8.0	Buy
	Forward contract	U.S.\$	RUB	U.S.\$ 15.0	Buy
	Forward contract	EUR	U.S.\$	EUR 35.5	Sell
	Option contract	U.S.\$	INR	U.S.\$ 100.0	Sell

Hedges of highly probable forecasted transactions	Forward contract	RUB	INR	RUB 600.0	Sell
	Option contract	EUR	INR	EUR 6.0	Sell
	Option contract	U.S.\$	INR	U.S.\$ 235.0	Sell

*Sensitivity Analysis of Exchange Rate Risk.*

In respect of our forward, option and currency swap contracts, a 10% decrease/increase in the respective exchange rates of each of the currencies underlying such contracts would have resulted in an approximately Rs.1,511/(424) million increase/(decrease) in our hedging reserve and an approximately Rs.1,277/(1,707) million increase/(decrease) in our net profit as at March 31, 2016.

For a detailed analysis of our foreign exchange rate risk, please refer to Notes 30 and 31 in our consolidated financial statements.

**Table of Contents*****Commodity Rate Risk***

Our exposure to market risk with respect to commodity prices primarily arises from the fact that we are a purchaser and seller of active pharmaceutical ingredients and the components for such active pharmaceutical ingredients. These are commodity products whose prices can fluctuate sharply over short periods of time. The prices of our raw materials generally fluctuate in line with commodity cycles, though the prices of raw materials used in our active pharmaceutical ingredients business are generally more volatile. Raw material expense forms the largest portion of our operating expenses. We evaluate and manage our commodity price risk exposure through our operating procedures and sourcing policies. We have not entered into any material derivative contracts to hedge our exposure to fluctuations in commodity prices.

***Interest Rate Risk***

As of March 31, 2016, we had foreign currency loans of Rs.29,552 million carrying a floating interest rate. These loans expose us to risks of changes in interest rates. Our treasury department monitors the interest rate movement and manages the interest rate risk based on its policies, which include entering into interest rate swaps as considered necessary.

***Interest Rate Profile.***

The interest rate profile of our short term borrowings from banks is as follows:

	As at March 31,			
	Currency	2016 Interest Rate	Currency	2015 Interest Rate
Packing credit borrowings	USD	LIBOR + (5) to 15 bps	USD	LIBOR + 10 to 40 bps
	EURO	LIBOR + 5 to 7.5 bps	EURO	LIBOR + 7.5 to 20 bps
	RUB	10.65% to 11.57%	RUB	9.80% to 22.30%
Other foreign currency borrowings	USD	LIBOR + 40 bps		
Other rupee borrowings			INR	10%

The interest rate profile of our long-term loans and borrowings is as follows:

	As at March 31,			
	Currency	2016 Interest Rate	Currency	2015 Interest Rate
Foreign currency borrowings	USD	LIBOR + 125 bps	USD	LIBOR+100 to 125 bps
			GBP	LIBOR+130 bps

***Maturity profile.***

The aggregate maturities of interest-bearing long term loans and borrowings, based on contractual maturities, as of March 31, 2016 are as follows:

**Maturing in the year ending**

<b>March 31,</b>	<b>Foreign currency obligations under finance</b>		
	<b>loan</b>	<b>leases</b>	<b>Total</b>
2017	Rs. 110	Rs. 110	Rs. 110
2018	1,988	101	2,089
2019	7,950	59	8,009
2020		54	54
2021		58	58
Thereafter		475	475
	<b>Rs. 9,938</b>	<b>Rs. 857</b>	<b>Rs. 10,795</b>

Counter-party risk encompasses settlement risk on derivative contracts and credit risk on cash and term deposits (i.e., certificates of deposit). Exposure to these risks is closely monitored and kept within predetermined parameters. Our group treasury department does not expect any losses from non-performance by these counter-parties.

**Table of Contents****ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES****A. Debt Securities.**

Not applicable.

**B. Warrants and Rights.**

Not applicable.

**C. Other Securities.**

Not applicable.

**D. American Depositary Shares.*****Fees and Charges for Holders of American Depositary Shares***

J.P. Morgan Chase Bank, N.A., as the depository for our ADSs (the Depository), collects fees for the issuance and cancellation of ADSs from the holders of our ADSs, or intermediaries acting on their behalf, against the deposit or withdrawal of ordinary shares in the custodian account. The Depository also collects the following fees from holders of ADRs or intermediaries acting in their behalf:

**Category (as defined by**

<b>SEC)</b>	<b>Depository actions</b>	<b>Associated Fee</b>
(a) Depositing or substituting the underlying shares	Issuing ADSs upon deposits of shares, including deposits and issuances in respect of share distributions, stock splits, rights, mergers, exchanges of securities or any other transaction or event or other distribution affecting the ADSs or the deposited shares.	U.S.\$5.00 for each 100 ADSs (or portion thereof) evidenced by the new shares deposited.
(b) Receiving or distributing dividends	Distribution of dividends.	U.S.\$0.02 or less per ADS (U.S.\$2.00 per 100 ADSs).
(c) Selling or exercising rights	Distribution or sale of securities.	U.S.\$5.00 for each 100 ADSs (or portion thereof), the fee being in an amount equal to the fee for the execution and delivery of ADSs which would have been charged as a result of the deposit of such securities.
(d) Withdrawing an underlying security	Acceptance of ADSs surrendered for withdrawal of deposited shares.	U.S.\$5.00 for each 100 ADSs (or portion thereof) evidenced by the shares withdrawn.
		U.S.\$1.50 per ADS.

(e) Transferring, splitting or grouping receipts	Transfers, combining or grouping of depositary receipts.	
(f) General depositary services, particularly those charged on an annual basis.	Other services performed by the depositary in administering the ADSs.	U.S.\$0.02 per ADS (or portion thereof) not more than once each calendar year.
(g) Other	Expenses incurred on behalf of holders in connection with:	The amount of such expenses incurred by the Depositary.
	<p>compliance with foreign exchange control regulations or any law or regulation relating to foreign investment;</p>	
	<p>the depositary or its custodian's compliance with applicable law, rule or regulation;</p>	
	<p>stock transfer or other taxes and other governmental charges;</p>	
	<p>cable, telex, facsimile transmission/delivery;</p>	
	<p>expenses of the depositary in connection with the conversion of foreign currency into U.S. dollars (which are paid out of such foreign currency); or</p>	
	<p>any other charge payable by depositary or its agents.</p>	

**Table of Contents**

As provided in the Deposit Agreement, the Depositary may charge fees for making cash and other distributions to holders by deduction from distributable amounts or by selling a portion of the distributable property. The Depositary may generally refuse to provide services until its fees for those services are paid.

***Fees paid by Depositary*****Direct Payments**

The Depositary has agreed to reimburse certain reasonable expenses related to our ADS program and incurred by us in connection with the program. In the year ended March 31, 2016, the Depositary reimbursed us for U.S.\$1,006,633.83 towards such expenses (inclusive of withholding tax of an amount of U.S.\$2,290.15). The amounts the Depositary reimburses are not related to the fees collected by the Depositary from ADS holders. Under certain circumstances, including termination of our ADS program prior to May 11, 2022, we are required to repay to the Depositary amounts reimbursed in prior periods. The table below sets forth the types of expenses that the Depositary has agreed to reimburse us for and the amounts reimbursed during the fiscal year ended March 31, 2016.

Category of expenses	Amount reimbursed during the year ended March 31, 2016
Legal and accounting fees incurred in connection with preparation of Form 20-F and ongoing SEC compliance and listing requirements	U.S.\$ 1,006,633.83
Listing fees	
Investor relations	
Advertising and public relations	
Broker reimbursements	

**Indirect Payments**

As part of its service to us, the Depositary has agreed to waive fees for the standard costs associated with the administration of our ADS program, associated operating expenses and investor relations advice. The Depositary has not paid any expenses on our behalf.



**Table of Contents**

**PART II**

**ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES**

None.

**ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS**

**Modification in the rights of security holders**

None.

**Use of Proceeds**

Not applicable.

**Table of Contents**

**ITEM 15. CONTROLS AND PROCEDURES**

*(a) Disclosure Controls and Procedures*

As of the end of the period covered by this Annual Report on Form 20-F, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act).

Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective, as of March 31, 2016, to provide reasonable assurance that the information required to be disclosed in filings and submissions under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified by the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions about required disclosure.

*(b) Management's Annual Report on Internal Control Over Financial Reporting*

Our management is responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of internal control over financial reporting. As defined by the SEC, internal control over financial reporting is a process designed under the supervision of our principal executive and principal financial officers, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board.

Our internal control over financial reporting is supported by written policies and procedures, that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Our management conducted an assessment of the effectiveness of our internal control over financial reporting as of March 31, 2016 based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO Framework). Based on this assessment, our management has concluded that our internal control over financial reporting was effective as of March 31, 2016.

The effectiveness of our internal control over financial reporting as of March 31, 2016 has been audited by KPMG, the independent registered public accounting firm that audited our financial statements, as stated in their report, a copy of which is included in this annual report on Form 20-F.

/s/ G.V. Prasad  
Co-Chairman and Chief Executive Officer

/s/ Saumen Chakraborty  
President and Chief Financial Officer

137

**Table of Contents**

(c) *Attestation Report of the Registered Public Accounting Firm.*

**Report of Independent Registered Public Accounting Firm**

The Board of Directors and Shareholders

Dr. Reddy s Laboratories Limited:

We have audited Dr. Reddy s Laboratories Limited s ( the Company ) internal control over financial reporting as of March 31, 2016, based on criteria, established in *Internal Control Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS). A company s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of March 31, 2016, based on criteria established in *Internal Control Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated statement of financial position of Dr. Reddy s Laboratories Limited and subsidiaries as of March 31, 2016 and 2015, and the related consolidated income statement, statements of comprehensive income, changes in equity and cash flows for each of the years in the three-year period ended March 31, 2016, and our report

dated June 23, 2016 expressed an unqualified opinion on those consolidated financial statements.

KPMG

Hyderabad, India

June 23, 2016

**Table of Contents***(d) Changes in internal control over financial reporting*

There were no changes to our internal control over financial reporting that occurred during the period covered by this Form 20-F that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**ITEM 16. [RESERVED]****ITEM 16.A. AUDIT COMMITTEE FINANCIAL EXPERT**

The Audit Committee of our Board of Directors is entirely composed of independent directors and brings in expertise in the fields of finance, economics, human resource development, strategy and management. Please see Item 6. Directors, Senior Management and Employees for the experience and qualifications of the members of the Audit Committee of our Board of Directors. Our Board of Directors has determined that Mr. Sridar Iyengar is an audit committee financial expert, as defined in Item 401(h) of Regulation S-K, and is independent pursuant to applicable NYSE rules.

**ITEM 16.B. CODE OF ETHICS**

We have adopted a Code of Business Conduct and Ethics (the CoBE), which applies to all of the Directors and all of the employees of our company and its subsidiaries and affiliates. The CoBE is available on our corporate website at <http://www.drreddys.com/investors/cobe.html>. The CoBE has provisions for employees and other stakeholders to raise concerns regarding possible violations of the CoBE to the Chief Compliance Officer or the Chief Ombudsperson. Further, our Ombudsperson Policy functions in coordination with the CoBE and includes certain anti-retaliation safeguards designed to protect persons who raise concerns in good faith.

**ITEM 16.C. PRINCIPAL ACCOUNTANT FEES AND SERVICES**

The following table sets forth for the years ended March 31, 2016 and 2015, the fees paid to our principal accountant and its associated entities for various services they provided us in these periods.

Type of Service	For the year ended March 31,		Description of Services
	2016	2015	
	(Rs. in millions)		
Audit fees	Rs. 78.49	Rs. 78.13	Audit and review of financial statements
Audit related fees	0.30	6.40	Due diligence and other related services
Tax fees	3.90	1.40	Tax returns filing and transfer pricing related services
All other fees	2.87	1.87	Statutory certifications and other matters.
<b>Total</b>	<b>Rs. 85.56</b>	<b>Rs. 87.80</b>	

In accordance with the requirement of the charter of the Audit Committee of our Board of Directors, we obtain the prior approval of the Audit Committee on every occasion we engage our principal accountants or their associated entities to provide us any non-audit services. We disclose to the Audit Committee of our Board of Directors the nature of services that are provided and the fees to be paid for the services. The fees listed in the above table as Tax fees and All other fees were approved by the Audit Committee of our Board of Directors.

**ITEM 16.D. EXEMPTION FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES**

We have not sought any exemption from the listing standards for audit committees applicable to us as a foreign private issuer.

**ITEM 16.E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS**

During the year ended March 31, 2016, there was no purchase made by or on behalf of us or any affiliated purchaser of shares of any class of our securities that are registered by us pursuant to Section 12 of the Exchange Act.

**ITEM 16.F. CHANGE IN REGISTRANT S CERTIFYING ACCOUNTANT**

None.

**Table of Contents**

**ITEM 16.G. CORPORATE GOVERNANCE**

Companies listed on the New York Stock Exchange ( NYSE ) must comply with certain standards regarding corporate governance as codified in Section 303A of the NYSE s Listed Company Manual. Listed companies that are foreign private issuers (as such term is defined in Rule 3b-4 under the Securities Exchange Act of 1934, as amended (the Exchange Act )) are permitted to follow home country practice in lieu of the provisions of Section 303A, except that such companies are required to comply with the requirements of Sections 303A.06, 303A.11 and 303A.12(b) and (c), which are as follows:

- (i) establish an independent audit committee that has specified responsibilities;
- (ii) provide prompt certification by its chief executive officer of any non-compliance with any corporate governance rules;
- (iii) provide periodic written affirmations to the NYSE with respect to its corporate governance practices; and
- (iv) provide a brief description of significant differences between its corporate governance practices and those followed by U.S. companies.

The following table compares our principal corporate governance practices to those required of U.S. NYSE listed companies.

**Standard for U.S. NYSE Listed Companies**

**Our practice**

<p>Listed companies must have a majority of independent directors, as defined by the NYSE.</p>	<p>We comply with this standard. Eight of our ten directors are independent directors, as defined by the NYSE.</p>
<p>The non-management directors of each listed company must meet at regularly scheduled executive sessions without management.</p>	<p>We comply with this standard. Our non-management directors meet periodically without management directors in scheduled executive sessions.</p>
<p>Listed companies must have a nominating/corporate governance committee composed entirely of independent directors. The nominating/corporate governance committee must have a written charter that is made available on the listed company s website and that addresses the committee purpose and responsibilities, subject to the minimum purpose and responsibilities established by the NYSE, and an annual evaluation of the committee.</p>	<p>We have a Nomination, Governance and Compensation Committee composed entirely of independent directors that meets these requirements. The committee has a written charter that meets these requirements. We have evaluated the performance of the Nomination, Governance and Compensation Committee.</p>
<p>Listed companies must have a compensation committee composed entirely of independent directors. The compensation committee must have a written charter that is</p>	<p>We have a Nomination, Governance and Compensation Committee composed entirely of independent directors that meets these requirements. The committee has a</p>



made available on the listed company's website and that addresses the committee's purpose and responsibilities, subject to the minimum purpose and responsibilities established by the NYSE, and an annual evaluation of the committee.

Listed companies must have an audit committee that satisfies the requirements of Rule 10A-3 under the Exchange Act. Our Audit Committee satisfies the requirements of Rule 10A-3 under the Exchange Act.

The audit committee must have a minimum of three members all being independent directors. The audit committee must have a written charter that is made available on the listed company's website and that addresses the committee's purpose and responsibilities, subject to the minimum purpose and responsibilities established by the NYSE, and an annual evaluation of the committee. We have an Audit Committee composed of four members, all being independent directors. The committee has a written charter that meets these requirements. We also have an internal audit function. We have evaluated the performance of our Audit Committee.

Each listed company must have an internal audit function. We have an internal audit function.

Shareholders must be given the opportunity to vote on all equity-compensation plans and material revisions thereto, with limited exceptions. We comply with this standard. Our Employee Stock Option Plans were approved by our shareholders.

Listed companies must adopt and disclose corporate governance guidelines. We have not adopted corporate governance guidelines.

**Table of Contents****Standard for U.S. NYSE Listed Companies****Our practice**

All listed companies, U.S. and foreign, must adopt and disclose a code of business conduct and ethics for directors, officers and employees that is made available on the listed company's website and, and promptly disclose any waivers of the code for directors or executive officers.

We comply with this standard. More details on our Code of Business Conduct and Ethics are given under Item 16.B.

Listed companies must solicit proxies for all meetings of shareholders.

We do not solicit proxies because we are prohibited from doing so under Section 105 of the Indian Companies Act, 2013. However, we give each of our shareholders written notices of all of our shareholder meetings.

Listed foreign private issuers must disclose any significant ways in which their corporate governance practices differ from those followed by domestic companies under NYSE listing standards.

This requirement is being addressed by way of this table.

Each listed company CEO must certify to the NYSE each year that he or she is not aware of any violation by the company of NYSE corporate governance listing standards, qualifying the certification to the extent necessary.

We do not have such a practice.

Each listed company CEO must promptly notify the NYSE in writing after any executive officer of the listed company becomes aware of any non-compliance with any applicable provisions of this Section 303A.

There have been no such instances.

Each listed company must submit an executed Written Affirmation annually to the NYSE. In addition, each listed company must submit an interim Written Affirmation each time that any of the following occurs:

We filed our most recent annual written affirmation, in the form specified by NYSE, on June 19, 2015.

an audit committee member who was deemed independent is no longer independent;

a member has been added to the audit committee;

the listed company or a member of its audit committee is eligible to rely on and is choosing to rely on a Securities Exchange Act Rule 10A-3 ( Rule 10A-3 ) exemption;

the listed company or a member of its audit committee is no longer eligible to rely on or is choosing to no longer rely on a previously applicable Rule 10A-3 exemption;

a member has been removed from the listed company's audit committee resulting in the company no longer having a Rule 10A-3 compliant audit committee; or

the listed company determined that it no longer qualifies as a foreign private issuer and will be considered a domestic company under Section 303A.

The annual and interim Written Affirmations must be in the form specified by the NYSE.

**ITEM 16.H. MINE SAFETY DISCLOSURE**

Not Applicable.

**Table of Contents**

**PART III**

**ITEM 17. FINANCIAL STATEMENTS**

Not applicable.

**ITEM 18. FINANCIAL STATEMENTS**

The following financial statement and auditor's report for the year ended March 31, 2016 are incorporated herein by reference and are included in this Item 18 of this report on Form 20-F:

<u>Report of Independent Registered Public Accounting Firm</u>	F - 1
<u>Consolidated statement of financial position as of March 31, 2016 and 2015</u>	F - 2
<u>Consolidated income statement for the years ended March 31, 2016, 2015 and 2014</u>	F - 4
<u>Consolidated statement of comprehensive income for the years ended March 31, 2016, 2015 and 2014</u>	F - 5
<u>Consolidated statement of changes in equity for the years ended March 31, 2016, 2015 and 2014</u>	F - 6
<u>Consolidated statement of cash flows for the years ended March 31, 2016, 2015 and 2014</u>	F - 9
<u>Notes to the consolidated financial statements</u>	F - 10

**Table of Contents**

**Report of Independent Registered Public Accounting Firm**

The Board of Directors and Shareholders

Dr. Reddy s Laboratories Limited:

We have audited the accompanying consolidated statement of financial position of Dr. Reddy s Laboratories Limited and subsidiaries ( the Company ) as of March 31, 2016 and 2015, and the related consolidated income statement, statements of comprehensive income, changes in equity, and cash flows for each of the years in the three-year period ended March 31, 2016. These consolidated financial statements are the responsibility of the Company s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of March 31, 2016, and 2015, and the results of their operations and their cash flows for each of the years in the three-year period ended March 31, 2016, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS).

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Dr. Reddy s Laboratories Limited s internal control over financial reporting as of March 31, 2016, based on criteria established in *Internal Control Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated June 23, 2016 expressed an unqualified opinion on the effectiveness of Dr. Reddy s Laboratories Limited s internal control over financial reporting.

KPMG

Hyderabad, India

June 23, 2016

F-1

Table of Contents**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****CONSOLIDATED STATEMENT OF FINANCIAL POSITION**

(in millions, except share and per share data)

Particulars	Note	As of			
		March 31, 2016 <i>Unaudited convenience translation into U.S.\$ (See Note 2(d))</i>	March 31, 2016	March 31, 2015	
<b>ASSETS</b>					
<b>Current assets</b>					
Cash and cash equivalents	15	U.S.\$ 74	Rs. 4,921	Rs. 5,394	
Other investments	11	529	35,034	34,259	
Trade and other receivables	13	623	41,306	40,755	
Inventories	12	386	25,578	25,529	
Derivative financial instruments	30	3	175	800	
Current tax assets		25	1,664	1,819	
Other current assets	14	166	11,010	11,282	
<b>Total current assets</b>		<b>U.S.\$ 1,807</b>	<b>Rs. 119,688</b>	<b>Rs. 119,838</b>	
<b>Non-current assets</b>					
Property, plant and equipment	7	U.S.\$ 815	Rs. 53,961	Rs. 48,090	
Goodwill	8	58	3,848	3,380	
Other intangible assets	9	314	20,796	13,050	
Investment in equity accounted investees	10	20	1,309	1,033	
Other investments non-current	11	30	1,988	2,817	
Deferred tax assets	27	75	4,997	5,792	
Other non-current assets	14	16	1,063	762	
<b>Total non-current assets</b>		<b>U.S.\$ 1,328</b>	<b>Rs. 87,962</b>	<b>Rs. 74,924</b>	
<b>Total assets</b>		<b>U.S.\$ 3,134</b>	<b>Rs. 207,650</b>	<b>Rs. 194,762</b>	
<b>LIABILITIES AND EQUITY</b>					
<b>Current liabilities</b>					
Trade and other payables	22	U.S.\$ 186	Rs. 12,300	Rs. 10,660	
Derivative financial instruments	30	2	108	462	
Current tax liabilities		39	2,581	2,506	
Short-term borrowings	18	343	22,718	21,857	
Long-term borrowings, current portion	18	2	110	6,962	

Edgar Filing: DR REDDYS LABORATORIES LTD - Form 20-F

Provisions	21	72	4,759	4,231
Other current liabilities	23	333	22,070	17,317
<b>Total current liabilities</b>		<b>U.S.\$ 976</b>	<b>Rs. 64,646</b>	<b>Rs. 63,995</b>
<b>Non-current liabilities</b>				
Long-term borrowings, excluding current portion	18	U.S.\$ 161	Rs. 10,685	Rs. 14,307
Provisions non-current	21	1	55	53
Deferred tax liabilities	27	12	767	1,779
Other non-current liabilities	23	48	3,161	3,326
<b>Total non-current liabilities</b>		<b>U.S.\$ 221</b>	<b>Rs. 14,668</b>	<b>Rs. 19,465</b>
<b>Total liabilities</b>		<b>U.S.\$ 1,197</b>	<b>Rs. 79,314</b>	<b>Rs. 83,460</b>

The accompanying notes form an integral part of these consolidated financial statements.

F-2

Table of Contents**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****CONSOLIDATED STATEMENT OF FINANCIAL POSITION****(in millions, except share and per share data)**

Particulars	Note	As of		
		March 31, 2016 <i>Unaudited convenience translation into U.S.\$ (See Note 2(d))</i>	March 31, 2016	March 31, 2015
<b>Equity</b>				
Share capital	16	U.S.\$ 13	Rs. 853	Rs. 852
Share premium		341	22,601	22,178
Share based payment reserve		17	1,100	1,081
Retained earnings		1,503	99,550	83,643
Other components of equity		64	4,232	3,548
<b>Total equity</b>		<b>U.S.\$ 1,937</b>	<b>Rs. 128,336</b>	<b>Rs. 111,302</b>
<b>Total liabilities and equity</b>		<b>U.S.\$ 3,134</b>	<b>Rs. 207,650</b>	<b>Rs. 194,762</b>

The accompanying notes form an integral part of these consolidated financial statements.



Table of Contents**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****CONSOLIDATED INCOME STATEMENT**

(in millions, except share and per share data)

Particulars	Note	For the Year Ended March 31,		2014
		2016	2015	
		<i>Unaudited convenience translation into U.S.\$ (See Note 2(d))</i>		
<b>Revenues</b>	24	<b>U.S.\$ 2,335</b>	<b>Rs. 154,708</b>	<b>Rs. 148,189</b>
Cost of revenues		942	62,427	62,786
<b>Gross profit</b>		<b>1,393</b>	<b>92,281</b>	<b>85,403</b>
Selling, general and administrative expenses		690	45,702	42,585
Research and development expenses		269	17,834	17,449
Other (income)/expense, net	25	(13)	(874)	(917)
<b>Total operating expenses</b>		<b>946</b>	<b>62,662</b>	<b>59,117</b>
<b>Results from operating activities</b>		<b>447</b>	<b>29,619</b>	<b>26,286</b>
Finance income		34	2,251	2,774
Finance expense		(75)	(4,959)	(1,092)
<b>Finance (expense)/income, net</b>	26	<b>(41)</b>	<b>(2,708)</b>	<b>1,682</b>
Share of profit of equity accounted investees, net of tax	10	3	229	195
<b>Profit before tax</b>		<b>410</b>	<b>27,140</b>	<b>28,163</b>
Tax expense	27	(108)	(7,127)	(5,984)
<b>Profit for the year</b>		<b>302</b>	<b>20,013</b>	<b>22,179</b>
<b>Attributable to:</b>				
Equity holders of the Company		302	20,013	22,179
Non-controlling interest				(3)
<b>Profit for the year</b>		<b>U.S.\$ 302</b>	<b>Rs. 20,013</b>	<b>Rs. 22,179</b>
				<b>Rs. 21,512</b>

<b>Earnings per share:</b>	17						
Basic earnings per share of Rs.5/- each		U.S.\$ 1.77	Rs. 117.34	Rs. 130.22	Rs. 126.52		
Diluted earnings per share of Rs.5/- each		U.S.\$ 1.77	Rs. 116.98	Rs. 129.75	Rs. 126.04		
<b>Weighted average number of equity shares used in computing earnings per share:</b>	17						
Basic			170,547,643	170,314,506	170,044,518		
Diluted			171,072,780	170,933,433	170,695,017		

The accompanying notes form an integral part of these consolidated financial statements.

Table of Contents

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME**

(in millions, except share and per share data)

Particulars	For the Year Ended March 31,			
	2016	2016	2015	2014
	<i>Unaudited convenience translation into U.S.\$ (See Note 2(d))</i>			
<b>Profit for the year</b>	<b>U.S.\$ 302</b>	<b>Rs. 20,013</b>	<b>Rs. 22,179</b>	<b>Rs. 21,512</b>
<b>Other comprehensive income/(loss)</b>				
<b><i>Items that will not be reclassified to profit or loss:</i></b>				
Actuarial gains/(losses) on post- employment benefit obligations	U.S.\$ (3)	Rs. (185)	Rs. (47)	Rs. 68
Tax on items that will not be reclassified to profit or loss	1	64	16	(20)
<b>Total items that will not be reclassified to profit or loss</b>	<b>U.S.\$ (2)</b>	<b>Rs. (121)</b>	<b>Rs. (31)</b>	<b>Rs. 48</b>
<b><i>Items that may be reclassified subsequently to profit or loss:</i></b>				
Changes in fair value of available for sale financial instruments	U.S.\$ (0)	Rs. (19)	Rs. 1,429	Rs. 40
Foreign currency translation adjustments	0	31	(196)	554
Effective portion of changes in fair value of cash flow hedges, net	15	966	99	(1,650)
Tax on items that may be reclassified subsequently to profit or loss	(3)	(173)	(96)	64
<b>Total items that may be reclassified subsequently to profit or loss</b>	<b>U.S.\$ 12</b>	<b>Rs. 805</b>	<b>Rs. 1,236</b>	<b>Rs. (992)</b>
<b>Other comprehensive income/(loss) for the year, net of tax</b>	<b>U.S.\$ 10</b>	<b>Rs. 684</b>	<b>Rs. 1,205</b>	<b>Rs. (944)</b>
<b>Total comprehensive income for the year</b>	<b>U.S.\$ 312</b>	<b>Rs. 20,697</b>	<b>Rs. 23,384</b>	<b>Rs. 20,568</b>
<b>Attributable to:</b>				
Equity holders of the Company	312	20,697	23,384	20,567
Non-controlling interests				1

<b>Total comprehensive income for the year</b>	<b>U.S.\$ 312</b>	<b>Rs. 20,697</b>	<b>Rs. 23,384</b>	<b>Rs. 20,568</b>
--	-------------------	-------------------	-------------------	-------------------

The accompanying notes form an integral part of these consolidated financial statements.

F-5

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**

(in millions, except share and per share data and where otherwise stated)

Particulars	Share capital		Share premium Amount	Fair value reserve Amount
	Shares	Amount		
<b>Balance as of April 1, 2013</b>	<b>169,836,475</b>	<b>Rs. 849</b>	<b>Rs. 21,214</b>	<b>Rs. 52</b>
Issue of equity shares on exercise of options	272,393	2	339	
Share based payment expense				
Profit for the period				
Dividend paid (including corporate dividend tax)				
Transfer to debenture redemption reserve				
Net change in fair value of available for sale financial instruments, net of tax expense of Rs.14				26
Foreign currency translation adjustments, net of tax expense of Rs.2				
Effective portion of changes in fair value of cash flow hedges, net of tax benefit of Rs.80				
Actuarial gain/(loss) on post-employment benefit obligations, net of tax expense Rs.20				
Acquisition of non-controlling interests				
Transfer to general reserve				
<b>Balance as of March 31, 2014</b>	<b>170,108,868</b>	<b>Rs. 851</b>	<b>Rs. 21,553</b>	<b>Rs. 78</b>
<b>Balance as of April 1, 2014</b>	<b>170,108,868</b>	<b>Rs. 851</b>	<b>Rs. 21,553</b>	<b>Rs. 78</b>
Issue of equity shares on exercise of options	272,306	1	429	
Share based payment expense				
Profit for the period				
Dividend paid (including corporate dividend tax)				
Sale of equity shares held by controlled trust <sup>(1)</sup>			196	
Net change in fair value of available for sale financial instruments, net of tax expense of Rs.366				1,063
Foreign currency translation adjustments, net of tax benefit of Rs.174				
Effective portion of changes in fair value of cash flow hedges, net of tax benefit of Rs.96				
Actuarial gain/(loss) on post-employment benefit obligations, net of tax benefit of Rs.16				
<b>Balance as of March 31, 2015</b>	<b>170,381,174</b>	<b>Rs. 852</b>	<b>Rs. 22,178</b>	<b>Rs. 1,141</b>
<b>Balance as of April 1, 2015</b>	<b>170,381,174</b>	<b>Rs. 852</b>	<b>Rs. 22,178</b>	<b>Rs. 1,141</b>

Issue of equity shares on exercise of options	226,479	1	423	
Share based payment expense				
Profit for the period				
Dividend paid (including corporate dividend tax)				
Net change in fair value of available for sale financial instruments, net of tax expense of Rs.88				(107)
Foreign currency translation adjustments, net of tax expense of Rs.62				
Effective portion of changes in fair value of cash flow hedges, net of tax expense of Rs.23				
Actuarial gain/(loss) on post-employment benefit obligations, net of tax benefit of Rs.64				
<b>Balance as of March 31, 2016</b>	<b>170,607,653</b>	<b>Rs. 853</b>	<b>Rs. 22,601</b>	<b>Rs. 1,034</b>
<b>Unaudited convenience translation into U.S.\$ (See Note 2(d))</b>		<b>U.S.\$ 13</b>	<b>U.S.\$ 341</b>	<b>U.S.\$ 16</b>

[Continued on next page]

The accompanying notes form an integral part of these consolidated financial statements.

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****CONSOLIDATED STATEMENT OF CHANGES IN EQUITY****(in millions, except share and per share data and where otherwise stated)**

[Continued from above table, first column repeated]

Particulars	Foreign currency translation reserve		Hedging reserve		Share based payment reserve		Equity shares held by a controlled trust	
	Amount		Amount		Amount		Amount	
	Rs.		Rs.		Rs.		Rs.	
<b>Balance as of April 1, 2013</b>	<b>Rs.</b>	<b>3,928</b>	<b>Rs.</b>	<b>(390)</b>	<b>Rs.</b>	<b>911</b>	<b>Rs.</b>	<b>(5)</b>
Issue of equity shares on exercise of options						(339)		
Share based payment expense						436		
Profit for the period								
Dividend paid (including corporate dividend tax)								
Transfer to debenture redemption reserve								
Net change in fair value of available for sale financial instruments, net of tax expense of Rs.14								
Foreign currency translation adjustments, net of tax expense of Rs.2		549						
Effective portion of changes in fair value of cash flow hedges, net of tax benefit of Rs.80				(1,570)				
Actuarial gain/(loss) on post-employment benefit obligations, net of tax expense of Rs.20								
Acquisition of non-controlling interests								
Transfer to general reserve								
<b>Balance as of March 31, 2014</b>	<b>Rs.</b>	<b>4,477</b>	<b>Rs.</b>	<b>(1,960)</b>	<b>Rs.</b>	<b>1,008</b>	<b>Rs.</b>	<b>(5)</b>
<b>Balance as of April 1, 2014</b>	<b>Rs.</b>	<b>4,477</b>	<b>Rs.</b>	<b>(1,960)</b>	<b>Rs.</b>	<b>1,008</b>	<b>Rs.</b>	<b>(5)</b>
Issue of equity shares on exercise of options						(425)		
Share based payment expense						498		
Profit for the period								
Dividend paid (including corporate dividend tax)								
Sale of equity shares held by controlled trust <sup>(1)</sup>								5
Net change in fair value of available for sale financial instruments, net of tax expense of Rs.366								
Foreign currency translation adjustments, net of tax benefit of Rs.174		(22)						
Effective portion of changes in fair value of cash flow hedges, net of tax benefit of Rs.96				195				
Actuarial gain/(loss) on post-employment benefit obligations, net of tax benefit of Rs.16								

<b>Balance as of March 31, 2015</b>	<b>Rs.</b>	<b>4,455</b>	<b>Rs.</b>	<b>(1,765)</b>	<b>Rs.</b>	<b>1,081</b>	<b>Rs.</b>
<b>Balance as of April 1, 2015</b>	<b>Rs.</b>	<b>4,455</b>	<b>Rs.</b>	<b>(1,765)</b>	<b>Rs.</b>	<b>1,081</b>	<b>Rs.</b>
Issue of equity shares on exercise of options						(423)	
Share based payment expense						442	
Profit for the period							
Dividend paid (including corporate dividend tax)							
Net change in fair value of available for sale financial instruments, net of tax expense of Rs.88							
Foreign currency translation adjustments, net of tax expense of Rs.62			(31)				
Effective portion of changes in fair value of cash flow hedges, net of tax expense of Rs.23					943		
Actuarial gain/(loss) on post-employment benefit obligations, net of tax benefit of Rs.64							
<b>Balance as of March 31, 2016</b>	<b>Rs.</b>	<b>4,424</b>	<b>Rs.</b>	<b>(822)</b>	<b>Rs.</b>	<b>1,100</b>	<b>Rs.</b>
<b>Unaudited convenience translation into U.S.\$ (See Note 2(d))</b>	<b>U.S.\$</b>	<b>67</b>	<b>U.S.\$</b>	<b>(12)</b>	<b>U.S.\$</b>	<b>17</b>	<b>U.S.\$</b>

[Continued on next page]

The accompanying notes form an integral part of these consolidated financial statements.



**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****CONSOLIDATED STATEMENT OF CHANGES IN EQUITY****(in millions, except share and per share data and where otherwise stated)**

[Continued from above table, first column repeated]

<b>Particulars</b>	<b>Retained earnings Amount</b>	<b>Debenture redemption reserve Amount</b>	<b>Non- controlling interests Amount</b>	<b>Actuarial gains/ (losses) Amount</b>	<b>Total Amount</b>
<b>Balance as of April 1, 2013</b>	<b>Rs. 44,815</b>	<b>Rs. 1,711</b>	<b>Rs. 20</b>	<b>Rs. (300)</b>	<b>Rs. 72,805</b>
Issue of equity shares on exercise of options					2
Share based payment expense					436
Profit for the period	21,515		(3)		21,512
Dividend paid (including corporate dividend tax)	(2,985)				(2,985)
Transfer to debenture redemption reserve	(828)	828			
Net change in fair value of available for sale financial instruments, net of tax expense of Rs.14					26
Foreign currency translation adjustments, net of tax expense of Rs.2			3		552
Effective portion of changes in fair value of cash flow hedges, net of tax benefit of Rs.80					(1,570)
Actuarial gain/(loss) on post-employment benefit obligations, net of tax expense of Rs.20				48	48
Acquisition of non-controlling interests	(5)		(20)		(25)
Transfer to general reserve	2,539	(2,539)			
<b>Balance as of March 31, 2014</b>	<b>Rs. 65,051</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs. (252)</b>	<b>Rs. 90,801</b>
<b>Balance as of April 1, 2014</b>	<b>Rs. 65,051</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs. (252)</b>	<b>Rs. 90,801</b>
Issue of equity shares on exercise of options					5
Share based payment expense					498
Profit for the period	22,179				22,179

Dividend paid (including corporate dividend tax)		(3,587)					(3,587)
Sale of equity shares held by controlled trust <sup>(1)</sup>							201
Net change in fair value of available for sale financial instruments, net of tax expense of Rs.366							1,063
Foreign currency translation adjustments, net of tax benefit of Rs.174							(22)
Effective portion of changes in fair value of cash flow hedges, net of tax benefit of Rs.96							195
Actuarial gain/(loss) on post-employment benefit obligations, net of tax benefit of Rs.16					(31)		(31)
<b>Balance as of March 31, 2015</b>	<b>Rs.</b>	<b>83,643</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>	<b>(283)</b>	<b>Rs. 111,302</b>
<b>Balance as of April 1, 2015</b>	<b>Rs.</b>	<b>83,643</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>	<b>(283)</b>	<b>Rs. 111,302</b>
Issue of equity shares on exercise of options							1
Share based payment expense							442
Profit for the period		20,013					20,013
Dividend paid (including corporate dividend tax)		(4,106)					(4,106)
Net change in fair value of available for sale financial instruments, net of tax expense of Rs.88							(107)
Foreign currency translation adjustments, net of tax expense of Rs.62							(31)
Effective portion of changes in fair value of cash flow hedges, net of tax expense of Rs.23							943
Actuarial gain/(loss) on post-employment benefit obligations, net of tax benefit of Rs.64						(121)	(121)
<b>Balance as of March 31, 2016</b>	<b>Rs.</b>	<b>99,550</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>	<b>(404)</b>	<b>Rs. 128,336</b>
<b>Unaudited convenience translation into U.S.\$ (See Note 2(d))</b>	<b>U.S.\$</b>	<b>1,503</b>	<b>U.S.\$</b>	<b>U.S.\$</b>	<b>U.S.\$</b>	<b>(6)</b>	<b>U.S.\$ 1,937</b>

- (1) During the year ended March 31, 2015, the Company disposed of all of the shares held by its controlled trust for a total consideration of Rs.201. A gain of Rs.196 arising from this transaction is recorded in share premium.  
The accompanying notes form an integral part of these consolidated financial statements.

F-8

Table of Contents**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****CONSOLIDATED STATEMENT OF CASH FLOWS**

(in millions, except share and per share data and where otherwise stated)

Particulars	Note	For the Year Ended March 31,			
		2016	2016	2015	2014
		<i>Unaudited convenience translation into U.S.\$ (See Note 2(d))</i>			
<b>Cash flows from/(used in) operating activities:</b>					
Profit for the period		U.S.\$ 302	Rs. 20,013	Rs. 22,179	Rs. 21,512
<i>Adjustments for:</i>					
Income tax expense		108	7,127	5,984	5,094
Dividend and profit on sale of investments		(13)	(852)	(755)	(217)
Depreciation and amortization		155	10,250	8,100	7,106
Impairment loss/(reversal of impairment loss) on property, plant and equipment and other intangible assets		4	288	629	(497)
Inventory write-downs		41	2,746	3,635	1,941
Allowance for doubtful trade and other receivables		2	137	168	162
Loss/(profit) on sale of property, plant and equipment and other intangible assets, net		2	112	144	(53)
Allowance for sales returns		49	3,272	3,535	2,454
Share of profit of equity accounted investees		(3)	(229)	(195)	(174)
Exchange (gain)/loss, net		16	1,066	673	(1,014)
Exchange loss related to Venezuela operations	41	70	4,621	843	
Interest (income)/expense, net		(9)	(573)	31	189
Share based payment expense		7	471	498	436
<i>Changes in operating assets and liabilities:</i>					
Trade and other receivables		13	833	(10,905)	118
Inventories		(38)	(2,522)	(5,447)	(3,971)
Trade and other payables		11	746	55	(2,130)
Other assets and other liabilities		11	755	1,257	(4,406)
<b>Cash generated from operations</b>		<b>728</b>	<b>48,261</b>	<b>30,431</b>	<b>26,550</b>
Income tax paid		(106)	(7,014)	(5,396)	(7,087)
<b>Net cash from operating activities</b>		<b>U.S.\$ 623</b>	<b>Rs. 41,247</b>	<b>Rs. 25,033</b>	<b>Rs. 19,463</b>

**Cash flows from/(used in) investing activities:**

Expenditure on property, plant and equipment		U.S.\$ (181)	Rs. (12,017)	Rs. (9,339)	Rs. (10,081)
Proceeds from sale of property, plant and equipment		1	84	172	85
Expenditure on other intangible assets		(43)	(2,858)	(5,988)	(546)
Proceeds from sale of other intangible assets					29
Purchase of other investments		(1,030)	(68,249)	(53,466)	(44,811)
Proceeds from sale of other investments		1,046	69,270	45,176	37,721
Cash paid for acquisition of business, net of cash acquired	6	(120)	(7,936)	(276)	
Interest and dividend received		19	1,283	817	983
<b>Net cash used in investing activities</b>		<b>U.S.\$ (308)</b>	<b>Rs. (20,423)</b>	<b>Rs. (22,904)</b>	<b>Rs. (16,620)</b>

**Cash flows from/(used in) financing activities:**

Proceeds from issuance of equity shares		U.S.\$ 0	Rs. 1	Rs. 5	Rs. 2
Proceeds from sale of equity shares held by a controlled trust				201	
Proceeds from/(repayment of) of short term borrowings, net		(4)	(273)	4,068	(858)
Proceeds from long term borrowings					10,100
Repayment of long term borrowings		(177)	(11,706)	(3,716)	(207)
Redemption of bonus debentures	33				(5,078)
Dividend paid (including corporate dividend tax)		(62)	(4,106)	(3,587)	(2,985)
Cash paid for acquisition of non-controlling interests					(25)
Interest paid		(14)	(917)	(1,090)	(1,166)
<b>Net cash used in financing activities</b>		<b>U.S.\$ (257)</b>	<b>Rs. (17,001)</b>	<b>Rs. (4,118)</b>	<b>Rs. (217)</b>

Net increase/(decrease) in cash and cash equivalents		58	3,823	(1,989)	2,626
Effect of exchange rate changes on cash and cash equivalents		(65)	(4,296)	(1,068)	771
Cash and cash equivalents at the beginning of the period	15	81	5,394	8,451	5,054

**Cash and cash equivalents at the end of the period**

<b>15</b>	<b>U.S.\$ 74</b>	<b>Rs. 4,921</b>	<b>Rs. 5,394</b>	<b>Rs. 8,451</b>
-----------	------------------	------------------	------------------	------------------

**Supplemental schedule of non-cash investing and financing activities:**

Investment in shares of Curis, Inc.	34	U.S.\$	Rs.	Rs. 1,452	Rs.
Acquisition of select products portfolio of UCB	6	1	64		
Property, plant and equipment and intangibles purchased on credit during the		16	1,064	323	469

year, including contingent consideration on  
purchase of intangibles

Property, plant and equipment purchased  
under capital lease

107

195

The accompanying notes form an integral part of these consolidated financial statements.

F-9

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**1. Reporting entity**

Dr. Reddy s Laboratories Limited ( DRL or the parent company ), together with its subsidiaries (collectively, the Company ), is a leading India-based pharmaceutical company headquartered in Hyderabad, Telangana, India. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients ( APIs ), Custom Pharmaceutical Services ( CPS ), generics, biosimilars, differentiated formulations and New Chemical Entities ( NCEs ). The Company s principal research and development facilities are located in Telangana, India, Cambridge, United Kingdom and Leiden, the Netherlands; its principal manufacturing facilities are located in Telangana, India, Andhra Pradesh, India, Himachal Pradesh, India, Cuernavaca-Cuautla, Mexico, Mirfield, United Kingdom, Louisiana, United States, and Tennessee, United States; and its principal markets are in India, Russia, the United States, the United Kingdom, Venezuela and Germany. The Company s shares trade on the Bombay Stock Exchange and the National Stock Exchange in India and also on the New York Stock Exchange in the United States.

**2. Basis of preparation of financial statements**

***a. Statement of compliance***

These consolidated financial statements as at and for the year ended March 31, 2016 have been prepared in accordance with the International Financial Reporting Standards and its interpretations ( IFRS ) as issued by the International Accounting Standards Board ( IASB ).

These consolidated financial statements have been prepared for the Company as a going concern on the basis of relevant IFRS that are effective or elected for early adoption at the Company s annual reporting date, March 31, 2016. These consolidated financial statements were authorized for issuance by the Company s Board of Directors on June 23, 2016.

***b. Basis of measurement***

These consolidated financial statements have been prepared on the historical cost convention and on an accrual basis, except for the following material items in the statement of financial position:

derivative financial instruments are measured at fair value;

available-for-sale financial assets are measured at fair value;

employee defined benefit assets/(liability) are recognized as the net total of the fair value of plan assets, plus actuarial losses, less actuarial gains and the present value of the defined benefit obligation;

long term borrowings, except obligations under finance leases, are measured at amortized cost using the effective interest rate method; and

investments in jointly controlled entities which are accounted for using the equity method.

***c. Functional and presentation currency***

These consolidated financial statements are presented in Indian rupees, which is the functional currency of the parent company. All financial information presented in Indian rupees has been rounded to the nearest million.

In respect of all non-Indian subsidiaries that operate as marketing arms of the parent company in their respective countries/regions, the functional currency has been determined to be the functional currency of the parent company (i.e., the Indian rupee). The operations of these entities are largely restricted to importing of finished goods from the parent company in India, sales of these products in the foreign country and making of import payments to the parent company. The cash flows realized from sales of goods are available for making import payments to the parent company and cash is paid to the parent company on a regular basis. The costs incurred by these entities are primarily the cost of goods imported from the parent company. The financing of these subsidiaries is done directly or indirectly by the parent company. In respect of subsidiaries whose operations are self-contained and integrated within their respective countries/regions, the functional currency has been determined to be the local currency of those countries/regions.



**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**2. Basis of preparation of financial statements (continued)**

***d. Convenience translation (unaudited)***

These consolidated financial statements have been prepared in Indian rupees. Solely for the convenience of the reader, these consolidated financial statements as of and for the year ended March 31, 2016 have been translated into U.S. dollars at the certified foreign exchange rate of U.S.\$1.00 = Rs.66.25, as published by the Federal Reserve Board of Governors on March 31, 2016. No representation is made that the Indian rupee amounts have been, could have been or could be converted into U.S. dollars at such a rate or any other rate. Such convenience translation is not subject to audit by the Company's independent auditors.

***e. Use of estimates and judgments***

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In particular, information about significant areas of estimation uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes:

Note 3(a) Evaluation of joint arrangements;

Note 3(b) Assessment of functional currency;

Note 3(c) and 30 Financial instruments;

Notes 3(d) Business combinations;

Notes 3(e) and (f) Useful lives of property, plant and equipment and intangible assets;

Note 3(h) Valuation of inventories;

Notes 3(i), 8 and 9 Measurement of recoverable amounts of cash-generating units;

Note 3 (j) and 19 Assets and obligations relating to employee benefits;

Note 3 (j) Share based payments;

Note 3(k) Provisions;

Note 3(l) Sales returns, rebates and charge back provisions;

Note 3(o) Evaluation of recoverability of deferred tax assets; and

Note 43 Contingencies

***f. Changes in accounting policies***

During the year ended March 31, 2014, the Company adopted the following new standards and amendments to standards, including any consequential amendments to other standards, with a date of initial application of April 1, 2013:

IFRS 10, Consolidated Financial Statements ;

IFRS 11, Joint Arrangements ;

IFRS 12, Disclosure of Interests in Other Entities ;

IFRS 13, Fair Value Measurement ;

Amendments to IAS 1, Presentation of Items of Other Comprehensive Income ;

IAS 19, Employee Benefits (2011) ;

Amendments to IAS 32, Financial Instruments: Income taxes arising from distribution to equity holders ;

Amendments to IAS 34, Interim Financial Reporting: Segment information for total assets and liabilities ; and

Amendments to IFRS 7, Financial instruments: Disclosures .

*(i) Subsidiaries*

As a result of IFRS 10, the Company has changed its accounting policy with respect to the basis for determining control. IFRS 10 replaces the guidance on consolidation in IAS 27, Consolidated and Separate Financial Statements , and SIC 12, Consolidation Special Purpose Entities .

IFRS 10 introduces a new control model that is applicable to all investees, by focusing on whether the Company has power over an investee, exposure or rights to variable returns from its involvement with the investee and ability to use its power to affect those returns. In particular, IFRS 10 requires the Company to consolidate investees that it controls on the basis of de facto circumstances. Subsidiaries are consolidated from the date control commences until the date control ceases.

In accordance with the transitional provisions of IFRS 10, the Company reassessed the control conclusion at April 1, 2013 and has concluded that there is no change to the scope of the entities to be consolidated as a result of the adoption of IFRS 10.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**2. Basis of preparation of financial statements (continued)**

***f. Changes in accounting policies (continued)***

*(ii) Joint arrangements*

Under IFRS 11, the Company classifies its interests in joint arrangements as either joint operations or joint ventures, depending on the Company's rights to the assets and obligations for the liabilities of the arrangements. When making this assessment, the Company considers the structure of the arrangements, the legal form of any separate vehicles, the contractual terms of the arrangements and other facts and circumstances. Previously, under IAS 31, the structure of the arrangement was the sole focus of classification.

The Company has re-evaluated its existing joint arrangements and concluded that adoption of IFRS 11 does not have any impact on the classification of such arrangements into joint operations and joint ventures.

*(iii) IFRS 12 Disclosure of interests in other entities*

IFRS 12 sets out the required disclosures for entities applying IFRS 10 and 11 and IAS 28 (as amended in 2011). The new standard combines, enhances and replaces the disclosure requirements for subsidiaries, associates, joint arrangements and unconsolidated structured entities. Necessary disclosures have been made in these consolidated financial statements, wherever necessary.

*(iv) Fair value measurement*

IFRS 13 establishes a single framework for measuring fair value and making disclosures about fair value measurements, when such measurements are required or permitted by other IFRS, and introduces more comprehensive disclosure requirements on fair value measurement. There was no material impact on these consolidated financial statements from the adoption of the measurement requirements of IFRS 13. The Company has provided necessary disclosures as required by IFRS 13 in these consolidated financial statements.

*(v) Presentation of items of other comprehensive income*

As a result of the amendments to IAS 1, the Company modified the presentation of items of other comprehensive income in its consolidated statement of comprehensive income, to present separately items that would be reclassified to profit or loss in the future from those that would never be reclassified to profit or loss. Comparative information has also been re-presented accordingly.

The adoption of the amendment to IAS 1 had no impact on the recognized assets, liabilities and comprehensive income of the Company.

*(vi) Employee benefits*

The Company has adopted revised IAS 19 effective April 1, 2013. The revised standard requires immediate recognition of unrecognized gains and losses through re-measurements of the net defined benefit liability/(asset) through other comprehensive income. As required by the revised standard, the consolidated financial statements as of April 1, 2011 have been retrospectively restated to reflect these changes. Consequently, the Company has recorded a loss of Rs.187 as of April 1, 2011 representing the unrecognized actuarial loss, net of tax, as of that date. Further, amounts of Rs.30 and Rs.(143), representing the actuarial gain/(loss), net of Rs.(14) and Rs.68, representing associated tax (expense)/benefit, have been recorded in the consolidated statement of comprehensive income for the years ended March 31, 2012 and 2013, respectively. Correspondingly, other liabilities were increased by Rs.278, Rs.234 and Rs.445 as on April 1, 2011, 2012 and 2013, respectively. Previously, these amounts were not recorded under the corridor approach specified in IAS 19.

Furthermore, revised IAS 19 also requires the interest expense/(income) on plan assets to be calculated by applying the discount rate used to measure the defined benefit obligation to the net defined benefit liability or asset. The actual return of the portfolio in excess of such yields is recognized through the other comprehensive income. The Company has provided necessary disclosures, as required by revised IAS 19, in these consolidated financial statements.

Revised IAS 19 also requires the effect of any plan amendments to be recognized immediately, through net profit, in the statement of comprehensive income. In addition, the revised standard amends the definitions of termination benefits and settlements. The effect of these changes is not considered material and, accordingly, no further disclosures have been made in these consolidated financial statements.

*(vii) Amendments to IAS 32, IAS 34 and IFRS 7*

The amendments to IAS 32, IAS 34 and IFRS 7 do not have any material impact on these consolidated financial statements of the Company.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**3. Significant accounting policies**

Except for the changes explained in Note 2(f), the Company has consistently applied the following accounting policies to all periods presented in these consolidated financial statements.

***a. Basis of consolidation***

*Subsidiaries*

Subsidiaries are all entities (including special purpose entities) that are controlled by the Company. Control exists when the Company is exposed to, or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through power over the entity. In assessing control, potential voting rights are considered only if the rights are substantive. The financial statements of subsidiaries are included in these consolidated financial statements from the date that control commences until the date that control ceases. For the purpose of preparing these consolidated financial statements, the accounting policies of subsidiaries have been changed where necessary to align them with the policies adopted by the Company.

*Associates and joint arrangements (equity accounted investees)*

Associates are those entities over which the Company has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the entities but is not control or joint control of those policies. Significant influence is generally presumed to exist when the Company holds between 20% and 50% of the voting power of another entity.

Joint arrangements are those arrangements over which the Company has joint control, established by contractual agreement and requiring unanimous consent for strategic financial and operating decisions.

Investments in associates and jointly controlled entities are accounted for using the equity method (equity accounted investees) and are initially recognized at cost. The carrying value of the Company's investment includes goodwill identified on acquisition, net of any accumulated impairment losses. The Company does not consolidate entities where the non-controlling interest ( NCI ) holders have certain significant participating rights that provide for effective involvement in significant decisions in the ordinary course of business of such entities. Investments in such entities are accounted by the equity method of accounting. When the Company's share of losses exceeds its interest in an equity accounted investee, the carrying amount of that interest (including any long-term investments) is reduced to zero and the recognition of further losses is discontinued except to the extent that the Company has an obligation or has made payments on behalf of the investee.

*Transactions eliminated on consolidation*

Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in full while preparing these consolidated financial statements. Unrealized gains or losses arising from transactions with equity accounted investees are eliminated against the investment to the extent of the Company's interest in the investee.

*Acquisition of non-controlling interests*

Acquisition of some or all of the NCI is accounted for as a transaction with equity holders in their capacity as equity holders. Consequently, the difference arising between the fair value of the purchase consideration paid and the carrying value of the NCI is recorded as an adjustment to retained earnings that is attributable to the parent company. The associated cash flows are classified as financing activities. No goodwill is recognized as a result of such transactions.

*Loss of Control*

Upon loss of control, the Company derecognizes the assets and liabilities of the subsidiary, any non-controlling interests and the other components of equity related to the subsidiary. Any surplus or deficit arising on the loss of control is recognized in the consolidated income statement. If the Company retains any interest in the previous subsidiary, then such interest is measured at fair value at the date that control is lost. Subsequently, it is accounted for as an equity-accounted investee or as an available-for-sale financial asset, depending on the level of influence retained.



***b. Foreign currency***

*Foreign currency transactions*

Transactions in foreign currencies are translated to the respective functional currencies of entities within the Company at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated into the functional currency at the exchange rate at that date. Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction. Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition during the period or in previous financial statements are recognized in the consolidated income statement in the period in which they arise.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**3. Significant accounting policies (continued)**

***b. Foreign currency (continued)***

When several exchange rates are available, the rate used is that at which the future cash flows represented by the transaction or balance could have been settled if those cash flows had occurred at the measurement date.

*Foreign operations*

Foreign exchange gains and losses arising from a monetary item receivable from a foreign operation, the settlement of which is neither planned nor likely in the foreseeable future, are considered to form part of the net investment in the foreign operation and are recognized in other comprehensive income/(loss) and presented within equity as a part of foreign currency translation reserve ( FCTR ).

In case of foreign operations whose functional currency is different from the parent company s functional currency, the assets and liabilities of such foreign operations, including goodwill and fair value adjustments arising upon acquisition, are translated to the reporting currency at exchange rates at the reporting date. The income and expenses of such foreign operations are translated to the reporting currency at the monthly average exchange rates prevailing during the year. Resulting foreign currency differences are recognized in other comprehensive income/(loss) and presented within equity as part of FCTR. When a foreign operation is disposed of, in part or in full, the relevant amount in the FCTR is transferred to the consolidated income statement.

***c. Financial instruments***

**Non-derivative financial instruments**

Non-derivative financial instruments consist of investments in mutual funds, equity securities, trade and other receivables, cash and cash equivalents, loans and borrowings, trade and other payables and certain other assets and liabilities.

Non-derivative financial instruments are recognized initially at fair value plus any directly attributable transaction costs, except for those instruments that are designated as being fair value through profit and loss upon initial recognition. Subsequent to initial recognition, non-derivative financial instruments are measured as described below:

*Cash and cash equivalents*

Cash and cash equivalents consist of cash on hand, demand deposits and short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value. For this purpose, short-term means investments having maturity of three months or less from the date of investment. Bank overdrafts that are repayable on demand form an integral part of the Company's cash management and are included as a component of cash and cash equivalents for the purpose of the consolidated statement of cash flows.

*Other investments*

Other investments consist of term deposits with original maturities of more than three months, investments in mutual funds and equity securities.

Investments in mutual funds and equity securities are classified as available-for-sale financial assets. Subsequent to initial recognition, they are measured at fair value and changes therein, other than impairment losses, are recognized in other comprehensive income/(loss) and presented within equity under fair value reserve. When an investment is derecognized, the cumulative gain or loss in equity is transferred to the consolidated income statement.

*Trade payables*

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if payment is expected within one year or within the normal operating cycle of the business.

*Trade receivables*

Trade receivables are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Trade receivables are classified as current assets if the collection is expected within one year or within the normal operating cycle of the business.

*Debt instruments and other financial liabilities*

The Company initially recognizes debt instruments issued on the date that they originate. All other financial liabilities are recognized initially on the trade date, which is the date that the Company becomes a party to the contractual provisions of the instrument. These are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, these financial liabilities are measured at amortized cost using the effective interest method.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**3. Significant accounting policies (continued)**

*c. Financial instruments (continued)*

*Others*

Other non-derivative financial instruments are initially recognized at fair value. Subsequent to initial recognition, these assets are measured at amortized cost using the effective interest method, less any impairment losses.

*De-recognition of financial assets and liabilities*

The Company derecognizes a financial asset when the contractual right to the cash flows from that asset expires, or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. If the Company retains substantially all the risks and rewards of ownership of a transferred financial asset, the Company continues to recognize the financial asset and also recognizes a collateralized borrowing, at amortized cost, for the proceeds received.

The Company derecognizes a financial liability when its contractual obligations are discharged, cancelled or expired. The difference between the carrying amount of the derecognized financial liability and the consideration paid is recognized as profit or loss.

*Offsetting financial assets and liabilities*

Financial assets and liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Company has a legal right and ability to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.

Derivative financial instruments

The Company is exposed to exchange rate risk which arises from its foreign exchange revenues and expenses, primarily in U.S. dollars, U.K. pounds sterling, Russian roubles, Venezuelan bolivars and Euros, and foreign currency debt in U.S. dollars, Russian roubles and Euros.

The Company uses foreign exchange forward contracts, option contracts and swap contracts (derivative financial instruments) to mitigate its risk of changes in foreign currency exchange rates. The Company also uses non-derivative financial instruments as part of its foreign currency exposure risk mitigation strategy.

*Hedges of highly probable forecasted transactions*

The Company classifies its derivative financial instruments that hedge foreign currency risk associated with highly probable forecasted transactions as cash flow hedges and measures them at fair value. The effective portion of such cash flow hedges is recorded in the Company's hedging reserve as a component of equity and re-classified to the consolidated income statement as revenue in the period corresponding to the occurrence of the forecasted transactions. The ineffective portion of such cash flow hedges is recorded in the consolidated income statement as finance costs immediately.

The Company also designates certain non-derivative financial liabilities, such as foreign currency borrowings from banks, as hedging instruments for hedge of foreign currency risk associated with highly probable forecasted transactions. Accordingly, the Company applies cash flow hedge accounting to such relationships. Remeasurement gain/loss on such non-derivative financial liabilities is recorded in the Company's hedging reserve as a component of equity and reclassified to the consolidated income statement as revenue in the period corresponding to the occurrence of the forecasted transactions.

Upon initial designation of a hedging instrument, the Company formally documents the relationship between the hedging instrument and hedged item, including the risk management objectives and strategy in undertaking the hedge transaction and the hedged risk, together with the methods that will be used to assess the effectiveness of the hedging relationship. The Company makes an assessment, both at the inception of the hedge relationship as well as on an ongoing basis, of whether the hedging instruments are expected to be highly effective in offsetting the changes in the fair value or cash flows of the respective hedged items attributable to the hedged risk, and whether the actual results of each hedge are within a range of 80%-125% relative to the gain or loss on the hedged items. For cash flow hedges to be highly effective, a forecast transaction that is the subject of the hedge must be highly probable and must present an exposure to variations in cash flows that could ultimately affect profit or loss.

If the hedging instrument no longer meets the criteria for hedge accounting, expires or is sold, terminated or exercised, then hedge accounting is discontinued prospectively. The cumulative gain or loss previously recognized in other comprehensive income/(loss), remains there until the forecast transaction occurs. If the forecast transaction is no longer expected to occur, then the balance in other comprehensive income/(loss) is recognized immediately in the consolidated income statement.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**3. Significant accounting policies (continued)**

*c. Financial instruments (continued)*

*Hedges of recognized assets and liabilities*

Changes in the fair value of derivative contracts that economically hedge monetary assets and liabilities in foreign currencies, and for which no hedge accounting is applied, are recognized in the consolidated income statement. The changes in fair value of such derivative contracts, as well as the foreign exchange gains and losses relating to the monetary items, are recognized as part of net finance income/(expense) in the consolidated income statement.

*Hedges of changes in the interest rates*

Consistent with its risk management policy, the Company uses interest rate swaps to mitigate the risk of changes in interest rates. The Company does not use them for trading or speculative purposes.

*d. Business combinations*

The Company uses the acquisition method of accounting to account for business combinations that occurred on or after April 1, 2009. The acquisition date is the date on which control is transferred to the acquirer. Judgment is applied in determining the acquisition date and determining whether control is transferred from one party to another. Control exists when the Company is exposed to, or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through power over the entity. In assessing control, potential voting rights are considered only if the rights are substantive. The Company measures goodwill as of the applicable acquisition date at the fair value of the consideration transferred, including the recognized amount of any non-controlling interest in the acquiree, less the net recognized amount of the identifiable assets acquired and liabilities assumed. When the fair value of the net identifiable assets acquired and liabilities assumed exceeds the consideration transferred, a bargain purchase gain is recognized immediately in the consolidated income statement. Consideration transferred includes the fair values of the assets transferred, liabilities incurred by the Company to the previous owners of the acquiree, and equity interests issued by the Company. Consideration transferred also includes the fair value of any contingent consideration. Consideration transferred does not include amounts related to the settlement of pre-existing relationships. Any goodwill that arises on account of such business combination is tested annually for impairment.

Any contingent consideration is measured at fair value at the date of acquisition. If an obligation to pay contingent consideration that meets the definition of a financial instrument is classified as equity, then it is not re-measured and the settlement is accounted for within equity. Otherwise, other contingent consideration is re-measured at fair value at

each reporting date and subsequent changes in the fair value of the contingent consideration are recorded in the consolidated income statement.

A contingent liability of the acquiree is assumed in a business combination only if such a liability represents a present obligation and arises from a past event, and its fair value can be measured reliably. On an acquisition-by-acquisition basis, the Company recognizes any non-controlling interest in the acquiree either at fair value or at the non-controlling interest's proportionate share of the acquiree's identifiable net assets. Transaction costs that the Company incurs in connection with a business combination, such as finder's fees, legal fees, due diligence fees and other professional and consulting fees, are expensed as incurred.

Acquisitions of non-controlling interests are accounted for as transactions with equity holders in their capacity as equity holders. The difference between any consideration paid and the relevant share acquired of the carrying value of net assets of the subsidiary is recorded in equity.

***e. Property, plant and equipment***

*Recognition and measurement*

Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses, if any. Cost includes expenditures that are directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials and other costs directly attributable to bringing the asset to a working condition for its intended use. Borrowing costs that are directly attributable to the construction or production of a qualifying asset are capitalized as part of the cost of that asset.

When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

Gains and losses upon disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognized net within other (income)/expense, net in the consolidated income statement.

The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The costs of repairs and maintenance are recognized in the consolidated income statement as incurred.



**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****3. Significant accounting policies (continued)***e. Property, plant and equipment (continued)*

Items of property, plant and equipment acquired through exchange of non-monetary assets are measured at fair value, unless the exchange transaction lacks commercial substance or the fair value of either the asset received or asset given up is not reliably measurable, in which case the asset exchanged is recorded at the carrying amount of the asset given up.

*Depreciation*

Depreciation is recognized in the consolidated income statement on a straight line basis over the estimated useful lives of property, plant and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives. The depreciation expense is included in the costs of the functions using the asset. Land is not depreciated.

Leasehold improvements are depreciated over the period of the lease agreement or the useful life, whichever is shorter.

Depreciation methods, useful lives and residual values are reviewed at each reporting date. The estimated useful lives are as follows:

Buildings	
- Factory and administrative buildings	20 - 50 years
- Ancillary structures	3 - 15 years
Plant and equipment	3 - 15 years
Furniture, fixtures and office equipment	4 - 10 years
Vehicles	4 - 5 years
Computer equipment	3 - 5 years

Software for internal use, which is primarily acquired from third-party vendors and which is an integral part of a tangible asset, including consultancy charges for implementing the software, is capitalized as part of the related tangible asset. Subsequent costs associated with maintaining such software are recognized as expense as incurred. The capitalized costs are amortized over the estimated useful life of the software or the remaining useful life of the tangible fixed asset, whichever is lower.

Advances paid towards the acquisition of property, plant and equipment outstanding at each reporting date and the cost of property, plant and equipment not ready to use before such date are disclosed under capital work-in-progress. Assets not ready for use are not depreciated.

*f. Goodwill and other intangible assets*

*Goodwill*

Goodwill represents the excess of consideration transferred, together with the amount of non-controlling interest in the acquiree, over the fair value of the Company's share of identifiable net assets acquired.

Goodwill is measured at cost less accumulated impairment losses. In respect of equity accounted investees, the carrying amount of goodwill is included in the carrying amount of the investment, and any impairment loss on such an investment is not allocated to any asset, including goodwill, that forms part of the carrying value of the equity accounted investee.

*Other intangible assets*

Other intangible assets that are acquired by the Company and that have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses.

Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate.

*Research and development*

Expenditures on research activities undertaken with the prospect of gaining new scientific or technical knowledge and understanding are recognized in the consolidated income statement when incurred.

Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized only if:

development costs can be measured reliably;

the product or process is technically and commercially feasible;

future economic benefits are probable; and

the Company intends to and has sufficient resources to complete development and to use or sell the asset.

---

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**3. Significant accounting policies (continued)**

***f. Goodwill and other intangible assets (continued)***

The expenditures to be capitalized include the cost of materials and other costs directly attributable to preparing the asset for its intended use. Other development expenditures are recognized in the consolidated income statement as incurred.

Payments to third parties that generally take the form of up-front payments and milestones for in-licensed products, compounds and intellectual property are capitalized. The Company's criteria for capitalization of such assets are consistent with the guidance given in paragraph 25 of International Accounting Standard 38 ( IAS 38 ) (i.e., receipt of economic benefits out of the separately purchased transaction is considered to be probable).

Acquired research and development intangible assets that are under development are recognized as In-Process Research and Development assets ( IPR&D ). IPR&D assets are not amortized, but evaluated for potential impairment on an annual basis or when there are indications that the carrying value may not be recoverable. Any impairment charge on such IPR&D assets is recorded in the consolidated income statement under Research and Development expenses .

Subsequent expenditure on an in-process research or development project acquired separately or in a business combination and recognized as an intangible asset is:

- a) recognized as an expense when incurred, if it is research expenditure;
- b) recognized as an expense when incurred, if it is development expenditure that does not satisfy the criteria for recognition as an intangible asset in paragraph 57 of IAS 38; and
- c) added to the carrying amount of the acquired in-process research or development project, if it is development expenditure that satisfies the recognition criteria in paragraph 57 of IAS 38.

Intangible assets relating to products in development, other intangible assets not available for use and intangible assets having indefinite useful life are subject to impairment testing at each reporting date. All other intangible assets are tested for impairment when there are indications that the carrying value may not be recoverable. All impairment losses

are recognized immediately in the consolidated income statement.

#### *Amortization*

Amortization is recognized in the consolidated income statement on a straight-line basis over the estimated useful lives of intangible assets or on any other basis that reflects the pattern in which the asset's future economic benefits are expected to be consumed by the entity. Intangible assets that are not available for use are amortized from the date they are available for use.

The estimated useful lives are as follows:

Trademarks	3 - 12 years
Product related intangibles	5 - 15 years
Customer-related intangibles	1 - 11 years
Technology related intangibles	3 - 13 years
Other intangibles	3 - 15 years

The amortization period and the amortization method for intangible assets with a finite useful life are reviewed at each reporting date.

#### *De-recognition of intangible assets*

Intangible assets are de-recognized either on their disposal or where no future economic benefits are expected from their use. Losses arising on such de-recognition are recorded in the consolidated income statement, and are measured as the difference between the net disposal proceeds, if any, and the carrying amount of respective intangible assets as on the date of de-recognition.

***g. Leases***

At the inception of each lease, the lease arrangement is classified as either a finance lease or an operating lease, based on the substance of the lease arrangement.

*Finance leases*

A finance lease is recognized as an asset and a liability at the commencement of the lease, at the lower of the fair value of the asset and the present value of the minimum lease payments. Initial direct costs, if any, are also capitalized and, subsequent to initial recognition, the asset is accounted for in accordance with the accounting policy applicable to that asset. Minimum lease payments made under finance leases are apportioned between the finance expense and the reduction of the outstanding liability. The finance expense is allocated to each period during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**3. Significant accounting policies (continued)**

***g. Leases (continued)***

*Operating leases*

Other leases are operating leases, and the leased assets are not recognized on the Company's statements of financial position. Payments made under operating leases are recognized in the consolidated income statement on a straight-line basis over the term of the lease.

Operating lease incentives received from the landlord are recognized as a reduction of rental expense on a straight line basis over the lease term.

***h. Inventories***

Inventories consist of raw materials, stores and spares, work in progress and finished goods and are measured at the lower of cost and net realizable value. The cost of all categories of inventories is based on the weighted average method. Cost includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. In the case of finished goods and work in progress, cost includes an appropriate share of overheads based on normal operating capacity. Stores and spares consists of packing materials, engineering spares (such as machinery spare parts) and consumables (such as lubricants, cotton waste and oils), which are used in operating machines or consumed as indirect materials in the manufacturing process.

Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

The factors that the Company considers in determining the allowance for slow moving, obsolete and other non-saleable inventory include estimated shelf life, planned product discontinuances, price changes, ageing of inventory and introduction of competitive new products, to the extent each of these factors impact the Company's business and markets. The Company considers all these factors and adjusts the inventory provision to reflect its actual experience on a periodic basis.

***i. Impairment***

*Financial assets*

A financial asset is assessed at each reporting date to determine whether there is any objective evidence that it is impaired. A financial asset is considered to be impaired if objective evidence indicates that one or more events have had a negative effect on the estimated future cash flows of that asset.

An impairment loss in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount, and the present value of the estimated future cash flows discounted at the original effective interest rate. An impairment loss in respect of an available-for-sale financial asset is calculated by reference to its fair value.

Significant financial assets are tested for impairment on an individual basis. All impairment losses/(reversals of impairment losses) are recognized in the consolidated income statement.

When the fair value of available-for-sale financial assets declines below acquisition cost and there is objective evidence that the asset is impaired, the cumulative loss that has been recognized in other comprehensive income is transferred to the statement of income. An impairment loss may be reversed in subsequent periods, if the indicators for the impairment no longer exist. Such reversals are recognized in other comprehensive income.

#### *Non-financial assets*

The carrying amounts of the Company's non-financial assets, other than inventories and deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated. For goodwill and intangible assets that have indefinite lives or that are not yet available for use, an impairment test is performed each year at March 31.

The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or the cash-generating unit. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the cash-generating unit).

The goodwill acquired in a business combination is, for the purpose of impairment testing, allocated to cash-generating units that are expected to benefit from the synergies of the combination.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**3. Significant accounting policies (continued)**

***i. Impairment (continued)***

An impairment loss is recognized in the consolidated income statement if the estimated recoverable amount of an asset or its cash-generating unit is lower than its carrying amount. Impairment losses recognized in respect of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to the units and then to reduce the carrying amount of the other assets in the unit on a pro-rata basis.

An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. Goodwill that forms part of the carrying amount of an investment in an associate is not recognized separately, and therefore is not tested for impairment separately. Instead, the entire amount of the investment in an associate is tested for impairment as a single asset when there is objective evidence that the investment in an associate may be impaired.

An impairment loss in respect of equity accounted investee is measured by comparing the recoverable amount of investment with its carrying amount. An impairment loss is recognized in the consolidated income statement, and reversed if there has been a favorable change in the estimates used to determine the recoverable amount.

***j. Employee benefits***

*Short-term employee benefits*

Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

*Defined contribution plans*

The Company's contributions to defined contribution plans are charged to the consolidated income statement as and when the services are received from the employees.

*Defined benefit plans*



The liability in respect of defined benefit plans and other post-employment benefits is calculated using the projected unit credit method consistent with the advice of qualified actuaries. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating to the terms of the related defined benefit obligation. In countries where there is no deep market in such bonds, the market rates on government bonds are used. The current service cost of the defined benefit plan, recognized in the income statement in employee benefit expense, reflects the increase in the defined benefit obligation resulting from employee service in the current year, benefit changes, curtailments and settlements. Past service costs are recognized immediately in income. The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the income statement. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are charged or credited to equity in other comprehensive income in the period in which they arise.

*Termination benefits*

Termination benefits are recognized as an expense when the Company is demonstrably committed, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. Termination benefits for voluntary redundancies are recognized as an expense if the Company has made an offer encouraging voluntary redundancy, it is probable that the offer will be accepted, and the number of acceptances can be estimated reliably.

*Other long-term employee benefits*

The Company's net obligation in respect of other long term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and previous periods. That benefit is discounted to determine its present value. Re-measurements are recognized in the statement of profit and loss in the period in which they arise.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**3. Significant accounting policies (continued)**

***j. Employee benefits (continued)***

*Compensated absences*

The Company's current policies permit certain categories of its employees to accumulate and carry forward a portion of their unutilized compensated absences and utilize them in future periods or receive cash in lieu thereof in accordance with the terms of such policies. The Company measures the expected cost of accumulating compensated absences as the additional amount that the Company incurs as a result of the unused entitlement that has accumulated at the statements of financial position date. Such measurement is based on actuarial valuation as at the statements of financial position date carried out by a qualified actuary.

*Share-based payment transactions*

The grant date fair value of options granted to employees is recognized as an employee expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the options. The expense is recorded for each separately vesting portion of the award as if the award was, in substance, multiple awards. The increase in equity recognized in connection with share based payment transaction is presented as a separate component in equity under "share based payment reserve". The amount recognized as an expense is adjusted to reflect the actual number of stock options that vest.

The fair value of the amount payable to employees in respect of share based payment transactions which are settled in cash is recognized as an expense, with a corresponding increase in liabilities, over the period during which the employees become unconditionally entitled to payment. The liability is re-measured at each reporting date and at the settlement date based on the fair value of the share based payment transaction. Any changes in the liability are recognized in the income statement.

***k. Provisions***

A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

### *Restructuring*

A provision for restructuring is recognized when the Company has approved a detailed and formal restructuring plan, and the restructuring either has commenced or has been announced publicly. Future operating costs are not provided.

### *Onerous contracts*

A provision for onerous contracts is recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Company recognizes any impairment loss on the assets associated with that contract.

### *Reimbursement rights*

Expected reimbursements for expenditures required to settle a provision are recognized only when receipt of such reimbursements is virtually certain. Such reimbursements are recognized as a separate asset in the statement of financial position, with a corresponding credit to the specific expense for which the provision has been made.

## ***1. Revenue***

### *Sale of goods*

Revenue is recognized when the significant risks and rewards of ownership have been transferred to the buyer, recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, there is no continuing management involvement with the goods and the amount of revenue can be measured reliably. Revenue from the sale of goods includes excise duty and is measured at the fair value of the consideration received or receivable, net of returns, sales tax and applicable trade discounts and allowances. Revenue includes shipping and handling costs billed to the customer.

Revenue from sales of generic products in India is recognized upon delivery of products to distributors by clearing and forwarding agents of the Company. Significant risks and rewards in respect of ownership of generic products are transferred by the Company when the goods are delivered to distributors from clearing and forwarding agents. Clearing and forwarding agents are generally compensated on a commission basis as a percentage of sales made by them. Revenue from sales of active pharmaceutical ingredients and intermediates in India is recognized on delivery of products to customers (generally formulation manufacturers), from the factories of the Company.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**3. Significant accounting policies (continued)**

***1. Revenue (continued)***

Revenue from export sales and other sales outside of India is recognized when the significant risks and rewards of ownership of products are transferred to the customers, which occurs upon delivery of the products to the customers unless the terms of the applicable contract provide for specific revenue generating activities to be completed, in which case revenue is recognized once all such activities are completed.

*Profit share revenues*

The Company from time to time enters into marketing arrangements with certain business partners for the sale of its products in certain markets. Under such arrangements, the Company sells its products to the business partners at a non-refundable base purchase price agreed upon in the arrangement and is also entitled to a profit share which is over and above the base purchase price. The profit share is typically dependent on the business partner's ultimate net sale proceeds or net profits, subject to any reductions or adjustments that are required by the terms of the arrangement. Such arrangements typically require the business partner to provide confirmation of units sold and net sales or net profit computations for the products covered under the arrangement.

Revenue in an amount equal to the base purchase price is recognized in these transactions upon delivery of products to the business partners. An additional amount representing the profit share component is recognized as revenue in the period which corresponds to the ultimate sales of the products made by business partners only when the collectability of the profit share becomes probable and a reliable measurement of the profit share is available. Otherwise, recognition is deferred to a subsequent period pending satisfaction of such collectability and measurability requirements. In measuring the amount of profit share revenue to be recognized for each period, the Company uses all available information and evidence, including any confirmations from the business partner of the profit share amount owed to the Company, to the extent made available before the date the Company's Board of Directors authorizes the issuance of its financial statements for the applicable period.

*Milestone payments and out licensing arrangements*

Revenues include amounts derived from product out-licensing agreements. These arrangements typically consist of an initial up-front payment on inception of the license and subsequent payments dependent on achieving certain milestones in accordance with the terms prescribed in the agreement. Non-refundable up-front license fees received in connection with product out-licensing agreements are deferred and recognized over the period in which the Company has continuing performance obligations. Milestone payments which are contingent on achieving certain clinical

milestones are recognized as revenues either on achievement of such milestones, if the milestones are considered substantive, or over the period the Company has continuing performance obligations, if the milestones are not considered substantive. If milestone payments are creditable against future royalty payments, the milestones are deferred and released over the period in which the royalties are anticipated to be paid.

*Provision for chargeback, rebates and discounts*

Provisions for chargeback, rebates, discounts and Medicaid payments are estimated and provided for in the year of sales and recorded as reduction of revenue. A chargeback claim is a claim made by the wholesaler for the difference between the price at which the product is initially invoiced to the wholesaler and the net price at which it is agreed to be procured from the Company. Provisions for such chargebacks are accrued and estimated based on historical average chargeback rate actually claimed over a period of time, current contract prices with wholesalers/other customers and estimated inventory holding by the wholesaler.

*Shelf stock adjustments*

Shelf stock adjustments are credits issued to customers to reflect decreases in the selling price of products sold by the Company, and are accrued when the prices of certain products decline as a result of increased competition upon the expiration of limited competition or exclusivity periods. These credits are customary in the pharmaceutical industry, and are intended to reduce the customer inventory cost to better reflect the current market prices. The determination to grant a shelf stock adjustment to a customer is based on the terms of the applicable contract, which may or may not specifically limit the age of the stock on which a credit would be offered.

*Sales Returns*

The Company accounts for sales returns accrual by recording an allowance for sales returns concurrent with the recognition of revenue at the time of a product sale. This allowance is based on the Company's estimate of expected sales returns. The Company deals in various products and operates in various markets. Accordingly, the estimate of sales returns is determined primarily by the Company's historical experience in the markets in which the Company operates. With respect to established products, the Company considers its historical experience of sales returns, levels of inventory in the distribution channel, estimated shelf life, product discontinuances, price changes of competitive products, and the introduction of competitive new products, to the extent each of these factors impact the Company's business and markets. With respect to new products introduced by the Company, such products have historically been either extensions of an existing line of product where the Company has historical experience or in therapeutic categories where established products exist and are sold either by the Company or the Company's competitors.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**3. Significant accounting policies (continued)**

***l. Revenue (continued)***

*Services*

Revenue from services rendered, which primarily relate to contract research, is recognized in the consolidated income statement as the underlying services are performed. Upfront non-refundable payments received under these arrangements are deferred and recognized as revenue over the expected period over which the related services are expected to be performed.

*Export entitlements*

Export entitlements from government authorities are recognized in the consolidated income statement as a reduction from Cost of Revenues when the right to receive credit as per the terms of the scheme is established in respect of the exports made by the Company, and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

***m. Shipping and handling costs***

Shipping and handling costs incurred to transport products to customers, and internal transfer costs incurred to transport the products from the Company's factories to its various points of sale, are included in selling, general and administrative expenses.

***n. Finance income and expense***

Finance income consists of interest income on funds invested (including available-for-sale financial assets), dividend income and gains on the disposal of available-for-sale financial assets. Interest income is recognized in the consolidated income statement as it accrues, using the effective interest method. Dividend income is recognized in the consolidated income statement on the date that the Company's right to receive payment is established. The associated cash flows are classified as investing activities in the statement of cash flows. Finance expenses consist of interest expense on loans and borrowings.

Borrowing costs are recognized in the consolidated income statement using the effective interest method. The associated cash flows are classified as financing activities in the statement of cash flows.

Foreign currency gains and losses are reported on a net basis within finance income and expense. These primarily include: exchange differences arising on the settlement or translation of monetary items; changes in the fair value of derivative contracts that economically hedge monetary assets and liabilities in foreign currencies and for which no hedge accounting is applied; and the ineffective portion of cash flow hedges.

*o. Income tax*

Income tax expense consists of current and deferred tax. Income tax expense is recognized in the consolidated income statement except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years.

Deferred tax is recognized using the balance sheet method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit; differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future; and taxable temporary differences arising upon the initial recognition of goodwill. Deferred tax is measured at the tax rates that are expected to be applied to the temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.

A deferred tax asset is recognized to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

Any deferred tax asset or liability arising from deductible or taxable temporary differences in respect of unrealized inter-company profit or loss on inventories held by the Company in different tax jurisdictions is recognized using the tax rate of the jurisdiction in which such inventories are held. Withholding tax arising out of payment of dividends to shareholders under the Indian Income tax regulations is not considered as tax expense for the Company and all such taxes are recognized in the statement of changes in equity as part of the associated dividend payment.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**3. Significant accounting policies (continued)**

***p. Earnings per share***

The Company presents basic and diluted earnings per share ( EPS ) data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding for the effects of all dilutive potential ordinary shares, which includes all stock options granted to employees.

***q. Government grants***

The Company recognizes government grants only when there is reasonable assurance that the conditions attached to them will be complied with, and the grants will be received. Government grants received in relation to assets are presented as a reduction to the carrying amount of the related asset. Grants related to income are deducted in reporting the related expense.

***r. Segment Reporting***

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief executive officer of the Company is responsible for allocating resources and assessing performance of the operating segments and accordingly is identified as the chief operating decision maker.

***s. Recent accounting pronouncements***

**Standards issued but not yet effective and not early adopted by the Company**

***IFRS 9- Financial instruments***

In July 2014, the IASB issued the final version of IFRS 9, Financial instruments . IFRS 9 significantly differs from IAS 39, Financial Instruments: Recognition and Measurement , and includes a logical model for classification and measurement, a single, forward-looking expected loss impairment model and a substantially-reformed approach to hedge accounting. IFRS 9 is effective for annual periods beginning on or after January 1, 2018, with early application permitted. The Company believes that the new Standard will materially impact the classification and measurement of the Company s financial instruments, documentation relating to hedging financial exposures and recognition of certain fair value changes.



*Amendments to IAS 16 Property, plant and equipment and IAS 38 Intangible assets*

In May 2014, the IASB issued limited-scope amendments to IAS 16, Property, plant and equipment and IAS 38, Intangible assets, to clarify the use of a revenue-based depreciation or amortization method. With respect to property, plant and equipment, the IASB has clarified that the use of revenue-based methods to calculate the depreciation of an asset is not appropriate because revenue generated by an activity that includes the use of an asset generally reflects factors other than the consumption of the economic benefits embodied in the asset. With respect to intangible assets, the amended standard incorporates a rebuttable presumption that an amortization method based on the revenue generated by an activity that includes the use of an intangible asset is inappropriate. The amendments are effective for annual periods beginning on or after January 1, 2016, with early application permitted. The Company believes that these amendments will not have any material impact on its consolidated financial statements.

*IFRS 15, Revenue from Contracts with Customers.*

In May 2014, the IASB issued IFRS 15, Revenue from Contracts with Customers. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and improve guidance for multiple-element arrangements.

The new revenue recognition standard was issued with an effective date of January 1, 2017. However, in April 2015, the IASB voted to defer the effective date of the new revenue recognition standard to January 1, 2018. Early application of the new standard is permitted. The Company is in the process of evaluating the impact of the new standard on its consolidated financial statements.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**3. Significant accounting policies (continued)**

*s. Recent accounting pronouncements (continued)*

*IFRS 16, Leases*

In January 2016, the IASB issued a new standard, IFRS 16, *Leases*. The new standard brings most leases on-balance sheet for lessees under a single model, eliminating the distinction between operating and finance leases. Lessor accounting, however, remains largely unchanged and the distinction between operating and finance leases is retained. IFRS 16 supersedes IAS 17, *Leases*, and related interpretations and is effective for periods beginning on or after January 1, 2019. Earlier adoption of IFRS 16 is permitted if IFRS 15, *Revenue from Contracts with Customers*, has also been applied.

The Company is currently in the process of evaluating the impact of this new accounting standard on its consolidated financial statements.

*t. Share capital*

*Ordinary shares*

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and stock options are recognized as a deduction from equity, net of any tax effects.

When shares recognized as equity are repurchased, the amount of consideration paid, which includes costs that are directly attributable, is recognized as a deduction from equity.

**4. Determination of fair values**

The Company's accounting policies and disclosures require the determination of fair value, for certain financial and non-financial assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods. When applicable, further information about the assumptions made in determining fair values is disclosed in the notes specific to that asset or liability.

*(i) Property, plant and equipment*

Property, plant and equipment, if acquired in a business combination or through an exchange of non-monetary assets, is measured at fair value on the acquisition date. For this purpose, fair value is based on appraised market values and replacement cost.

***(ii) Intangible assets***

The fair value of brands, technology related intangibles, and patents and trademarks acquired in a business combination is based on the discounted estimated royalty payments that have been avoided as a result of these brands, technology related intangibles, patents or trademarks being owned (the relief of royalty method ). The fair value of customer related, product related and other intangibles acquired in a business combination has been determined using the multi-period excess earnings method after deduction of a fair return on other assets that are part of creating the related cash flows.

***(iii) Inventories***

The fair value of inventories acquired in a business combination is determined based on its estimated selling price in the ordinary course of business less the estimated costs of completion and sale, and a reasonable profit margin based on the effort required to complete and sell the inventories.

***(iv) Investments in equity and debt securities and units of mutual funds***

The fair value of available-for-sale marketable equity and debt securities is determined by reference to their quoted market price at the reporting date. For debt securities where quoted market prices are not available, fair value is determined using pricing techniques such as discounted cash flow analysis.

In respect of investments in mutual funds, the fair values represent net asset value as stated by the issuers of these mutual fund units in the published statements. Net asset values represent the price at which the issuer will issue further units in the mutual fund and the price at which issuers will redeem such units from the investors.

Accordingly, such net asset values are analogous to fair market value with respect to these investments, as transactions of these mutual funds are carried out at such prices between investors and the issuers of these units of mutual funds.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**4. Determination of fair values (continued)**

***(v) Derivatives***

The fair value of foreign exchange forward contracts is estimated by discounting the difference between the contractual forward price and the current forward price for the residual maturity of the contract using a risk-free interest rate (based on government bonds). The fair value of foreign currency option and swap contracts and interest rate swap contracts is determined based on the appropriate valuation techniques, considering the terms of the contract.

***(vi) Non-derivative financial liabilities***

Fair value, which is determined for disclosure purposes, is calculated based on the present value of future principal and interest cash flows, discounted at the market rate of interest at the reporting date. For finance leases the market rate of interest is determined by reference to similar lease agreements. In respect of the Company's borrowings that have floating rates of interest, their fair value approximates carrying value.

***(vii) Share-based payment transactions***

The fair value of employee stock options is measured using the Black-Scholes-Merton valuation model. Measurement inputs include share price on grant date, exercise price of the instrument, expected volatility (based on weighted average historical volatility), expected life of the instrument (based on historical experience), expected dividends, and the risk free interest rate (based on government bonds).

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**5. Segment reporting**

The Chief Operating Decision Maker ( CODM ) evaluates the Company s performance and allocates resources based on an analysis of various performance indicators by operating segments. The CODM reviews revenue and gross profit as the performance indicator for all of the operating segments, and does not review the total assets and liabilities of an operating segment.

The Company s reportable operating segments are as follows:

Global Generics;

Pharmaceutical Services and Active Ingredients ( PSAI ); and

Proprietary Products.

**Global Generics.** This segment consists of the Company s business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of the Company s biologics business.

**Pharmaceutical Services and Active Ingredients.** This segment consists of the Company s business of manufacturing and marketing active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are the principal ingredients for finished pharmaceutical products. Active pharmaceutical ingredients and intermediates become finished pharmaceutical products when the dosages are fixed in a form ready for human consumption such as a tablet, capsule or liquid using additional inactive ingredients. This segment also includes the Company s contract research services business and the manufacture and sale of active pharmaceutical ingredients and steroids in accordance with the specific customer requirements.

**Proprietary Products.** This segment consists of the Company s business that focuses on the research, development, and manufacture of differentiated formulations and new chemical entities ( NCEs ). These novel products fall within the dermatology and neurology therapeutic areas and are marketed and sold through Promius Pharma, LLC.

**Others.** This includes the operations of the Company s wholly-owned subsidiary, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with established pharmaceutical and biotechnology companies in early-stage collaborations, bringing drug candidates from hit generation through Investigational New Drug ( IND ) filing.

The measurement of each segment's revenues, expenses and assets is consistent with the accounting policies that are used in preparation of the Company's consolidated financial statements.

Information about segments: Reportable segments	For the Year Ended March 31,								
	Global Generics			PSAI			Proprietary Products		
	2016	2015	2014	2016	2015	2014	2016	2015	2014
Revenue (1) (2)	Rs. 128,062	Rs. 119,397	Rs. 104,483	Rs. 22,379	Rs. 25,456	Rs. 23,974	Rs. 2,659	Rs. 2,172	Rs. 2,172
Profit	Rs. 84,427	Rs. 77,569	Rs. 68,544	Rs. 4,931	Rs. 5,709	Rs. 4,848	Rs. 2,217	Rs. 1,796	Rs. 1,796
Research and development expenses									
Administrative expenses									
Goodwill impairment (income)/expense, net									
Income from operating activities									
Change in fair value of equity investments (expense)/income, net									
Share of profit of equity investments									
Share of profit of equity investments, net of tax									
Income before tax									
Income tax expense									
Income for the year									

[Continued on next page]

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

(in millions, except share and per share data and where otherwise stated)

**5. Segment reporting (continued)**

[Continued from above table, first column repeated]

Information about segments: Reportable segments	For the Year Ended March 31,					
	2016	Others 2015	2014	2016	Total 2015	2014
<b>Revenue</b> <sup>(1)</sup> <sup>(2)</sup>	<b>Rs. 1,608</b>	<b>Rs. 1,164</b>	<b>Rs. 1,254</b>	<b>Rs. 154,708</b>	<b>Rs. 148,189</b>	<b>Rs. 132,170</b>
<b>Gross profit</b>	<b>Rs. 706</b>	<b>Rs. 329</b>	<b>Rs. 199</b>	<b>Rs. 92,281</b>	<b>Rs. 85,403</b>	<b>Rs. 75,801</b>
Selling, general and administrative expenses				45,702	42,585	38,783
Research and development expenses				17,834	17,449	12,402
Other (income)/expense, net				(874)	(917)	(1,416)
<b>Results from operating activities</b>				<b>Rs. 29,619</b>	<b>Rs. 26,286</b>	<b>Rs. 26,032</b>
Finance (expense)/income, net				(2,708)	1,682	400
Share of profit of equity accounted investees, net of tax				229	195	174
<b>Profit before tax</b>				<b>Rs. 27,140</b>	<b>Rs. 28,163</b>	<b>Rs. 26,606</b>
Tax expense				(7,127)	(5,984)	(5,094)
<b>Profit for the year</b>				<b>Rs. 20,013</b>	<b>Rs. 22,179</b>	<b>Rs. 21,512</b>

(1) Revenue for the year ended March 31, 2016 does not include inter-segment revenues from PSAI to Global Generics which is accounted for at a cost of Rs.5,447 (as compared to Rs.6,904 and Rs.5,601 for the years ended March 31, 2015 and 2014, respectively).

(2) During the three months ended June 30, 2015, there was a change in the monitoring of performance of one product from the Global Generics segment to the Proprietary Products segment. Consequently, revenues and gross profit from such product for the years ended March 31, 2015 and 2014 have been reclassified to conform to the change.

**Analysis of revenue by geography:**

The following table shows the distribution of the Company's revenues by geography, based on the location of the customers:

<b>Country</b>	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
India	Rs. 23,913	Rs. 21,158	Rs. 19,502
United States	81,154	69,840	60,801
Russia	10,640	14,922	16,333
Others	39,001	42,269	35,534
	<b>Rs. 154,708</b>	<b>Rs. 148,189</b>	<b>Rs. 132,170</b>

#### **Analysis of revenue within the Global Generics segment:**

An analysis of revenues by therapeutic areas in the Company's Global Generics segment is given below:

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Gastrointestinal	Rs. 21,253	Rs. 21,524	Rs. 20,793
Oncology	19,410	19,459	14,970
Cardiovascular	19,009	17,569	14,962
Pain Management	16,240	16,591	15,808
Central Nervous System	14,739	14,935	12,094
Anti-Infective	12,711	8,393	6,310
Others	24,700	20,926	19,546
<b>Total</b>	<b>Rs. 128,062</b>	<b>Rs. 119,397</b>	<b>Rs. 104,483</b>



**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

(in millions, except share and per share data and where otherwise stated)

**5. Segment reporting (continued)****Analysis of revenue within the PSAI segment:**

An analysis of revenues by therapeutic areas in the Company's PSAI segment is given below:

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Cardiovascular	Rs. 5,077	Rs. 4,695	Rs. 5,126
Pain Management	4,085	3,793	4,150
Central Nervous System	3,021	2,800	3,686
Oncology	2,570	4,274	1,958
Anti-Infective	2,015	2,338	3,198
Gastrointestinal	1,310	1,395	1,816
Others	4,301	6,161	4,040
<b>Total</b>	<b>Rs. 22,379</b>	<b>Rs. 25,456</b>	<b>Rs. 23,974</b>

**Analysis of assets by geography:**

The following table shows the distribution of the Company's non-current assets (other than financial instruments and deferred tax assets) by country, based on the location of assets:

	<b>As of March 31,</b>	
	<b>2016</b>	<b>2015</b>
<b>Country</b>		
India	Rs. 54,987	Rs. 41,948
United States	7,519	7,550
Switzerland	6,576	5,033
Germany	4,200	4,414
Others	6,632	6,608
	<b>Rs. 79,914</b>	<b>Rs. 65,553</b>

The following table shows the distribution of the Company's property, plant and equipment including capital work in progress and intangible assets acquired during the year (other than goodwill arising on business combination) by country, based on the location of assets:

<b>Country</b>	<b>For the Year Ended March 31,</b>	
	<b>2016</b>	<b>2015</b>
India	Rs. 19,389	Rs. 9,215
Switzerland	2,325	5,104
United States	1,019	814
Others	586	733
	<b>Rs. 23,319</b>	<b>Rs. 15,866</b>

**Analysis of depreciation and amortization, included in cost of revenues, by reportable segments:**

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Global Generics	Rs. 2,742	Rs. 2,044	Rs. 1,762
PSAI	2,437	2,034	1,920
Proprietary Products			
Others	62	76	89
	<b>Rs. 5,241</b>	<b>Rs. 4,154</b>	<b>Rs. 3,771</b>

***Information about major customers***

Revenues from two of the customers of the Company's Global Generics segment were approximately Rs.21,600 and Rs.15,998, representing approximately 14% and 10%, respectively, of the Company's total revenues, for the year ended March 31, 2016.

Revenues from one of the customers of the Company's Global Generics segment were approximately Rs.17,364, representing approximately 12% of the Company's total revenues, for the year ended March 31, 2015.

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****6. Acquisition of select products portfolio of UCB**

On April 1, 2015, the Company entered into a definitive agreement with UCB India Private Limited and other UCB group companies (together referred to as UCB ) to acquire a select portfolio of products business in the territories of India, Nepal, Sri Lanka and Maldives. The transaction included approximately 350 employees engaged in operations of the acquired India business. The acquisition is expected to strengthen the Company's presence in the areas of dermatology, respiratory and pediatric products.

The total purchase consideration was Rs.8,000, payable in cash. The acquisition was closed on June 16, 2015. The Company has accounted for the transaction under IFRS 3, Business Combinations, and allocated the aggregate purchase consideration as follows:

<i>Particulars</i>	<i>Amount</i>
Total consideration	<b>Rs. 8,000</b>
<b><i>Identifiable assets acquired</i></b>	
Property, plant and equipment	6
Other intangible assets:	
Product related intangibles	6,734
Marketing rights	743
Current assets, net of current liabilities assumed	194
<b>Total identifiable net assets</b>	<b>Rs. 7,677</b>
<b>Goodwill</b>	<b>Rs. 323</b>

The total goodwill of Rs.323 is attributable primarily to the acquired employee workforce, intangible assets that do not qualify for separate recognition and the expected synergies. The entire amount of goodwill is deductible for tax purposes.

Acquisition related costs of Rs.9 were excluded from the consideration transferred and were recognized as expense under Selling, general and administrative expenses in the consolidated income statement for the year ended March 31, 2016.

Current assets, net of current liabilities assumed include trade receivables of Rs.118 which were expected to be fully recoverable.

Out of the total purchase consideration of Rs.8,000, the Company has paid Rs.7,936 to UCB as of March 31, 2016.

The amount of revenue included in the consolidated income statement since June 16, 2015 pertaining to the business acquired from UCB was Rs.1,345 for the year ended March 31, 2016.

No pro-forma information is disclosed in these consolidated financial statements, as the impact of this acquisition on these consolidated financial statements is immaterial.

F-30

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

(in millions, except share and per share data and where otherwise stated)

**7. Property, plant and equipment**

The following is a summary of the changes in carrying value of property, plant and equipment.

<b>Particulars</b>	<b>Land</b>	<b>Buildings</b>	<b>Plant and equipment</b>	<b>Computer equipment</b>	<b>Furniture, fixtures and office equipment</b>	<b>Vehicles</b>	<b>Total</b>
<b>Gross carrying value</b>							
Balance as at April 1, 2014	<b>Rs. 3,824</b>	<b>Rs. 15,319</b>	<b>Rs. 39,894</b>	<b>Rs. 1,879</b>	<b>Rs. 1,989</b>	<b>Rs. 539</b>	<b>Rs. 63,444</b>
Acquisitions through business combinations			22		10		32
Other additions	12	1,353	8,472	327	216	169	10,549
Disposals		(37)	(1,069)	(175)	(37)	(79)	(1,397)
Effect of changes in foreign exchange rates	(47)	(130)	(379)	(28)	(30)	(3)	(617)
<b>Balance as at March 31, 2015</b>	<b>Rs. 3,789</b>	<b>Rs. 16,505</b>	<b>Rs. 46,940</b>	<b>Rs. 2,003</b>	<b>Rs. 2,148</b>	<b>Rs. 626</b>	<b>Rs. 72,011</b>
Balance as at April 1, 2015	<b>Rs. 3,789</b>	<b>Rs. 16,505</b>	<b>Rs. 46,940</b>	<b>Rs. 2,003</b>	<b>Rs. 2,148</b>	<b>Rs. 626</b>	<b>Rs. 72,011</b>
Acquisitions through business combinations <sup>(1)</sup>				6			6
Other additions	24	2,402	7,890	372	208	186	11,082
Disposals	(7)	(3)	(651)	(144)	(105)	(33)	(943)
Effect of changes in foreign exchange rates	8	191	214	9	14	(2)	434
<b>Balance as at March 31, 2016</b>	<b>Rs. 3,814</b>	<b>Rs. 19,095</b>	<b>Rs. 54,393</b>	<b>Rs. 2,246</b>	<b>Rs. 2,265</b>	<b>Rs. 777</b>	<b>Rs. 82,590</b>
<b>Accumulated Depreciation</b>							
Balance as at April 1, 2014	<b>Rs.</b>	<b>Rs. 2,831</b>	<b>Rs. 19,767</b>	<b>Rs. 1,215</b>	<b>Rs. 1,610</b>	<b>Rs. 272</b>	<b>Rs. 25,695</b>
Depreciation for the year		701	4,401	272	237	109	5,720
Disposals		(3)	(827)	(156)	(24)	(72)	(1,082)
Effect of changes in foreign exchange rates		(57)	(183)	(23)	(27)	(3)	(293)
<b>Balance as at March 31, 2015</b>	<b>Rs.</b>	<b>Rs. 3,472</b>	<b>Rs. 23,158</b>	<b>Rs. 1,308</b>	<b>Rs. 1,796</b>	<b>Rs. 306</b>	<b>Rs. 30,040</b>

Balance as at April 1, 2015	<b>Rs.</b>	<b>Rs. 3,472</b>	<b>Rs. 23,158</b>	<b>Rs. 1,308</b>	<b>Rs. 1,796</b>	<b>Rs. 306</b>	<b>Rs. 30,040</b>
Depreciation for the year		763	5,341	325	243	108	6,780
Impairment loss <sup>(2)</sup>		20	46	23	4	1	94
Disposals		(0)	(615)	(108)	(100)	(25)	(848)
Effect of changes in foreign exchange rates		47	52	5	10	(1)	113
<b>Balance as at March 31, 2016</b>	<b>Rs.</b>	<b>Rs. 4,302</b>	<b>Rs. 27,982</b>	<b>Rs. 1,553</b>	<b>Rs. 1,953</b>	<b>Rs. 389</b>	<b>Rs. 36,179</b>
<b>Net carrying value</b>							
As at April 1, 2014	Rs. 3,824	Rs. 12,488	Rs. 20,127	Rs. 664	Rs. 379	Rs. 267	Rs. 37,749
As at March 31, 2015	Rs. 3,789	Rs. 13,033	Rs. 23,782	Rs. 695	Rs. 352	Rs. 320	Rs. 41,971
Add:							
Capital-work-in-progress							Rs. 6,119
Total as at March 31, 2015							Rs. 48,090
As at March 31, 2016	Rs. 3,814	Rs. 14,793	Rs. 26,411	Rs. 693	Rs. 312	Rs. 388	Rs. 46,411
Add:							
Capital-work-in-progress							Rs. 7,550
<b>Total as at March 31, 2016</b>							<b>Rs. 53,961</b>

- (1) Acquisitions through business combinations were on account of the Company's acquisition of UCB. Refer to Note 6 of these consolidated financial statements for further details.
- (2) Impairment loss pertains to the assets forming part of the Company's Venezuelan subsidiary. Refer to Note 41 of these consolidated financial statements for further details.

#### *Capital commitments*

As of March 31, 2016 and 2015, the Company was committed to spend Rs.5,065 and Rs.4,173, respectively, under agreements to purchase property, plant and equipment. This amount is net of capital advances paid in respect of such purchase commitments.

#### *Interest capitalization*

During the years ended March 31, 2016 and 2015, the Company capitalized interest cost of Rs.51 and Rs.31, respectively, with respect to qualifying assets. The rate for capitalization of interest cost for the years ended March 31, 2016 and 2015 was approximately 2.07% and 2.32%, respectively.

#### *Assets acquired under finance leases*

Property, plant and equipment include Rs.637 and Rs.739 of assets acquired (net of accumulated depreciation) under finance leases as of March 31, 2016 and 2015, respectively.

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****8. Goodwill**

Goodwill arising upon business acquisitions is not amortized but tested for impairment at least annually or more frequently if there is any indication that the cash generating unit to which goodwill is allocated is impaired.

The following table presents the changes in goodwill during the years ended March 31, 2016 and 2015:

	<b>As of March 31,</b>	
	<b>2016</b>	<b>2015</b>
Opening balance, gross <sup>(1)</sup>	Rs. 19,654	Rs. 19,702
Goodwill arising on business combinations during the year <sup>(2)(3)</sup>	323	203
Effect of translation adjustments	145	(251)
Impairment loss <sup>(4)</sup>	(16,274)	(16,274)
<b>Closing balance <sup>(1)</sup></b>	<b>Rs. 3,848</b>	<b>Rs. 3,380</b>

(1) This does not include goodwill arising upon investment in an associate of Rs.181, which is included in the carrying value of the investment in the equity accounted investees.

(2) Rs.323 represents goodwill arising from the acquisition of a select portfolio of products business from UCB during the three months ended June 30, 2015. Refer to Note 6 of these consolidated financial statements for further details.

(3) Rs.203 represents goodwill arising from the acquisition of net assets from Cherokee Pharma LLC during the year ended March 31, 2015. Total purchase consideration was Rs.292 and the fair value of the net assets acquired was Rs.89. The amount of goodwill was primarily attributable to the acquired workforce and expected synergies. The acquisition was not material to the Company and, accordingly, no further disclosures have been made in these consolidated financial statements.

(4) The impairment loss of Rs.16,274 includes Rs.16,003 pertaining to the Company's German subsidiary, betapharm Arzneimittel GmbH, which is part of the Company's Global Generics segment. This impairment loss was recorded during the years ended March 31, 2009 and 2010.

For the purpose of impairment testing, goodwill is allocated to a cash generating unit, representing the lowest level within the Company at which goodwill is monitored for internal management purposes and which is not higher than the Company's operating segment.

The carrying amount of goodwill (other than those arising upon investment in an associate) was allocated to cash generating units as follows:

	<b>As of March 31,</b>	
	<b>2016</b>	<b>2015</b>
PSAI- Active Pharmaceutical Operations	Rs. 997	Rs. 997
Global Generics- Complex Injectables <sup>(1)</sup>	1,249	1,113
Global Generics- North America Operations	998	989
Global Generics- Branded Formulations <sup>(2)</sup>	491	168
Others	113	113
	<b>Rs. 3,848</b>	<b>Rs. 3,380</b>

- (1) Represents goodwill arising on the acquisition of OctoPlus B.V (formerly OctoPlus N.V.) ( OctoPlus ) during the year ended March 31, 2013. Since its acquisition by the Company, OctoPlus has been engaged in internal drug development projects as well as providing pharmaceutical development services to external customers. During the year ended March 31, 2015, the Company decided to significantly increase the utilization of OctoPlus s technical know-how, its time and effort on internal drug development projects and scale-down its external pharmaceutical development services. Such change in the utilization of technical know-how also resulted in the change of composition of the cash-generating unit to which the goodwill was allocated and the segment to which such goodwill belongs. Accordingly, the Company reallocated the goodwill from its PSAI segment to its Global Generics segment and determined that its complex injectables portfolio was the relevant cash generating unit for the purpose of impairment testing.
- (2) Includes Rs.323 representing goodwill arising from the acquisition of a select portfolio of products business from UCB during the year ended March 31, 2016. Refer to Note 6 of these consolidated financial statements for further details.



The recoverable amounts of the above cash generating units have been assessed using a value-in-use model. Value in use is generally calculated as the net present value of the projected post-tax cash flows plus a terminal value of the cash generating unit to which the goodwill is allocated. Initially a post-tax discount rate is applied to calculate the net present value of the post-tax cash flows. Key assumptions on which the Company has based its determinations of value-in-use include:

- a) Estimated cash flows for five years based on management's budgets and estimates.
- b) Terminal value arrived by extrapolating last forecasted year cash flows to perpetuity, using a constant long-term growth rate of 0%. This long-term growth rate takes into consideration external macroeconomic sources of data. Such long-term growth rate considered does not exceed that of the relevant business and industry sector.

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****8. Goodwill (continued)**

- c) The post-tax discount rates used are based on the Company's weighted average cost of capital.
- d) Value-in-use is calculated using after tax assumptions. The use of after tax assumptions does not result in a value-in-use that is materially different from the value-in-use that would result if the calculation was performed using before tax assumptions. The after tax discount rates used range from 6.87% to 12.16% for various cash generating units. The before tax discount rates range from 9.14% to 18.99%.
- The Company believes that any reasonably possible change in the key assumptions on which a recoverable amount is based would not cause the aggregate carrying amount to exceed the aggregate recoverable amount of the cash-generating unit.

**9. Other intangible assets**

The following is a summary of changes in the carrying value of intangible assets:

	<b>Trademarks with finite useful life</b>	<b>Technology Product related intangibles</b>	<b>Technology related intangibles</b>	<b>Customer related intangibles</b>	<b>Others</b>	<b>Total</b>
<b>Gross carrying amount</b>						
Balance as at April 1, 2014	Rs. 11,049	Rs. 25,229	Rs. 1,717	Rs. 1,215	Rs. 700	Rs. 39,910
Acquisitions through business combinations		60				60
Other additions <sup>(1)</sup>		5,454	54		272	5,780
<b>Deletions</b>						
Effect of changes in foreign exchange rates	(1,700)	(3,120)	(178)	(50)	(20)	(5,068)
<b>Balance as at March 31, 2015</b>	<b>Rs. 9,349</b>	<b>Rs. 27,623</b>	<b>Rs. 1,593</b>	<b>Rs. 1,165</b>	<b>Rs. 952</b>	<b>Rs. 40,682</b>
Balance as at April 1, 2015	Rs. 9,349	Rs. 27,623	Rs. 1,593	Rs. 1,165	Rs. 952	Rs. 40,682
Acquisitions through business combinations <sup>(2)</sup>		6,734			743	7,477
Other additions		1,554	1,158		596	3,308
Deletions				(132)		(132)

Effect of changes in foreign exchange rates	829	1,829	96	67	4	2,825
<b>Balance as at March 31, 2016</b>	<b>Rs. 10,178</b>	<b>Rs. 37,740</b>	<b>Rs. 2,847</b>	<b>Rs. 1,100</b>	<b>Rs. 2,295</b>	<b>Rs. 54,160</b>
<b>Amortization/impairment loss</b>						
Balance as at April 1, 2014	Rs. 7,080	Rs. 19,477	Rs. 800	Rs. 856	Rs. 428	Rs. 28,641
Amortization for the year	541	1,610	152	33	45	2,381
Impairment loss		285	95	249		629
Deletions						
Effect of changes in foreign exchange rates	(933)	(2,959)	(87)	(20)	(20)	(4,019)
<b>Balance as at March 31, 2015</b>	<b>Rs. 6,688</b>	<b>Rs. 18,413</b>	<b>Rs. 960</b>	<b>Rs. 1,118</b>	<b>Rs. 453</b>	<b>Rs. 27,632</b>
Balance as at April 1, 2015	Rs. 6,688	Rs. 18,413	Rs. 960	Rs. 1,118	Rs. 453	Rs. 27,632
Amortization for the year	504	2,414	254	11	287	3,470
Impairment loss		174		20		194
Deletions				(132)		(132)
Effect of changes in foreign exchange rates	494	1,598	39	68	1	2,200
<b>Balance as at March 31, 2016</b>	<b>Rs. 7,686</b>	<b>Rs. 22,599</b>	<b>Rs. 1,253</b>	<b>Rs. 1,085</b>	<b>Rs. 741</b>	<b>Rs. 33,364</b>
<b>Net carrying amount</b>						
As at April 1, 2014	Rs. 3,969	Rs. 5,752	Rs. 917	Rs. 359	Rs. 272	Rs. 11,269
As at March 31, 2015	Rs. 2,661	Rs. 9,210	Rs. 633	Rs. 47	Rs. 499	Rs. 13,050
<b>As at March 31, 2016</b>	<b>Rs. 2,492</b>	<b>Rs. 15,141</b>	<b>Rs. 1,594</b>	<b>Rs. 15</b>	<b>Rs. 1,554</b>	<b>Rs. 20,796</b>

- (1) Other additions during the year ended March 31, 2015 includes Rs.5,097 towards the acquisition from Novartis Consumer Health Inc. of the title and rights to its Habitrol® brand. Refer to Note 39 of these consolidated financial statements for further details.
- (2) Acquisitions through business combinations were on account of the Company's acquisition of UCB. Refer to Note 6 of these consolidated financial statements for further details.

The selling, general and administrative expenses included Rs.3,262, Rs.2,326 and Rs.2,301 of amortization of other intangible assets and Rs.61, Rs.509 and Rs.(497) of impairment loss/(reversal of impairment loss) on other intangible assets for the years ended March 31, 2016, 2015 and 2014, respectively. Research and development expenses included Rs.98, Rs.55 and Rs.0 of amortization of other intangible assets and Rs.133, Rs.120 and Rs.0 of impairment loss on other intangible assets for the years ended March 31, 2016, 2015 and 2014, respectively. Cost of revenues included Rs.110, Rs.0 and Rs.0 of amortization of other intangible assets for the years ended March 31, 2016, 2015 and 2014, respectively.

The weighted average remaining useful life of intangibles was approximately 8.5 years as at March 31, 2016.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**9. Other intangible assets (continued)**

*Impairment losses recorded for the year ended March 31, 2016*

**In-process research and development ( IPR&D ) intangibles**

As a result of the Company's decision to discontinue further development of certain IPR&D assets pertaining to its Proprietary Products segment and Global Generics segment, Rs.100 and Rs.33, respectively, was recorded as impairment loss for the year ended March 31, 2016 under research and development expenses in the Company's consolidated income statement.

**Others**

The balance impairment loss of Rs.61 pertains to a write down of certain customer and product related intangibles forming part of the Company's Global Generics segment, which was recorded under Selling, general and administrative expenses in the Company's consolidated income statement.

*Impairment losses recorded for the year ended March 31, 2015*

For the year ended March 31, 2015, the Company recorded impairment losses of Rs.629 in the consolidated income statement, primarily relating to the following:

**Customer related intangibles**

Since its acquisition during the year ended March 31, 2013, OctoPlus B.V., a wholly owned subsidiary of the Company, has been engaged in the Company's internal drug development projects as well as providing pharmaceutical development services to external customers.

During the year ended March 31, 2015, the Company decided to significantly increase the utilization of OctoPlus B.V.'s technical know-how, its time and effort on internal drug development projects and scale-down its external pharmaceutical development services. As a result of such decision, the Company reassessed the recoverable amounts of associated customer related intangibles and determined that the carrying amount of such customer related intangibles was higher than their recoverable amount. Accordingly, Rs.249 was recorded as an impairment loss for the year ended March 31, 2015 under Selling, general and administrative expenses in the Company's consolidated income statement.

The above impairment loss relate to the Company's PSAI segment. As at March 31, 2015, the carrying amount of such customer related intangibles after impairment loss was Rs.0.

Product related intangibles

Based on the performance of and expected cash flows from some of the Company's product related intangibles pertaining to its Global Generics segment, the Company reassessed the recoverable amounts of such product related intangibles and determined that the carrying amount of such product-related intangibles was higher than their recoverable amount. Accordingly, Rs.201 was recorded as an impairment loss for the year ended March 31, 2015 under Selling, general and administrative expenses in the Company's consolidated income statement. As at March 31, 2015, the carrying amount of such product related intangibles after impairment loss was Rs.0.

In-process research and development ( IPR&D ) intangibles

Due to the Company's decision to discontinue further development of certain IPR&D assets pertaining to its Proprietary Products segment, Rs.95 was recorded as impairment loss for the year ended March 31, 2015 under research and development expenses in the Company's consolidated income statement.

*Reversal of impairment losses recorded for the year ended March 31, 2014*

As a result of the increase in expected cash flows of some of the products forming part of the product related intangibles pertaining to the Company's Global Generics segment, the Company, following the guidance under IAS 36 Impairment of assets, estimated the recoverable amount of such intangible asset and assessed that the impairment loss recorded in an earlier period should be reversed. Accordingly, a reversal of impairment loss of Rs.497 for such product related intangibles was recorded for the year ended March 31, 2014 under Selling, general and administrative expenses in the consolidated income statement. The expected cash flows increased primarily due to various market dynamics, such as reduced competition and favorable pricing position.

The above reversal of impairment losses relate to the Company's Global Generics segment. The pre-tax cash flows have been discounted based on a pre-tax discount rate of 5.68%. As at March 31, 2014, the carrying amount of such product related intangibles after reversal of impairment loss was Rs.1,287.

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****10. Investment in equity accounted investees**

Kunshan Rotam Reddy Pharmaceuticals Co. Limited ( Reddy Kunshan ) is engaged in manufacturing and marketing of formulations in China. The Company s interest in Reddy Kunshan was 51.3% as of March 31, 2016 and 2015. Three directors of the Company are on the board of directors of Reddy Kunshan, which consists of seven directors. Under the terms of the joint venture agreement, all major decisions with respect to operating activities, significant financing and other activities are taken by the approval of at least five of the seven directors of Reddy Kunshan s board. As the Company does not control Reddy Kunshan s board and the other partners have significant participating rights, the Company s interest in Reddy Kunshan has been accounted for under the equity method of accounting under IFRS 11.

Summary financial information of Reddy Kunshan, as translated into the reporting currency of the Company and not adjusted for the percentage ownership held by the Company, is as follows:

	<b>As of/for the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Ownership	51.3%	51.3%	51.3%
Total current assets	Rs. 2,876	Rs. 2,090	Rs. 1,768
Total non-current assets	377	389	346
<b>Total assets</b>	<b>Rs. 3,253</b>	<b>Rs. 2,479</b>	<b>Rs. 2,114</b>
Equity	Rs. 2,129	Rs. 1,656	Rs. 1,213
Total current liabilities	1,124	823	901
<b>Total equity and liabilities</b>	<b>Rs. 3,253</b>	<b>Rs. 2,479</b>	<b>Rs. 2,114</b>
Revenues	Rs. 4,246	Rs. 3,377	Rs. 2,794
Expenses	3,800	2,998	2,455
<b>Profit for the year</b>	<b>Rs. 446</b>	<b>Rs. 379</b>	<b>Rs. 339</b>

The Company s share of profits in Reddy Kunshan for the years ended March 31, 2016, 2015 and 2014 was Rs.229, Rs.195 and Rs.174, respectively. The carrying value of the Company s investment in Reddy Kunshan as of March 31, 2016 and 2015 was Rs.1,309 and Rs.1,033, respectively. The translation adjustment arising out of translation of foreign currency balances amounted to Rs.239 and Rs.192 as of March 31, 2016 and 2015, respectively.

**11. Other investments**

Other investments consist of investments in units of mutual funds, equity securities and term deposits (i.e., certificates of deposit having an original maturity period exceeding 3 months) with banks. The details of such investments as of March 31, 2016 are as follows:

	<b>Cost</b>	<b>Gain recognized directly in equity</b>	<b>Fair value</b>
Investment in units of mutual funds	Rs. 21,335	Rs. 1,223	Rs. 22,558
Investment in equity securities <sup>(1)</sup>	1,458	293	1,751
Term deposits with banks	12,713		12,713
	<b>Rs. 35,506</b>	<b>Rs. 1,516</b>	<b>Rs. 37,022</b>
<b>Current portion</b>			
Investment in units of mutual funds	Rs. 21,122	Rs. 1,199	Rs. 22,321
Term deposits with banks	12,713		12,713
	<b>Rs. 33,835</b>	<b>Rs. 1,199</b>	<b>Rs. 35,034</b>
<b>Non-current portion</b>			
Investment in units of mutual funds	Rs. 213	Rs. 24	Rs. 237
Investment in equity securities <sup>(1)</sup>	1,458	293	1,751
	<b>Rs. 1,671</b>	<b>Rs. 317</b>	<b>Rs. 1,988</b>

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****11. Other investments (continued)**

As of March 31, 2015, the details of such investments were as follows:

	<b>Cost</b>	<b>Gain recognized directly in equity</b>	<b>Fair value</b>
Investment in units of mutual funds	Rs. 21,237	Rs. 404	Rs. 21,641
Investment in equity securities <sup>(1)</sup>	1,456	1,131	2,587
Term deposits with banks	12,848		12,848
	<b>Rs. 35,541</b>	<b>Rs. 1,535</b>	<b>Rs. 37,076</b>
<b>Current portion</b>			
Investment in units of mutual funds	Rs. 21,024	Rs. 398	Rs. 21,422
Term deposits with banks	12,837		12,837
	<b>Rs. 33,861</b>	<b>Rs. 398</b>	<b>Rs. 34,259</b>
<b>Non-current portion</b>			
Investment in units of mutual funds	Rs. 213	Rs. 6	Rs. 219
Investment in equity securities <sup>(1)</sup>	1,456	1,131	2,587
Term deposits with banks	11		11
	<b>Rs. 1,680</b>	<b>Rs. 1,137</b>	<b>Rs. 2,817</b>

<sup>(1)</sup> Primarily represents the shares of Curis, Inc. Refer to Note 34 of these consolidated financial statements for further details.

**12. Inventories**

Inventories consist of the following:

**As of March 31,**



	<b>2016</b>	<b>2015</b>
Raw materials	Rs. 5,769	Rs. 6,753
Packing materials, stores and spares	2,057	1,981
Work-in-progress	7,049	6,769
Finished goods	10,703	10,026
	<b>Rs. 25,578</b>	<b>Rs. 25,529</b>

The above table includes inventories of Rs.730 and Rs.901, which were carried at fair value less cost to sell as at March 31, 2016 and 2015, respectively.

During the years ended March 31, 2016, 2015 and 2014, the Company recorded inventory write-downs of Rs.2,746, Rs.3,635 and Rs.1,941, respectively. These adjustments were included in cost of revenues.

Cost of revenues for the years ended March 31, 2016, 2015 and 2014 includes raw materials, consumables and changes in finished goods and work in progress recognized in the income statement of Rs.33,051, Rs.36,806 and Rs.31,711, respectively. Cost of revenues for the years ended March 31, 2016, 2015 and 2014 includes other expenditures recognized in the income statement of Rs.29,376, Rs.25,980 and Rs.24,658, respectively.

### 13. Trade and other receivables

	<b>As of March 31,</b>	
	<b>2016</b>	<b>2015</b>
Trade and other receivables, gross	Rs. 42,095	Rs. 41,422
Less: Allowance for doubtful trade and other receivables	(789)	(667)
<b>Trade and other receivables, net</b>	<b>Rs. 41,306</b>	<b>Rs. 40,755</b>

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****13. Trade and other receivables (continued)**

The Company maintains an allowance for impairment of doubtful accounts based on financial condition of the customer, aging of the customer accounts receivable and historical experience of collections from customers. The activity in the allowance for impairment of trade account receivables is given below:

	<b>For the Year Ended March 31,</b>	
	<b>2016</b>	<b>2015</b>
Balance at the beginning of the year	Rs. 667	Rs. 683
Provision for doubtful trade and other receivables, net	137	168
Trade and other receivables written off and exchange differences	(15)	(184)
<b>Balance at the end of the year</b>	<b>Rs. 789</b>	<b>Rs. 667</b>

**14. Other assets**

Other assets consist of the following:

	<b>As of March 31,</b>	
	<b>2016</b>	<b>2015</b>
<b>Current</b>		
Balances and receivables from statutory authorities <sup>(1)</sup>	Rs. 4,059	Rs. 5,268
Export benefits receivable <sup>(2)</sup>	3,239	2,572
Prepaid expenses	679	695
Others	3,033	2,747
	<b>Rs. 11,010</b>	<b>Rs. 11,282</b>
<b>Non-current</b>		
Deposits	Rs. 620	Rs. 536
Others	443	226
	<b>Rs. 1,063</b>	<b>Rs. 762</b>

- (1) Balances and receivables from statutory authorities primarily consist of amounts receivable from the excise, value added tax and customs authorities of India and the unutilized excise input credits on purchases. These are regularly utilized to offset the Indian excise and service tax liability on goods produced by and services provided by the Company. Accordingly, these balances have been classified as current assets.
- (2) Export benefits receivables primarily consist of amounts receivable from various government authorities of India towards incentives on export sales made by the Company.

### 15. Cash and cash equivalents

Cash and cash equivalents consist of the following:

	<b>As of March 31,</b>	
	<b>2016</b>	<b>2015</b>
Cash balances	Rs. 2	Rs. 3
Balances with banks	1,642	3,939
Term deposits with banks (original maturities up to 3 months)	3,277	1,452
<b>Cash and cash equivalents in the statement of financial position</b>	<b>4,921</b>	<b>5,394</b>
Bank overdrafts used for cash management purposes		
<b>Cash and cash equivalents in the statement of cash flow</b>	<b>Rs. 4,921</b>	<b>Rs. 5,394</b>

Cash and cash equivalents included restricted cash of Rs.257 and Rs.1,971, respectively, as of March 31, 2016 and March 31, 2015, which consisted of:

Rs.62 as of March 31, 2016 and Rs.57 as of March 31, 2015, representing amounts in the Company's unclaimed dividend and debenture interest accounts;

Rs.124 as of March 31, 2016 and Rs.1,796 as of March 31, 2015, representing cash and cash equivalents of the Company's subsidiary in Venezuela, which are subject to foreign exchange controls (Refer to Note 41 of these consolidated financial statements for further details);

Rs.0 as of March 31, 2016 and Rs.107 as of March 31, 2015, representing amounts deposited as security for a bond executed for an environmental liability relating to the Company's site in Mirfield, United Kingdom; and

Rs.71 as of March 31, 2016 and Rs.11 as of March 31, 2015, representing other restricted cash amounts.

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****16. Equity**

	<b>For the Year Ended March 31,</b>	
	<b>2016</b>	<b>2015</b>
<b>Par value per share</b>	Rs. 5	Rs. 5
<b>Authorized share capital</b>	1,200	1,200
<b>Fully paid up share capital</b>		
As at April 1	Rs. 852	Rs. 851
Add: Shares issued on exercise of stock options	1	1
<b>As at March 31</b>	<b>Rs. 853</b>	<b>Rs. 852</b>

The Company presently has only one class of equity shares. For all matters submitted to vote in a shareholders meeting of the Company, every holder of an equity share, as reflected in the records of the Company on the date of the shareholders meeting, shall have one vote in respect of each share held.

Should the Company declare and pay any dividends, such dividends will be paid in Indian rupees to each holder of equity shares in proportion to the number of shares held to the total equity shares outstanding as on that date. Indian law on foreign exchange governs the remittance of dividends outside India.

In the event of liquidation of the Company, all preferential amounts, if any, shall be discharged by the Company. The remaining assets of the Company shall be distributed to the holders of equity shares in proportion to the number of shares held to the total equity shares outstanding as on that date.

Final dividends on equity shares (including dividend tax on distribution of such dividends) are recorded as a liability on the date of their approval by the shareholders and interim dividends are recorded as a liability on the date of declaration by the Company's Board of Directors. The Company paid dividends of Rs.3,411, Rs.3,067 and Rs.2,552 and dividend distribution tax thereon of Rs.695, Rs.520 and Rs.433 during the years ended March 31, 2016, 2015 and 2014, respectively. The dividend paid per share was Rs.20, Rs.18 and Rs.15 during the years ended March 31, 2016, 2015 and 2014, respectively.

At the Company's Board of Directors' meeting held on May 12, 2016, the Board proposed a dividend of Rs.20 per share and aggregating to Rs.3,405 which is subject to the approval of the Company's shareholders and the number of shares that are bought back by the Company pursuant to the share buyback scheme commenced on April 18, 2016 (refer to Note 45 of these consolidated financial statements for further details). Upon such approval, there will be an additional cash outflow of Rs.693 for payment of dividend distribution tax thereon.

**17. Earnings per share**

The calculation of basic and diluted earnings per share for the years ended March 31, 2016, 2015 and 2014 was based on the profit attributable to equity shareholders of Rs.20,013, Rs.22,179 and Rs.21,515, respectively.

The weighted average number of equity shares outstanding, used for calculating the basic earnings per share, are as follows:

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Issued equity shares as on April 1	170,381,174	170,108,868	169,836,475
Effect of shares issued on exercise of stock options	166,469	205,638	208,043
Weighted average number of equity shares at March 31	170,547,643	170,314,506	170,044,518
Earnings per share Basic	Rs. 117.34	Rs. 130.22	Rs. 126.52

The weighted average number of equity shares outstanding, used for calculating the diluted earnings per share, are as follows:

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Weighted average number of equity shares (Basic)	170,547,643	170,314,506	170,044,518
Dilutive effect of stock options outstanding	525,137	618,927	650,499
Weighted average number of equity shares (Diluted)	171,072,780	170,933,433	170,695,017
Earnings per share Diluted	Rs. 116.98	Rs. 129.75	Rs. 126.04

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****18. Loans and borrowings****Short term borrowings**

The Company had net short term borrowings of Rs.22,718 as of March 31, 2016, as compared to Rs.21,857 as of March 31, 2015. The borrowings primarily consist of packing credit and other rupee loans drawn by the parent company and other foreign currency unsecured loan drawn by Dr. Reddy s Laboratories SA (one of the Company s subsidiaries in Switzerland).

Short term borrowings consist of the following:

	<b>As at March 31,</b>	
	<b>2016</b>	<b>2015</b>
Packing credit borrowings	Rs. 20,896	Rs. 20,857
Other foreign currency borrowings	1,822	
Other rupee borrowings		1,000
	<b>Rs. 22,718</b>	<b>Rs. 21,857</b>

The interest rate profile of short term borrowings from banks is given below:

	<b>As at March 31,</b>			
	<b>2016</b>		<b>2015</b>	
	<b>Currency</b>	<b>Interest Rate</b>	<b>Currency</b>	<b>Interest Rate</b>
Packing credit borrowings	USD	LIBOR + (5) to 15 bps	USD	LIBOR + 10 to 40 bps
	EURO	LIBOR + 5 to 7.5 bps	EURO	LIBOR + 7.5 to 20 bps
	RUB	10.65% to 11.57%	RUB	9.80% to 22.30%
Other foreign currency borrowings	USD	LIBOR + 40 bps		
Other rupee borrowings			INR	10%

**Long term borrowings**

Long term borrowings, measured at amortized cost, consist of the following:

	<b>As at March 31</b>	
	<b>2016</b>	<b>2015</b>
Foreign currency borrowing by the Company's Swiss subsidiary <sup>(1)</sup>	Rs.	Rs. 10,292
Foreign currency borrowing by the parent company	9,938	9,375
Foreign currency borrowing by the Company's U.K. subsidiary <sup>(1)</sup>		740
Obligations under finance leases	857	862
	<b>Rs. 10,795</b>	<b>Rs. 21,269</b>
<b>Current portion</b>		
Foreign currency borrowing by the Company's Swiss subsidiary <sup>(1)</sup>	Rs.	Rs. 6,875
Obligations under finance leases	110	87
	<b>Rs. 110</b>	<b>Rs. 6,962</b>
<b>Non-current portion</b>		
Foreign currency borrowing by the Company's Swiss subsidiary <sup>(1)</sup>	Rs.	Rs. 3,417
Foreign currency borrowing by the parent company	9,938	9,375
Foreign currency borrowing by the Company's U.K. subsidiary <sup>(1)</sup>		740
Obligations under finance leases	747	775
	<b>Rs. 10,685</b>	<b>Rs. 14,307</b>

<sup>(1)</sup> During the year ended March 31, 2016, the Company's U.K. Subsidiary and Swiss Subsidiary repaid the foreign currency borrowings.

In the above table, the term "Swiss subsidiary" refers to Dr. Reddy's Laboratories, SA and the term "U.K. Subsidiary" refers to Dr. Reddy's Laboratories (EU) Limited.

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****18. Loans and borrowings (continued)***Long term borrowings (continued)**Long-term bank loan of Swiss Subsidiary*

During the year ended March 31, 2012, Dr. Reddy s Laboratories, SA (one of the Company s subsidiaries in Switzerland) (the Swiss Subsidiary ) borrowed U.S.\$220 from certain institutional lenders. The Swiss Subsidiary was required to repay the loan in eight equal quarterly installments commencing at the end of the 39th month and continuing until the end of the 60th month from September 30, 2011. The parent company had guaranteed all obligations of the Swiss Subsidiary under the loan agreement.

As part of this arrangement, the Company incurred U.S.\$3.73 in arrangement fees and other administrative charges. The Company accounted for these costs as transaction costs under IAS 39 and they were amortized over the term of the loan using the effective interest method.

The carrying amount of the foregoing loan, measured at amortized cost using the effective interest rate method, as on March 31, 2015 was Rs.10,292 (U.S.\$165).

*Repayments during the year*

Tabulated below are the details of repayment of the loan taken by the Swiss Subsidiary during the year ended March 31, 2016:

<b>Particulars</b>	<b>Amount in U.S.\$</b>		<b>Amount in Rs.</b>	
During the quarter ended June 30, 2015	U.S.\$	27.5	Rs.	1,750
During the quarter ended September 30, 2015 (including the prepayment of U.S.\$110)		137.5		9,018
<b>Total</b>	<b>U.S.\$</b>	<b>165.0</b>	<b>Rs.</b>	<b>10,768</b>

As a result of the above repayment, the unamortized portion of arrangement fees and other administrative charges of U.S.\$0.26 was recognized as finance cost during the year ended March 31, 2016.



*New loans taken during the year*

Further, during the three months ended September 30, 2015, a short-term borrowing of U.S.\$82.5 and a packing credit borrowing of U.S.\$27.5 were taken by the Swiss Subsidiary and by the parent company, respectively. As both of these loans are repayable within a period of 12 months, they are disclosed as part of short-term borrowings. During the six months ended March 31, 2016, the Company repaid U.S.\$55 of the short-term borrowings taken by the Swiss Subsidiary.

*Long-term bank loan of the parent company*

During the year ended March 31, 2014, the Company borrowed the sum of U.S.\$150. The Company is required to repay the loan in five equal quarterly installments commencing at the end of the 54th month and continuing until the end of the 66th month from August 12, 2013.

The loan agreement imposes various financial covenants on the Company. As of March 31, 2016, the Company was in compliance with such financial covenants.

*Undrawn lines of credit from bankers*

The Company has undrawn lines of credit of Rs.14,771 and Rs.10,438 as of March 31, 2016 and 2015, respectively, from its banks for working capital requirements. The Company has the right to draw upon these lines of credit based on its working capital requirements.

*Non-derivative financial liabilities designated as cash flow hedges*

The Company has designated some of its foreign currency borrowings from banks (non-derivative financial liabilities) as hedging instruments for hedge of foreign currency risk associated with highly probable forecasted transactions and, accordingly, applies cash flow hedge accounting for such relationships. Re-measurement gain/loss on such non-derivative financial liabilities is recorded in the Company's hedging reserve as a component of equity and re-classified to the income statement as revenue in the period corresponding to the occurrence of the forecasted transactions. The carrying value of such non-derivative financial liabilities as of March 31, 2016 and March 31, 2015 was Rs.3,644 and Rs.10,313, respectively.

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

(in millions, except share and per share data and where otherwise stated)

**18. Loans and borrowings (continued)***Long term borrowings (continued)*

The interest rate profile of long-term borrowings (other than obligations under finance leases) is given below:

	As at March 31,			
	Currency	2016 Interest Rate	Currency	2015 Interest Rate
Foreign currency borrowings	USD	LIBOR + 125 bps	USD GBP	LIBOR + 100 to 125 bps LIBOR+130 bps

The aggregate maturities of long term loans and borrowings, based on contractual maturities, as of March 31, 2016 were as follows:

Maturing in the year ending	Obligations under			
March 31,	Foreign currency loan	finance leases		Total
	Rs.	Rs.		Rs.
2017			110	110
2018	1,988		101	2,089
2019	7,950		59	8,009
2020			54	54
2021			58	58
Thereafter			475	475
	<b>Rs. 9,938</b>	<b>Rs. 857</b>		<b>Rs. 10,795</b>

The aggregate maturities of long term loans and borrowings, based on contractual maturities, as of March 31, 2015 were as follows:

Maturing in the year ending	Total
-----------------------------	-------

<b>March 31,</b>	<b>Foreign currency loan</b>	<b>Obligations under finance leases</b>		
2016	Rs. 6,875	Rs. 87	Rs. 6,962	
2017	4,177	89	4,266	
2018	1,875	82	1,957	
2019	7,500	48	7,548	
2020		44	44	
Thereafter		512	512	
	<b>Rs. 20,427</b>	<b>Rs. 862</b>	<b>Rs. 21,289</b>	

*Obligations under finance leases*

The Company has leased buildings, plant and machinery and vehicles under finance leases. Future minimum lease payments under finance leases as at March 31, 2016 were as follows:

<b>Particulars</b>	<b>Present value of minimum lease payments</b>	<b>Interest</b>	<b>Future minimum lease payments</b>
Not later than one year	Rs. 110	Rs. 106	Rs. 216
Between one and five years	272	203	475
More than five years	475	125	600
	<b>Rs. 857</b>	<b>Rs. 434</b>	<b>Rs. 1,291</b>

Future minimum lease payments under finance leases as at March 31, 2015 were as follows:

<b>Particulars</b>	<b>Present value of minimum lease payments</b>	<b>Interest</b>	<b>Future minimum lease payments</b>
Not later than one year	Rs. 87	Rs. 117	Rs. 204
Between one and five years	263	249	512
More than five years	512	185	697
	<b>Rs. 862</b>	<b>Rs. 551</b>	<b>Rs. 1,413</b>

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****19. Employee benefits*****Gratuity benefits provided by the parent company***

In accordance with applicable Indian laws, the Company has a defined benefit plan which provides for gratuity payments (the Gratuity Plan ) and covers certain categories of employees in India. The Gratuity Plan provides a lump sum gratuity payment to eligible employees at retirement or termination of their employment. The amount of the payment is based on the respective employee s last drawn salary and the years of employment with the Company. Effective September 1, 1999, the Company established the Dr. Reddy s Laboratories Gratuity Fund (the Gratuity Fund ) to fund the Gratuity Plan. Liabilities in respect of the Gratuity Plan are determined by an actuarial valuation, based upon which the Company makes contributions to the Gratuity Fund. Trustees administer the contributions made to the Gratuity Fund. Amounts contributed to the Gratuity Fund are primarily invested in Indian government bonds and corporate debt securities. A small portion of the fund is also invested in equity securities of Indian companies.

The components of gratuity cost recognized in the income statement for the years ended March 31, 2016, 2015 and 2014 consist of the following:

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Current service cost	Rs. 177	Rs. 148	Rs. 126
Interest on net defined benefit liability/(asset)	2	7	9
<b>Gratuity cost recognized in income statement</b>	<b>Rs. 179</b>	<b>Rs. 155</b>	<b>Rs. 135</b>

Details of the employee benefits obligations and plan assets are provided below:

	<b>As of March 31,</b>	
	<b>2016</b>	<b>2015</b>
Present value of funded obligations	Rs. 1,540	Rs. 1,236
Fair value of plan assets	(1,303)	(1,157)
<b>Net defined benefit liability recognized</b>	<b>Rs. 237</b>	<b>Rs. 79</b>

Details of changes in the present value of defined benefit obligations are as follows:

	<b>As of March 31,</b>	
	<b>2016</b>	<b>2015</b>
Defined benefit obligations at the beginning of the year	Rs. 1,236	Rs. 1,040
Current service cost	177	148
Interest on defined obligations	93	87
Re-measurements due to:		
<i>Actuarial loss/(gain) due to change in financial assumptions</i>	35	12
<i>Actuarial loss/(gain) due to demographic assumptions</i>	11	6
<i>Actuarial loss/(gain) due to experience changes</i>	106	27
Benefits paid	(118)	(84)
<b>Defined benefit obligations at the end of the year</b>	<b>Rs. 1,540</b>	<b>Rs. 1,236</b>

Details of changes in the fair value of plan assets are as follows:

	<b>As of March 31,</b>	
	<b>2016</b>	<b>2015</b>
Fair value of plan assets at the beginning of the year	Rs. 1,157	Rs. 909
Employer contributions	190	209
Interest on plan assets	91	80
Re-measurements due to:		
<i>Return on plan assets excluding interest on plan assets</i>	(17)	43
Benefits paid	(118)	(84)
<b>Plan assets at the end of the year</b>	<b>Rs. 1,303</b>	<b>Rs. 1,157</b>

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****19. Employee benefits (continued)***Sensitivity Analysis:*

	<b>As of March 31, 2016</b>
Defined benefit obligation without effect of projected salary growth	Rs. 840
Add: Effect of salary growth	700
Defined benefit obligation with projected salary growth	1,540
Defined benefit obligation, using discount rate minus 50 basis points	1,600
Defined benefit obligation, using salary growth rate plus 50 basis points	1,599

*Summary of the actuarial assumptions:* The actuarial assumptions used in accounting for the Gratuity Plan are as follows:

The assumptions used to determine benefit obligations:

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Discount rate	7.80%	8.00%	9.00%
Rate of compensation increase	10% per annum for first 2 years and 9% per annum thereafter	10% per annum for first 2 years and 9% per annum thereafter	11% per annum for first 2 years and 10% per annum thereafter

The assumptions used to determine gratuity cost:

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Discount rate	8.00%	9.00%	7.95%

Rate of compensation increase	10% per annum for first 2 years and 9% per annum thereafter	11% per annum for first 2 years and 10% per annum thereafter	10% per annum for first 2 years and 9% per annum thereafter
-------------------------------	---	--	---

*Contributions:* The Company expects to contribute Rs.237 to the Gratuity Plan during the year ending March 31, 2017.

*Disaggregation of plan assets:* The Gratuity Plan's weighted-average asset allocation at March 31, 2016 and 2015, by asset category, was as follows:

	As of March 31,	
	2016	2015
Funds managed by insurers	99%	99%
Others	1%	1%

The expected future cash flows in respect of gratuity as at March 31, 2016 were as follows:

Expected contribution	Amount
During the year ended March 31, 2017 (estimated)	Rs. 237
<b>Expected future benefit payments</b>	
March 31, 2017	167
March 31, 2018	151
March 31, 2019	165
March 31, 2020	161
March 31, 2021	159
Thereafter	2,420

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****19. Employee benefits (continued)*****Pension plan of the Company's subsidiary, Industrias Quimicas Falcon de Mexico***

All employees of the Company's Mexican subsidiary, Industrias Quimicas Falcon de Mexico ( Falcon ), are entitled to a pension benefit in the form of a defined benefit pension plan. The Falcon pension plan provides for payment to vested employees at retirement or termination of employment. Liabilities in respect of the pension plan are determined by an actuarial valuation, based on which the Company makes contributions to the pension plan fund. This fund is administered by a third party, who is provided guidance by a technical committee formed by senior employees of Falcon.

The components of net pension cost recognized in the income statement for the years ended March 31, 2016, 2015 and 2014 consist of the following:

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Current service cost	Rs. 14	Rs. 13	Rs. 18
Interest on net defined benefit liability/(asset)	11	9	11
<b>Total cost recognized in income statement</b>	<b>Rs. 25</b>	<b>Rs. 22</b>	<b>Rs. 29</b>

Details of the employee benefits obligation and plan assets are provided below:

	<b>As of March 31,</b>	
	<b>2016</b>	<b>2015</b>
Present value of funded obligations	Rs. 249	Rs. 252
Fair value of plan assets	(61)	(68)
<b>Net defined benefit liability recognized</b>	<b>Rs. 188</b>	<b>Rs. 184</b>

Details of changes in the present value of defined benefit obligations are as follows:



	<b>As of March 31,</b>	
	<b>2016</b>	<b>2015</b>
Defined benefit obligations at the beginning of the year	Rs. 252	Rs. 252
Current service cost	14	13
Interest on defined obligations	17	18
Re-measurements due to:		
<i>Actuarial loss/(gain) due to change in financial assumptions</i>	(7)	13
<i>Actuarial loss/(gain) due to demographic assumptions</i>	7	0
<i>Actuarial loss/(gain) due to experience changes</i>	3	25
Benefits paid	(22)	(42)
Foreign exchange differences	(15)	(27)
<b>Defined benefit obligations at the end of the year</b>	<b>Rs. 249</b>	<b>Rs. 252</b>

Details of changes in the fair value of plan assets are as follows:

	<b>As of March 31,</b>	
	<b>2016</b>	<b>2015</b>
Fair value of plan assets at the beginning of the year	Rs. 68	Rs. 110
Employer contributions	16	3
Interest on plan assets	6	9
Re-measurements due to:		
<i>Return on plan assets excluding interest on plan assets</i>	(2)	(2)
Benefits paid	(22)	(42)
Foreign exchange differences	(5)	(11)
<b>Plan assets at the end of the year</b>	<b>Rs. 61</b>	<b>Rs. 68</b>

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****19. Employee benefits (continued)***Sensitivity Analysis:*

	<b>As of March 31, 2016</b>	
Defined benefit obligation without effect of projected salary growth	Rs.	155
Plus effect of salary growth		94
Defined benefit obligation with projected salary growth		249
Defined benefit obligation, using discount rate minus 50 basis points		263
Defined benefit obligation, using salary growth rate plus 50 basis points		263

*Contributions:* The Company expects to contribute Rs.38 to the Falcon defined benefit plans during the year ending March 31, 2017.

*Summary of the actuarial assumptions:* The actuarial assumptions used in accounting for the Falcon defined benefit plans are as follows:

Assumptions used to determine defined benefit obligations:

	<b>Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Discount rate	7.75%	7.50%	8.00%
Rate of compensation increase	4.50%	4.50%	4.50%

Assumptions used to determine defined benefit cost:

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Discount rate	7.50%	8.00%	6.50%
Rate of compensation increase	4.50%	4.50%	4.50%

*Plan assets:* The Falcon pension plan's weighted-average asset allocation at March 31, 2016 and 2015, by asset category is as follows:

	<b>As of March 31,</b>	
	<b>2016</b>	<b>2015</b>
Corporate bonds	51%	51%
Others	49%	49%

The expected future cash flows in respect of post-employment benefit plans in Mexico as at March 31, 2016 were as follows:

<b>Expected contribution</b>	<b>Amount</b>
During the year ended March 31, 2017 (estimated)	Rs. 38
<b>Expected future benefit payments</b>	
March 31, 2017	2
March 31, 2018	4
March 31, 2019	7
March 31, 2020	9
March 31, 2021	11
Thereafter	606

***Provident fund benefits***

Certain categories of employees of the Company receive benefits from a provident fund, a defined contribution plan. Both the employee and employer each make monthly contributions to a government administered fund equal to 12% of the covered employee's qualifying salary. The Company has no further obligations under the plan beyond its monthly contributions. The Company contributed Rs.574, Rs.492 and Rs.411 to the provident fund plan during the years ended March 31, 2016, 2015 and 2014, respectively.

***Superannuation benefits***

Certain categories of employees of the Company participate in superannuation, a defined contribution plan administered by the Life Insurance Corporation of India. The Company makes annual contributions based on a specified percentage of each covered employee's salary. The Company has no further obligations under the plan beyond its annual contributions. The Company contributed Rs.71, Rs.68 and Rs.63 to the superannuation plan during the years ended March 31, 2016, 2015 and 2014, respectively.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**19. Employee benefits (continued)**

***Other contribution plans***

In the United States, the Company sponsors a defined contribution 401(k) retirement savings plan for all eligible employees who meet minimum age and service requirements. The Company contributed Rs.204, Rs.195 and Rs.162 to the 401(k) retirement savings plan during the years ended March 31, 2016, 2015 and 2014, respectively. The Company has no further obligations under the plan beyond its annual matching contributions.

In the United Kingdom, certain social security benefits (such as pension, unemployment and disability) are funded by employers and employees through mandatory National Insurance contributions. The contribution amounts are determined based upon the employee's salary. The Company has no further obligations under the plan beyond its monthly contributions. The Company contributed Rs.156, Rs.151 and Rs.151 to the National Insurance during the years ended March 31, 2016, 2015 and 2014, respectively.

***Compensated absences***

The Company provides for accumulation of compensated absences by certain categories of its employees. These employees can carry forward a portion of the unutilized compensated absences and utilize it in future periods or receive cash in lieu thereof as per the Company's policy. The Company records a liability for compensated absences in the period in which the employee renders the services that increases this entitlement. The total liability recorded by the Company towards this obligation was Rs.792 and Rs.616 as at March 31, 2016 and 2015, respectively.

***Long term incentive plan***

Certain senior management employees of the Company participate in a long term incentive plan which is aimed at rewarding the individual, based on performance of such individual, their business unit/function and the Company as a whole, with significantly higher rewards for superior performances. The total liability recorded by the Company towards this benefit was Rs.881 as of March 31, 2016.

Total employee benefit expenses, including share based payments, incurred during the years ended March 31, 2016, 2015 and 2014 amounted to Rs.31,174, Rs.28,967 and Rs.24,937, respectively.

**20. Employee stock incentive plans**

***Dr. Reddy s Employees Stock Option Plan -2002 (the DRL 2002 Plan ):***

The Company instituted the DRL 2002 Plan for all eligible employees pursuant to the special resolution approved by the shareholders in the Annual General Meeting held on September 24, 2001. The DRL 2002 Plan covers all employees of DRL and its subsidiaries and directors (excluding promoter directors) of DRL and its subsidiaries (collectively, eligible employees ). The Nomination, Governance and Compensation Committee of the Board of DRL (the Committee ) administers the DRL 2002 Plan and grants stock options to eligible employees. The Committee determines which eligible employees will receive options, the number of options to be granted, the exercise price, the vesting period and the exercise period. The vesting period is determined for all options issued on the date of grant. The options issued under the DRL 2002 Plan vest in periods ranging between one and four years and generally have a maximum contractual term of five years.

The DRL 2002 Plan, as amended at annual general meetings of shareholders held on July 28, 2004 and on July 27, 2005, provides for stock option grants in two categories:

Category A: 300,000 stock options out of the total of 2,295,478 options reserved for grant having an exercise price equal to the fair market value of the underlying equity shares on the date of grant; and

Category B: 1,995,478 stock options out of the total of 2,295,478 options reserved for grant having an exercise price equal to the par value of the underlying equity shares (i.e., Rs.5 per option).

Under the DRL 2002 Plan, the exercise price of the fair market value options granted under Category A above is determined based on the average closing price for 30 days prior to the grant in the stock exchange where there is highest trading volume during that period. Notwithstanding the foregoing, the Committee may, after obtaining the approval of the shareholders in the annual general meeting, grant options with a per share exercise price other than fair market value and par value of the equity shares.

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

(in millions, except share and per share data and where otherwise stated)

**20. Employee stock incentive plans (continued)***Dr. Reddy s Employees Stock Option Plan -2002 (the DRL 2002 Plan ) (continued)*

After the stock split effected in the form of stock dividend issued by the Company in August 2006, the DRL 2002 Plan provides for stock option grants in the above two categories as follows:

<b>Particulars</b>	<b>Number of options reserved under category A</b>	<b>Number of options reserved under category B</b>	<b>Total</b>
Options reserved under original Plan	300,000	1,995,478	2,295,478
Options exercised prior to stock dividend date (A)	94,061	147,793	241,854
Balance of shares that can be allotted on exercise of options (B)	205,939	1,847,685	2,053,624
Options arising from stock dividend (C)	205,939	1,847,685	2,053,624
Options reserved after stock dividend (A+B+C)	<b>505,939</b>	<b>3,843,163</b>	<b>4,349,102</b>

Stock option activity under the DRL 2002 Plan for the two categories of options during the years ended March 31, 2016 and 2015 is as follows:

**Category A Fair Market Value Options:** There was no stock options activity under this category during the year March 31, 2016 and there were no options outstanding under this category as of March 31, 2016.

<b>Category B Par Value Options</b>	<b>For the Year Ended March 31, 2016</b>				
	<b>Shares arising out of options</b>	<b>Range of exercise prices</b>	<b>Weighted average exercise price</b>	<b>Weighted average remaining useful life (months)</b>	
Outstanding at the beginning of the period	585,454	Rs. 5.00	Rs. 5.00		71
Granted during the period	102,224	5.00	5.00		90
Expired/forfeited during the period	(66,319)	5.00	5.00		

Edgar Filing: DR REDDYS LABORATORIES LTD - Form 20-F

Exercised during the period	(194,011)		5.00		5.00
Outstanding at the end of the period	<b>427,348</b>	<b>Rs.</b>	<b>5.00</b>	<b>Rs.</b>	<b>5.00</b>
Exercisable at the end of the period	<b>53,801</b>	<b>Rs.</b>	<b>5.00</b>	<b>Rs.</b>	<b>5.00</b>

**For the Year Ended March 31, 2015**

<b>Category A Fair Market Value Options</b>	<b>Shares arising out of options</b>	<b>Range of exercise prices</b>	<b>Weighted average exercise price</b>	<b>Weighted average remaining useful life (months)</b>
Outstanding at the beginning of the period	10,000	Rs. 448	Rs. 448	44
Granted during the period				
Expired/forfeited during the period				
Exercised during the period	(10,000)	Rs. 448	Rs. 448	
Outstanding at the end of the period				
Exercisable at the end of the period				

F-47



**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

(in millions, except share and per share data and where otherwise stated)

**20. Employee stock incentive plans (continued)***Dr. Reddy s Employees Stock Option Plan -2002 (the DRL 2002 Plan ) (continued)*

Category B Par Value Options	For the Year Ended March 31, 2015				
	Shares arising out of options	Range of exercise prices	Weighted average exercise price	Weighted average remaining useful life (months)	
Outstanding at the beginning of the period	641,674	Rs. 5.00	Rs. 5.00	78	
Granted during the period	230,840	5.00	5.00	90	
Expired/forfeited during the period	(59,148)	5.00	5.00		
Exercised during the period	(227,912)	5.00	5.00		
<b>Outstanding at the end of the period</b>	<b>585,454</b>	<b>Rs. 5.00</b>	<b>Rs. 5.00</b>	<b>71</b>	
Exercisable at the end of the period	<b>43,425</b>	<b>Rs. 5.00</b>	<b>Rs. 5.00</b>	<b>40</b>	

The weighted average grant date fair value of par value options granted under category B above of the DRL 2002 Plan during the years ended March 31, 2016 and 2015 was Rs.3,350 and Rs.2,318 per option, respectively. The weighted average share price on the date of exercise of options during the years ended March 31, 2016 and 2015 was Rs.3,504 and Rs.2,525 per share, respectively.

The aggregate intrinsic value of options exercised under the DRL 2002 Plan (both category A and B) during the years ended March 31, 2016 and 2015 was Rs.679 and Rs.595, respectively. As of March 31, 2016, options outstanding under the DRL 2002 Plan (both category A and B) had an aggregate intrinsic value of Rs.1,295 and options exercisable under the DRL 2002 Plan (both category A and B) had an aggregate intrinsic value of Rs.163.

The term of the DRL 2002 plan was extended for a period of 10 years effective as of January 29, 2012 by the shareholders at the Company s Annual General Meeting held on July 20, 2012.

*Dr. Reddy s Employees ADR Stock Option Plan, 2007 (the DRL 2007 Plan )*

The Company instituted the DRL 2007 Plan for all eligible employees in pursuance of the special resolution approved by the shareholders in the Annual General Meeting held on July 27, 2005. The DRL 2007 Plan became effective upon its approval by the Board of Directors on January 22, 2007. The DRL 2007 Plan covers all employees and directors

(excluding promoter directors) of DRL and its subsidiaries (collectively, eligible employees ). The Committee administers the DRL 2007 Plan and grants stock options to eligible employees. The Committee determines which eligible employees will receive the options, the number of options to be granted, the exercise price, the vesting period and the exercise period. The vesting period is determined for all options issued on the date of grant. The options issued under the DRL 2007 Plan vest in periods ranging between one and four years and generally have a maximum contractual term of five years.

The DRL 2007 Plan provides for option grants in two categories:

Category A: 382,695 stock options out of the total of 1,530,779 stock options reserved for grant having an exercise price equal to the fair market value of the underlying equity shares on the date of grant; and

Category B: 1,148,084 stock options out of the total of 1,530,779 stock options reserved for grant having an exercise price equal to the par value of the underlying equity shares (i.e., Rs.5 per option).

No options have been granted under Category A as of March 31, 2016. Stock options activity for category B options under the DRL 2007 Plan during the years ended March 31, 2016 and 2015 is as follows:

		<b>For the Year Ended March 31, 2016</b>			<b>Weighted average</b>
		<b>Shares</b>	<b>Range</b>	<b>Weighted</b>	<b>remaining</b>
<b>Category B Par Value Options</b>	<b>arising out of</b>	<b>options</b>	<b>of</b>	<b>average</b>	<b>useful</b>
			<b>exercise</b>	<b>exercise price</b>	<b>life</b>
			<b>prices</b>		<b>(months)</b>
Outstanding at the beginning of the period	98,350	Rs. 5.00	Rs. 5.00	5.00	72
Granted during the period	40,184	5.00	5.00	5.00	90
Expired/forfeited during the period	(14,023)	5.00	5.00	5.00	
Exercised during the period	(32,468)	5.00	5.00	5.00	
<b>Outstanding at the end of the period</b>	<b>92,043</b>	<b>Rs. 5.00</b>	<b>Rs. 5.00</b>	<b>5.00</b>	<b>79</b>
Exercisable at the end of the period	7,141	Rs. 5.00	Rs. 5.00	5.00	45

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

(in millions, except share and per share data and where otherwise stated)

**20. Employee stock incentive plans (continued)***Dr. Reddy s Employees ADR Stock Option Plan, 2007 (the DRL 2007 Plan ) (continued)*

		<b>For the Year Ended March 31, 2015</b>			
		<b>Shares</b>	<b>Range</b>	<b>Weighted</b>	<b>Weighted average</b>
		<b>arising out of</b>	<b>of</b>	<b>average</b>	<b>remaining</b>
<b>Category B</b>	<b>Par Value Options</b>	<b>options</b>	<b>exercise</b>	<b>exercise price</b>	<b>useful</b>
			<b>prices</b>		<b>life</b>
				<b>Rs.</b>	<b>(months)</b>
	Outstanding at the beginning of the period	97,463	Rs. 5.00	Rs. 5.00	79
	Granted during the period	45,796	5.00	5.00	90
	Expired/forfeited during the period	(10,515)	5.00	5.00	
	Exercised during the period	(34,394)	5.00	5.00	
	<b>Outstanding at the end of the period</b>	<b>98,350</b>	<b>Rs. 5.00</b>	<b>Rs. 5.00</b>	<b>72</b>
	<b>Exercisable at the end of the period</b>	<b>6,730</b>	<b>Rs. 5.00</b>	<b>Rs. 5.00</b>	<b>42</b>

The weighted average grant date fair value of par value options granted under category B of the DRL 2007 Plan during the years ended March 31, 2016 and 2015 was Rs.3,465 and Rs.2,283, respectively. The weighted average share price on the date of exercise of options during the years ended March 31, 2016 and 2015 was Rs.3,575 and Rs.2,604, respectively.

The aggregate intrinsic value of options exercised under the DRL 2007 Plan during the years ended March 31, 2016 and 2015 was Rs.116 and Rs.89, respectively. As of March 31, 2016, options outstanding under the DRL 2007 Plan had an aggregate intrinsic value of Rs.279 and options exercisable under the DRL 2007 Plan had an aggregate intrinsic value of Rs.22.

During the year ended March 31, 2015, the Company adopted a new program to grant performance linked stock options to certain employees under the DRL 2002 Plan and the DRL 2007 Plan. Under this program, performance targets are measured each year against pre-defined interim targets over the three year period ending on March 31, 2017 and eligible employees are granted stock options upon meeting such targets. The stock options so granted are ultimately vested with the employees who meet subsequent service vesting conditions which range from 1 to 4 years. After vesting, such stock options generally have a maximum contractual term of five years.

**Valuation of stock options:**

The fair value of stock options granted under the DRL 2002 Plan and the DRL 2007 Plan has been measured using the Black-Scholes-Merton model at the date of the grant.

The Black-Scholes-Merton model includes assumptions regarding dividend yields, expected volatility, expected terms and risk free interest rates. In respect of par value options granted under category B, the expected term of an option (or option life) is estimated based on the vesting term, contractual term, as well as expected exercise behavior of the employees receiving the option. In respect of fair market value options granted under category A, the option life is estimated based on the simplified method. Expected volatility of the option is based on historical volatility, during a period equivalent to the option life, of the observed market prices of the Company's publicly traded equity shares. Dividend yield of the options is based on recent dividend activity. Risk-free interest rates are based on the government securities yield in effect at the time of the grant. These assumptions reflect management's best estimates, but these assumptions involve inherent market uncertainties based on market conditions generally outside of the Company's control. As a result, if other assumptions had been used in the current period, stock-based compensation expense could have been materially impacted. Further, if management uses different assumptions in future periods, stock based compensation expense could be materially impacted in future years.

The estimated fair value of stock options is charged to income on a straight-line basis over the requisite service period for each separately vesting portion of the award as if the award was, in-substance, multiple awards.

The weighted average inputs used in computing the fair value of options granted were as follows:

	<b>Grants made on</b>			
	<b>May 11, 2015</b>	<b>July 14, 2014</b>	<b>June 15, 2014</b>	<b>May 25, 2014</b>
Expected volatility	25.98%	23.20%	23.15%	22.52%
Exercise price	Rs. 5.00	Rs. 5.00	Rs. 5.00	Rs. 5.00
Option life	2.5 Years	2.5 Years	2.5 Years	2.5 Years
Risk-free interest rate	7.87%	8.55%	8.38%	8.50%
Expected dividends	0.60%	0.67%	0.74%	0.78%
Grant date share price	Rs. 3,359.70	Rs. 2,695.00	Rs. 2,445.15	Rs. 2,308.70

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****20. Employee stock incentive plans (continued)***Valuation of stock options (continued)*

The fair value of services received in return for stock options granted to employees is measured by reference to the fair value of stock options granted. The fair value of stock options has been measured using the Black-Scholes-Merton valuation model at the date of the grant.

*Share-based payment expense*

For the years ended March 31, 2016, 2015 and 2014, the Company recorded employee share based payment expense of Rs.471, Rs.498 and Rs.436, respectively. As of March 31, 2016, there was approximately Rs.437 of total unrecognized compensation cost related to unvested stock options. This cost is expected to be recognized over a weighted-average period of 3.10 years.

**21. Provisions**

The details of changes in provisions during the year ended March 31, 2016 are as follows:

<b>Particulars</b>	<b>Allowance for sales return<sup>(1)</sup></b>	<b>Environmental liability<sup>(2)</sup></b>	<b>Legal and others</b>	<b>Total</b>
Balance as at April 1, 2015	Rs. 3,905	Rs. 53	Rs. 326	Rs. 4,284
Provision made during the year	3,272		12	3,284
Provision used or reversed during the year	(2,937)			(2,937)
Effect of changes in foreign exchange rates	181	2		183
<b>Balance as at March 31, 2016</b>	<b>Rs. 4,421</b>	<b>Rs. 55</b>	<b>Rs. 338</b>	<b>Rs. 4,814</b>
Current	Rs. 4,421	Rs.	Rs. 338	Rs. 4,759
Non-current		55		55

**Rs. 4,421      Rs. 55      Rs. 338      Rs. 4,814**

- (1) Provision for sales returns is accounted by recording a provision based on the Company's estimate of expected sales returns. See Note 3(1) for the Company's accounting policy on sales returns.
- (2) As a result of the acquisition of a unit of The Dow Chemical Company in April 2008, the Company assumed a liability for contamination of the Mirfield site acquired of Rs.39 (carrying value Rs.55). The seller is required to indemnify the Company for this liability. Accordingly, a corresponding asset has also been recorded in the statements of financial position.

## 22. Trade and other payables

Trade and other payables consist of the following:

	As at March 31,	
	2016	2015
Due to related parties	Rs. 0	Rs. 4
Others	12,300	10,656
	<b>Rs. 12,300</b>	<b>Rs. 10,660</b>

## 23. Other liabilities

Other liabilities consist of the following:

	As at March 31,	
	2016	2015
<b>Current</b>		
Advance from customers	Rs. 335	Rs. 280
Statutory dues payable	535	596
Accrued expenses <sup>(1)</sup>	16,658	12,529
Deferred revenue	324	776
Others	4,218	3,136
	<b>Rs. 22,070</b>	<b>Rs. 17,317</b>
<b>Non-current</b>		
Statutory dues payable	Rs. 5	Rs. 8
Deferred revenue	1,528	2,112
Others	1,628	1,206
	<b>Rs. 3,161</b>	<b>Rs. 3,326</b>

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****23. Other liabilities (continued)**

- (1) The increase in accrued expenses was primarily on account of (i) professional services for remediation activities relating to the warning letter received from the U.S. FDA for three of the Company's manufacturing facilities in India, (ii) rebates payable to the various statutory healthcare insurance ( SHI ) funds in Germany and (iii) accruals for the Company's long-term incentive plan (refer to Note 19 of these consolidated financials for further details on the Company's long term incentive plan).

**24. Revenue**

Revenue consists of the following:

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Sales	Rs. 152,476	Rs. 146,131	Rs. 130,287
Services	1,466	1,689	1,632
License fees	766	369	251
	<b>Rs. 154,708</b>	<b>Rs. 148,189</b>	<b>Rs. 132,170</b>

Revenue includes excise duties of Rs.842, Rs.829 and Rs.820 for the years ended March 31, 2016, 2015 and 2014, respectively.

**25. Other (income)/expense, net**

Other (income)/expense, net consists of the following:

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Loss/(profit) on sale/disposal of property, plant and equipment and other intangibles, net	Rs. 112	Rs. 144	Rs. (53)
Sale of spent chemical	(271)	(521)	(481)
Miscellaneous income, net <sup>(1)</sup>	(715)	(540)	(882)
	<b>Rs. (874)</b>	<b>Rs. (917)</b>	<b>Rs. (1,416)</b>

- (1) Miscellaneous income for the year ended March 31, 2014 includes Rs.415 (CAD6.75) from the resolution of litigation associated with the sale of one of the Company's generic products in North America.

## 26. Finance (expense)/income, net

Finance (expense)/income, net consists of the following:

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Interest income	Rs. 1,399	Rs. 1,061	Rs. 1,085
Dividend and profit on sale of other investments <sup>(1)</sup>	852	755	217
Foreign exchange gain/(loss), net <sup>(2)</sup>	(4,133)	958	372
Interest expense	(826)	(1,092)	(1,274)
	<b>Rs. (2,708)</b>	<b>Rs. 1,682</b>	<b>Rs. 400</b>

- (1) Profit on sale of other investments primarily represents amounts reclassified from other comprehensive income to the income statement on redemption of the Company's available for sale financial instruments.
- (2) Includes the foreign exchange losses related to the Company's Venezuela operations of Rs.4,621 and Rs.843 for the year ended March 31, 2016 and 2015, respectively. Refer to Note 41 of these consolidated financial statements for further details.



**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****27. Income taxes*****a. Income tax (expense)/benefit recognized in the income statement***

Income tax (expense)/benefit recognized in the income statement consists of the following:

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
<b>Current taxes</b>			
Domestic	Rs. (4,331)	Rs. (4,461)	Rs. (5,090)
Foreign	(3,046)	(2,545)	(1,472)
	<b>Rs. (7,377)</b>	<b>Rs. (7,006)</b>	<b>Rs. (6,562)</b>
<b>Deferred taxes (expense)/benefit</b>			
Domestic	Rs. 132	Rs. 637	Rs. (294)
Foreign	118	385	1,762
	<b>Rs. 250</b>	<b>Rs. 1,022</b>	<b>Rs. 1,468</b>
<b>Total income tax expense recognized in the income statement</b>	<b>Rs. (7,127)</b>	<b>Rs. (5,984)</b>	<b>Rs. (5,094)</b>

***b. Income tax (expense)/benefit recognized directly in equity***

Income tax (expense)/benefit recognized directly in equity consist of the following:

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Tax effect on changes in fair value of other investments	Rs. (88)	Rs. (366)	Rs. (14)
Tax effect on foreign currency translation differences	(62)	174	(2)
Tax effect on effective portion of change in fair value of cash flow hedges	(23)	96	80
Tax effect on actuarial gains/losses on defined benefit obligations	64	16	(20)

	<b>Rs. (109)</b>	<b>Rs. (80)</b>	<b>Rs. 44</b>
--	------------------	-----------------	---------------

**c. Reconciliation of effective tax rate**

The following is a reconciliation of the Company's effective tax rates for the years ended March 31, 2016, 2015 and 2014:

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
<b>Profit before income taxes</b>	<b>Rs. 27,140</b>	<b>Rs. 28,163</b>	<b>Rs. 26,606</b>
Enacted tax rate in India	34.61%	33.99%	33.99%
<b>Computed expected tax benefit/(expense)</b>	<b>Rs. (9,393)</b>	<b>Rs. (9,572)</b>	<b>Rs. (9,043)</b>
<b>Effect of:</b>			
Differences between Indian and foreign tax rates	Rs.1,122	Rs.566	Rs.1,003
Impairment of product related intangibles and goodwill			169
(Unrecognized deferred tax assets) / recognition of previously unrecognized deferred tax assets, net	(1,600)	18	(687)
Expenses not deductible for tax purposes	(138)	(110)	(117)
Share-based payment expense			684
Income exempt from income taxes	731	794	661
Foreign exchange differences	(836)	(380)	230
Incremental deduction allowed for research and development costs	2,782	2,265	2,026
Deferred tax expense on undistributed earnings of subsidiary outside India	(519)		
Qualified domestic production activities deduction in the United States	38	4	9
Effect of change in tax rate	(30)	(25)	
Investment allowance deduction	177	251	67
Others	539	205	(96)
<b>Income tax benefit/(expense)</b>	<b>Rs. (7,127)</b>	<b>Rs. (5,984)</b>	<b>Rs. (5,094)</b>
<b>Effective tax rate</b>	<b>26%</b>	<b>21%</b>	<b>19%</b>

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**27. Income taxes (continued)**

The Company's consolidated weighted average tax rates for the years ended March 31, 2016 and 2015 were 26% and 21%, respectively. Income tax expense was Rs.7,127 for the year ended March 31, 2016, as compared to income tax expense of Rs.5,984 for the year ended March 31, 2015.

The increase in the Company's effective tax rate for the year ended March 31, 2016 was primarily attributable to the following:

non-deductible losses related to the Company's Venezuela operations, which resulted in an increase in the effective tax rate by approximately 3.80% (Refer to Note 41 of these consolidated financial statements for further details);

deferred tax expense on undistributed earnings of a subsidiary outside of India, which resulted in an increase in the effective tax rate by approximately 1.9%;

an increase in the effective tax rate by approximately 1.8% due to non-recognition of certain deferred tax assets, as the Company believes that availability of taxable profits against which the temporary differences can be utilized is not probable;

recognition of a previously unrecognized deferred tax asset pertaining to a jurisdiction outside of India, which resulted in a decrease in effective tax rate by approximately 1.1%; and

an increase in weighted deduction on eligible research and development expenditure in India during the year ended March 31, 2016, as compared to the year ended March 31, 2015, has resulted in a decrease in the effective tax rate by 1.8%. The rate of weighted deduction on the Company's eligible research and development expenditure was equal to 200% for the years ended March 31, 2016 and 2015, respectively.

***d. Unrecognized deferred tax assets and liabilities***

The details of unrecognized deferred tax assets and liabilities are summarized below:

	<b>As at March 31,</b>	
	<b>2016</b>	<b>2015</b>
Deductible temporary differences, net	Rs. 1,157	Rs. 590
Operating tax loss carry forward	3,166	2,391
	<b>Rs. 4,323</b>	<b>Rs. 2,981</b>

During the year ended March 31, 2016, the Company, based on probable future taxable profit, has recognized previously unrecognized deferred tax assets of Rs.267 pertaining primarily to interest loss carry forward in Reddy Holding GmbH, Germany.

During the year ended March 31, 2016, the Company did not recognize deferred tax assets of Rs.775 on operating tax losses pertaining primarily to Dr. Reddy s Venezuela, C.A., Dr. Reddy s Laboratories New York, Inc. and certain other subsidiaries of the Company. The above tax losses expire at various dates ranging from 2017 through 2037. During the year ended March 31, 2016, the Company did not recognize deferred tax assets of Rs.567 on certain deductible temporary differences, as the Company believes that availability of taxable profits against which such temporary differences can be utilized is not probable.

Deferred income taxes are not provided on undistributed earnings of Rs.30,997 as at March 31, 2016, of subsidiaries outside India, where it is expected that earnings of the subsidiaries will not be distributed in the foreseeable future. Generally, the Company indefinitely reinvests all the accumulated undistributed earnings of foreign subsidiaries, and accordingly, has not recorded any deferred taxes in relation to such undistributed earnings of its foreign subsidiaries. It is impracticable to determine the taxes payable when these earnings are remitted. However, the Company intends to repatriate a portion of undistributed earnings from one of its overseas subsidiaries on a one-time basis and, accordingly, deferred tax liability has been recognized on such portion intended to be repatriated.

*e. Deferred tax assets and liabilities*

The tax effects of significant temporary differences that resulted in deferred tax assets and liabilities and a description of the items that created these differences is given below:

	<b>For the Year Ended March 31,</b>	
	<b>2016</b>	<b>2015</b>
<b><u>Deferred tax assets/(liabilities):</u></b>		
Inventory	Rs. 2,579	Rs. 3,477
Minimum Alternate Tax*	1,614	644
Trade and other receivables	412	316
Operating tax loss and interest loss carry-forward	548	810
Other current assets and other current liabilities, net	2,026	1,267
Property, plant and equipment	(1,745)	(1,230)
Other intangible assets	(482)	(1,145)
Others	(722)	(126)
<b>Net deferred tax assets</b>	<b>Rs. 4,230</b>	<b>Rs. 4,013</b>

\* As per Indian tax laws, companies are liable for a Minimum Alternate Tax ( MAT tax) when current tax, as computed under the provisions of the Income Tax Act, 1961 ( Tax Act ), is determined to be below the MAT tax computed under section 115JB of the Tax Act. The excess of MAT tax over current tax is eligible to be carried forward and set-off in the future against the current tax liabilities over a period of 10 years.

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****27. Income taxes (continued)**

In assessing whether the deferred income tax assets will be realized, management considers whether some portion or all of the deferred income tax assets will not be realized. The ultimate realization of the deferred income tax assets and tax loss carry forwards is dependent upon the generation of future taxable income during the periods in which the temporary differences become deductible. Management considers the scheduled reversals of deferred tax liabilities, projected future taxable income and tax planning strategy in making this assessment. Based on the level of historical taxable income and projections of future taxable income over the periods in which the deferred tax assets are deductible, management believes that the Company will realize the benefits of those recognized deductible differences and tax loss carry forwards. Recoverability of deferred tax assets is based on estimates of future taxable income. Any changes in such future taxable income would impact the recoverability of deferred tax assets.

Operating loss carry forward consists of business losses, unabsorbed depreciation and unabsorbed interest carry-forwards. A portion of this total loss can be carried indefinitely and the remaining amounts expire at various dates ranging from 2017 through 2037.

***f. Movement in deferred tax assets and liabilities during the years ended March 31, 2016 and 2015.***

	As at March 31, 2014	Recognized in income statement	Recognized in equity	Acquired in business combination	As at March 31, 2015
<b><u>Deferred tax assets/(liabilities)</u></b>					
Inventory	Rs. 3,875	Rs. (398)	Rs.	Rs.	Rs. 3,477
Minimum Alternate Tax		644			644
Trade and other receivables	265	51			316
Operating tax loss and interest loss carry-forward	909	(99)			810
Other current assets and other current liabilities, net	942	433	(108)		1,267
Property, plant and equipment	(1,141)	(89)			(1,230)
Intangible assets	(1,717)	572			(1,145)
Others	177	(40)	(263)		(126)
<b>Net deferred tax assets/(liabilities)</b>	<b>Rs. 3,310</b>	<b>Rs. 1,074</b>	<b>Rs. (371)</b>	<b>Rs.</b>	<b>Rs. 4,013</b>

[Continued from above table, first column(s) repeated]

	As at March 31, 2015	Recognized in income statement	Recognized in equity	Acquired in business combination	As at March 31, 2016
<b><u>Deferred tax assets/(liabilities)</u></b>					
Inventory	Rs. 3,477	Rs. (898)	Rs.	Rs.	Rs. 2,579
Minimum Alternate Tax	644	970			1,614
Trade and other receivables	316	96			412
Operating tax loss and interest loss carry-forward	810	(262)			548
Other current assets and other current liabilities, net	1,267	1,036	(277)		2,026
Property, plant and equipment	(1,230)	(515)			(1,745)
Intangible assets	(1,145)	663			(482)
Others	(126)	(872)	276		(722)
<b>Net deferred tax assets/(liabilities)</b>	<b>Rs. 4,013</b>	<b>Rs. 218</b>	<b>Rs. (1)</b>	<b>Rs.</b>	<b>Rs. 4,230</b>

The amounts recognized in the income statement during the years ended March 31, 2016 and 2015 include Rs.(32) and Rs.52, respectively, which represent exchange differences arising due to foreign currency translations.

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****28. Operating leases**

The Company has leased offices and vehicles under various operating lease agreements that are renewable on a periodic basis at the option of both the lessor and the lessee. Rental expense under these leases was Rs.819, Rs.822 and Rs.749 for the years ended March 31, 2016, 2015 and 2014, respectively.

The schedule of future minimum rental payments in respect of non-cancellable operating leases is set out below:

	<b>As of March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Less than one year	Rs. 396	Rs. 384	Rs. 359
Between one and five years	1,185	1,259	1,007
More than five years	663	852	937
	<b>Rs. 2,244</b>	<b>Rs. 2,495</b>	<b>Rs. 2,303</b>

During the year ended March 31, 2014, the Company entered into a non-cancellable operating lease for an office and laboratory facility in the United States. The future minimum rental payments in respect of this lease are Rs.1,394 (U.S.\$21), Rs.1,458 (U.S.\$23) and Rs.1,556 (U.S.\$26) as of March 31, 2016, 2015 and 2014, respectively.

**29. Related parties**

The Company has entered into transactions with the following related parties:

Green Park Hotel and Resorts Limited for hotel services;

Dr. Reddy s Foundation towards contributions for social development;

Pudami Educational Society towards contributions for social development;

Dr. Reddy s Institute of Life Sciences for research and development services; and



Stamlo Hotels Limited for hotel services.

These are enterprises over which key management personnel have control or significant influence. Key management personnel consists of the Company's Directors and members of the Company's Management Council.

The Company has also entered into cancellable operating lease transactions with key management personnel and their relatives.

Further, the Company contributes to the Dr. Reddy's Laboratories Gratuity Fund, which maintains the plan assets of the Company's Gratuity Plan for the benefit of its employees. See Note 19 of these consolidated financial statements for information on transactions between the Company and the Gratuity Fund. The following is a summary of significant related party transactions:

	<b>For the Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Purchases of raw materials	Rs. 102	Rs. 92	Rs. 141
Purchases of assets <sup>(1)</sup>		5	1,264
Sales of raw materials			49
Sales of assets			14
Research and development services received	102	92	141
Contributions towards social development	249	237	170
Hotel expenses paid	51	41	31
Lease rentals paid under cancellable operating leases to key management personnel and their relatives	37	36	36

<sup>(1)</sup> The figures for the year ended March 31, 2014 include transactions with Ecologic Chemicals Limited. Refer to Note 32 of these consolidated financial statements for further details. Further, Ecologic Chemicals Limited is not a related party of the Company for the year ended March 31, 2016.

The Company has the following amounts due from related parties:

	<b>As at March 31,</b>	
	<b>2016</b>	<b>2015</b>
Key management personnel (towards rent deposits)	Rs. 8	Rs. 8
Other related parties	1	

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****29. Related parties (continued)**

The Company has the following amounts due to related parties:

	<b>As at March 31,</b>	
	<b>2016</b>	<b>2015</b>
Due to related parties	Rs. 0	Rs. 4

The following table describes the components of compensation paid or payable to key management personnel for the services rendered during the year ended:

	<b>Year Ended March 31,</b>		
	<b>2016</b>	<b>2015</b>	<b>2014</b>
Salaries and other benefits <sup>(1)</sup>	Rs. 336	Rs. 300	Rs. 261
Contributions to defined contribution plans	19	16	15
Commission to directors	263	285	280
Share-based payments expense	76	72	64
<b>Total</b>	<b>Rs. 694</b>	<b>Rs. 673</b>	<b>Rs. 620</b>

<sup>(1)</sup> In addition to the above, the Company has accrued Rs.169 and Rs.67 towards a long term incentive plan for the services rendered by key management personnel during the years ended March 31, 2016 and 2015, respectively. Refer to Note 19 of these consolidated financial statements for further details.

Some of the key management personnel of the Company are also covered under the Company's Gratuity Plan along with the other employees of the Company. Proportionate amounts of gratuity accrued under the Company's Gratuity Plan have not been separately computed or included in the above disclosure.

**30. Financial instruments***Financial instruments by category*

The carrying value and fair value of financial instruments by each category as at March 31, 2016 were as follows:

	Note	Loans and receivables	Available for sale	Other financial liabilities	Derivative financial instruments	Total carrying value	Total fair value
<b>Assets:</b>							
Cash and cash equivalents	15	Rs. 4,921	Rs.	Rs.	Rs.	Rs. 4,921	Rs. 4,921
Other investments	11	12,713	24,309			37,022	37,022
Trade and other receivables	13	41,306				41,306	41,306
Derivative financial instruments					175	175	175
Other assets <sup>(1)</sup>	14	2,270				2,270	2,270
<b>Total</b>		<b>Rs. 61,210</b>	<b>Rs. 24,309</b>	<b>Rs.</b>	<b>Rs. 175</b>	<b>Rs. 85,694</b>	<b>Rs. 85,694</b>
<b>Liabilities:</b>							
Trade and other payables	22	Rs.	Rs.	Rs. 12,300	Rs.	Rs. 12,300	Rs. 12,300
Derivative financial instruments					108	108	108
Long-term borrowings	18			10,795		10,795	10,795
Short-term borrowings	18			22,718		22,718	22,718
Other liabilities and provisions <sup>(2)</sup>	21 & 23			25,387		25,387	25,387
<b>Total</b>		<b>Rs.</b>	<b>Rs.</b>	<b>Rs. 71,200</b>	<b>Rs. 108</b>	<b>Rs. 71,308</b>	<b>Rs. 71,308</b>

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****30. Financial instruments (continued)**

The carrying value and fair value of financial instruments by each category as at March 31, 2015 were as follows:

	Note	Loans and receivables	Available for sale	Other financial liabilities	Derivative financial instruments	Total carrying value	Total fair value
<b>Assets:</b>							
Cash and cash equivalents	15	Rs. 5,394	Rs.	Rs.	Rs.	Rs. 5,394	Rs. 5,394
Other investments	11	12,848	24,228			37,076	37,076
Trade and other receivables	13	40,755				40,755	40,755
Derivative financial instruments					800	800	800
Other assets <sup>(1)</sup>	14	1,585				1,585	1,585
<b>Total</b>		<b>Rs. 60,582</b>	<b>Rs. 24,228</b>	<b>Rs.</b>	<b>Rs. 800</b>	<b>Rs. 85,610</b>	<b>Rs. 85,610</b>
<b>Liabilities:</b>							
Trade and other payables	22	Rs.	Rs.	Rs. 10,660	Rs.	Rs. 10,660	Rs. 10,660
Derivative financial instruments					462	462	462
Long-term borrowings	18			21,289		21,289	21,289
Short-term borrowings	18			21,857		21,857	21,857
Other liabilities and provisions <sup>(2)</sup>	21 & 23			19,440		19,440	19,440
<b>Total</b>		<b>Rs.</b>	<b>Rs.</b>	<b>Rs. 73,246</b>	<b>Rs. 462</b>	<b>Rs. 73,708</b>	<b>Rs. 73,708</b>

(1) Other assets that are not financial assets (such as receivables from statutory authorities, export benefit receivables, prepaid expenses, advances paid and certain other receivables) of Rs.11,467 and Rs.12,278 as of

- March 31, 2016 and March 31, 2015, respectively, are not included.
- (2) Other liabilities that are not financial liabilities (such as statutory dues payable, deferred revenue, advances from customers and certain other accruals) of Rs.7,239 and Rs.7,993 as of March 31, 2016 and March 31, 2015, respectively, are not included.

#### Fair value hierarchy

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

The following table presents the fair value hierarchy of assets and liabilities measured at fair value on a recurring basis as of March 31, 2016:

Particulars	Level 1	Level 2	Level 3	Total
Available for sale - Financial asset - Investments in units of mutual funds	Rs. 22,558	Rs.	Rs.	Rs. 22,558
Available for sale - Financial asset - Investment in equity securities	1,751			1,751
Derivative financial instruments - gain/(loss) on outstanding foreign exchange forward, option and swap contracts and interest rate swap contracts <sup>(1)</sup>		67		67

The following table presents the fair value hierarchy of assets and liabilities measured at fair value on a recurring basis as of March 31, 2015:

Particulars	Level 1	Level 2	Level 3	Total
Available for sale - Financial asset - Investments in units of mutual funds	Rs. 21,641	Rs.	Rs.	Rs. 21,641
Available for sale - Financial asset - Investment in equity securities	2,587			2,587
Derivative financial instruments - gain/(loss) on outstanding foreign exchange forward, option and swap contracts and interest rate swap contracts <sup>(1)</sup>		338		338

- (1) The Company enters into derivative financial instruments with various counterparties, principally financial institutions and banks. Derivatives valued using valuation techniques with market observable inputs are mainly interest rate swaps, foreign exchange forward option and swap contracts. The most frequently applied valuation techniques include forward pricing, swap models and Black-Scholes-Merton models (for option valuation), using present value calculations.

The models incorporate various inputs including foreign exchange spot and forward rates, interest rate curves and forward rate curves. As at March 31, 2016, the changes in counterparty credit risk had no material effect on the hedge effectiveness assessment for derivatives designated in hedge relationships and other financial instruments recognized

at fair value.

F-57

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**30. Financial instruments (continued)**

*Derivative financial instruments*

The Company is exposed to exchange rate risk that arises from its foreign exchange revenues and expenses, primarily in U.S. dollars, U.K. pounds sterling, Russian roubles, Venezuelan bolivars and Euros, and foreign currency debt in U.S. dollars, Russian roubles and Euros. The Company uses forward contracts, option contracts and currency swap contracts (collectively, derivatives) to mitigate its risk of changes in foreign currency exchange rates.

The counterparty for these contracts is generally a bank or a financial institution. The Company had a derivative financial asset and derivative financial liability of Rs.175 and Rs.108, respectively, as of March 31, 2016 as compared to derivative financial asset and derivative financial liability of Rs.800 and Rs.462, respectively, as of March 31, 2015 towards these derivative financial instruments.

Further, in respect of these foreign exchange derivative contracts, the Company has recorded, as part of finance costs, a net gain of Rs.231, a net gain of Rs.2,226 and a net loss of Rs.426, for the years ended March 31, 2016, 2015, and 2014, respectively.

*Hedges of highly probable forecasted transactions*

The Company classifies its derivative contracts that hedge foreign exchange risk associated with its highly probable forecasted transactions as cash flow hedges and measures them at fair value. The effective portion of such cash flow hedges is recorded as a component of equity within the Company's hedging reserve, and re-classified in the income statement as revenue in the period corresponding to the occurrence of the forecasted transactions. The ineffective portion of such cash flow hedges is immediately recorded in the income statement as a finance cost.

The Company also designates certain non-derivative financial liabilities, such as foreign currency borrowings from banks, as hedging instruments for the hedge of foreign exchange risk associated with highly probable forecasted transactions and, accordingly, applies cash flow hedge accounting for such relationships. Re-measurement gain/loss on such non-derivative financial liabilities is recorded as a component of equity within the Company's hedging reserve, and re-classified in the income statement as revenue in the period corresponding to the occurrence of the forecasted transactions.

In respect of the aforesaid hedges of highly probable forecasted transactions, the Company recorded, as a component of equity, a net gain of Rs.966, a net gain of Rs.99 and a net loss of Rs.1,650 for the years ended March 31, 2016, 2015 and 2014, respectively.

The Company also recorded, as a component of revenue, a net loss of Rs.1,172, a net gain of Rs.300 and a net loss of Rs.1,093 during the years ended March 31, 2016, 2015 and 2014, respectively.

The net carrying amount of the Company's hedging reserve as a component of equity before adjusting for tax impact was a loss of Rs.839 as at March 31, 2016, as compared to a loss of Rs.1,805 as at March 31, 2015.

*Hedges of recognized assets and liabilities*

Changes in the fair value of forward contracts and option contracts that economically hedge monetary assets and liabilities in foreign currencies, and for which no hedge accounting is applied, are recognized in the income statement. The changes in fair value of the forward contracts and option contracts, as well as the foreign exchange gains and losses relating to the monetary items, are recognized as part of net finance costs .

*Outstanding foreign exchange derivative contracts*

The following table gives details in respect of the notional amount of outstanding foreign exchange derivative contracts as of March 31, 2016.



<b>Category</b>	<b>Instrument</b>	<b>Currency</b>	<b>Cross Currency<sup>(1)</sup></b>	<b>Amounts</b>	<b>Buy/Sell</b>
Hedges of recognized assets and liabilities	Forward contract	U.S.\$	INR	U.S.\$ 97.0	Sell
	Forward contract	U.S.\$	RON	U.S.\$ 8.0	Buy
	Forward contract	U.S.\$	RUB	U.S.\$ 15.0	Buy
	Forward contract	EUR	U.S.\$	EUR 35.5	Sell
	Option contract	U.S.\$	INR	U.S.\$ 100.0	Sell
Hedges of highly probable forecasted transactions	Forward contract	RUB	INR	RUB 600.0	Sell
	Option contract	EUR	INR	EUR 6.0	Sell
	Option contract	U.S.\$	INR	U.S.\$ 235.0	Sell

(1) INR means Indian Rupees, RON means Romanian new leus, and RUB means Russian roubles.

F-58

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****30. Financial instruments (continued)**

The following table gives details in respect of the notional amount of outstanding foreign exchange derivative contracts as of March 31, 2015.

<b>Category</b>	<b>Instrument</b>	<b>Currency</b>	<b>Cross Currency</b>	<b>Amounts</b>	<b>Buy/Sell</b>
Hedges of recognized assets and liabilities	Forward contract	U.S.\$	RON	U.S.\$ 10.0	Buy
	Forward contract	U.S.\$	INR	U.S.\$ 146.9	Sell
	Forward contract	U.S.\$	RUB	U.S.\$ 20.0	Buy
	Forward contract	U.S.\$	RUB	U.S.\$ 20.0	Sell
	Forward contract	EUR	U.S.\$	EUR 35.0	Sell
	Forward contract	EUR	U.S.\$	EUR 6.0	Buy
	Option contract	U.S.\$	INR	U.S.\$ 90.0	Sell
Hedges of highly probable forecasted transactions	Forward contract	U.S.\$	INR	U.S.\$ 30.0	Sell
	Forward contract	RUB	INR	RUB 300.0	Sell
	Option contract	U.S.\$	INR	U.S.\$ 250.0	Sell

The table below summarizes the periods when the cash flows associated with highly probable forecasted transactions that are classified as cash flow hedges are expected to occur:

	<b>As of March 31,</b>	
	<b>2016</b>	<b>2015</b>
<b>Cash flows in U.S. Dollars</b>		
Not later than one month	Rs. 2,816	Rs. 2,969
Later than one month and not later than three months	5,300	5,625
Later than three months and not later than six months	7,123	8,594
Later than six months and not later than one year	3,975	7,188
Later than one year		3,438
	<b>Rs. 19,214</b>	<b>Rs. 27,814</b>

**Cash flows in Roubles**

Not later than one month	Rs.	123	Rs.	27
Later than one month and not later than three months		246		54
Later than three months and not later than six months		222		81
Later than six months and not later than one year				161
	<b>Rs.</b>	<b>591</b>	<b>Rs.</b>	<b>323</b>

**Cash flows in Euros**

Not later than one month	Rs.	38	Rs.	
Later than one month and not later than three months		75		
Later than three months and not later than six months		113		
Later than six months and not later than one year		226		
	<b>Rs.</b>	<b>452</b>	<b>Rs.</b>	

*Hedges of changes in the interest rates:*

Consistent with its risk management policy, the Company uses interest rate swaps (including cross currency interest rate swaps) to mitigate the risk of changes in interest rates. The Company does not use them for trading or speculative purposes.

The changes in fair value of such interest rate swaps (including cross currency interest rate swaps) are recognized as part of finance cost. Accordingly, the Company has recorded, as part of finance cost, a net loss of Rs.0 and Rs.10 for the years ended March 31, 2016 and 2015, respectively.

As on March 31, 2016, the Company had no outstanding interest rate swap arrangements.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**31. Financial risk management**

The Company's activities expose it to a variety of financial risks, including market risk, credit risk and liquidity risk. The Company's primary risk management focus is to minimize potential adverse effects of market risk on its financial performance. The Company's risk management assessment and policies and processes are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor such risks and compliance with the same. Risk assessment and management policies and processes are reviewed regularly to reflect changes in market conditions and the Company's activities. The Board of Directors and the Audit Committee is responsible for overseeing the Company's risk assessment and management policies and processes.

***a. Credit risk***

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers and investment securities. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Company grants credit terms in the normal course of business. The Company establishes an allowance for doubtful debts and impairment that represents its estimate of incurred losses in respect of trade and other receivables and investments.

*Trade and other receivables*

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. The demographics of the customer, including the default risk of the industry and country in which the customer operates, also has an influence on credit risk assessment. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Company grants credit terms in the normal course of business.

*Investments*

The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Company does not expect any losses from non-performance by these counter-parties, and does not have any significant concentration of exposures to specific industry sectors or specific country risks.

*Financial assets that are neither past due nor impaired*

None of the Company's cash equivalents, including term deposits (i.e., certificates of deposit) with banks, were past due or impaired as at March 31, 2016. Of the total trade and other receivables, Rs.34,840 as at March 31, 2016 and Rs.33,226 as at March 31, 2015 consisted of customer balances that were neither past due nor impaired.

*Financial assets that are past due but not impaired*

The Company's credit period for customers generally ranges from 20 - 180 days. The aging of trade and other receivables that are past due but not impaired is given below:

<b>Period (in days)</b>	<b>As of March 31,</b>	
	<b>2016</b>	<b>2015</b>
1 - 90	Rs. 5,151	Rs. 6,229
90 - 180	577	766
More than 180	738	534
<b>Total</b>	<b>Rs. 6,466</b>	<b>Rs. 7,529</b>

See Note 13 of these consolidated financial statements for the activity in the allowance for impairment of trade and other receivables.

Other than trade and other receivables, the Company has no significant class of financial assets that is past due but not impaired.

***b. Liquidity risk***

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risk to the Company's reputation.

As of March 31, 2016 and 2015, the Company had unutilized credit limits from banks of Rs.14,771 and Rs.10,438, respectively.

As of March 31, 2016, the Company had working capital of Rs.55,042, including cash and cash equivalents of Rs.4,921, investments in term deposits (i.e., bank certificates of deposit having original maturities of more than 3 months) of Rs.12,713 and investments in available-for-sale financial assets of Rs.24,309. As of March 31, 2015, the Company had working capital of Rs.55,843, including cash and cash equivalents of Rs.5,394, investments in term deposits (i.e., bank certificates of deposit having original maturities of more than 3 months) of Rs.12,848 and investments in available-for-sale financial assets of Rs.24,228.

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****31. Financial risk management (continued)*****b. Liquidity risk (continued)***

The table below provides details regarding the contractual maturities of significant financial liabilities (other than long term loans, borrowings and obligations under finance leases, which have been disclosed in Note 18 to these consolidated financial statements) as at March 31, 2016:

<b>Particulars</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>	<b>Thereafter</b>	<b>Total</b>
Trade and other payables	Rs. 12,300	Rs.	Rs.	Rs.	Rs.	Rs. 12,300
Bank overdraft, short-term loans and borrowings	22,718					22,718
Other liabilities and provisions	23,861	702	40	14	770	25,387
Derivative financial instruments - liabilities	108					108

The table below provides details regarding the contractual maturities of significant financial liabilities (other than long term loans, borrowings and obligations under finance leases, which have been disclosed in Note 18 to these consolidated financial statements) as at March 31, 2015:

<b>Particulars</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>Thereafter</b>	<b>Total</b>
Trade and other payables	Rs. 10,660	Rs.	Rs.	Rs.	Rs.	Rs. 10,660
Bank overdraft, short-term loans and borrowings	21,857					21,857
Other liabilities and provisions	18,732	30	29	28	621	19,440
Derivative financial instruments - liabilities	462					462

***c. Market risk***

Market risk is the risk of loss of future earnings, fair values or future cash flows that may result from adverse changes in market rates and prices (such as interest rates, foreign currency exchange rates and commodity prices) or in the price of market risk-sensitive instruments as a result of such adverse changes in market rates and prices. Market risk is attributable to all market risk-sensitive financial instruments, all foreign currency receivables and payables and all short term and long-term debt. The Company is exposed to market risk primarily related to foreign exchange rate risk, interest rate risk and the market value of its investments. Thus, the Company's exposure to market risk is a function of

investing and borrowing activities and revenue generating and operating activities in foreign currencies.

*Foreign exchange risk*

The Company's foreign exchange risk arises from its foreign operations, foreign currency revenues and expenses, (primarily in U.S. dollars, Russian roubles, U.K. pounds sterling, Venezuelan bolivars and Euros) and foreign currency borrowings (in U.S. dollars, Russian roubles and Euros). A significant portion of the Company's revenues are in these foreign currencies, while a significant portion of its costs are in Indian rupees. As a result, if the value of the Indian rupee appreciates relative to these foreign currencies, the Company's revenues measured in Indian rupees may decrease. The exchange rate between the Indian rupee and these foreign currencies has changed substantially in recent periods and may continue to fluctuate substantially in the future. Consequently, the Company uses both derivative and non-derivative financial instruments, such as foreign exchange forward contracts, option contracts, currency swap contracts and foreign currency financial liabilities, to mitigate the risk of changes in foreign currency exchange rates in respect of its highly probable forecasted transactions and recognized assets and liabilities.

The details in respect of the outstanding foreign exchange forward and option contracts are given in Note 30 above.

In respect of the Company's forward contracts, option contracts and currency swap contracts, a 10% decrease/increase in the respective exchange rates of each of the currencies underlying such contracts would have resulted in:

an approximately Rs.1,511/(424) increase/(decrease) in the Company's hedging reserve and an approximately Rs.1,277/(1,707) increase/(decrease) in the Company's net profit from such contracts, as at March 31, 2016;

an approximately Rs.1,308/(631) increase/(decrease) in the Company's hedging reserve and an approximately Rs.1,598/(1,790) increase/(decrease) in the Company's net profit from such contracts, as at March 31, 2015; and

an approximately Rs.1,254/(945) increase/(decrease) in the Company's hedging reserve and an approximately Rs.3,863/(4,011) increase/(decrease) in the Company's net profit from such contracts, as at March 31, 2014.

In respect of the Company's foreign currency borrowings designated in a cash flow hedge relationship, a 10% decrease/increase in the respective exchange rates of each of the currencies underlying such borrowings would have resulted in an approximately Rs.364, Rs.1,031 and Rs.1,318 increase/decrease in the Company's hedging reserve as at March 31, 2016, 2015 and 2014, respectively.



**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

(in millions, except share and per share data and where otherwise stated)

**31. Financial risk management (continued)***c. Market risk (continued)*

The following table analyzes foreign currency risk from non-derivative financial instruments as at March 31, 2016:

	<b>U.S. dollars</b>	<b>Euro</b>	<b>Russian roubles</b>	<b>Others<sup>(1)</sup></b>	<b>Total</b>
<b>Assets:</b>					
Cash and cash equivalents	Rs. 1,378	Rs. 93	Rs. 258	Rs. 614	Rs. 2,343
Other investments	832				832
Trade and other receivables	30,518	891	4,125	1,816	37,350
Other assets	190		76	320	586
<b>Total</b>	<b>Rs. 32,918</b>	<b>Rs. 984</b>	<b>Rs. 4,459</b>	<b>Rs. 2,750</b>	<b>Rs. 41,111</b>
<b>Liabilities:</b>					
Trade and other payables	Rs. 2,681	Rs. 875	Rs.	Rs. 369	Rs. 3,925
Long-term borrowings	9,946		113		10,059
Short-term borrowings	13,846	5,768	3,104		22,718
Other liabilities and provisions	9,880	99	1,448	867	12,294
<b>Total</b>	<b>Rs. 36,353</b>	<b>Rs. 6,742</b>	<b>Rs. 4,665</b>	<b>Rs. 1,236</b>	<b>Rs. 48,996</b>

The following table analyzes foreign currency risk from non-derivative financial instruments as at March 31, 2015:

	<b>U.S. dollars</b>	<b>Euro</b>	<b>Russian roubles</b>	<b>Others<sup>(1)</sup></b>	<b>Total</b>
<b>Assets:</b>					
Cash and cash equivalents	Rs. 513	Rs. 410	Rs. 249	Rs. 2,462	Rs. 3,634
Other investments	3,063				3,063
Trade and other receivables	26,214	1,369	4,376	3,780	35,739

Other assets	91	1	62	180	334
<b>Total</b>	<b>Rs. 29,881</b>	<b>Rs. 1,780</b>	<b>Rs. 4,687</b>	<b>Rs. 6,422</b>	<b>Rs. 42,770</b>
<b>Liabilities:</b>					
Trade and other payables	Rs. 2,397	Rs. 438	Rs. 66	Rs. 642	Rs. 3,543
Long-term borrowings	19,701		140		19,841
Short-term borrowings	14,875	2,116	3,866		20,857
Other liabilities and provisions	7,645	163	1,598	854	10,260
<b>Total</b>	<b>Rs. 44,618</b>	<b>Rs. 2,717</b>	<b>Rs. 5,670</b>	<b>Rs. 1,496</b>	<b>Rs. 54,501</b>

(1) Others include currencies such as U.K. pounds sterling, Swiss francs and Venezuelan bolivars. For the years ended March 31, 2016 and 2015, every 10% depreciation/appreciation in the exchange rate between the Indian rupee and the respective currencies for the above mentioned financial assets/liabilities would affect the Company's net profit by approximately Rs.789 and Rs.1,173, respectively.

Further, in February 2016, the Venezuelan government announced changes to its foreign currency exchange mechanisms, including the devaluation of its official exchange rate. Refer to Note 41 of these consolidated financial statements for further details.

#### *Interest rate risk*

As of March 31, 2016 and March 31, 2015, the Company had Rs.29,552 of foreign currency loans carrying a floating interest rate of LIBOR minus 5 bps to LIBOR plus 125 bps and Rs.37,419 of foreign currency loans carrying a floating interest rate of LIBOR plus 7.5-130 bps, respectively. These loans expose the Company to risk of changes in interest rates. The Company's treasury department monitors the interest rate movement and manages the interest rate risk based on its policies, which include entering into interest rate swaps as considered necessary.

For details of the Company's short-term and long term loans and borrowings, including interest rate profiles, refer to Note 18 of these consolidated financial statements.

For the years ended March 31, 2016, 2015 and 2014, every 10% increase or decrease in the floating interest rate component (i.e., LIBOR) applicable to its loans and borrowings would affect the Company's net profit by approximately Rs.12, Rs.6 and Rs.13, respectively.

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****31. Financial risk management (continued)***c. Market risk (continued)*

The Company's investments in term deposits (i.e., certificates of deposit) with banks and short-term liquid mutual funds are for short durations, and therefore do not expose the Company to significant interest rates risk.

*Commodity rate risk*

Exposure to market risk with respect to commodity prices primarily arises from the Company's purchases and sales of active pharmaceutical ingredients, including the raw material components for such active pharmaceutical ingredients. These are commodity products, whose prices may fluctuate significantly over short periods of time. The prices of the Company's raw materials generally fluctuate in line with commodity cycles, although the prices of raw materials used in the Company's active pharmaceutical ingredients business are generally more volatile. Cost of raw materials forms the largest portion of the Company's cost of revenues. Commodity price risk exposure is evaluated and managed through operating procedures and sourcing policies. As of March 31, 2016, the Company had not entered into any material derivative contracts to hedge exposure to fluctuations in commodity prices.

**32. Assets acquisition from Ecologic Chemicals Limited**

On September 13, 2013, the Company entered into an asset purchase agreement with Ecologic Chemicals Limited, an entity in which two directors of the Company have equity interests. The Company paid Rs.1,264 (U.S.\$20), excluding taxes and duties, for the purchase of certain non-current and current assets relating to the manufacture of intermediates and API. The acquisition of these assets will help to augment the Company's manufacturing capacity and assist it in meeting the future business requirements of its PSAI segment.

The acquisition has been accounted for as a purchase of assets. The total purchase consideration has been allocated to the acquired assets as of September 13, 2013 based on a fair valuation carried out by the Company's management as tabulated below:

	<b>Amount</b>
<b>Category</b>	
Land	Rs. 66
Buildings	382

Plant and machinery	702
Inventories	113
Other current assets	1
<b>Grand total</b>	<b>Rs. 1,264</b>

Buildings and plant and machinery are depreciated over the remaining useful life of the respective assets.

### 33. Bonus Debentures

On March 24, 2011, the Company issued to its shareholders in-kind (i.e., for no cash consideration) 9.25% unsecured, non-convertible, redeemable debentures (sometimes referred to as bonus debentures), effected by way of capitalization of its retained earnings. These bonus debentures matured on March 24, 2014 and were redeemed by the Company for cash in an amount equal to their face value of Rs.5 each, along with the third and final interest payment thereon. The aggregate amount of principal payment for all such bonus debentures on March 24, 2014 was Rs.5,078.

### 34. Collaboration agreement with Curis, Inc.

On January 18, 2015, Aurigene Discovery Technologies Limited (Aurigene), a wholly owned subsidiary of the parent company, entered into a Collaboration, License and Option Agreement (the Collaboration Agreement) with Curis, Inc. (Curis) to discover, develop and commercialize small molecule antagonists for immuno-oncology and precision oncology targets.

Under the Collaboration Agreement, Aurigene has the responsibility for conducting all discovery and preclinical activities, including Investigational New Drug (IND) enabling studies and providing Phase 1 clinical trial supply, and Curis is responsible for all clinical development, regulatory and commercialization efforts worldwide, excluding India and Russia. The Collaboration Agreement provides that the parties will collaborate exclusively in immuno-oncology for an initial period of approximately two years, with the option for Curis to extend the broad immuno-oncology exclusivity.

As partial consideration for the collaboration, pursuant to a Stock Purchase Agreement dated January 18, 2015, Curis issued to Aurigene 17.1 million shares of its common stock, representing 19.9% of its outstanding common stock immediately prior to the transaction (approximately 16.6% of its outstanding common stock immediately after the transaction). The shares issued to Aurigene are subject to a lock-up agreement until January 18, 2017, with the shares being released from such lock-up in 25% increments on each of July 18, 2015, January 18, 2016, July 18, 2016 and January 18, 2017, subject to acceleration of release of all the shares in connection with a change of control of Curis. During the year ended March 31, 2016, lock-up restrictions were released on 8.55 million shares of common stock, representing 50% of the shares which Aurigene received from Curis. In connection with the issuance of such shares, Curis and Aurigene entered into a Registration Rights Agreement dated January 18, 2015 which provides for certain registration rights with respect to resale of the shares. The common stock of Curis is listed for quotation on the NASDAQ Global Market.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**34. Collaboration agreement with Curis, Inc. (continued)**

The fair value of the shares of common stock on the date of the Stock Purchase Agreement was Rs.1,452 (U.S.\$23.5). These shares are classified as available-for-sale financial instruments and are re-measured at fair value at every reporting date. Accordingly, Rs.272, representing the gain arising from changes in the fair value of such shares of common stock, was recorded in other comprehensive income as of March 31, 2016.

Revenues under the Collaboration Agreement consist of upfront consideration (including the shares of common stock) and the development and commercial milestone payments described below, which are deferred and recognized as revenue over the period for which Aurigene has continuing performance obligations.

Under the Collaboration Agreement, Aurigene is entitled to development and commercial milestone payments as follows:

for the first two programs: up to U.S.\$52.5 per program, including U.S.\$42.5 for approval and commercial milestones, plus pre-specified approval milestone payments for additional indications, if any;

for the third and fourth programs: up to U.S.\$50 per program, including U.S.\$42.5 for approval and commercial milestones, plus pre-specified approval milestone payments for additional indications, if any; and

for any program thereafter: up to U.S.\$140.5 per program, including U.S.\$87.5 for approval and commercial milestones, plus pre-specified approval milestone payments for additional indications, if any.

In addition, Curis has agreed to pay Aurigene royalties, ranging between high single digits to 10%, on its net sales in territories where it commercializes products. Furthermore, Aurigene is entitled to receive a share of Curis' revenues from sublicenses, which share varies based upon specified factors such as the sublicensed territory, whether the sublicense revenue is royalty based or non-royalty based and, in some cases, the stage of the applicable molecule and product at the time the sublicense is granted.

This arrangement is accounted for as a joint operation under IFRS 11.

**35. Agreement with Merck Serono**

On June 6, 2012, the Company and the biosimilars division of Merck KGaA, Darmstadt, Germany, formerly known as Merck Serono (hereinafter, Merck KGaA ), entered into a collaboration agreement to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The arrangement covers co-development, manufacturing and commercialization of the compounds around the globe, with some specific country exceptions. During the year ended March 31, 2016, the collaboration agreement was amended to rearrange and realign the development of compounds, territory rights and royalty payments. Both parties will undertake commercialization based on their respective regional rights as defined in the agreement. The Company will lead and support early product development towards or including Phase I development. Merck KGaA will carry out manufacturing of the compounds and will lead further development for its territories. In its exclusive and co-exclusive territories, the Company will carry out its own development, wherever applicable, for commercialization. As before, the Company will continue to receive royalty payments upon commercialization by Merck KGaA in its territories.

During the three months ended December 31, 2015, the Company received from Merck KGaA certain amounts relating to its share of development costs and other amounts linked to the achievement of milestones for the development of compounds under the collaboration agreement, as amended.

### **36. Agreement with Pierre Fabre**

On February 11, 2014, Aurigene entered into a collaborative license, development and commercialization agreement with Pierre Fabre, the third largest French pharmaceutical company. This agreement granted Pierre Fabre global worldwide rights (excluding India) to a new immune checkpoint modulator, AUNP-12. AUNP-12 will be in development for numerous cancer indications.

Under the terms of this agreement, Aurigene received a non-refundable upfront payment from Pierre Fabre, which was deferred and recognized as revenue over the period in which Aurigene had continuing performance obligations.

During the three months ended September 30, 2015, Aurigene entered into another agreement with Pierre Fabre to transfer back to Aurigene the rights earlier out-licensed for the development and commercialization of AUNP-12. As a result of such arrangement, Aurigene paid to Pierre Fabre a portion of the upfront consideration received and retained and recognized the remaining upfront consideration as revenue, as there are no pending performance obligations.

### **37. Asset purchase agreement with Hatchtech Pty Limited**

On September 7, 2015, the Company entered into an asset purchase agreement with Hatchtech Pty Limited ( Hatchtech ) for the purchase of intellectual property rights to an innovative prescription head lice product, Xeglyze Lotion. The exclusive rights for this product are applicable for the territories of the United States, Canada, India, Russia and other countries of the former Soviet Union, Australia, New Zealand and Venezuela.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**37. Asset purchase agreement with Hatchtech Pty Limited (continued)**

As partial consideration for the purchase of these assets, the Company paid Hatchtech an upfront amount of Rs.606 (U.S.\$9.25). In addition to the foregoing payments, the Company is also required to pay certain development and commercial milestones related payments to Hatchtech for purchase of these assets.

During the three months ended December 31, 2015, the Company paid Hatchtech development milestone payments of Rs.341 (U.S.\$5).

The transaction was recorded as an acquisition of product related intangible asset. As the intangible asset is not yet available for use, it is not subject to amortization.

The carrying amount of the intangible asset as on March 31, 2016 was Rs.947 (U.S.\$14.25).

**38. Asset purchase agreement with Alchemia**

In November 2015, the Company entered into an asset purchase agreement with Alchemia Limited ( Alchemia ) for the purchase of worldwide, exclusive intellectual property rights to fondaparinux sodium. The closing conditions for the transaction included the approval of Alchemia s shareholders which was obtained on November 10, 2015. As per the terms of the agreement, the Company paid net consideration of Rs.1,158 (U.S.\$17.5) upon the closing of the transaction in exchange for the acquired intellectual property rights.

Prior to this asset purchase agreement, the Company had worldwide, exclusive rights from Alchemia to market fondaparinux sodium in all territories in exchange for Alchemia s right to an agreed share of the net profits generated from sales in those territories. As a result of the closing of the asset purchase agreement, Alchemia is not entitled to receive any further profit share revenues from fondaparinux sales on or after July 1, 2015.

The transaction was recorded as an acquisition of technology related intangible asset with an estimated useful life of 4 years.

**39. Agreement with Novartis Consumer Health Inc.**

On October 18, 2014, the Company, through its wholly owned subsidiary Dr. Reddy s Laboratories SA, entered into an asset purchase agreement with Novartis Consumer Health Inc. to acquire the title and rights to its Habitrol® brand (an over-the-counter nicotine replacement therapy transdermal patch) and to market the product in the United States.

After obtaining the necessary approvals from the U.S. Federal Trade Commission, the Company completed the acquisition of Habitrol® on December 17, 2014. The total purchase consideration was Rs.5,097 (U.S.\$80).



The transaction has been recorded as an acquisition of a product related intangible asset with a useful life of 8 years. The carrying amount of the asset as at March 31, 2016 was Rs.4,265.

#### **40. Receipt of warning letter from the U.S. FDA**

The Company received a warning letter dated November 5, 2015 from the U.S. FDA relating to cGMP deviations at its API manufacturing facilities at Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as violations at its oncology formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh previously raised in Form 483 observations following inspections of these sites by the U.S. FDA in November 2014, January 2015 and February-March 2015, respectively.

The warning letter does not restrict production or shipment of the Company's products from these facilities. However, unless and until the Company is able to correct outstanding issues to the U.S. FDA's satisfaction, the U.S. FDA may withhold approval of new products and new drug applications of the Company, refuse admission of products manufactured at the facilities noted in the warning letter into the United States, and/or take additional regulatory or legal action against the Company. Any such further action could have a material and negative impact on the Company's ongoing business and operations.

The Company submitted its response to the warning letter on December 7, 2015. Further, the Company provided updates on the progress of its corrective actions to the U.S. FDA in January 2016, March 2016 and May 2016.

The Company believes that it can resolve the issues raised by the U.S. FDA satisfactorily in a timely manner. The Company takes the matters identified by U.S. FDA in the warning letter seriously, and will continue to work diligently to address the observations identified in the warning letter, and is concurrently continuing to develop and implement its corrective action plans relating to the warning letter.

#### **41. Venezuela operations**

Dr. Reddy's Venezuela, C.A., a wholly owned subsidiary of the Company, is primarily engaged in the import of pharmaceutical products from the parent company and other subsidiaries of the Company and the sale of such products in Venezuela. During the years ended March 31, 2016 and 2015, the Company's revenues from Venezuela were Rs.4,666 (Venezuelan bolivar ( VEF ) 457) and Rs.8,335 (VEF 813) respectively.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**41. Venezuela operations (continued)**

In February 2015, the Venezuelan government launched an overhaul of the exchange rate system and introduced a new exchange rate mechanism. The Marginal Currency System (known as SIMADI ) is the third mechanism in the new three-tier exchange rate regime and allows for legal trading of the Venezuelan bolivar for foreign currency with fewer restrictions than other mechanisms in Venezuela (CENCOEX and SICAD).

The new second tier, SICAD, is a combination of the former second and third tiers, SICAD I and SICAD II, with an initial rate of approximately 12 VEF per U.S.\$1.00. The first tier, the official exchange rate, is unchanged and sells dollars at 6.3 VEF per U.S.\$1.00 for preferential goods.

*Nine months ended December 31, 2015*

For the nine months ended December 31, 2015, all the monetary assets and liabilities that were eligible for exchange at the CENCOEX preferential rate of 6.3 VEF per U.S.\$1.00 and were pending for approval have been translated at such rate. The balance of the Company s Venezuelan monetary assets and liabilities for the nine months ended December 31, 2015, which the Company believes may not qualify for the CENCOEX preferential rate of 6.3 VEF per U.S.\$1.00, have been translated using the SIMADI rate. Consequently, foreign exchange loss of Rs.776 and Rs.843 on translation of such monetary assets and liabilities at the SIMADI rate was recorded under finance expenses for the nine months ended December 31, 2015 and the year ended March 31, 2015, respectively.

During the nine months ended December 31, 2015, the Company received approvals for only U.S.\$4 from the CENCOEX for remittance towards the importation of pharmaceutical products at the CENCOEX preferential rate.

*Update during the three months ended March 31, 2016*

The economic conditions in Venezuela continued to deteriorate further during the three months ended March 31, 2016. In February 2016, the Venezuelan government announced changes to its foreign currency exchange mechanisms, including the devaluation of its official exchange rate. The following changes became effective as of March 10, 2016:

The CENCOEX preferential rate was replaced with a new DIPRO rate. The DIPRO rate is only available for purchases and sales of essential items. Further, the preferential exchange rate was devalued from 6.3 VEF per U.S.\$1.00 to 10 VEF per U.S.\$1.00.

The SICAD exchange rate mechanism, which last auctioned USD for approximately 13 VEF per U.S.\$1.00, was eliminated.

The SIMADI exchange rate mechanism was replaced with a new DICOM rate, which governs all transactions not subject to the DIPRO exchange rate and will fluctuate according to market supply and demand. As of March 31, 2016, the DICOM exchange rate was 272.5 VEF per U.S.\$1.00.

The Company has not yet received approvals from the Venezuelan government to repatriate any amount at preferential rates beyond the U.S.\$4 already approved and received during the year ended March 31, 2016. The Company fully considered all the aforesaid developments, facts and circumstances and, following the guidance available in IAS 21, believes that it is appropriate to use the DICOM rate (i.e. 272.5 VEF per U.S.\$1.00) for translating the monetary assets and liabilities of the Venezuelan subsidiary as at March 31, 2016.

Tabulated below is the impact of the foregoing on the financial statements of the Company:

<b>Particulars</b>	<b>Year ended March 31, 2015</b>	<b>Nine months ended December 31, 2015</b>	<b>Three months ended March 31, 2016</b>	<b>Year ended March 31, 2016</b>
Foreign exchange loss on account of currency devaluation and translation of monetary assets and liabilities using SIMADI / DICOM rate recorded under finance expense	Rs. 843	Rs. 776	Rs. 3,845	Rs. 4,621
Impact of inventory write down and reversal of export incentives recorded under cost of revenues			341	341
Impairment of property, plant and equipment recorded under selling, general and administrative expenses			123	123
<b>Total</b>	<b>Rs. 843</b>	<b>Rs. 776</b>	<b>Rs. 4,309</b>	<b>Rs. 5,085</b>

Including the foreign exchange loss of Rs.843 recognized during the year ended March 31, 2015, total loss recognized on account of operations in Venezuela was Rs.5,928 as of March 31, 2016.

Notwithstanding the ongoing uncertainty, the Company continues to actively engage with the Venezuelan Government and seek approval to repatriate funds at preferential rates.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**42. License agreement with Xenoport**

On March 28, 2016, the Company and Xenoport, Inc. ( Xenoport ) entered into a license agreement pursuant to which the Company was granted exclusive U.S. rights for the development and commercialization of Xenoport s clinical stage oral new chemical entity. The Company plans to develop the in-licensed compound as a potential treatment for moderate-to-severe chronic plaque psoriasis and for relapsing forms of multiple sclerosis.

The transaction was subject to satisfaction of certain customary closing conditions, including among other things the expiration or early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the HSR Act ), following the Company s premerger notification filing under the HSR Act with the applicable governmental authorities regarding its intention to acquire these rights.

Upon the completion of all closing conditions, in May 2016, the Company paid a U.S.\$47.5 up-front payment and an additional U.S.\$2.5 for the transfer of certain clinical trial materials as per the terms of the agreement.

In addition to the up-front payment, Xenoport will also be eligible to receive up to U.S.\$190 upon the achievement by the Company of certain regulatory milestones, which could be achieved over a period of several years. In addition, Xenoport will be eligible to receive up to U.S.\$250 upon the achievement by the Company of certain commercial milestones, and up to mid-teens percentage rate royalty payments based on the Company s net sales of the product in the United States.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**43. Contingencies**

The Company is involved in disputes, lawsuits, claims, governmental and/or regulatory inspections, inquiries, investigations and proceedings, including patent and commercial matters that arise from time to time in the ordinary course of business. The more significant matters are discussed below. Most of the claims involve complex issues. Often, these issues are subject to uncertainties and therefore the probability of a loss, if any, being sustained and an estimate of the amount of any loss is difficult to ascertain. Consequently, for a majority of these claims, it is not possible to make a reasonable estimate of the expected financial effect, if any, that will result from ultimate resolution of the proceedings. This is due to a number of factors, including: the stage of the proceedings (in many cases trial dates have not been set) and the overall length and extent of pre-trial discovery; the entitlement of the parties to an action to appeal a decision; clarity as to theories of liability; damages and governing law; uncertainties in timing of litigation; and the possible need for further legal proceedings to establish the appropriate amount of damages, if any. In these cases, the Company discloses information with respect to the nature and facts of the case. The Company also believes that disclosure of the amount sought by plaintiffs, if that is known, would not be meaningful with respect to those legal proceedings.

Although there can be no assurance regarding the outcome of any of the legal proceedings or investigations referred to in this Note, the Company does not expect them to have a materially adverse effect on its financial position, as it believes that possibility of loss in excess of amounts accrued (if any) is not probable. However, if one or more of such proceedings were to result in judgments against the Company, such judgments could be material to its results of operations in a given period.

***Product and patent related matters***

***Norfloxacin, India litigation***

The Company manufactures and distributes Norfloxacin, a formulations product and in limited quantities, the active pharmaceutical ingredient norfloxacin. Under the Drugs Prices Control Order (the DPCO ) the National Pharmaceutical Pricing Authority (the NPPA ) established by the Government of India had the authority to designate a pharmaceutical product as a specified product and fix the maximum selling price for such product. In 1995, the NPPA issued a notification and designated Norfloxacin as a specified product and fixed the maximum selling price. In 1996, the Company filed a statutory Form III before the NPPA for the upward revision of the maximum selling price and a writ petition in the Andhra Pradesh High Court (the High Court ) challenging the validity of the designation on the grounds that the applicable rules of the DPCO were not complied with while fixing the maximum selling price. The High Court had previously granted an interim order in favor of the Company; however it subsequently dismissed the case in April 2004.

The Company filed a review petition in the High Court in April 2004 which was also dismissed by the High Court in October 2004. Subsequently, the Company appealed to the Supreme Court of India, New Delhi (the Supreme Court ) by filing a Special Leave Petition, which is currently pending.

During the year ended March 31, 2006, the Company received a notice from the NPPA demanding the recovery of the price charged by the Company for sales of Norfloxacin in excess of the maximum selling price fixed by the NPPA, which was Rs.285 including interest. The Company filed a writ petition in the High Court challenging this demand order. The High Court admitted the writ petition and granted an interim order, directing the Company to deposit 50% of the principal amount claimed by the NPPA, which was Rs.77. The Company deposited this amount with the NPPA in November 2005. In February 2008, the High Court directed the Company to deposit an additional amount of Rs.30, which was deposited by the Company in March 2008. In November 2010, the High Court allowed the Company's application to include additional legal grounds that the Company believes will strengthen its defense against the demand. For example, the Company has added as grounds that trade margins should not be included in the computation of amounts overcharged, and that it is necessary for the NPPA to set the active pharmaceutical ingredient price before the process of determining the ceiling on the formulation price. In October 2013, the Company filed an additional writ petition before the Supreme Court challenging the inclusion of Norfloxacin as a specified product under the DPCO, which is currently pending. In January 2015, the NPPA filed a counter affidavit stating that the inclusion of Norfloxacin was based upon the recommendation of a committee consisting of experts in the field.

Based on its best estimate, the Company has recorded a provision for the potential liability related to the allegedly overcharged amount including interest thereon, and believes that possibility of any liability that may arise on account of penalties pursuant to this litigation is not probable. In the event the Company is unsuccessful in this litigation in the Supreme Court, it will be required to remit the sale proceeds in excess of the notified selling prices to the Government of India with interest and including penalties, if any, which amounts are not readily ascertainable.

#### *Nexium United States litigations*

Five federal antitrust class action lawsuits were brought on behalf of direct purchasers of Nexium<sup>®</sup>, and ten federal class action lawsuits were brought under both state and federal law on behalf of end-payors of Nexium<sup>®</sup>. These actions were filed against various generic manufacturers, including the Company and its U.S. subsidiary Dr. Reddy's Laboratories, Inc. These actions were consolidated in the United States District Court for the District of Massachusetts.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**43. Contingencies (continued)**

*Product and patent related matters (continued)*

The complaints alleged that AstraZeneca and the involved generic manufacturers settled patent litigation related to Nexium<sup>®</sup> capsules in ways that violated antitrust laws. The Company consistently maintained that its conduct complied with all applicable laws and that the complaints were without merit. In response to a motion for summary judgment made by the Company, the Court granted the motion in part and denied it in part, finding that the plaintiffs had failed to demonstrate that the Company's settlement of patent litigation with AstraZeneca included any large or unjustified reverse payment, but preserving other claims for trial.

On October 20, 2014, the Company reached a settlement with all plaintiffs who had cases pending in the District of Massachusetts. The settlements with the class plaintiffs were subject to the Court's approval. Under the terms of the settlement, the Company made no payment to the class plaintiffs. The remaining defendants went to trial and prevailed, and that matter is on appeal.

The Court granted preliminary approval of the Company's settlements with the class plaintiffs on January 28, 2015, and granted final approval of such settlements on September 29, 2015.

In addition, two complaints, similar in nature to those referenced above, were filed in the Court of Common Pleas in Philadelphia, Pennsylvania by plaintiffs who chose to opt out of the class action lawsuit. No dispositive motions have been filed in these actions.

*Reclast and Zometa United States litigation*

In January 2013, Novartis AG (Novartis) brought patent infringement actions against the Company and a number of other generic companies in the United States District Court for the District of New Jersey. Novartis asserted that the Company's ANDA referencing Reclast<sup>®</sup> would infringe Novartis' U.S. Patent No. 8,052,987 and that the Company's ANDA referencing Zometa<sup>®</sup> would infringe Novartis' U.S. Patent No. 8,324,189. In February 2013, Novartis sought a temporary restraining order and a preliminary injunction prohibiting the Company and the other defendants from launching generic equivalents to the Reclast<sup>®</sup> and Zometa<sup>®</sup> products. The Court denied Novartis' motion for a temporary restraining order on March 1, 2013 and, later that month, the Company launched its generic version of Novartis' Zomet<sup>®</sup> Injection (zoledronic acid, 4 mg/5mL product). The Company launched its generic version of Novartis' Reclast<sup>®</sup> Injection (zoledronic acid, 5 mg/100mL product) in April 2013.

In January 2016, the parties reached an agreement settling litigation regarding these products. Under the terms of the agreement, the Company made a one-time payment to Novartis in exchange for a license to all relevant patents. The settlement ended the potential patent related liability associated with the Company's sale of these products.

Pursuant to this agreement, the Company paid Rs.430 (U.S.\$6.5) to Novartis as a settlement amount for past and future sales of the products. Of the total amount, Rs.69 (U.S.\$1.04) represents the payment for a non-exclusive license and is recognized as a product related intangible asset and the balance of Rs.361 (U.S.\$5.46) is recorded as Selling, general and administrative expense in the Company's consolidated income statement for the year ended March 31, 2016.

*Child resistant packaging matter*

In May 2012, the Consumer Product Safety Commission (the CPSC) requested that Dr. Reddy's Laboratories Inc., a wholly-owned subsidiary of the Company in the United States, provide certain information with respect to compliance with requirements of special packaging for child resistant blister packs for 6 products sold by the Company in the United States during the period commencing in 2002 through 2011. The Company provided the requested information. The CPSC subsequently alleged in a letter dated April 30, 2014 that the Company has violated the Consumer Product Safety Act (the CPSA) and the Poison Prevention Packaging Act (the PPPA) and intends to seek civil penalties. Specifically, the CPSC asserted, among other things, that from or about August 14, 2008 through June 1, 2012, the Company sold prescription drugs having unit dose packaging that failed to comply with the CPSC's special child resistant packaging regulations under the PPPA and failed to issue general certificates of conformance. In addition, the CPSC asserted that the Company violated the CPSA by failing to immediately advise the CPSC of the alleged violations. The Company disagrees with the CPSC's allegations and is engaged in discussions with the CPSC regarding its compliance with the regulations.

Simultaneously, the Department of Justice (the DOJ) had begun to investigate a sealed complaint which was filed in the United States District Court for the Eastern District of Pennsylvania under the Federal False Claims Act (FCA) related to these same issues (the FCA Complaint). The Company cooperated with the DOJ in its investigation. The DOJ and all States involved in the investigation declined to intervene in the FCA Complaint. On November 10, 2015, the FCA Complaint was unsealed and the plaintiff whistleblowers (the Relators), who are two former employees of the Company, have proceeded without the DOJ's and States' involvement. The unsealed FCA Complaint relates to the 6 blister pack products originally subject to the investigation and also 38 of the Company's generic prescription products sold in the U.S. in various bottle and cap packaging. The Company disputes the allegations in the FCA Complaint and intends to vigorously defend against those allegations.



**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**43. Contingencies (continued)**

*Product and patent related matters (continued)*

Although the DOJ and States have declined to intervene in the FCA Complaint filed by the Relators, the parallel investigation by the CPSC under the CPSCA and the PPPA was referred by the CPSC to the DOJ in April 2016, with the recommendation that the DOJ initiate a civil penalty action against the Company. The CPSC related matter referred to the DOJ relates to 5 of the blister pack products. The Company cannot conclude that the likelihood of an unfavorable outcome is either probable or remote. Accordingly, no provision related to these investigations and claims is made in the Company's consolidated financial statements as of March 31, 2016. An unfavorable outcome in these matters could result in significant liabilities, which could have a material adverse effect on the Company.

*Namenda United States Litigations*

In August 2015, Sergeants Benevolent Assoc. Health & Welfare Fund (Sergeants) filed suit against the Company in the United States District Court for the Southern District of New York. Sergeants alleged that certain parties, including the Company, violated federal antitrust laws as a consequence of having settled patent litigation related to the Alzheimer's drug Namenda® (memantine) tablets during a period from about 2009 until 2010. Sergeants seeks to represent a class of end-payor purchasers of Namenda® tablets (i.e., insurers, other third-party payors and consumers).

Sergeants seeks damages based upon an allegation made in the complaint that the defendants entered into patent settlements regarding Namenda® tablets for the purpose of delaying generic competition and facilitating the brand innovator's attempt to shift sales from the original immediate release product to the more recently introduced extended release product. The Company believes that the complaint lacks merit and that the Company's conduct complied with all applicable laws and regulations. All defendants, including the Company, have moved to dismiss the claims.

Four other class action complaints, each containing similar allegations to the Sergeants complaint, have also been filed in the Southern District of New York. However, two of those complaints were voluntarily dismissed, and the other two do not name the Company as a defendant.

In addition, the State of New York filed an antitrust case in the Southern District of New York. The case brought by the State of New York contained some (but not all) of the allegations set out in the class action complaints, but the Company was not named as a party. The case brought by the State of New York was dismissed by stipulation on November 30, 2015.

*Private Party Class Action Litigation on Pricing/Reimbursement Matters*

On December 30, 2015, a class action complaint was filed against the Company and eighteen other pharmaceutical defendants (the Action) in State Court in the Commonwealth of Pennsylvania. In the Action, class action plaintiffs allege that the Company and other defendants, individually or in some cases in concert with one another, have engaged in pricing and price reporting practices in violation of various Pennsylvania state laws. More specifically, plaintiffs allege that: (1) the Company provided false and misleading pricing information to third party drug compendia companies for the Company's generic drugs, and such information was relied upon by private third party payers that reimbursed for drugs sold by the Company in the United States, and (2) the Company acted in concert with certain other defendants to unfairly raise the prices of generic divalproex sodium ER (bottle of 80, 500 mg tablets ER 24H) and generic pravastatin sodium (bottle of 500, 10 mg tablets). The Company disputes these allegations and intends to vigorously defend against these allegations.

### ***Environmental matters***

#### *Land pollution*

The Indian Council for Environmental Legal Action filed a writ in 1989 under Article 32 of the Constitution of India against the Union of India and others in the Supreme Court of India for the safety of people living in the Patancheru and Bollaram areas of Medak district of the then existing undivided state of Andhra Pradesh. The Company has been named in the list of polluting industries. In 1996, the Andhra Pradesh District Judge proposed that the polluting industries compensate farmers in the Patancheru, Bollaram and Jeedimetla areas for discharging effluents which damaged the farmers' agricultural land. The compensation was fixed at Rs.0.0013 per acre for dry land and Rs.0.0017 per acre for wet land. Accordingly, the Company has paid a total compensation of Rs.3. The Company believes that the possibility of additional liability is remote. The Andhra Pradesh High Court disposed of the writ petition on February 12, 2013 and transferred the case to the National Green Tribunal (NGT), Chennai, India. The interim orders passed in the writ petitions will continue until the matter is decided by the NGT. The NGT has, through its order dated October 30, 2015, constituted a Fact Finding Committee. The NGT has also permitted the alleged polluting industries to appoint a person on their behalf in the Fact Finding Committee. However, the Company along with the alleged polluting industries have challenged the constitution and composition of the Fact Finding Committee. The NGT has directed that until all the applications challenging the constitution and composition of the Fact Finding Committee are disposed of, the Fact Finding Committee shall not commence its operation.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**43. Contingencies (continued)**

*Environmental matters (continued)*

*Water pollution and air pollution*

During the year ended March 31, 2012, the Company, along-with 14 other companies, received a notice from the Andhra Pradesh Pollution Control Board ( APP Control Board ) to show cause as to why action should not be initiated against them for violations under the Indian Water Pollution Act and the Indian Air Pollution Act. Furthermore, the APP Control Board issued orders to the Company to (i) stop production of all new products at the Company s manufacturing facilities in Hyderabad, India without obtaining a Consent for Establishment , (ii) cease manufacturing products at such facilities in excess of certain quantities specified by the APP Control Board and (iii) furnish a bank guarantee to assure compliance with the APP Control Board s orders.

The Company appealed the APP Control Board orders to the Andhra Pradesh Pollution Appellate Board (the APP Appellate Board ). The APP Appellate Board, on the basis of a report of a fact-finding advisory committee, recommended to the Andhra Pradesh Government to allow expansion of units fully equipped with Zero-Liquid Discharge ( ZLD ) facilities and otherwise found no fault with the Company (on certain conditions). The APP Appellate Board s decision was challenged by one of the petitioners in the National Green Tribunal and the matter is currently pending before it.

Separately, the Andhra Pradesh Government, following recommendations of the APP Appellate Board, published a notification in July 2013 that allowed expansion of production of all types of existing bulk drug and bulk drug intermediate manufacturing units subject to the installation of ZLD facilities and the outcome of cases pending in the National Green Tribunal. Importantly, the notification directed pollution load of industrial units to be assessed at the point of discharge (if any) as opposed to point of generation.

In September 2013, the Ministry of Environment and Forests, based on the revised Comprehensive Environment Pollution Index, issued a notification that re-imposed a moratorium on expansion of industries in certain areas where some of the Company s manufacturing facilities are located. This notification overrides the Andhra Pradesh Government s notification that conditionally permitted expansion.

*Indirect taxes related matters*

*Assessable value of products supplied by a vendor to the Company*

During the year ended March 31, 2003, the Central Excise Authorities of India (the Central Excise Authorities ) issued a demand notice to a vendor of the Company regarding the assessable value of products supplied by this vendor to the Company. The Company has been named as a co-defendant in this demand notice. The Central Excise Authorities demanded payment of Rs.176 from the vendor, including penalties of Rs.90. Through the same notice, the Central Excise Authorities issued a penalty claim of Rs.70 against the Company. During the year ended March 31, 2005, the Central Excise Authorities issued an additional notice to this vendor demanding Rs.226 from the vendor, including a penalty of Rs.51. Through the same notice, the Central Excise Authorities issued a penalty claim of Rs.7 against the Company. Furthermore, during the year ended March 31, 2006, the Central Excise Authorities issued an additional notice to this vendor demanding Rs.34. The Company filed appeals against these notices with the Customs, Excise and Service Tax Appellate Tribunal (the CESTAT ). In October 2006, the CESTAT passed an order in favor of the Company setting aside all of the above demand notices. In July 2007, the Central Excise Authorities appealed against CESTAT s order in the Supreme Court of India, New Delhi.

On November 27, 2015, the Supreme Court of India dismissed the appeal of the Central Excise Authorities and passed an order in favor of the Company.

*Distribution of input service tax credits*

The Central Excise Authorities have issued various show cause notices to the Company objecting to the Company s methodology of distributing input service tax credits claimed for one of the Company s facilities. The below table shows the details of each of such show cause notices and the consequential actions on and status of the same.

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****(in millions, except share and per share data and where otherwise stated)****43. Contingencies (continued)***Indirect taxes related matters (continued)***Period covered**

<b>under the notice</b>	<b>Amount demanded</b>	<b>Status</b>
March 2008 to September 2009	Rs.102 plus 100% penalties and interest thereon	The Company has filed an appeal before the CESTAT.
October 2009 to March 2011	Rs.125 plus penalties of Rs.100 and interest thereon	The Company has filed an appeal before the CESTAT.
April 2011 to March 2012	Rs.51 plus interest and penalties	The Company has filed an appeal before the CESTAT.
April 2012 to March 2013	Rs.54 plus interest and penalties	The Company has filed an appeal before the CESTAT.
April 2013 to March 2014	Rs.69 plus interest and penalties	The Company has filed an appeal before the CESTAT.
April 2014 to March 2015	Rs.108 plus interest and penalties	The Company is in the process of responding to such notice.

The Company believes that the possibility of any liability that may arise on account of the allegedly inappropriate distribution of input service tax credits is not probable. Accordingly, no provision relating to these claims has been made in the Company's consolidated financial statements as of March 31, 2016.

*Value Added Tax ( VAT ) matter*

The Company received various show cause notices from the Government of Telangana's Commercial Taxes Department objecting to the Company's methodology of calculation of VAT input credit. The below table shows the details of each of such show cause notices and the consequential actions on and status of the same.

<b>Period covered</b>	<b>Amount demanded</b>	<b>Status</b>
-----------------------	------------------------	---------------

**under the notice**

April 2006 to March 2009	Rs.66 plus 10% penalty	The Company has filed an appeal before the Sales Tax Appellate Tribunal.
April 2009 to March 2011	Rs.59 plus 10% penalty	The Company has filed an appeal before the Sales Tax Appellate Tribunal.
April 2011 to March 2013	Rs.16 plus 10% penalty	The Appellate Deputy Commissioner issued an order partially in favor of the Company. In January 2016, the Assistant Commissioner issued an order partially in favor of the Company.

The Company has recorded a provision of Rs.27 as of March 31, 2016, and believes that the possibility of any further liability that may arise on account of the allegedly inappropriate claims to VAT credits is not probable.

*Others*

Additionally, the Company is in receipt of various show cause notices from the Indian Sales Tax authorities. The disputed amount is Rs.57. The Company has responded to such show cause notices and believes that the chances of any liability arising from such notices are less than probable. Accordingly, no provision is made in the Company's consolidated financial statements as of March 31, 2016.

***Fuel Surcharge Adjustments***

The Andhra Pradesh Electricity Regulatory Commission (the APERC) passed various orders approving the levy of Fuel Surcharge Adjustment (FSA) charges for the period from April 1, 2008 to March 31, 2013 by power distribution companies from all the consumers of electricity in the then existing undivided state of Andhra Pradesh, India where the Company's headquarters and principal manufacturing facilities are located. Separate writ petitions filed by the Company for various periods, challenging and questioning the validity and legality of this levy of FSA charges by the APERC, are pending before the High Court of Andhra Pradesh and the Supreme Court of India.

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**43. Contingencies (continued)**

***Fuel Surcharge Adjustments (continued)***

After taking into account all of the available information and legal provisions, the Company has recorded Rs.219 as the potential liability towards FSA charges. The total amount approved by APERC for collection by the power distribution companies from the Company in respect of FSA charges for the period from April 1, 2008 to March 31, 2013 is Rs.482. As of March 31, 2016, the Company has made payments under protest of Rs.354 as demanded by the power distribution companies as part of monthly electricity bills. The Company remains exposed to additional financial liability should the orders passed by the APERC be upheld by the Courts.

***Direct taxes related matters***

During the year ended March 31, 2014, the Indian Income Tax authorities disallowed for tax purposes certain business transactions entered into by the parent company with its wholly-owned subsidiaries. The associated tax impact is Rs.570. The Company believes that such business transactions are allowed for tax deduction under Indian Income Tax laws and has accordingly filed an appeal with the Income Tax Appellate Authorities. The Company further believes that the probability of succeeding in this matter is more likely than not and therefore no provision was made in respect of this matter in the Company's consolidated financial statements as of March 31, 2016.

Additionally, the Company is contesting various other disallowances by the Indian Income Tax authorities. The associated tax impact is Rs.845. The Company believes that the chances of an unfavorable outcome in each of such disallowances are less than probable and accordingly, no provision was made in respect of these matters in the Company's consolidated financial statements as of March 31, 2016.

During the years ended March 31, 2014, 2015 and 2016, Industrias Quimicas Falcon de Mexico, S.A. de CV, a wholly owned subsidiary of the Company in Mexico, received a notice from Mexico's Tax Administration Service, Servicio de Administracion Tributaria ( SAT ), with respect to disallowance on account of transfer pricing adjustments pertaining to the calendar years ended on December 31, 2006, December 31, 2007 and December 31, 2008. The associated tax impact is Rs.663 (MXN172.5). The Company disagrees with the SAT's allegations and filed an appeal with the SAT. The Company believes that possibility of any liability that may arise on account of this litigation is not probable and hence, no provision has been made in the financial statements.

***Others***

Additionally, the Company is involved in other disputes, lawsuits, claims, governmental and/or regulatory inspections, inquiries, investigations and proceedings, including patent and commercial matters that arise from time to time in the ordinary course of business. Except as discussed above, the Company does not believe that there are any such contingent liabilities that are expected to have any material adverse effect on its financial statements.

#### 44. Nature of Expense

The following table shows supplemental information related to certain nature of expense items for the years ended March 31, 2016, 2015 and 2014:

<b>Particulars</b>	<b>Cost of revenues</b>	<b>For the Year Ended March 31, 2016</b>		<b>Total</b>
		<b>Selling, general and administrative expenses</b>	<b>Research and development expenses</b>	
Employee benefits	Rs. 9,574	Rs. 16,641	Rs. 4,959	Rs. 31,174
Depreciation and amortization	5,241	3,933	1,076	10,250

<b>Particulars</b>	<b>Cost of revenues</b>	<b>For the Year Ended March 31, 2015</b>		<b>Total</b>
		<b>Selling, general and administrative expenses</b>	<b>Research and development expenses</b>	
Employee benefits	Rs. 9,469	Rs. 15,400	Rs. 4,098	Rs. 28,967
Depreciation and amortization	4,154	3,023	923	8,100



<b>Particulars</b>	<b>For the Year Ended March 31, 2014</b>				
	<b>Cost of revenues</b>	<b>Selling, general and administrative expenses</b>		<b>Research and development expenses</b>	<b>Total</b>
Employee benefits	Rs. 8,526	Rs.	13,727	Rs. 2,684	Rs. 24,937
Depreciation and amortization	3,771		2,901	434	7,106

F-73

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**45. Subsequent events**

*Buyback of equity shares*

The Board of Directors of the Company, in their meeting held on February 17, 2016, approved a proposal to buyback equity shares of the Company, subject to approval by the Company's shareholders, for an aggregate amount not exceeding Rs.15,694 (referred to as the "Maximum Buyback Size") and at a price not exceeding Rs.3,500 per equity share (referred to "Maximum Buyback Price") from shareholders of the Company (including persons who become shareholders by cancelling American Depository Shares and receiving underlying equity shares, and excluding the promoters and promoter group of the Company) under the open market route in accordance with the provisions contained in the Securities and Exchange Board of India (Buy Back of Securities) Regulations, 1998 and the Companies Act, 2013 and rules made thereunder. The shares bought back under this plan shall be extinguished in accordance with the provisions of the Securities and Exchange Board of India (Buy Back of Securities) Regulations, 1998 and the Companies Act, 2013 and rules made thereunder.

The Company obtained the approval of the shareholders for the buyback plan on April 1, 2016 and the buyback plan commenced on April 18, 2016.

As of June 22, 2016, the Company has bought back 5,024,178 equity shares pursuant to this buyback plan for an aggregate purchase price of Rs.15,526.

*Asset purchase agreement with Ducere Pharma LLC*

On May 23, 2016, the Company entered into an asset purchase agreement with Ducere Pharma LLC for the purchase of a portfolio of certain pharmaceutical brands for a total consideration of Rs.1,144 (U.S.\$17). The acquisition is expected to strengthen the Company's presence in the dermatology, cough-and-cold and pain therapeutic areas forming part of the Company's over-the-counter ("OTC") business in the United States.

*Asset purchase agreement with Teva Pharmaceutical Industries Ltd.*

On June 10, 2016, the Company entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. ("Teva") and an affiliate of Allergan plc ("Allergan") to acquire a portfolio of eight Abbreviated New Drug Applications ("ANDAs") in the United States for U.S.\$350 in cash at closing. The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business. The acquisition of these ANDAs is also contingent on the closing of the Teva/Allergan generics purchase transaction and approval by the U.S. Federal Trade Commission of the Company as a buyer.

**46. Organizational structure**

Dr. Reddy's Laboratories Limited is the parent company. Tabulated below is the list of subsidiaries, associates and joint ventures as of March 31, 2016:

<b>Name of the subsidiary</b>	<b>Country of Incorporation</b>	<b>Percentage of Direct/Indirect Ownership Interest</b>
Aurigene Discovery Technologies (Malaysia) Sdn. Bhd.	Malaysia	100% <sup>(3)</sup>
Aurigene Discovery Technologies Inc.	U.S.A.	100% <sup>(3)</sup>
Aurigene Discovery Technologies Limited	India	100%
beta Institut gemeinnützige GmbH	Germany	100% <sup>(8)</sup>
betapharm Arzneimittel GmbH	Germany	100% <sup>(8)</sup>
Cheminor Investments Limited	India	100%
Chienna B.V.	Netherlands	100% <sup>(13)</sup>
Chirotech Technology Limited	United Kingdom	100% <sup>(5)</sup>
DRANU LLC	U.S.A.	50% <sup>(15)</sup>
Dr. Reddy's Bio-Sciences Limited	India	100%
Dr. Reddy's Farmaceutica Do Brasil Ltda.	Brazil	100%
Dr. Reddy's Laboratories (Australia) Pty. Limited	Australia	100% <sup>(10)</sup>
Dr. Reddy's Laboratories Canada, Inc.	Canada	100% <sup>(10)</sup>
Dr. Reddy's Laboratories (EU) Limited	United Kingdom	100% <sup>(10)</sup>
Dr. Reddy's Laboratories Inc.	U.S.A.	100% <sup>(10)</sup>
Dr. Reddy's Laboratories International SA	Switzerland	100% <sup>(10)</sup>
Dr. Reddy's Laboratories Japan KK (from April 21, 2015)	Japan	100% <sup>(10)</sup>
Dr. Reddy's Laboratories, LLC	Ukraine	100% <sup>(10)</sup>

**Table of Contents****DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES****NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

(in millions, except share and per share data and where otherwise stated)

**46. Organizational structure (continued)**

<b>Name of the subsidiary</b>	<b>Country of Incorporation</b>	<b>Percentage of Direct/Indirect Ownership Interest</b>
Dr. Reddy s Laboratories Louisiana LLC	U.S.A.	100% <sup>(6)</sup>
Dr. Reddy s Laboratories New York, Inc.	U.S.A.	100% <sup>(10)</sup>
Dr. Reddy s Laboratories (Proprietary) Limited	South Africa	100% <sup>(10)</sup>
Dr. Reddy s Laboratories Romania S.R.L.	Romania	100% <sup>(10)</sup>
Dr. Reddy s Laboratories SA	Switzerland	100%
Dr. Reddy s Laboratories SAS (from November 4, 2014)	Colombia	100% <sup>(10)</sup>
Dr. Reddy s Laboratories Tennessee, LLC	U.S.A.	100% <sup>(6)</sup>
Dr. Reddy s Laboratories (UK) Limited	United Kingdom	100% <sup>(5)</sup>
Dr. Reddy s New Zealand Limited.	New Zealand	100% <sup>(10)</sup>
Dr. Reddy s Pharma SEZ Limited	India	100%
Dr. Reddy s Singapore PTE Limited	Singapore	100% <sup>(10)</sup>
Dr. Reddy s Srl	Italy	100% <sup>(11)</sup>
Dr. Reddy s Venezuela, C.A.	Venezuela	100% <sup>(10)</sup>
DRL Impex Limited	India	100%
Eurobridge Consulting B.V.	Netherlands	100% <sup>(1)</sup>
Industrias Quimicas Falcon de Mexico, S.A. de CV	Mexico	100%
Idea2Enterprises (India) Pvt. Limited	India	100%
Kunshan Rotam Reddy Pharmaceutical Co. Limited	China	51.33% <sup>(4)</sup>
Lacock Holdings Limited	Cyprus	100% <sup>(10)</sup>
OOO Dr. Reddy s Laboratories Limited	Russia	100% <sup>(10)</sup>
OOO DRS LLC	Russia	100% <sup>(9)</sup>
OctoPlus B.V. (formerly OctoPlus N.V.)	Netherlands	100% <sup>(12)</sup>
OctoPlus Development B.V.	Netherlands	100% <sup>(13)</sup>
OctoPlus Sciences B.V.	Netherlands	100% <sup>(13)</sup>
OctoPlus PolyActive Sciences B.V.	Netherlands	100% <sup>(14)</sup>
OctoPlus Technologies B.V.	Netherlands	100% <sup>(13)</sup>
OctoShare B.V.	Netherlands	100% <sup>(13)</sup>
Promius Pharma LLC	U.S.A.	100% <sup>(6)</sup>
Reddy Antilles N.V.	Netherlands	100%
Reddy Specialities GmbH (till November 21, 2015)	Germany	100% <sup>(8)</sup>
Reddy Cheminor S.A.	France	100% <sup>(2)</sup>
Reddy Holding GmbH	Germany	100% <sup>(10)</sup>
Reddy Netherlands B.V.	Netherlands	100% <sup>(10)</sup>
Reddy Pharma Iberia SA	Spain	100%

Reddy Pharma Italia S.R.L. (formerly Reddy Pharma Italia S.p.A.)	Italy	100% <sup>(7)</sup>
Reddy Pharma SAS (from October 29, 2015)	France	100% <sup>(10)</sup>
DRSS Solar Power Private Limited	India	26% <sup>(16)</sup>
DRES Solar Power Private Limited (from October 6, 2015)	India	26% <sup>(16)</sup>

- (1) Indirectly owned through Reddy Antilles N.V.
- (2) Subsidiary under liquidation.
- (3) Indirectly owned through Aurigene Discovery Technologies Limited.
- (4) Kunshan Rotam Reddy Pharmaceutical Co. Limited is a subsidiary, as the Company holds a 51.33% stake. However, the Company accounts for this investment by the equity method and does not consolidate it in the Company's financial statements.
- (5) Indirectly owned through Dr. Reddy's Laboratories (EU) Limited.
- (6) Indirectly owned through Dr. Reddy's Laboratories Inc.

F-75

**Table of Contents**

**DR. REDDY S LABORATORIES LIMITED AND SUBSIDIARIES**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**(in millions, except share and per share data and where otherwise stated)**

**46. Organizational structure (continued)**

- (7) Indirectly owned through Lacock Holdings Limited.
- (8) Indirectly owned through Reddy Holding GmbH.
- (9) Indirectly owned through Eurobridge Consulting B.V.
- (10) Indirectly owned through Dr. Reddy s Laboratories SA.
- (11) Indirectly owned through Reddy Pharma Italia S.R.L.
- (12) Indirectly owned through Reddy Netherlands B.V.
- (13) Indirectly owned through OctoPlus B.V.
- (14) Indirectly owned through OctoPlus Sciences B.V.
- (15) DRANU LLC is consolidated in accordance with guidance available in IFRS 10.
- (16) Accounted in accordance with IFRS 11 Joint Arrangements .

F-76

**Table of Contents****Item 19. EXHIBITS**

<b>Exhibit Number</b>	<b>Description of Exhibits</b>	<b>Footnotes</b>
1.1.	Memorandum and Articles of Association of the Registrant dated February 4, 1984.	(1)(3)(5)
1.2.	Certificate of Incorporation of the Registrant dated February 24, 1984.	(1)(3)
1.3.	Amended Certificate of Incorporation of the Registrant dated December 6, 1985.	(1)(3)
1.4.	Amendment to Memorandum and Articles of Association of the Registrant dated June 12, 2009 (regarding an increase in our authorized share capital pursuant to the amalgamation of Perlecan Pharma Private Limited into Dr. Reddy's Laboratories Limited, its parent company).	(6)
1.5.	Amendment to Memorandum and Articles of Association of the Registrant dated July 19, 2010 Order of the Hon'ble High Court of Andhra Pradesh, India dated July 19, 2010 (regarding Amendment to Memorandum and Articles of Association of the Registrant and capitalization or utilization of undistributed profit or retained earnings or security premium account or any other reserve or fund in connection with our bonus debentures).	(8)
1.6.	Amended and Restated Articles of Association of the Registrant dated September 17, 2015	(9)
2.1.	Form of Deposit Agreement, including the form of American Depositary Receipt, among Registrant, Morgan Guaranty Trust Company as Depositary, and holders from time to time of American Depositary Receipts Issued there under, including the form of American Depositary.	(1)
2.2.	Order of the Hon'ble High Court of Andhra Pradesh, India dated July 19, 2010 (regarding capitalization or utilization of undistributed profit or retained earnings or security premium account or any other reserve or fund in connection with our bonus debentures).	(8)
2.3.	Scheme of Arrangement between the Registrant and its members for issue of bonus debentures, including Notice of Meeting of Members to approve same dated April 29, 2010 and Explanatory Statement dated April 29, 2010.	(8)
2.4.	Debenture Trust Deed dated March 16, 2011 between the Registrant and IDBI Trusteeship Services Limited (regarding trustee services for our bonus debentures).	(8)
2.5.	Liquidity Facility Services Agreement dated April 2, 2011 between the Registrant and DSP Merrill Lynch Capital Limited (regarding liquidity facility for our bonus debentures).	(8)
4.1.	Agreement by and between Dr. Reddy's Laboratories Limited and Dr. Reddy's Research Foundation regarding the undertaking of research dated February 27, 1997.	(1)
4.2.	Dr. Reddy's Laboratories Limited Employee Stock Option Scheme, 2002.	(2)
4.3.	Sale and Purchase Agreement Regarding the Entire Share Capital of Beta Holding GmbH dated February 15th/16th 2006	(4)

- 4.4. Dr. Reddy s Employees ADR Stock Option Scheme, 2007. (7)
8. List of subsidiaries, associates and joint ventures of the Registrant.
- 23.1 Consent of Independent Registered Public Accounting Firm
- 99.1 Certification of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 99.2 Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 99.3 Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 99.4 Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- (1) Previously filed on March 26, 2001 with the SEC along with Form F-1
- (2) Previously filed on October 31, 2002 with the SEC along with Form S-8.
- (3) Previously filed with the Company s Form 20-F for the fiscal year ended March 31, 2003.
- (4) Previously filed with the Company s Form 20-F/A for the fiscal year ended March 31, 2006 pursuant to a request for confidential treatment.
- (5) Previously filed with the Company s Form 20-F for the fiscal year ended March 31, 2006.
- (6) Previously filed with the Company s Form 20-F for the fiscal year ended March 31, 2010.
- (7) Previously filed on March 5, 2007 with the SEC along with Form S-8.
- (8) Previously filed with the Company s Form 20-F for the fiscal year ended March 31, 2011.
- (9) Incorporated by reference to Exhibit 99.1 to the Company s Form 6-K dated September 25, 2015.



**Table of Contents**

**SIGNATURES**

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf.

DR. REDDY'S LABORATORIES LIMITED

By: /s/ G.V. Prasad  
G.V. Prasad  
Co-Chairman and Chief Executive Officer

By: /s/ Saumen Chakraborty  
Saumen Chakraborty  
President and Chief Financial Officer

Hyderabad, India

June 23, 2016